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For most drugs, the high prevalence of medicine-related morbidity rather reflects their extensive use than 
their intrinsic toxic potential. 
In cutaneous adverse drug reactions, it makes sense to isolate syndromes rather than to consider the whole 
as a continuum, if it helps in finding original clinical patterns, courses, causes, mechanisms and treatment. 
The main point in dealing with Stevens-Johnson syndrome/toxic epidermal necrolysis is to restore the barrier 
function of the skin and mucosae as quickly as possible and in the meantime to prevent the effects of this 
barrier loss. 
The general negative opinion on corticosteroids in Stevens Johnson Syndrome/toxic epidermal necrolysis is 
probably because they are often given too late, in too low a dose, and for too long during the process. 
The controversy if histopathological characteristics of plaque type psoriasis can be seen in pustular psoriasis 
is mainly a matter of timing of the sample. 
There are no grounds to assume that an acute pustular eruption, occurring in patients with known psoriasis, 
is necessarily generalized pustular psoriasis or that acute generalized exanthematous pustulosis is a variant 
of psoriasis. 
A flare-up of a skin reaction during oral provocation with systemic medication on sites, implicated in previous 
patch testing with the same drug, possibly reflects the presence of local memory in the skin. 
The term skin rash is a deplorable and reprehensible idiotism adored by non-dermatologists. Can you have a 
rash on any other organ? 
(Jerome Litt) 
More is missed by not looking than by not knowing. 
(Thomas McCrae) 
To study the phenomenon of disease without books is to sail an uncharted sea, while to study books without 
patients is not to go to sea at all. 
(Sir William Osler) 
Primum non nocere. 
(Thomas Seydenham, after Hippocrates) 
In the consulting room, evidence based medicine meets Google based medicine. 
Eigentlich weiB man nur, wenn man wenig weiB. Mit dem Wissen wachst der Zweifel. 
(Johann Wolfgang von Goethe) 
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Introduction 
It is to be expected that despite the high standards for safety and quality control on the part 
of pharmaceutical companies in the western world, cutaneous adverse drug reactions (cADR) 
cannot be prevented from occurring or even increasing in future. This is due to the rising drug 
consumption worldwide, and because of the introduction of new therapies for major diseases. 
Although all age categories can fall victim to ADR, especially the elderly are more at risk. The 
types of severe cutaneous adverse reactions (SCAR) studied in this thesis, Stevens Johnson 
syndrome (SJS), toxic epidermal necrolysis (TEN), acute generalized exanthematous pustulosis 
(AGEP), and drug rash with eosinophilia and systemic symptoms (DRESS), are no exception to 
this with an average age of over fifty years of patients, suffering from this event. Adverse drug 
reactions (ADR), including cADR and in particular SCAR, have a vast influence on the quality of life 
of patients that experience them. This makes study of mechanisms implicated and prevention 
an integral part of the concept of "healthy aging'� 
SCAR regularly presents a diagnostic challenge as several differential diagnoses have to 
be considered. SJS, SJS/TEN-overlap and TEN (SJS/TEN) undoubtedly constitutes the condition 
with the highest mortality and morbidity, also long term, while DRESS is the most complex to 
diagnose and presents a multitude of diagnostic traps. Although rare, the implications of SCAR 
can be vast; not only for the individual patient, but also for his physician, as well as for the health 
care system. Early diagnosis is essential to prevent unnecessary investigations and therapeutic 
interventions. Crucial in this respect are awareness of and knowledge on the condition at hand 
but also a clear case definition. Apart from early diagnosis, withdrawal of the eliciting agent, and 
supportive care, no evidenced treatment is currently available. 
The main targets for further study of SCAR are aimed at a better understanding of the (non) 
immunological processes that underlie the different reaction patterns and at investigation of 
the genetic background and other risk factors that determine why a specific patient reacts with 
a specific, often "bizarre" reaction towards a drug while another one does not. This may also lead 
to finding better methods for testing the causality of potential suspected drugs. First results of 
pre-screening patients for a specific HLA-type in assessment of the potential risk for a reaction 
to a restricted number of drugs are promising, but up till now it is far from clear whether this will 
eventually lead to prevention of the majority of SCAR. 
Due to the rarity of SCAR, it is difficult to create homogenous groups of patients for further 
study. Multinational cooperation, phenotypical standardisation and strict case definition, and 
validation are keys to create such groups for further analysis. 
12 
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1.1 General introduction cutaneous adverse drug 
reactions 
1.1.1 Introduction 
Quality, safety and efficacy of drugs are issues of all ages. Adverse drug reactions (ADR), an 
inevitable consequence of drug therapy, are amongst the most important causes of iatrogenic 
illness in terms of morbidity and mortality, and are as old as medicine itself. The term iatrogenic 
from the Greek words iatros (healer) and genie (origin) nowadays reflects any adverse effect of 
medical or nursing care, including acts of omission.1 
The concept of harm related to medical practice has been recognized for more than 4500 
years. The ancient Egyptians had a lot of knowledge on herbal medicine and adopted an ethical 
code centuries before the Hippocratic Oath as shown by an inscription on the tomb of Nenkh­
Sekhmet, chief of the Physicians during the 5th Dynasty (2494 to 2345 BC): "Never did I do evil 
towards any person'� Homer, aware of the toxic nature of some herbs, comments in the Iliad: 
"there the earth, the giver of grain, bears greatest store of drugs, many that are healing when 
mixed, and many that are baneful; there every man is a physician, wise above human kind; 
for they are of the race of Paeon"2 The leading principle in the Hippocratic Oath, originating 
somewhat after the 5th century BC, often cited as "Primum non nocere': is underlined with the 
statement against giving "pharmacon oudeni': translated as "/ will give no deadly drug'? In 10th 
century Italy, the medical school of Salerno was authorised to hang offending druggists if they 
had sold a poison or noxious drug. Frederic the Great (1712-1786) dictated that the life of a seller 
of a magic elixir or love potion would be forfeit if a purchaser died.4 
Wouter van Doeveren (1730-1783), professor of Medicine in Groningen and first advocate 
of the foundation of a general hospital in this town, precursor of the current University Medical 
Center Groningen (UMCG), warns in his lecture "de remedio morbo" in 1779: "geef niet te snel een 
geneesmiddel met het risico een tweede ziekte aan de bestaande ziekte toe te voegen of mogelijk de 
dood te versnellen" (do not give a drug too soon, with the risk of adding a second disease to the 
existing one, or even to speed up death).5 
Crucial for the development of modern pharmacovigilance was the drama with thalidomide, 
claimed as outstandingly safe in promotional literature. After its first marketing in 1956, large 
numbers of newborns with a peculiar malformation of the extremities resembling a seal's flipper 
(phocomelia) were noticed.6 This resulted in national and international regulations on reporting 
of ADR, culminating in foundation of the drug monitoring program of the World Health 
Organisation (WHO) in 1967. Important in pharmacovigilance is the spontaneous frequency of 
an illness or symptom. If it is common (e.g. myocardial infarction in the elderly) and only rarely 
caused by a drug, the adverse reaction will not be readily identifiable in an observational study, 




drug causes it frequently, it may already be recognized without properly designed observational 
studies.7 
In 1951, more than a decade before the thalidomide affaire, Leopold Meyler (1903-1973), 
published his "Side effects of drugs':8 Now in its 15th edition and expanded into 6 volumes, 
"Meyler's Side effects ofDrugs"is still the reference tool for ADR.9 1 nitially there was a lot of criticism 
on Meyler and he was accused of collaborating with alternative medicine since that was "also 
against the use of chemicals': To his defence he stated:"one is able to use medicines better, if next to 
the advantages one is also informed about their disadvantages': Gradually he gained recognition 
and became professor of Clinical Pharmacology at the University of Groningen. Had his work 
been appreciated earlier, the thalidomide disaster might have been more limited. 
In the past most drugs have been discovered either by identifying the active ingredient from 
traditional remedies or by serendipitous discovery. Nowadays, along increasing knowledge 
on diseases at the molecular and physiological level, new types of medicines are also being 
developed, referred to as molecular-targeted therapies and other biologicals or body response 
modifiers. Biologicals, closely related to substances naturally made by the body's immune 
system, are natural proteins such as antibodies, cytokines or fragments of proteins, or synthetic 
peptides that switch off specific signal proteins, thus influencing disease processes such as 
cancer, rheumatoid arthritis, and psoriasis. Unlike cytotoxic drugs, the interaction of molecularly 
targeted drugs with their target (receptor) is quite selective and can be described by the classical 
drug-receptor theory.1° For targeted drugs, toxicities of conventional chemotherapeutic agents 
on healthy tissue, such as bone marrow suppression and mucositis, are quite rare and frequently 
replaced by unique and agent-specific toxicities, based on the drug's pharmacological 
characteristics. These side effects are usually dose related and often associated with an adverse 
impact on patient's quality of life.11 
Moreover, ADR significantly hamper drug development. The number of newly marketed 
drugs shows a steady decline; many drugs never make it to the market because of problems 
already encountered in the early phase, while others are withdrawn post marketing because 
harm exceeds benefits.12 Well known examples of withdrawal from the market are Softenon® 
(thalidomide) in the early 60's because of teratogenicity, Trancopal® (chlormezanone) in 1996 
because of rare but severe cases of toxic epidermal necrolysis and Vioxx® rofecoxib in 2004 after 
a study showed a raised risk for heart attacks and strokes.6•13•14 
With improved living conditions and increased life expectancy, pharmaceutical drugs have 
become widely consumed. Many ADR may not be severe enough to warrant admission, but can 
nevertheless lead to significant deterioration in quality of life or require medical assessment and 
treatment. Some however, do not only reduce patients' quality of life, but also represent a source 
of morbidity and mortality and have a major impact on public health. The high prevalence of 
this drug-related morbidity and mortality rather reflects extensive drug usage than an intrinsic 
toxic potential of particular drugs.15 
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ADR are diverse and the wide range is probably based on differences in pathomechanism. 
Any tissue can be the principal target, while sometimes several organ systems are involved 
simultaneously. The skin is one of the most common targets of ADR. Although each drug 
by itself is only rarely responsible, virtually every drug can provoke cutaneous adverse drug 
reactions (cADR). Moreover, in case of polypharmacy, it is often difficult to assign a single drug 
as the responsible culprit. CADR represent a diagnostic challenge for the treating physician 
and are easily misdiagnosed because of their huge clinical variability and heterogeneity and 
resemblance to idiopathic conditions. This may result in both under- and over-diagnosis. 
Misclassification as drug allergy may result in less effective and/or more expensive treatment, 
while under-diagnosis may result in even more severe reactions at subsequent re-exposure. 
Dermatologists in particular will be confronted with patients with early signs of severe 
(muco)cutaneous adverse reactions (SCAR), requiring hospitalisation for diagnosis, stabilisation 
and treatment. Even though rare, SCAR have a significant impact on public health, frequently 
causing morbidity, mortality, lasting disability, and reluctance of patients and their physicians to 
subsequent use of medications. 
Early recognition of ADR and the causative agent is important, looking at the potentially far­
reaching consequences. Although progress has been made in improving case definitions and 
criteria for diagnosis and understanding of pathogenesis, especially in the last decades, better 
understanding of pathogenesis, improvement of case definition, including recognition of (early) 
symptoms, and development of effective (new) specific therapies are still needed. For balancing 
the risk-benefit ratio of drug prescription, improved predictability which drug candidates are 
likely to cause ADR and which patients are at increased risk, is important. 
1.1.2 Definitions 
Adverse drug events are unexpected events following drug use, without evidence of 
causality. In 1972, the WHO defined an ADR as "a response to a drug that is noxious and 
unintended and occurs at doses normally used in man for the prophylaxis, diagnosis or therapy 
of disease, or for modification of physiological function':16 The more recent definition: "An 
appreciably harmful or unpleasant reaction, resulting from an intervention related to the use of 
a medicinal product, which predicts hazard from future administration and warrants prevention 
or specific treatment, or alteration of the dosage regimen, or withdrawal of the product, 
includes the concept of error and highlights opportunities of preventive action to avoid adverse 
effects.17 ADR should be distinguished from side effects, defined as "any unintended effect 
of a pharmaceutical product occurring at doses normally used in man that is related to the 
pharmacological properties of the drug': This also implies that side effects can be beneficial, 
sometimes even leading to new indications for prescription. 
An ADR is defined as serious when it requires hospital admission or prolongation of existing 
hospital stay, results in persistent or significant disability, or is life-threatening. The term "severe" 
15 
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is often used to describe the intensity of a medical event. The terms "severe" and "serious" when 
applied to ADR are technically very different. They are easily confused and should not be used 
interchangeably.17 
1.1.3 Classification of Adverse Drug Reactions 
In a widely used pharmacological classification, also used by the WHO, ADR are divided in 6 
subtypes. Originally ADR were distinguished in dose-related and non-dose-related reactions.18 
Later, for mnemonic purposes, these were labelled respectively type A ("Augmented") and type 
B ("Bizarre") reactions (Table 1 ). 
Type A reactions, most frequent with about 80%, are caused by the pharmacological or toxic 
properties of a drug. They also include drug interactions, accumulation and side effects and may 
occur in anyone. These reactions are predictable and dose dependent and can be diminished or 
alleviated by dose reduction. 
Type B reactions, manifest in about 10-15% of all ADR, are presumably proportionally more 
frequent in cADR. The term bizarre was given because of their unpredictable and uncommon 
character. They occur in people with a certain predisposition, and may demonstrate a manifold 
of novel presentations, not to be expected from the known pharmacological properties of the 
medicine. Their unpredictable and serious nature makes them a significant clinical problem, also 
hampering drug development. Type B reactions, including both non-immunological reactions 
and immunologically determined hypersensitivity, are mainly dose-independent, and usually 
Table 1. Pharmacologic classification of main types of ADR: type A and B 
Type A predictable, common, related to the pharmacological action, low mortality 
-Toxicity, overdose, Antimetabolites (cyclophosphamide) almost invariably cause alopecia; hepatic 
accumulation failure with high dose acetaminophen; chrysiasis after long term gold salts 
- Side effect Sedation with antihistamines 
- Secondary effect Diarrhoea with antibiotics due to altered gastrointestinal bacterial flora, 
candidiasis with (broad spectrum) antibiotics 
- Drug interaction Petechiae/ecchymoses with coumarins when combined with acetylsalicylic acid 







Tinnitus with acetylsalicylic acid 
Immunological reaction, e.g. anaphylaxis with penicillin 
Non-immunological urticaria with radiocontrast; NSAID intolerance 
Anemia with anti-oxidant drugs in glucose-6 phosphate dehydrogenase 
deficiency 
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require drug withdrawal for resolution. They are proportionally more severe and life-threatening 
than type A reactions. 
Subsequently, the reaction types C (dose related and time related, "Chronic"), D (time 
related, "Delayed"), E (withdrawal, "End of use") and F (unexpected failure of therapy, "Failure") 
were added.1 7-19 
Severe cutaneous adverse reactions (SCAR) can be defined in various ways but are 
fortunately rare. In this thesis SCAR is restricted to Stevens-Johnson syndrome/toxic epidermal 
necrolysis (SJS/TEN), acute generalized exanthematous pustulosis (AGEP) and drug reaction with 
eosinophilia and systemic symptoms (DRESS), also known under various other names including 
hypersensitivity syndrome (HSS). Other severe cADR, such as anaphylaxis, serum sickness-like 
syndrome, and vasculitis, will not be not discussed. 
1.1.4 Case definition and classification 
Establishing diagnosis, reaction type, and drug causality can be challenging because of the 
variable clinical and biological presentation and overlap with other diseases. cADR can mimic 
a wide range of idiopathic dermatoses such as bacterial and viral exanthemas, neoplastic or 
paraneoplastic manifestations (e.g. lymphoma, leukemia, Sweet syndrome), autoimmune 
(blistering) and inflammatory conditions (e.g. connective tissue disease, serum sickness, 
Kawasaki disease), and therefore present a challenging diagnostic problem. 
Clear case definition is important, not only for the patient and his treating physician, but 
also because it improves comparability of literature, while lack of it impairs accurate case 
identification and results in under- or over-diagnosis and -reporting. 
Case definition and classification of cADR, as of idiopathic dermatoses, are mainly based 
on morphology and distribution of the (muco)cutaneous lesions. The morphology of cADR is 
myriad and encompasses a large variety of clinical patterns, ranging from the most common 
transient and benign macular or maculopapular erythema, often occurring 6-9 days after 
introduction of a new drug in O - 8 % of its users, to the most severe forms such as TEN, which 
fortunately are quite rare.20,2 1  
Although some cases show overlap or are currently unclassifiable, it is important to recognize 
and distinguish the various clinical patterns, not mixing them all under the denomination of 
"hypersensitivity reactions" because of differences in risk factors, extra-cutaneous involvement, 
culprit drugs, pathogenesis, treatment, prognosis, and sequelae.22 The estimated mortality rate 
for AGEP is 1-5%, for DRESS 1 0% and for TEN over 40%, while for the vast majority of cADR it 
practically is nil. In addition some medications are "usual suspects" for all reaction types, while 
others are more specific for a given reaction pattern. Inconsistencies in case definition can 
also hamper the quality of information to patients and other health care takers with potential 
negative future implications. 
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In the last decades substantial progress has been made on case definition and delineation 
of SCAR from other closely resembling clinical entities, including their causative drugs and 
other risk factors.23-28 Unfortunately however, despite growing consensus on case definitions of 
SCAR, their respective criteria are not yet always strictly followed by all physicians, maintaining 
confusion and complicating comparison between the various studies. 
1 . 1 .5 Epidemiology 
Epidemiologic data are scarce and reported numbers may be over- or underestimated. The 
reported incidence of the various types of ADR is amongst others influenced by definitions 
used, region, setting of the study population, prevailing diseases, prescription habits, and 
genetic differences. Results of a large meta-analysis in 1998 and later studies suggest that ADR 
present an important clinical issue with high mortality (4th-6th cause of death) in hospitalized 
patients.29•30 Moreover, ADR frequently necessitate cessation of otherwise effective drug therapy 
in patients, result in hospitalization or significantly increase the length of hospital stay and 
costs.31-33 Several meta-analyses and other studies have calculated that ADR account for 2.4 -
6.5% of all hospital admissions in Western countries.29•30•32•34-37 A recent prospective, nested case 
control study on hospital admissions related to medication (HARM) in the Netherlands in 2006 
indicates that 2.4% of all admissions and 5.6% of acute admissions are related to ADR, while 46% 
of these were potentially preventable.38 
The skin belongs to the most affected organs in ADR. Skin eruptions are observed in 0.1-
1 % of treated patients in pre-marketing trials of most drugs. However, a number of currently 
used drugs are associated with higher rates of cADR, e.g. 5-7% for aminopenicillins, 3-4% for 
antibacterial sulfonamides and 5-10% for many antiepileptic drugs. In reported series 90% of 
the drug eruptions are benign.39 Because underreporting is expected to be more frequent for 
benign reactions, it can be assumed that about 2% of cADR are severe. 
Epidemiologic studies on SCAR are scarce and knowledge mainly relies on case reports and 
case series. Furthermore, reliable data on drug use of patients with SCAR as well as of the general 
population are needed for risk assessment. SCAR need to be well defined and separated from 
other conditions for assessment of the risks of a specific drug. A prerequisite for data analysis 
and study is consensus on case definition of SCAR. For the spectrum of SJS/TEN case definitions, 
already elaborated in 1993, and for AGEP a scoring system for case validation, published in 
2001, are nowadays generally accepted and used.23•24 Slightly different is the situation for DRESS, 
still lacking a clear case definition and consensus on nosology. Recently a proposal has been 
developed for case definition for HSS/DRESS, while demographics and risk factors are subject of 
further study.25•28 
Very often it is quite hard to determine whether the early symptoms of SCAR, including fever 
or mucosa I symptoms, are signs of e.g. an acute infection or the beginning of SCAR. Therefore it is 
crucial to determine the index day, i.e. the day of onset of the adverse reaction, since prodromes 
18 
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may last for several days. Notification of prodromes is important for drug causality assessment 
as they are also often treated by medication. 
For SJS/TEN large epidemiological studies have meanwhile provided information on 
incidence, demography, and also on risk factors including drugs, while for AGEP those studies 
exist at a smaller scale.26•27•40.41 For DRESS, the first large series, following the newly introduced 
validation score system has been submitted for publication.28 
1.1.6 Pathogenesis of hypersensitivity reactions 
Drug hypersensitivity is a major clinical problem. Hypersensitivity can be defined as a "state 
of altered reactivity in which the body reacts with an exaggerated immune response to what 
is perceived as a foreign substance.42 This definition implies unexpected, immunologically 
mediated reactions, and individual predisposition. Although many cADR are not immunologically 
mediated, including phototoxic reactions, hyperpigmentation, anticoagulant skin necrosis, 
toxicity towards hairs or skin of anticancer drugs, and effects on skin and appendages of 
corticosteroids and other hormones, there is increasing evidence that most acute cADR 
including SCAR are of immunological origin.22A3 
The immune response in drug hypersensitivity is normally explained by the hapten 
hypothesis. It postulates that drugs with a molecular weight of less than 1000 D are too small 
to cause an immune response per se. However, if a chemically reactive drug or drug metabolite 
binds covalently to a protein and thus forms a so-called hapten-carrier complex, this modified 
protein can induce an immune response.44 Many drugs that incite a delayed-type immune­
mediated reaction are believed to be metabolized to a chemically reactive form or undergo 
bioactivation to generate haptens that are recognized by sensitized lymphocytes. The ability to 
detoxify reactive metabolites may be an important determinant in the development of cADR. 
Reactive metabolites may affect cells in various ways: they may bind to macromolecules and 
cause direct cellular damage, they may bind to nucleic acids and produce an altered gene 
product, or they may bind covalently to larger macromolecular targets, form an immunogenic 
complex and induce an immune response.45.46 Growing evidence indicates thatT-cell recognition 
of drugs is a critical step in generating hypersensitivity reactions.4749 T-cell activation in cADR 
has been evidenced in numerous studies wherein drug-specificT-cell clones have been derived 
from the peripheral blood of patients reacting to e.g. amoxicillin, carbamazepine (CBZ), or 
sulfamethoxazole (SMX).49·50 T-cells possess clonally distributed receptors (TCR) that recognize 
antigen on the cell surface when presented to products of the major histocompatibility complex 
(MHC) genes. CD4+ T-helper cells recognize antigen presented by MHC Class II, while antigens 
presented by MHC Class I are recognized by CD8+ cytotoxic T-cells. This cell surface-dependent 
recognition is referred to as MHC-restricted antigen recognition. 
The earlier mentioned hapten hypothesis has recently been supplemented by the p-i 
concept (or pharmacological interaction with immune receptors), which postulates that some 
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drugs that lack hapten characteristics can bind directly and reversibly (noncovalently) to 
immune receptors and thereby stimulate cells. Drugs may also bind to the MHC based on their 
conformation rather than their reactivity. This kind of binding, referred to as pharmacological 
interaction (p-i), is labile and more effective when it is on the MHC and within proximity of the 
T cell receptor (TCR).46 The p-i concept has been used to explain hypersensitivity of drugs such 
as SMX, celecoxib, CBZ, lamotrigine, and ciprofloxacin which are not haptens/prohaptens but 
still elicit an immune response because their conformation allows them to fit into the MHC-TCR 
sandwich.51-55 
The phenotypic diversity of cADR can be explained by engagement of a variety of cytokines 
and inflammatory cells and by regulatory mechanisms. For example, memory cytotoxic T-cells 
are key effectors in both localized blisters of (generalized) bullous fixed drug eruptions and 
in extensive blisters of epidermal necrolysis. This could result from distinct T-lymphocyte 
recruitment: CDS+ cytotoxic cells largely predominate in lesions of blistering reactions (fixed 
drug eruption (FOE), SJS, TEN), whereas CD4+ cells predominate in "common" rashes, AGEP, and 
DRESS.56 Differences in cytokine production may also contribute to different clinical features: 
perforin/granzyme, Fas-L, granulysin and TNF- a play an important role in SJS/TEN, interleukin 5 
(IL-5) and eotaxin in DRESS, while interleukin S (IL-S) is important in AGEP.57-60 Next to this, a role 
for regulatory T-cells (Treg) has been proposed to explain for instance the limited progression 
of blisters in FOE, compared to SJS/TEN.6 1 The traditional classification of hypersensitivity 
reactions of Gell and Coombs not fully explains the various clinical features of hypersensitivity 
to drugs.62•63 Most immunologically mediated type B reactions are supposedly related to delayed 
hypersensitivity, the phenotypic diversity of the final expression of these cADR is large. Therefore 
Pichler proposed a sub-classification of delayed type IV hypersensitivity reactions which seems 
to correspond better with the clinical heterogeneity of drug hypersensitivity (see Table 2), 
according to the cytotoxic activity of the T cells, the cytokine production and the participation 
of different effector cells.64 According to this classification cytotoxicity (type IVc) from CD4+ or 
cos+ T cells seems to participate in many drug reactions, while the final pattern is modulated 
by preferential activation and recruitment of monocytes (type IVa), eosinophils (type IVb) or 
neutrophils (type IVd).64 
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Table 2. Types of hypersensitivity reaction: mechanisms and clinical correlations 
Type of hypersensitivity Immune effector mechanisms Clinical manifestations 
hypersensitivity 
Immediate / anaphylactic: lgE bound to surface of mast cells or Urticaria, angioedema, 
anaphylaxis (insulin) type I basophils. Antigen-binding causes 
mast cell degranulation, release of 
histamine and other mediators 
Cytotoxic: type II 







Antigenic determinants on cell 
surfaces: targets for antibodies, either 
lgG or lgM. Antibodies damage cells/ 
tissues by activating complement, 
or by binding to cells through Fe 
receptors and activate cytotoxic killing, 
e.g. by NK cells 
Pemphigus, 
blood cell cytopenias: haemolytic 
anaemia, neutropenia, 
thrombocytopenia with purpura 
(penicillin) 
Circulating immune complexes Vasculitis, hypersensitivity 
deposited on vascular endothelium or vasculitis, Henoch-Schonlein 
tissue surfaces➔. 
complement activation & attraction of 
neutrophils➔ tissue damage 
purpura, 
Serum sickness and urticaria( 
vasculitis (sulfonamides) 
T lymphocytes, (CD4+ or cos+) Different clinical patterns 
producing different cytokine patterns e.g. contact dermatitis, 
and/or cytotoxic factors exanthematous and photo­
allergic reactions 
Thl /Tcl cells: IFN-y, TNFa, (11-1 ,  11-2) 
monocytes/ macrophages 
Th2 cells: IL-4/-1 3, IL-5, eosinophils 
Contact dermatitis, tuberculin 
reaction 
Maculopapular rash, toxic 
erythema with eosinophilia, 
DRESS 
Cytotoxic T cells: perforin, granzyme B, Contact dermatitis, 
granulysin maculopapular rash , toxic 
erythema, bullous eruptions (SJS/ 
TEN) 
T cells: CXCLB, GM-CSF, neutrophils AGEP (acute generalized 
exanthematous pustulosis) 
Drug hypersensitivity reactions, classified as type I to IV reactions according to the cytokine production, the 
cytotoxic activity of the T cells and the participation of different effector cells. 
modified from Pichler WJ et a/.64 
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1.1.7 Risk Factors 
Premarketing studies are often conducted in young healthy males, neglecting factors of co­
morbidities, changes in metabolism and other risk factors. Moreover, rare reactions are seldom 
observed premarketing due to their low incidence and the limited study population in pre­
clinical trials. Hence post marketing surveillance and - studies are essential for further risk 
assessment. 
Risk factors can be patient-related (both genetic and acquired) or drug-related. Although 
in most cases, factors that predispose individuals to adverse reactions with individual drugs are 
unknown, groups more at risk are the elderly and patients who experienced an earlier ADR, with 
females outweighing males.20•33•36•65 Pharmacological, immunological and hormonal differences 
and the fact that women take more medications may explain some gender differences.66•67 
Though allergic reactions are considered to be less common in the aged, because of 
dampening of immunological responsiveness, ADR frequently occur with increasing age, 
especially above 65 years. The most important determinant of risk for ADR-related hospital 
admissions in older patients is the number of drugs taken.34 Age associated changes in 
pharmacokinetics and pharmacodynamics, altered homeostasis, multiple co-morbidities, and 
use of drugs with narrow therapeutic margins may also predispose the elderly.68 Contrarily, 
cADR are quite rare in infants and children.69•70 Moreover, �-lactam allergy seems clearly over 
diagnosed in children; the skin eruption is only rarely reproducible (6.8%) at subsequent 
rechallenge, and viral infections seem to be an important alternative aetiology in many of these 
reactions.71 
Some co-morbidities, including infection with the human immunodeficiency virus (HIV) or 
infectious mononucleosis, systemic lupus erythematodes (SLE), and M. Sjogren increase the 
propensity for cADR.nao This is amongst others demonstrated by the 10- to SO-fold increased 
risk for an exanthematous eruption to SMX in an advanced HIV infected patient (CD4 count 
<200 cells/µL).81 •82 Moreover, the importance of genetic factors has been postulated since 
long. These include an aberrant drug metabolism, often determined by genes encoding for 
drug-metabolizing enzymes and transporters, and certain human leukocyte antigen (HLA) 
phenotypes, which can be etnicity related. Recently several drugs have been linked to a raised 
risk for (c)ADR in specific HLA phenotypes.83•87 
1.1.8 Drug causality 
Assessment of drug causality in ADR is important, not only for evaluation of the benefit-risk 
ratio of drugs in pharmacovigilance, but also for management of the reaction and prevention of 
future reactions in a specific patient. Timely recognition of the culprit is of eminent importance 
in SCAR; prompt withdrawal of the culprit within the first 24 hours after the start of blistering for 
example lowers the rate of mortality in SJS/TEN.88 
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Key in assessment of drug causality is a thorough evaluation of the temporal relation of 
drug intake to onset of the ADR. The use of flow sheets documenting symptoms, drugs and 
dates can be very helpful. Consideration must be given to the likelihood according to literature 
of a particular drug to cause the symptoms, particularly in case of polypharmacy. Naranjo et 
al. devised an algorithm to assess drug culpability, leading to a score of probability (Table 
3).89 Although of limited value because the algorithm has not been validated, it mentions 
important points of attention when assessing drug causality. Another regularly used method 
for determining the causal relationship between a potential causative drug and the adverse 
reaction, "doing it the French way': is adapted from Begaud et al.90•91 
1.1.9 Diagnostic Tests 
Rechallenge tests, including re-administration of a small test dose of the suspected culprit to 
determine the causative drug, should not be undertaken in severe cADR as they may result in 
a quick recurrence of signs and symptoms and even near-fatal reactions.92 Other in vivo and in 
vitro tests with the suspected drugs may be of use to confirm diagnosis and to assign the culprit, 
although these tests are still not routinely conducted because they can be time-consuming and 
complex. Sensitivity and specificity are variable, depending on the drug, type of cADR, and 
Table 3. Naranjo causality scale for adverse drug reactions 
Question: 
1 .  Are there previous conclusive reports on this reaction? 
2. Did the adverse event appear after the suspected drug was given? 
3. Did the adverse reaction improve when the drug was discontinued or a 
specific antagonist was given? 
4. Did the adverse reaction reappear when the drug was readministered? 
5. Is there an alternative explanation/cause that could have caused the 
reaction? 
6. Did the reaction reappear when a placebo was given? 
7. Was the drug detected in any body fluid in toxic concentrations? 
8. Was the reaction more severe when the dose was increased, or less 
severe when the dose was decreased? 
9. Did the patient have a similar reaction to the same or similar drugs in 
any previous exposure? 
1 0. Was the adverse event confirmed by any objective evidence? 
Scoring > 9 = definite, 5-8 = probable, 1 -4 = possible, 0 = doubtful ADR. Yes 2 2 - 1  -1 No Unknown 0 0 -1 0 0 0 -1 0 2 0 0 0 0 0 0 0 0 0 0 
Naranjo et al. 89 
23 
Chapter 1.1 
timing of the test, while testing should most often only be performed when the reaction has 
already subsided.93-95 
Santiago et al. observed positive patch test reactions in 32.1 % of DRESS cases, most 
often concerning aromatic antiepileptic drugs (AED), in particular CBZ.96 On the other hand, 
Wolkenstein et al. have shown that sensitivity of patch testing is extremely low in SJS/TEN, as 
only two of 22 tested patients had a relevant positive patch test, whereas positive patch tests are 
proportionally overrepresented in AGEP.97·98 
Currently the focus of allergological testing has shifted to ex vivo/in vitro tests. Only few 
studies are available regarding the sensitivity of the lymphocyte transformation test (LTT) that 
measures the proliferation of T cells to a drug in peripheral blood mononuclear cells; some 
authors report frequent positive test results.95·99 Test results can be markedly influenced by their 
timing, which seems to be reaction specific. Actually, in several cases a positive LTT was not 
obtained until 3 months after onset of the disease in cases of DRESS.95·100 Unfortunately, the 
sensitivity of the LTT is still very low in SJS/TEN, even when performed within the reaction specific 
optimal window of one week after onset of the disease.95 Measuring a panel of inflammatory 
cytokines, especially IL-5, instead of proliferated lymphocytes by means of flow cytometry, the 
enzyme-linked immuno sorbent assay (ELISA) test, or a combination of both, might increase 
the sensitivity of the LTT in general.99·101 ·1 02 Another recently reported approach evaluates up­
regulation of CD69 on T-lymphocytes, two days after lymphocyte stimulation in vitro, as a sign 
of drug hypersensitivity.103 Novel other in vitro methods, e.g. detection of CD 107a upregulation 
with or without 1 1-7 /15 preincubation, to help to identify the culprit in drug allergic patients, are 
still under development.104 
For cases in which toxic metabolites are involved, the in vitro lymphocyte toxicity assay with 
the suspected drug(s) could provide an additional diagnostic tool as it helps to increase the 
accuracy of causality assessment of the likely agent. Additionally it could serve as a screening 
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1 .2 Stevens-Johnson syndrome/ toxic epiderma l 
necrolysis (SJS/TEN) 
1.2.1 Introduction 
Stevens Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe ADR 
characterised by massive epidermal necrosis.1 -3 Even though rare, they have a significant 
impact on public health because of high mortality (20-25% overall and over 40% in TEN), 
frequent lasting disability, and reluctance of survivors and their physicians to subsequent use 
of medications.4•5 While in the past, erythema exsudativum multiforme (EEM), SJS, and TEN were 
regarded diseases belonging to the same spectrum, SJS, SJS/TEN-overlap, and TEN (SJS/TEN) are 
nowadays considered to represent a single disease, whereas EEM is a different entity. 
EEM has been reported under a variety of labels and eponyms, and is surrounded by 
confusion. The original description of this polymorphous erythema is ascribed to the Austrian 
dermatologist Ferdinand Von Hebra in his publication of the "Atlas der Hautkrankheiten" in 
1860.6 He described EEM as "a mild illness causing the sudden onset of many red papules that 
are recurrent in some patients, due to systemic invasion by some unknown factors': Some of 
these pa pules develop into what Von Hebra named "target" or "iris" lesions. 
In 1922, the American paediatricians Stevens and Johnson reported severe oral involvement, 
conjunctivitis, and skin lesions in two boys. EEM was excluded as diagnosis because of a variety 
of symptoms that didn't fit Von Hebra's description of EEM. Moreover, skin lesions were more 
severe than the pa pules associated with EEM, showing terminal heavy crusting, and the patients 
had subjective symptoms with high fever. Stevens and Johnson believed the disorder to be an 
infection of unknown origin.7 
In 1950 Bernard Thomas distinguished EEM minus, the entity as previously described by 
von Hebra, from EEM majus (EEMM), showing in addition bullous lesions and intensive mucosal 
involvement as can be seen in SJS.8This subdivision resulted in a lot of confusion between EEM 
and SJS: although the cases reported by Stevens and Johnson in 1922 differed in many aspects 
from EEMM, the terms EEMM and SJS became used interchangeably or as synonyms. 
After an earlier description of "erythroderma with epidermolysis" by Debre et al. in 1939, 
Alan Lyell reported four cases with very extensive "epidermal necrolysis': distinct from EEM or 
SJS and believed to be of toxic origin, for which he coined the term "toxic epidermal necrolysis" 
in 1956.9•1 0  Included in these four was one case of adult staphylococcal scalded skin syndrome 
(5555), leading to two decades of confusion with overlapping nomenclature for 5555 and TEN, 
such as staphylococcal-induced toxic epidermal necrolysis and drug-induced scalded skin 
syndrome. Moreover, one of the other cases in his original series was later on considered to have 
had generalized bullous fixed drug eruption. Although TEN is a meaningful acronym, the terms 




Table 1 .  Differences between erythema exsudativum multiforme majus (EEMM), Stevens­

































< 1 0% 
SJS/TEN overlap *TEN 
Flat atypical Flat atypical target 
target lesions, lesions, poorly 
poorly defined defined (dusky) 
erythematous/ erythema 
purpuric maculae 
Isolated lesions, Isolated lesions, 
partly confluent, partly confluent, 
widespread ++ widespread +++ 
Generally Generally 
Always Always 
1 0-30% ;;;:: 30%* 
* NB: including TEN with large confluent erythema without discrete lesions with a detached BSA ;;;: 1 0% 
+ = mi ld, ++ = moderate, +++ = severe 
The EuroSCAR study group proposed a consensus on case definition, classification 
and nosology, recognizing five categories varying from EEMM to TEN (Table I) in 1993.1 This 
classification is based on three clinical criteria: pattern of the individual lesions, distribution, 
and extent of detachment. Important for differentiation of EEMM and SJS/fEN are the individual 
pattern and distribution of skin lesions. EEMM is characterized by mainly acrally distributed 
"typical targets" or "raised atypical targets"fitting the original description of EEM by Von Hebra, 
and epidermal detachment < 10% of the body surface area (BSA). In SJS/fEN on the other hand, 
skin lesions are widespread and show blisters arising on erythematous or purpuric macules 
and/or flat atypical targets, closely resembling the original description of SJS and TEN. Mucous 
membrane erosions can be present in both EEMM and SJS/fEN. Besides, EEMM significantly differs 
from SJS/TEN by occurrence in younger males, frequent recurrences, less fever, milder mucosal 
lesions, and lack of association with collagen vascular diseases, human immunodeficiency virus 
infection, cancer, and drug aetiology. 1 1 SJS/fEN is considered a spectrum of severity variants of a 
single disease based on similar pathogenesis, risk factors and causality. The principal difference 
between SJS and TEN is the extent of detachment, while SJS can progress into TEN. 
Although this consensus on case definition and nosology is generally accepted nowadays, 
confusion can still regularly be met in literature, even in some textbooks. This hampers 
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comparison of literature on clinical and histopathological aspects, risk factors including drug 
causality, prognosis and therapy. 
1.2.2 Epidemiology 
The incidence of SJS is estimated at 1.2-6.0 per million per year and that of TEN at 0.4-1.2 per 
million per year in Europeans.2.4·12•1 3The mean age for SJS/TEN ranks between 48.2 years and 53.4 
years (range 1-98), and a female preponderance of around 60% is observed.5•14 
1.2.3 Clinical characteristics 
The onset of SJS/TEN is abrupt. Prodromes, usually starting as flu-like symptoms with fever, 
sore throat, rhinorrhea, anorexia and malaise, are often followed by erosive stomatitis and eye 
involvement.1 5  
Next, painful and often ill defined erythematous and/or purpuric maculae (spots) and 
atypical target lesions occur. Maculae, sometimes slightly infiltrated, frequently start on the face, 
neck, and upper trunk in a symmetrical distribution, extend proximally, and have a tendency 
to rapid coalescence. Most often within 24 hours extensive mucocutaneous blistering and 
detachment on an erythematous base is developing, a process that may last for about up to 
15 days. Blisters are flaccid and can become confluent, while large sheets of epidermis slough 
off, leaving an exposed, weeping dermis and leading to large areas of detachment. At gentle 
pressure, blisters can often be moved laterally due to detachment of the blister from the dermis. 
This phenomenon is often referred to as "a positive Nikolsky sign" (Nikolsky II) or Asboe Hansen 
sign. Also pressure on erythematous skin may cause detachment (often called "a positive 
Nikolsky sign" or pseudo-Nikolsky sign).16 Total detachment of BSA is often less extensive than 
the area of erythema, and the moment of maximal detachment is regarded to present the full 
blown stage of the disease. 
Target lesions in SJS/TEN are atypical and differ from typical target lesions in EEM(M). Typical 
targets have regular round and well-defined borders with at least 3 different concentric zones: 
a purpuric central disk with or without a blister, a raised oedematous, pale intermediate ring, 
and an erythematous outer ring. (Fig. 1 a,b,c) By contrast, raised and flat atypical targets have 
an appearance reminiscent of targets, but present with only 2 zones and/or a poorly defined 
border, while the centre can be vesicular or bullous; a central blister however is not enough to 
classify a lesion as raised (Fig. 1 d,2a). 
In SJS, maculae, atypical target lesions, small blisters and small areas of detachment are most 
often predominant on the upper chest. Maculae have a more purpuric component and are often 
more defined compared with SJS/TEN-overlap and TEN (Fig. 2b,c,d). Although these boundaries 
are rather artificial, total detachment in SJS is < 10% of the BSA, in SJS/TEN-overlap between 
10% and 30% (Fig. 3a,b,c,d), whereas in TEN detachment is over 30% (Fig. 4a,b,c,d). TEN is also 
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defined in case of presence of large confluent erythema without spots with a detachment of 
� 10% of the total BSA. 
Multiple mucosal membranes are generally affected in SJS/TEN, with haemorrhagic 
blistering and erosions (Fig. 2c,d). Significant involvement of mucous membranes includes 
oral, ocular, nasal, urethral and vaginal mucosae, while tracheobronchial and gastrointestinal 
mucosae can also be affected. 
Visceral involvement, especiallyof the liver has been reported.1 7· 1 9 Anaemia and lymphopenia 
are frequent, while neutropenia often predicts bad prognosis. 
Complete healing, especially in TEN, can last 3-6 weeks; hospitalization for TEN generally 
takes longer than for SJS.2•20 The period of re-epithelialisation in SJS/TEN is variable and typically 
takes 1-3 weeks, but especially erosions on the back, buttocks, and mucosae often take longer 
to heal; lesions on the glans penis for example can persist up to 2 months.21 Herpes simplex 
can be a complicating factor, sometimes responsible for unexpected worsening and/or delayed 
healing of (muco)cutaneous symptoms.22 
1.2.4 Prognosis/sequelae 
Mortality rates differ for the diverse entities with virtually no death in EEM, 1 % in EEMM and about 
10% in SJS, 30% in SJS/TEN overlap and over 40% in TEN.4•1 1•23•24 Multi-organ failure (particularly 
cardiovascular), metabolic failures, and septicaemia (often caused by Staphylococcus aureus or 
Pseudomonas aeruginosa) following loss of epidermal integrity are the most important causes 
of death. The mortality rate of SJS/TEN remains high and even seems to increase over the years 
despite advances in early diagnosis and management. 
Important prognostic factors are age, extent of denuded skin, neutropenia, serum 
urea nitrogen level, and visceral involvement. Involvement of mucosae of airways and the 
gastrointestinal tract often indicates an unfavourable prognosis.25•26 Culprit drugs with long half­
lives are more likely to result in a fatal outcome than those with short half-lives.27 
In 2000 SCORTEN, a validated, prognostic severity-of-illness score for SJS/TEN, predicting 
in hospital mortality, was developed. This mathematical tool is based on seven independently 
predicting clinico-biologic risk factors, including age, recent malignancy, percentage detached 
skin, tachycardia, and serum urea, glucose and bicarbonate levels (Table 2). The number of risk 
factors progressively attributes to the predicted mortality rate (Table 3).28 The score has also 
been found useful for comparison of different studies and evaluation of efficacy of therapeutic 
interventions.22-29•31  Due to lacking laboratory data, this score is not always applicable. Recently 
a simplified score yielding comparable results has been proposed, which is especially useful for 
evaluating retrospective cases and for settings with limited laboratory facilities. In this model, 
the auxiliary score, laboratory parameters are no longer included.23 
In SJS/TEN, late sequelae are encountered in the majority of patients. Although (muco) 
cutaneous healing usually is complete, mucosa! scarring may result in strictures with 
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Table 2. SCORTEN 
Independent prognosis factors 
Age 
Malignancy* 






� 40 years 
Yes 
� 1 0% 
� 1 20/min 
> 10 mmol/I 
> 1 4 mmol/l 
< 20 mmol/l 
* Recent cancer and haematological malignancies 
Weight 
7 
Presence of variable parameter is scored as 1, its absence scored as 0. The sum total of al l  individual  scores 
predicts the risk of mortality. 
Table 3. Mortality rates and relative risks according to SCORTEN 
SCORTEN Mortality rate Odds ratio (95% Cl 0) 
Percent 95% (1 
0-1 3.2 (0. 1- 1 6.7) 1 
2 1 2.1 (5.4-22.5) 4.1 (0.5-35.2) 
3 35.3 ( 1 9.8-53.5) 1 4.6 (2.0-1 38.0) 
4 58.3 (36.6-77.9) 42.0 (4.8-367.0) 
5 90.0 (55.5-99.8) 270.0 ( 1 5.0-487.0) 
• Confidence interva l. 
functional impairment. Also known are for example tooth problems including caries, nail loss, 
cutaneous scarring, dry skin, hypohidrosis, and pigment abnormalities (Fig. Sa), especially 
hypopigmentation. 
Much more frequent and chronic than initially presumed are eye complications (Fig. 4d). 
Residual potentially disabling lesions do occur in over half the of SJS/TEN (Fig. Sb).32 Serious late 
ocular complications are not restricted to cases with severe acute ocular involvement and care 
should be taken, even in mild cases. Loss of corneal epithelial stem cells during the acute stage 
due to severe ocular surface inflammation results in conjunctivalisation and vascularisation on 
the cornea, leading to serious visual impairment. Cicatrisation of conjunctiva! erosions may lead 
to inverted eyelashes, photophobia, burning or watery eyes, a sicca-like syndrome, and corneal 
and conjunctiva! neovascularisation. 
Also after discharge, extended care is needed for ophthalmologic and other mucous 
membrane sequelae like oesophageal, urethral, penile, vaginal and anal strictures/scarring and 




1 .2.5 Histopathology 
Early lesions most often show sparse superficial perivascular and interstitial lymphocytic 
infiltrates, some lymphocytes at the dermo-epidermal junction (DEJ), and widespread 
keratinocyte apoptosis scattered throughout the lower epidermis (Fig. 6a). Additionally, in 
fully developed lesions, subepidermal vesiculation appears secondary to extensive presence of 
necrotic keratinocytes, which may result in full-thickness epidermal necrosis and separation at 
the DEJ (Fig. 6a,b). Sometimes, the upper infundibulae and eccrine ducts can be involved as 
well. The cornified layer retains its basket-weave pattern.33 Biopsies, taken at a later phase, may 
complicate diagnosis by showing secondary changes. 
Whereas blister fluid cells mainly contain lymphocytes, immunohistochemical staining of 
the skin from TEN patients shows predominance of cells of the monocyte-macrophage lineage 
with variable numbers of CDS+ lymphocytes and macrophages in the epidermis and CD4+ 
lymphocytes in the papillary dermis, with TNF-a as a major cytokine. Paquet et al. showed that 
macrophages are the most numerous cells in the epidermis, while factor Xllla + dendritic cells are 
abundant in the dermis.34 
For rapid differentiation of SSSS from SJS/TEN, a frozen section of a biopsy or of peeled skin 
can be analyzed. The level of skin cleavage in SSSS is the epidermal granular cell layer, whereas 
in SJS/TEN full-thickness epidermal necrosis is seen together with subepidermal blistering (Fig. 
6c). 
1 .2.6 Differential diagnosis 
Although diagnosis of SJS/TEN usually is obvious, based on history and clinical presentation, 
histopathology and immunofluorescence studies may be needed to exclude other (immuno) 
bullous diseases, particularly in the early stage when the full-blown clinical picture is not yet 
apparent. 
It is important to differentiate SJS/TEN from exfoliative dermatitis and blistering diseases, 
in particular EEMM (Fig. 7a), GFBDE (Fig. 7b), graft versus host disease (GvHD) (Fig. 7c), second 
degree burns (Fig. 7d), non-specific bullous drug reactions (Fig. 7e), AGEP, DRESS, and SSSS 
(Fig. 7f). Also (bullous) autoimmune dermatoses such as (para neoplastic) pemphigus (Fig. 7g,h), 
pemphigoid, linear lgA disease, and (systemic) lupus erythematosus/ (drug induced) subacute 
cutaneous lupus erythematosus (Fig. 7i,j,k) have to be considered. 
Clear overlap of SJS/TEN with AGEP and DRESS, although increasingly reported, is probably 
more exceptional then sometimes assumed. A supposed overlap of AGEP and SJS/TEN can 
often be attributed to confluence of pustules in AGEP, leading to a "positive Nikolsky sign" and 
superficial blistering resembling TEN. Histopathology can be of help in the differentiation of these 
cases,35·37 SJS/TEN may suggest overlap with DRESS when accompanied by visceral involvement, 
most often of liver or lungs. Most important for differentiation, is a strict application of their 
respective case definitions.1•38•39 
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1.2.7 Diagnostic Tests 
Patch testing is an investigational option, but sensitivity is relatively weak in SJS/TEN; in one 
study only two of 22 cases had a relevant positive test.40•41 The lymphocyte transformation test 
(LTT) can also help to determine the offending drug, although it is time consuming and its 
sensitivity also is rather low in SJS/TEN, compared to other cADR.42Crucial for the LTT appears to 
be the time of testing, which can vary, depending on the type of cADR. According to one study 
it should be performed within 1 week after the onset of the eruption in patients with SJS/TEN.43 
1.2.8 Pathogenesis 
Pathogenesis is not yet fully elucidated and controversial; several mechanisms have been 
postulated. Although no mechanism has been definitely proven, SJS/TEN is nowadays 
considered to represent an immune-mediated process in which an inappropriate immune 
activation is triggered in response to certain drugs or their metabolites and in which massive 
keratinocyte apoptosis is the main feature and cytotoxic T cells are the main effector cells. The 
link between drugs and the apoptosis of keratinocytes has been established by demonstrating 
the presence of drug-specific cytotoxic memory T cells within the skin lesions. Activated drug­
specific cytotoxic T-cells have been demonstrated in lesional skin with CDS+ T-cells in the 
epidermis and CD4+ T-cells in the dermis. Drug specific CDS + cytotoxic lymphocytes in the 
epidermis and early blister fluid possess natural killer activity and probably kill keratinocytes 
by direct contact.44 Apart from immunologic mediated mechanisms, provoked by the inciting 
agent, clonal expansion of cytotoxic T lymphocytes together with mononuclear cells induce 
apoptosis in keratinocytes, resulting in splitting and detachment of large parts of the skin at 
the DEJ. 
Massive apoptosis of keratinocytes in SJS/TEN has been explained by an altered ability 
to metabolize the offending drug in some patients. This may cause formation of reactive 
metabolites that bind to and alter cell proteins, triggering a T-cell-mediated cytotoxic reaction 
to drug antigens in keratinocytes.45•46 Some drugs may impair detoxification pathways resulting 
in the production of reactive oxygen species, which can be also involved in the etiology of SJS/ 
TEN. These chemically reactive molecules may cause damage to the intracellular machinery and 
membranes and trigger pro-apoptotic processes including Fasl expression and inflammatory 
cytokine production such as TNF-a.47 Moreover, patients with sulfonamide-induced TEN are 
usually slow acetylators.4a-so 
Cytotoxic T cells can activate the caspase cascade, inducing apoptosis either through the 
Fas-Fas ligand (Fasl) or the perforin/granzyme B pathway, which is responsible for keratinocyte 
death in SJS/TEN.44•51 •52 It has been suggested that there is an increased rate of keratinocyte 
apoptosis in lesional skin of patients due to increased expression of keratinocyte membrane 
bound Fas and Fasl. Binding of the suicide antigen Fas (CD95) to its ligand (Fasl, CD95L) induces 
downstream signalling for triggering apoptosis.51 Later studies however contradict a crucial 
37 
I 
Chapter 1 .2 
role of Fas-Fasl interaction or perforin and granzyme B, because both pathways seem not to be 
specific for SJS/TEN.53 
Recent findings suggest that granulysin, a powerful pro-inflammatory cytotoxic protein 
released from cytotoxic T lymphocytes and natural killer (NK) cells, also "turns on" extensive 
keratinocyte apoptosis (Fig. 8), also highlighting a mechanism for cytotoxic T cell- or NK cell­
mediated cytotoxicity that does not require direct cellular contact.54 Granulysin concentrations 
in SJS/TEN blister fluids were two to four times higher than those of perforin, granzyme B or 
soluble Fas ligand. Moreover, depletion of granulysin reduced cytotoxicity, whereas injection of 
granulysin into mouse skin resulted in SJS/TEN mimicking features.54 It was suggested that an 
increasing serum level of granulysin could serve as an early diagnostic biomarker for SJS/TEN.55 
Cytotoxic T cells however, are not solely responsible for the massive apoptosis, considering 
e.g. the relative paucity of infiltrating cells compared to the diffuse epidermal apoptosis.56 Drug­
specific cytotoxic T cells secrete large amounts of IFN-y initiating the MHC-restricted lysis of 
keratinocytes involving perforin and granzyme B. IFN-y on the other hand also promotes the 
recruitment and activation of macrophages, monocytes and dendritic cells. These cells in turn 
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Figure 8: Model of keratinocyte apoptosis induced by the immune synapse of drug HLA - T cell receptor 
interaction of CDS+ cytotoxic T cells. 
Wen-Hung Chung and Shuen-/u Hung. 
Genetic Markers and Danger Signals in Stevens-Johnson Syndrome and Toxic Epidermal Necro/ysis. 
Al/ergo logy International 20 1 O; 59: 325-332. 
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apoptosis-inducing ligand), TWEAK (TNF-related weak apoptosis inducer) and possibly other 
cytokines. TNF-a derived from macrophages and keratinocytes may also play a role by inducing 
apoptosis of epidermal cells or by attracting cytotoxic effector cells, including cytotoxic T- and 
NK cells. 56 Moreover, upregulation of innate immune cells and molecules such as macrophages, 
dendritic cells, and a-defensins in T cells from patients with SJS/fEN may also be involved in the 
etiopathology. 57 This process culminates in a cooperative keratinocyte killing process through 
an MHC dependent pathway. The aggressive epidermal destruction in TEN and probably 
also the progression from SJS to TEN occurs in conjunction with amplification mechanisms 
that are not yet all elucidated. In particular the role of cytotoxic CDS+ cells in initiating the 
phenomenon, of regulary T cells (Treg cells) controlling the response, and of dendritic cells and 
monocytes should be further addressed.5B A role for defective Treg cells has been proposed.sB ,s9 
Treg cells present in normal numbers but functionally ineffective in the acute stage of TEN, 
regain their function at disease resolution.5B Following an initial apoptotic stimulus, it is likely 
that apoptotic signals are amplified by cytokines. The massive release of (proinflammatory) 
cytokines by activated mononuclear cells and keratinocytes into the systemic circulation can 
induce metabolic imbalance, multiorgan failure, pulmonary embolism, and gastrointestinal 
haemorrhage, and besides contribute to local cell death, fever, and malaise.21 
A genetic predisposition is probably of importance.60 The immune reaction in SJS/fEN is 
proposed to be initiated by a HLA class I-restricted presentation of antigens (drugs or their 
metabolites) to T lymphocytes. The important role of HLA-B in the pathogenesis of cADR has 
been demonstrated before, although the exact mechanism of how the antigen modulates 
cytotoxic activity via the HLA gene is still poorly understood. 
1.2.9 Risk factors 
SJS/fEN nearly always represents an idiosyncratic reaction to medication, although incidentally, 
SJS/fEN has also been reported after vaccinations and exposure to chemicals and fumigants.61-63 
The reaction is not dose-dependent and latency time is shorter after drug reintroduction. Recent 
or recurrent herpes, the principal risk factor for EEM(M), has a small but still significant role in 
the aetiology of SJS, but not in SJS/fEN-overlap or TEN.11 ·64-67 Also infection by Mycoplasma 
pneumoniae, regularly found in EEM(M), is quite rare in SJS/fEN.1 1  
A relatively higher prevalence of connective tissue disease, HIV, but also of cancer, was 
confirmed in a case control study, while a recent study has shown that patients with lupus are 
considerably overrepresented in SJS/fEN.6B·69 An increased risk for TEN in patients with AIDS 
might be explained by the large number of drugs administered to these patients, the altered 
immune system function, and the possible abnormal pattern of production and detoxification 
of drug metabolites. 
The association of SJS/fEN with drug-specific HLA antigens has been emphasized recently: 
HLA-B*l 502 is strongly associated with CBZ-, and HLA-8*5801 with allopurinol-induced SJS/fEN 
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in patients of Southeast Asian ancestry, especially in Han Chinese.7o-77These "markers" can be 
used for pretreatment screening in high risk populations. The sensitivity and specificity of the 
HLA-8*5801 allele for prediction of allopurinol-induced SJS/TEN in the Thai for instance were 
100 and 87% respectively, suggesting that HLA-8*5801 is a valid genetic marker for screening.78 
Moreover this type of drug reactions is more commonly seen in slow drug metabolizers due 
to a genetic polymorphism. Polymorphism is observed in position 308 and 328 of the promoter 
region of the TNF- a gene in CBZ hypersensitivity.79 
1 .2.1 0 Drug causal ity 
The offending drugs for SJS and TEN do not differ. The risks of SJS/TEN related to medication was 
first assessed in a case-control study (SCAR-study) in 1995.80 Although more than 100 different 
causative drugs have been described, high relative risks (RR) were observed for anti-infective 
sulfonamides (especially co-trimoxazole), CBZ, phenytoin, phenobarbital, non-steroidal anti­
inflammatory drugs (NSAIDs) of the oxicam type, allopurinol, chlormezanone, aminopenicillins, 
cephalosporins, quinolones, and cycline antibiotics.80 Among medication more recently 
introduced into the market nevirapine and lamotrigine were highly associated with SJS/TEN.68 
A lower but still significant RR was found for sertraline, while for other medications with prior 
alerts, such as terbinafine, fluconazole, cyclooxygenase 2 inhibitors, and leflunomide, numbers 
of exposed cases and controls were too small for risk assessment.68 However, since SJS and TEN 
are rare conditions absolute risks remain low, even for drugs with a high RR. 
SJS/TEN occur in 1 to 10 per 10,000 new users of older AED, especially CBZ, and 2.5 per 
10,000 new users of lamotrigine, a newer class of anticonvulsants, 90% of which within the first 
63 days after its initiation. Sodium valproate and other newer anticonvulsants rarely cause cADR. 
Therefore, AED should be used cautiously and especially when used for pain management, safer 
alternatives should be considered.81 
Allopurinol is the most common cause of SJS and TEN in Europe and Israel; besides a raised 
risk was found with daily dosages of 200 mg or more.82 Ha levy et al. did not find an increased 
risk in case of co-medication with diuretics, aminopenicillins, angiotensin converting enzyme 
inhibitors, acetylsalicylic acid or diclofenac.82 Noteworthy, allopurinol was often administered 
for asymptomatic hyperuricemia in these cases. Since other studies also revealed inappropriate 
indications for allopurinol in up to 86% of patients, judicious prescription of allopurinol is 
recommended.83•84 
In SJS/TEN, a latency of 4-28 days (mean 12-14 days) is the most suggestive timing to support 
drug causality. However, this period can be up to 8 weeks for AED.68•85 Recently, a new algorithm 
of drug causality for epidermal necrolysis (ALDEN) was proposed for assessing drug causality in 
SJS/TEN. Based on case-control data from the EuroSCAR study, ALDEN pointed to a "probable" or 
"very probable" causality in 69% of cases compared to 23% with the French method (P < 0.001 ), 
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while it scored a "very unlikely" causality for 64% of medication compared to none with the 
French method.86•87 
Because of potential recurrences, patients must avoid any future exposure to the agents 
that were implicated in SJS/TEN; accidental rechallenge with a small amount of the culprit drug 
has led to fatal TEN.88 
1.2.11 Management and treatment 
Patients with SJS and TEN are usually hospitalised for observation and treatment. Treatment of 
SJS/TEN is highly specialized and requires specific expertise and facilities. First line of treatment 
is cessation of the suspected culprit drug. In case of doubt, preferably all medication, especially 
those started the month before the event, should be stopped. For drugs with short half lives 
prompt cessation has a positive effect on the outcome and lowers mortality.27 
Attempts have been made to decrease mortality by improved supportive care and several 
modalities of specific treatment, but apart from direct withdrawal of the culprit and intensive 
supportive care, generally accepted guidelines for specific treatment are lacking. Restoring the 
barrier function of skin and mucosae as quickly as possible and in the meantime preventing 
negative effects of its loss is of eminent importance.22•89 
Intensive monitoring includes evaluation of SCORTEN and vital parameters (blood pressure, 
body temperature, respiratory and heart rate, oxygen saturation), laboratory investigations 
(blood count, electrolytes, renal-, liver function, blood gases, bicarbonate, glucose, blood 
culture, urine analysis), skin cultures (bacterial swabs), and BSA involvement. To protect 
patients from infection, nursing has to be barrier protected. Because of massive loss of body 
temperature and fluid through the skin, the patient is preferably treated on an "air-fluidized" 
bed in a temperature and moisture regulated room with, for aseptic reasons, a laminar down 
flow stream. The hypercatabolic state induced by SJS/TEN demands nutritional correction to 
support the process of healing. Enteral feeding should be instituted early and the parenteral way 
should only be used when enteral feeding is impossible. The fluid balance should be monitored 
regularly, combined with timely supplementation of fluid, and electrolytes.89 
Extensive wound care includes emollients, local antibiotics, and non adhesive hydrocolloid 
dressings. Antibiotics, pain treatment and sedatives are given as needed.22•90 Removing only 
epidermis that is curled up is preferred over debridement of all detachable epidermis - a 
procedure in many burn centres - to support regeneration of the skin. Painful involvement of 
mucous membranes (oropharynx, eyes, genitalia and anus) requires attentive nursing care. The 
tracheobronchial epithelium and, less often, gastrointestinal epithelium can also be affected, 
causing high morbidity and mortality. 
Besides optimal supportive care, various additional treatment options have been suggested 
by numerous small studies and reviews.91•92 For most of these treatments however, results are 
variable and placebo controlled trials are difficult to accomplish because of the low incidence of 
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SJS and TEN and the large number of patients required for a study to be statistically meaningful. 
Unfortunately, all suggested therapies for SJS/TEN probably do not target the initiating events 
but rather abrogate later events once the process of epidermal apoptosis has started. 
The only randomized controlled trial that has been conducted regarded thalidomide 
compared with placebo. This trial had to be ended because of an excess of deaths in, what later 
turned out to be, the active treatment arm. Thalidomide had been proposed because it is a 
potent inhibitor ofTNF-a.93 
Historically, corticosteroids were advocated, but after several reports with a negative 
outcome in the '80s, they were increasingly regarded as harmful and even detrimental by some 
authors.2•94-98The negative outcome was possibly due to the fact that low dose corticosteroids, 
given too long and too late in the process, are hardly therapeutically effective, raise the risk for 
infection, and possibly have a negative effect on wound healing. A short course of high dose 
corticosteroids, given early in the process however, might positively influence the immune 
mediated cascade, leading to apoptosis. This was the rationale to introduce an overall treatment 
protocol with high dosed pulse therapy with 1.5 mg/kg bodyweight dexamethasone on three 
consecutive days.22•99 The general opinion on corticosteroids is less negative nowadays.92 Based 
on retrospectively collected heterogeneous data from the EuroSCAR study, it was noted that, 
although corticosteroids did not have a significant effect on mortality in comparison with 
supportive care alone, a trend for a beneficial effect was seen.1 0° Current opinion, according to 
most authors, is that systemic corticosteroids are clearly deleterious in the late stage of SJS/TEN, 
while in the early stage their benefit is not yet evidenced. The precise action of corticosteroids in 
inflammatory diseases is still not well understood. They have pleiomorphic immune modulating 
effects, e.g. through inhibition of numerous cytokines.22•1 0 1  
The supposed rationale of intravenous immunoglobulins (IVIG) is their property for 
inhibiting activation by Fas-inhibiting antibodies of the death receptor; the reported clinical 
results however are not consistent and therefore controversial.1 5,5 1,100,102,103 
Recently, a favourable outcome was mentioned for treatment with ciclosporin in an 
open trial (orally 3 mg/ kg/ day for 10 days, tapered over a month).1 04 Other options such as 
plasmapheresis, aiming at clearing drug metabolites and cytokines, or cyclophosphamide, 
blocking immune activation, have also been suggested, all with varying results.105•1 1 0 
Consultation of an ophtalmologist at an early stage of the disease can help to diminish 
the risk for permanent visual loss due to corneal scarring or neo-vascularisation. Failure to lyse 
adhesions and treat keratitis and corneal erosions can result in blindness. To rescue corneal 
epithelial cells, steroid pulse therapy and topical steroid application should be considered.1 1 1•112  
Sustained treatment using artificial tears and antibiotic and corticosteroid-containing 
ointments are warranted.1 1 3•1 14 Amniotic membrane transplantation at the acute stage and 
scleral contact lenses have shown to be promising to prevent late sight-threatening cicatricial 
complications.1 1 5•1 16 But even meticulous care can not always prevent long-term ophthalmologic 
sequelae.32•1 1 7 
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Stevens-Johnson syndrome/ toxic epidermal necrolysis (SJS/TEN) 
1 a. EEM with typical target lesions with round and 
well defined borders and three concentric zones. 
1 b. EEM with typical target lesions with round and 
well defined borders and three concentric zones. 
1 c. EEMM with typical target lesions with round 
and well defined borders and three concentric 
zones. 





2a. Flat atypical targets. 
2b. SJS with erythematous macules, purpuric 
lesions and small erosions on the torso. 
2c. SJS with haemorrhagic blistering of the l ips. 
2d. SJS with erosive lesions on eyes, mouth, neck 
and upper thorax. 
Stevens-Johnson syndrome/ toxic epidermal necrolysis (SJS/TEN) 
3a. SJS/fEN overlap with extensive blistering and erosions. 
3b. SJS/fEN overlap with extensive blistering and erosions 
(late stage). 
3c. SJS/fEN overlap with extensive blistering and 
erosions. 
3d. SJS/fEN overlap with extensive blistering and 
erosions. 
5 1  
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4a. Evolution ofTEN, extensive 
erythema with spots and bl istering. 
4b. Further evolution ofTEN, extending 
erosions. 
4c. TEN, healing phase with 
reepithelialisation. 
4d. TEN, healing skin with eye 
involvement. 
Stevens-Johnson syndrome/ toxic epidermal necrolysis (SJS/TEN) 
Sa. Hypo- and hyperpigmentation, 1 year after event. 
Sb. Neovascularisation, 1 year after event. 
6a. Early biopsy ofTEN with evolving epidermal 
apoptosis and subepidermal blistering (H&E, original 
magnification 10 x 10). 
6b. Fully developed TEN with extensive epidermal 





6c. SSSS with epidermal splitting at 
the stratum granulosum (H&E, original 
magnification 20x1 0). 
7a. EEMM with typical and atypical 
target lesions, evolving to blistering. 
7b. Generalised bullous fixed drug 
eruption. 
7c. Graft versus host d isease. 
Stevens-Johnson syndrome/ toxic epidermal necrolysis (SJS/TEN) 
I 
7d. Second degree burn wound . 
7e. Non-specific bul lous drug reaction. 
7f. Staphylococcal scalded skin syndrome. 




7h. Paraneoplastic pemphigus. 
7i. Subacute cutaneous lupus erythematosus. 
7j. TEN-like systemic lupus erythematosus, early 
phase. 
7k. TEN-like systemic lupus erythematosus, late 
phase. 
1.3 Acute generalised exanthematous pustulosis 
(AGEP) 
1.3.1 Introduction 
Acute generalised exanthematous pustulosis (AGEP) is a rare, most often drug induced, severe 
pustular reaction pattern, characterised by an acute-onset and typical clinical picture and 
course. 
In the past, most widespread sterile pustular eruptions were classified as generalised 
pustular psoriasis (GPP), a rare variant of psoriasis. In 1 968, in a comprehensive review of 
1 04 cases of GPP, Baker and Ryan identified on clinical grounds five cases of what they called 
"exanthematic pustular psoriasis'�1 These concerned non recurrent pustular eruptions with a 
very acute and short self-limiting course, presumably precipitated by infections and/or drugs, 
while a history of psoriasis was absent. In 1 980, this reaction type was better characterized by 
Beylot et al. and termed "pustulose exanthematique aigues generalisee" (PEAG).2 Its translation, 
acute generalised exanthematous pustulosis (AGEP), is nowadays widely used for an uncommon 
clinical and histopathological pustular reaction pattern, demonstrating features discussed 
below. Subsequently, Roujeau et al. further described this reaction type in a larger series and 
observed psoriasis in quite a high number of patients in his series.3 In 2001 , the EuroSCAR study 
group proposed a standardised validation score system based on the morphology of the lesions, 
course of the disease, and laboratory and histopathological features (Table 1 ).4 Nowadays, this 
validation score is generally used to establish the diagnosis of AGEP. 
Pustular rashes similar to AGEP have been reported under various other names such as toxic 
pustuloderma, pustular drug rash, (subcorneal) pustular drug eruption or drug-induced GPP, 
and pustular psoriasiform eruption with leukocytosis.5•1 0 Moreover, cases of AGEP have been 
classified as pustular psoriasis with or without recognising a drug as the etiologic agent, or 
interpreted as special variants of other pustular diseases.1 1 •1 3 
1.3.2 Epidemiology 
The incidence of AGEP is estimated to be in the range of 1 to 5 cases per million per year in 
Western Europe; more representative data are missing.4 Although AGEP can present at any age 
(mean 56 years), it is uncommon in children.14•1 5  Primarily it was suggested that AGEP affects men 
and women equally; more recent reports however show a trend towards female predominance, 
with a men to women ratio of about 0.8.4•1 5•1 6  Reported prevalence of a history of psoriasis is 
higher than could be expected from the general population.3•1 5  20 
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Table 1. Acute generalised exanthematous pustulosis validation score (EuroSCAR study 
Group) 
Morphology 
Pustules Typical 2 
Compatible 1 
I nsufficient 0 
Erythema Typical 2 
Compatible 1 
Insufficient 0 
Distribution/pattern Typical 2 
Compatible 
Insufficient 0 
Post-pustular desquamation Yes 
Noli nsufficient 0 
Course 
Mucosa/ involvement Yes -2 
No 0 
Acute onset (s 10 days) Yes 0 
No -2 
Resolution (s 15 days) Yes 0 
No -4 
Fever � 38°C Yes 1 
No 0 
Neutrophils : >7000/mm3 Yes 1 
No 0 
Histology 
Other disease - 1 0  
Not representative/no histology 0 
Exocytosis of neutrophils 
Compatible* 2 
Typical** 3 
*Compatible: subcorneal and/or intra-epidermal non-spongiform or unspecified pustule(s) with papil lary 
oedema or subcorneal and/or intra-epidermal spongiform or unspecified pustule(s) without papillary 
oedema. **Spongiform subcorneal and/or intra-epidermal pustule(s) with papil lary oedema. 
Interpretation: s 0: no AGEP, 1 -4: possible, 5-7: probable, 8-1 2: definite AGEP. 
Sidoroff et al. 4 
1.3.3 Clinical characteristics 
The cl inical course of AGEP is very characteristic, showing an  acute, quickly spreading eruption. 
In  typical AGEP, dozens of small non-foll icular steri le pustules arise on a burning and/or pruritic 
oedematous erythema (Fig. 1 a,b,c,d,e). High fever above 38°( usually begins abruptly on the 
same day, or in a window of 2-3 days before or after onset of the pustular eruption. In most 
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cases, skin symptoms start in the face or in intertriginous areas (Fig. 2a,b) and extend to the 
trunk and lower limbs in a few hours, often with accentuation in the main folds (Fig. 3a,b). 
Although not typical for AGEP, additional skin symptoms can comprise marked oedema of 
the face and unspecific lesions such as purpura, 'atypical' targets or blisters.3.4·21 Mild mucous 
membrane involvement on a single site (mostly oral) may occur in about 20% of cases.3 After 
elimination of the culprit, pustules disappear in a few days, typically followed by post-pustular 
pin-point desquamation for a few days, while the reaction resolves within 15 days (Fig. 4a,b).4 
In 2005, the term acute localised exanthematous pustulosis (ALEP) was introduced to describe a 
localised pustular eruption on the face, otherwise fulfilling the criteria for AGEP.22 
Cutaneous manifestations are often accompanied by systemic signs and symptoms such as 
fever, elevated neutrophilic blood counts (> 7 x 109/L in 90% of the cases), and mild eosinophilia 
(in 30%). Although internal organs are usually not evidently involved, renal function can be 
transiently slightly reduced (creatinine clearance < 60 ml/min in 30%), with features of"prerenal" 
kidney injury. Liver function tests are usually normal, but mild elevations of aminotransferase 
(< twice normal upper limit) and hypocalcaemia can be observed. No involvement of other 
internal organs has to be expected. The pustules are sterile, although secondary infection may 
occur.1 ,3A,23 
Overall prognosis is good, although lethal outcome has been reported. Complications and 
mortality (1-5%) are rare and are mostly seen in the elderly or patients in poor condition or with 
chronic diseases such as cardiovascular impairment. In those cases AGEP may precipitate death 
by an increased skin blood flow or super-infection of the lesions.4•23•24 
1.3.4 Histopathology 
Whereas the clinical picture and course of AGEP are usually very typical, the contribution 
of histopathology to diagnosis was less evident until recently, particularly for cases with a 
differential diagnosis of GPP. Previous knowledge on the histopathology of AGEP was mainly 
based on case reports and few small clinical studies, not providing a detailed description.2•3•2 1 •25-29 
Findings of a large multinational study in 2010, aimed at the description of the 
histopathological spectrum of AGEP were that the histopathology of AGEP is characterised by 
superficial spongiform pustules, spongiosis, exocytosis of neutrophils, necrotic keratinocytes, 
papillary oedema, mixed dermal infiltrates, including mid/deep-dermal and interstitial infiltrates, 
containing neutrophils and eosinophils, and the paucity of classical plaque-type psoriatic 
changes (i.e., Munro abscesses, absence of the granular layer, suprapapillary plate thinning, 
tortuous and dilated blood vessels) (Fig. 5).20 A further single centre comparative study, aimed at 
a systematic histopathological description of both erythematous and pustular lesions in AGEP, 
and the acute and more chronic pustular lesions in GPP showed that differentiating features 
pointing at AGEP instead of acute GPP are the presence of eosinophils in the pustules or dermis, 
necrotic keratinocytes, mixed neutrophil-rich interstitial and (lower) middermal infiltrates, and 
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absence of tortuous, dilated blood vessels, while in addition epidermal psoriasiform changes 
are prominent in chronic GPP.1 6 
1.3.5 Differential diagnosis 
In view of the self-limiting character of AGEP it is essential to differentiate AGEP from a wide range 
of sterile, mainly non-follicular pustular eruptions. Most of these can easily be distinguished from 
AGEP on clinical and histopathological grounds, e.g. bacterial folliculitis, acne, dermatophyte 
infections, (bullous) impetigo, infantile chronic acropustulosis, Sweet syndrome, lgA 
pemphigus, necrolytic migratory erythema, bowel bypass syndrome, Beh�et disease, impetigo 
herpetiformis, and staphylococcal scalded skin syndrome (SSSS). Differentiation from SJS/TEN, 
DRESS, subcorneal pustulosis (Sneddon-Wilkinsons disease), pustular vasculitis, symmetrical 
drug-related intertriginous and flexural exanthema (SDRIFE), and acneiform eruptions in 
targeted therapies can be more complicated.30-33 
Presence of 'atypical' targets or blisters and extensive coalescence of pustules, resulting in 
a "positive Nikolsky's sign': detachment of the epidermis and superficial erosions, may give rise 
to some similarity with SJS/TEN (Fig. 6a,b,c) In such cases, histopathology is almost pivotal for 
differentiation, by showing subcorneal/intra-epidermal pustules in AGEP and full-thickness 
necrosis of the epidermis in TEN. The distinction is important because of the worse prognosis in 
cases with SJS/TEN.33-35 Because DRESS may initially comprise papulovesicles or papulopustules 
it may resemble AGEP at first glance. However, pustules are less prominent and often follicular 
in DRESS, while also the prolonged course, different blood count abnormalities, and severity of 
visceral involvement allow distinction from AGEP. 
Most challenging however is differentiation from pustulosis acuta generalisata, a post 
streptococcal disease arising mainly in children, and GPP, especially the acute von Zumbusch 
type.1 6•36 Clinically, pustules in both AGEP and GPP are indistinguishable. Major differences 
however, are the more acute onset and short duration of symptoms in AGEP compared with 
GPP (mean duration fever and pustules 7.5 respectively 9.4 days versus 16.1 respectively 37.0 
days) and recent drug introduction.3 Moreover, additional lesions including petechial purpura, 
EEM-like atypical target lesions, vesicles or blisters on a background of a generalised pustular 
eruption may facilitate diagnosis of AGEP in cases where pustular psoriasis is also considered.37 
Occasionally, drug patch testing may help to narrow the differential diagnosis in ambiguous 
cases.33 
1.3.6 Diagnostic Tests 
Diagnosis is based on criteria, defined by the EuroSCAR study group (Table 1 ).4 The value of 
in-vivo and/or in-vitro testing for the identification of causative drugs has been extensively 
demonstrated.28•33•35•38 Both positive and negative patch tests and lymphocyte proliferation 
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responses to the culprit drugs have been observed in AGEP, although results are not always 
concordant.28•35•39 
In-vivo patch testing is generally a safe and irrefutable method for determining the culprit 
drug. The proportion of positive drug patch tests in AGEP is approximately 50%, and up to 80% 
for certain antibiotics, which is higher than encountered in other types of cADR.4042 Moreover, 
patch-test reactions sometimes nicely mirror the events of the acute reaction and can be 
strongly positive.33•35.43 Different in-vitro tests, including the lymphocyte transformation test 
(LTT), measuring lymphocyte proliferation and/or their cytokine release, macrophage migration 
inhibition factor test, interferon-gamma release test, and mast cell degranulation test may be of 
help in appointing the causative drugs, but are rarely performed in daily practice, due to their 
complexity, costs and efforts.28•38·� 
1.3.7 Pathogenesis 
Etiopathogenesis of AGEP is still not fully elucidated, although some progress has been made, 
particularly in the last decennium. The regularly observed tissue and blood eosinophilia, 
hallmark of many drug-induced allergic reactions, are in favour of a hypersensitivity reaction. 
This is also supported by positive patch test and/or LTT reactions towards the suspected culprit 
drug. Histology and immunochemistry of skin lesions, including those of positive patch test 
reactions, and immunochemistry of the LTT provide further clues for the pathogenesis of 
AGEP.28•38•39.42 Drug-specific CD4+ but also CDB+ T cells can be isolated and cultured from patch 
test sites and blood of AGEP patients.38.45.47-49 
AGEP appears to represent a peculiar subtype of delayed hypersensitivity type IV reaction 
where cytotoxicT cells emigrate and kill keratinocytes, with specificT cells playing a crucial role, 
producing large amounts of neutrophil-attracting cytokines, such as IL-8. This contributes to the 
accumulation of neutrophils in the skin lesions, an important characteristic of AGEP. Apparently 
T cells can be involved in some neutrophil-rich inflammatory responses, in which they may 
orchestrate the immune reaction directly by high IL-8/ CXCL8 production or indirectly via IL-
22 production by Th 17 cells, inducing CXCL8 production in various cell types.50 Drug-specific 
CXCL8-producing CD4+ T cell clones revealed a predominant T helper cell (Th 1 )-type cytokine 
profile with high production of GM-CSF and IFN y and various levels of the pro-inflammatory 
cytokine TNF-a.48The release of chemokines and neutrophil-activating cytokines (IL-4, IL-8, and 
GM-CSF), preferentially activates and recruits neutrophils, resulting in a type IVd immunologic 
reaction with blood neutrophilia and accumulation of neutrophils at the site of the lesions.45•5 1 
Moreover, it was recently appreciated that IL-8, apart from T cells, is also secreted by keratinocytes, 
enhancing neutrophilic inflammation and survival, attributing to sterile pustule formation.45•52 
Of note, neither IL-8 production nor neutrophilic infiltration is seen to such an extent in other 
types of drug allergy. Besides, few CXCL8+ T cells displaying a Th2-type cytokine profile with 
high IL-4 and IL-5 secretions may contribute to eosinophilia, regularly observed in AGEP.45•48•52-54 
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1.3.8 Risk factors 
The etiological relation between drugs and AGEP is well described and more than 90% of all 
cases seems to be drug induced. Next to medicines, other causes such as acute viral infections 
(especially enterovirus such as Coxsackie virus A9 and B4, and echovirus 11 and 30, but also 
cytomegalovirus, Epstein-Barr virus, hepatitis B virus, and Parvovirus B l  9), Escherichia coli, 
Chlamydia pneumoniae, Mycoplasma pneumoniae, Echinococcus granulosus, spider bites, 
heavy metals (mercury), dietary supplements, chemotherapy, radiation and PUVA have been 
associated occasionally.3 1 Of note, viral infections (e.g. Coxsackie B4/ Epstein-Barr virus) and 
vaccinations are relatively more often suggested as triggers in the paediatric population.14•55•56 
Analysis in a large case-control study however did not reveal a significant association with 
infections.4•15 
Based on individual case reports and short series, dozens of medications have been 
implicated. Evaluation of risk factors for AGEP in the multinational case-control EuroSCAR study 
revealed a strong association with a broad spectrum of drugs, especially pristinamycin, ampicillin 
/amoxicillin, quinolones, (hydroxy)chloroquine, anti-infective sulphonamides, terbinafine and 
diltiazem.1 5 Also carbamazepine and paracetamol are regularly mentioned as culprit drugs.29•31 
Interestingly, the EuroSCAR study revealed two different temporal patterns: after antibiotics a 
rapid onset of only a few hours to 2-3 days after drug introduction (median 1 day) was observed, 
while all other associated drugs had an interval of 1 to 3 weeks (median 11 days). This obvious 
peculiarity in the dynamics of the reaction may suggest different pathomechanisms. The short 
interval might indicate previous sensitization and/or an immunological recall phenomenon 
induced byT cell reactivation, directT cell activation, or activation of the innate immune system, 
whereas the longer latency time fits the classical pattern of primary sensitization. Another 
noteworthy finding in comparing studies of the EuroSCAR study group was the different 
spectrum of causative drugs in AGEP compared with SJS/fEN.15•57•58 
Whether AGEP is an entity distinct from pustular psoriasis is sometimes raised as a point 
of discussion. Several studies show a higher prevalence of plaque-type psoriasis in AGEP than 
could be expected from the general population, suggesting that AGEP could be a reaction 
pattern favoured by a psoriatic background.3•1 5•1 6•20•33 Patients with a pustular form of psoriasis 
and patients who develop a pustular drug reaction may share a common genetic background 
which directs them towards reacting with neutrophil-attracting mechanisms.1 5  In a small study, 
human leukocyte antigen (HLA) B51 DRB1 *07, DR1 1, and DQ3 were found more frequently in 
AGEP compared to the average population; further studies however are needed to confirm 
the hypothesis of genetic susceptibility to pustular drug eruptions linked to the major 
histocompatibility complex.59 Of note, the HLA-DRB7*07 allele is also associated with psoriasis.60 
Mutations in genes that encode cytokines, their receptors or inhibitors, could also play a 
role. In GPP it was demonstrated that an aberrant interleukin by inhibiting an anti-inflammatory 
cytokine-induced response may lead to unregulated secretion of inflammatory cytokines (IL-8 
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in particular) by keratinocytes and pustular psoriasis.61 Noteworthy, comparison of a sub-group 
of AGEP patients with a personal history of psoriasis showed no significant histopathological 
differences with cases without pre-existing psoriasis except for slight psoriasiform changes, 
especially the presence of tortuous/dilated blood vessels.1 6 However, the fact that most drugs 
known to induce psoriasis, e.g. beta-blockers or angiotensin-converting enzyme (ACE) inhibitors, 
are not associated with AGEP, additional ly supports that AGEP is different from psoriasis.1 5 
1.3.9 Management and treatment 
Early recognition of AGEP is of clinical relevance as discontinuation of the causative agent is the 
most important action to be taken. Due to its self-limiting course and favourable prognosis in 
most cases, specific treatment is general ly not required. Corticosteroid treatment, often taken 
into consideration, is usually not necessary.4•62 At present, no therapy has been evidenced to 
prevent extension of lesions or a further decline of patient's general condition. Sometimes 
supportive therapy is needed. Systemic antipyretics/ non steroidal anti-inflammatory drugs can 
be given symptomatically, provided they are not suspected to be the causative drug. Antibiotics 
should not be administered, unless there is super-infection of the skin lesions. 
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1 a. Dozens of small non-fol l icular steri le pustules on 
oedematous erythema and atypical targets. 
1 b. Dozens of small non-fol l icular sterile pustules on 
bright erythema. 
1 c. Dozens of small non-follicular, partly confluent 
sterile pustels on oedematous erythema in pigmented 
skin. 
1 d. Dozens of tiny pin-headed non-follicular sterile 





1 e. Detail 1 a: lower arm and wrist showing dozens of pin­
headed pustules. 
2a. Early onset of the eruption on the axi l lary intertriginous area. 
2b. Early onset of the eruption on the intertriginous area of the 
groin. 
3a. Evolution with accentuation in the main folds: neck, axi l lary, 
ellbow, abdomen. 
Acute generalised exanthematous pustulosis AGEP 
3b. Late stage, stil l with accentuation in the folds: axil lary, 
submammary, el lbows, abdomen, groins. 
4a. Healing phase with post-pustular pin-point desquamation. 
4b. Healing phase with extensive post-pustular pin-point 
desquamation. 
5. Histopathology of AGEP. Slightly spongiform subcorneal­
intraepidermal pustule, minor acanthotic rete ridge changes, � 
spongiosis, neutrophilic exocytosis, papi l lary edema and mixed 
perivascular and interstitial infi ltrates. 
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6a. TEN-like AGEP. Detail, showing pustules 
and superficial erosions. 
6b. TEN-like AGEP. Detail, showing oedematous 
erythema, pustules and erosions. 
6c. TEN-like AGEP, recovery phase. 
1 .4 Drug reaction with eosinophi l ia and systemic 
symptoms 
1.4.1 Introduction 
Reviewing the literature, a multitude of different names appears to describe a type of severe 
drug-induced hypersensitivity reaction with a distinct clinical reaction pattern. 
In 1939, after their review on the toxic symptoms of phenytoin, Merritt and Putnam 
distinguished mild morbilliform eruptions, healing after withdrawal and most often not 
recurring after re-administration, from other eruptions with fever, exfoliative dermatitis and 
eosinophilia.1 Later, lymphadenopathy and multivisceral involvement were associated as well. In 
1950, after the association of systemic involvement, the reaction was recognized as a syndrome, 
often presenting with the classic triad of fever, rash, and lymphadenopathy.2•3 
Si nee the early 1940s, shortly after introduction of hydantoi n and its derivatives for convulsive 
disorders, drug reactions clinically and/or histopathologically mimicking malignant lymphomas 
were observed.4 In 1959 Saltzstein grouped these observations from literature, added some new 
cases of lymphadenopathy induced by anticonvulsant drugs, and introduced the term drug­
induced pseudolymphoma.5 Thereafter, because the inciting drugs often were the same, both 
multisystem hypersensitivity reactions and drug-induced pseudolymphoma were sometimes 
interpreted as a single entity.6-9 
Later however, it was recognized that both reaction types were two different kinds of adverse 
drug reactions (ADR): drug-induced pseudolymphoma having a more insidious beginning 
with nodules and infiltrated plaques appearing several weeks after the start of a drug without 
constitutional symptoms, histologically mimicking cutaneous lymphoma, and on the other 
hand an acute clinical entity associated with fever, a cutaneous eruption, lymphadenopathy, 
eosinophilia, and visceral involvement in which histopathology of the skin and/or lymph nodes 
may also mimic lymphoma.8•1 0  
Since the landmark article of Merrit and Putnam, similar rare but potentially life-threatening 
ADR with cutaneous as well as internal organ involvement and eosinophilia have been 
repeatedly reported under a variety of names. The nosology often referred to the drug involved 
(e.g. dilantin/ dapsone/ sulfone/ allopurinol hypersensitivity syndrome), the most affected 
internal organ (e.g. nephritis, hepatitis), or the disease mimicked (e.g. mononucleosis-like illness, 
Kawasaki-like syndrome, pseudolymphoma).3•8•1 1 -1 8 After recognizing that several aromatic 
anti-epileptic drugs (AED) did cause similar symptoms, Shear and Spielberg coined the term 
anticonvulsant hypersensitivity syndrome in 1988 and suggested that this reaction due to AED 
was caused by a genetic defect in drug metabolism.19 After hypothesizing that other drugs could 
elicit a similar reaction pattern, names and acronyms like hypersensitivity syndrome (HSS), drug 
reaction with eosinophilia and systemic symptoms (DRESS), drug induced delayed multi-organ 
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hypersensitivity syndrome (DIDMOHS) and drug (induced) hypersensitivity syndrome (D(l)HS) 
were proposed.20-25 
Since the word hypersensitivity is rather uninformative and ambiguous, the more informative, 
clinically relevant acronym DRESS, was introduced by Bocquet et al. in 1996 to distinguish the 
syndrome from other cADR, not associated with systemic symptoms and eosinophilia.22 This 
acronym is gaining use, although names, referring to e.g. the drug or most affected internal 
organ are still encountered. Also, full consensus on the definition of the entity and its precise 
criteria are still missing. Because a clinically meaningful name and a standardised definition are 
important for purposes of clinical recognition and further investigation, the RegiSCAR group 
proposed a score to validate potential cases of DRESS.26 
1.4.2 Epidemiology 
The incidence of DRESS is difficult to define due to the rarity of epidemiologic studies on the 
disease and inconsistencies in reporting, caused by a lack of consensus on nosology and case 
definition.26-29 Moreover, because of the variability of the clinical and biological presentation, 
DRESS regularly goes unrecognized. However, the risk for developing DRESS by CBZ and 
phenytoine in new users within 60 days at first or second prescription was estimated at 1.0-4.1 
in 10,000 and 2.3-4.5 in 10.000 respectively.30 Although no sex or age predilection was observed 
in earlier reports, females were predominant and significantly younger than males in a recent 
large multinational study, especially for cases related to antiepileptics and antibiotics.29•3 1  
1.4.3 Clinical characteristics 
In its complete form, DRESS refers to a severe, idiosyncratic reaction, defined by a widespread 
and long-lasting skin eruption, accompanied by fever, lymphadenopathy, haematological 
abnormalities, and visceral involvement.22•26•29•32 Because a single organ is usually dominant in 
its clinical presentation, DRESS may go unrecognised as a syndrome. Evolution of signs and 
symptoms is often relatively slow and can present in haphazard combinations, also in time, 
resulting in an academic approach from different medical specialties and treatment of individual 
symptoms. 
Fever, often accompanied by malaise or pharyngitis, cervical lymphadenopathy and "rash" 
are often the first symptoms.1 1•22•29•3 1-33 Mild to high-grade spiking fever, ranging from 38 to over 
40°(, may persist for weeks and usually generates concern for an underlying infection; cultures 
however are negative. 
The "rash" often starts with a morbilliform eruption, and is initially often hard to distinguish 
from benign drug eruptions or viral rashes. The face, upper trunk, and upper extremities are 
first affected; the eruption often extends and erythroderma or even exfoliative dermatitis 
may evolve.22•3 1 Reported skin reactions however vary and include maculopapular (Fig. 1 a,b), 
urticaria! (Fig. 1 c,d), erythematous, exfoliative (Fig. 1 e), lichenoid (Fig. 1 f), purpuric (Fig. 1 g), 
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and eczematous-type reactions (Fig. 1 h).29•31•32 Blistering and sterile follicle-centred pustules may 
occur, as well as nonfollicular small pustules, while facial oedema is frequent (Fig. 2a,b,c). 1 1 •22•29•31 •34 
Enlarged, tender lymph nodes, resolving slowly after cessation of the inciting drug, are frequent 
as well.29,31 
Haematologic abnormalities are quite characteristic and concern leukocytosis, often with 
prominent eosinophilia, and mononucleosis-like atypical lymphocytes. 10·29·31 ·32 Hyperleukocytosis 
can be considerable, sometimes above 50 x 109/L.22·29 Also neutrophilia in the initial phase and 
monocytosis later in the reaction are frequently met.29 An absolute eosinophil count of more 
than 1.5 x 109/L, which is regularly encountered in DRESS, is toxic to endothelial cells and can 
lead to cardiac, gastrointestinal, central nervous system, pulmonary, and renal dysfunction, 
including coronary artery thrombosis and eosinophilic pneumonia.35·36 Although haematological 
abnormalities can point towards a diagnosis of DRESS, viral infections such Epstein-Barr virus 
infections or haematologic diseases can be difficult to distinguish. 
Most common participating viscera are the liver, kidney, and lungs.29 Isolated elevation of 
liver transaminases is usual, but (acute) liver failure due to massive hepatocellular necrosis may 
occur and accounts for the principal cause of mortality.3·1 2·29·32·37·38 Hepatitis, generally anicteric 
but sometimes presenting as hepato-splenomegaly, may worsen during several weeks after 
drug withdrawal and may take months to resolve completely.1 1 •31 ·32 Other organ involvement 
includes (interstitial) nephritis/ pneumonitis, heart failure (eosinophilic myocarditis), pericarditis, 
symptoms of the central nervous system (meningo- encephalitis), tonsillary pharyngitis, arthritis, 
myalgia, myositis and sporadically hypothyreoiditis, diabetes and pancreatitis. 1 1 •15·16·22·29·31 ·32·3941 
Shock with respiratory distress and hypotension has also been also described. Sequential 
reactivation of several herpes viruses, especially human herpes virus type 6 (HHV-6), can be 
observed and is often regarded responsible for a more severe or protracted course.42.43 
The onset of DRESS is more delayed than most other cADR, often starting 2-6 weeks after 
initiation of the inciting drug, although latency time can be shorter when the drug was supplied 
previously. Due to clinical similarity to e.g. infectious diseases, the relatively long latency, and 
the prolonged course, even after withdrawal of the culprit drug, diagnosis of DRESS may be 
delayed or the reaction goes unrecognized as drug-related. 
1.4.4 Prognosis/sequelae 
DRESS is serious and may cause considerable morbidity and mortality. The mortality rate, 
mostly due to visceral involvement, is estimated at near 10%, but is not exactly known since the 
incidence of the reaction is unknown due to misdiagnosis and underreporting.40•44 In particular 
liver and renal involvement can be serious, even necessitating transplantation and/or dialysis.45 
Otherwise, recovery is usual and total after drug withdrawal, although particularly the skin 
eruption and hepatitis may persist for weeks and sometimes even months. Rechallenge with 
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the offending drug results in a quick recurrence of signs and symptoms. Even near-fatal liver 
necrosis has been reported after re-administrating small amounts of phenytoin.46 
1.4.5 Histopathology 
Histopathology of the skin can vary substantially, in parallel with the variability in clinical 
appearance. Rather dense diffuse or superficial and perivascular lymphocytic infiltrates 
with variable amounts of eosinophils and dermal oedema are seen regularly. lntraepidermal 
vesiculo-pustules may occur; focal vacuolar degeneration of the basal layer, band-like infiltrates, 
sometimes including atypical lymphocytes, and epidermotropia mimicking lymphoma can be 
observed (Fig. 3a,b,c,d).8•22•3 1 A7A5 
1.4.6 Differential Diagnoses 
Because of the variability of signs and symptoms DRESS may resemble several other diseases 
and it is typically a diagnosis by exclusion.26•29•44 Differential diagnostically one might consider in 
particular other cADR including AGEP and SJS/TEN, acute infections including bacterial sepsis, 
SSSS, toxic shock syndrome, acute viral infections (including Epstein-Barr virus, hepatitis virus, 
influenza virus, cytomegalovirus, human immunodeficiency virus), Kawasaki syndrome, Still's 
disease, (pseudo)lymphoma, idiopathic hypereosinophilic syndrome, collagen diseases, and 
angioimmunoblastic lymphadenopathy.4•5•8•1 8.44,49-5 1 
In some cases of SJS/TEN with systemic involvement, most often of liver or lungs, overlap 
with DRESS may be suggested, however visceral involvement in SJS/TEN is generally milder 
than in DRESS.52 Also, cases with DRESS with blistering might suggest such overlap, but 
blisters in DRESS are more limited, caused by dermal oedema, and tense instead of flaccid as 
in SJS/TEN. Moreover, mucosal involvement in DRESS is not prominent, generally mild and not 
haemorrhagic. Most important for differentiation is a strict application of the case definition 
of both conditions.26•53 Because DRESS may initially comprise papulovesicles or papulopustules 
it might resemble AGEP. However, pustules in DRESS are less prominent and often follicular, 
while a prolonged course, differences in blood count abnormalities, and severity of visceral 
involvement also allows differentiation from AGEP. 
1.4.7 Diagnostic Tests 
Rechallenge, including re-administration of a small test dose of the suspected culprit, should 
not be performed in DRESS as it may result in a quick recurrence of signs and symptoms and 
even near-fatal reactions.46 Other in vivo and also vitro testing with the suspected drug(s) may 
be helpful to confirm diagnosis and assign the culprit. Sensitivity and specificity of these tests 
however, are variable, depending amongst others on the drug involved, and testing should only 
be performed when the reaction has subsided.54•55 
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Santiago et al. observed positive patch test reactions in 32.1 o/o of DRESS cases, most often 
elicited by AED, in particular CBZ.55 The sensitivity of the lymphocyte transformation test (LTT) 
in DRESS has not yet been established in larger series; some authors however, report frequent 
positive test results.56•57 More sensitive in vitro lymphocyte reactivity in peripheral blood 
mononuclear cells might be yielded by flow cytometry, the ELISA test, or a combination of both, 
by measuring inflammatory cytokines, especially IL-5, instead of proliferated lymphocytes.56•58•59 
Test results however, can be markedly influenced by their timing. Actually, in several cases a 
positive LTT was not obtained until 3 months after the onset of the disease.57•60 
The in vitro lymphocyte toxicity assay with the suspected drug(s) could provide an 
additional diagnostic tool in increasing the accuracy of causality assessment of the likely agent. 
Additionally, this method could serve as a screening test for potential 'cross-reacting' drugs by 
measuring the lymphocyte phenotypic detoxification systems.19•61 
1.4.8 Pathogenesis 
DRESS represents an idiosyncratic delayed immunologic reaction, probably to rather a 
limited number of drugs. Pathogenesis appears to be multifactorial, involving immunological 
mechanisms and particular drug detoxification pathways. Although several theories have 
been proposed, complete pathogenesis is still unknown. The long latency time after start of 
medication suggests involvement of idiosyncratic metabolic mechanisms, and also supports a 
role for viral infections in triggering and/or activation of DRESS. DRESS is possibly the result of a 
cascade of successive events on a predisposed genetic background. 
It has been demonstrated that reactive metabolites rather than their parent drug can be 
responsible for idiosyncratic drug reactions.32 Pharmacogenetic variations in drug metabolism 
and detoxification are important and slow acetylation is probably one of the risk factors; a 
slow acetylator phenotype and increased susceptibility of lymphocytes to toxic hydroxylamine 
metabolites in vitro have been associated with an increased risk of developing DRESS to 
sulfonamides.22•62-64 A relation between DRESS due to AED or sulfonamides and an individual 
genetic defect of the enzymes involved in the metabolic cascade of these drugs has been 
suggested since long, implying siblings may be at increased risk of developing the same 
reaction.62•65 
After bio- transformation of e.g. aromatic AED by cytochrome P-450, insufficient detoxification 
can result in accumulation of reactive toxic metabolites (arene oxide intermediates). These 
metabolites can bind to tissue macro-molecules and may cause cell damage or cell death, or act 
as a hapten and provoke an immune response. Insufficient detoxification has been suggested to 
be based on a genetic defect for the enzyme epoxide hydroxylase. This "toxic metabolite theory" 
can be substantiated by a lymphocyte toxicity assay.32•63•65-67 
Besides,a relation between viral infections and the simultaneous or subsequent development 
of allergic inflammation has been observed in various clinical situations. Examples of a role 
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for virus are the strongly increased risk in HIV-positives to develop severe drug reactions, in 
particular for sulfamethoxazole, and the increased risk in EBV infection for ampicillin rashes. It is 
further hypothesised that viral infections may induceautoantibodies against cytochrome P-450 
enzymes and that reactivation of HHV-6 may have potentially serious interactions with enzymes 
that detoxify drugs, such as cytochrome P-450.48•68 More recent studies suggest an intimate 
relationship between reactivations of herpes viruses, especially HHV-6, and the development 
of DRESS. Reactivation of herpes viruses is even considered a criterion by Japanese experts, and 
often held responsible for a more severe and/or protracted course.25A3A5,69-75 
A transient state of immune suppression with subsequent reactivation of latent virus 
infections has been observed in DRESS. In DRESS two phases can be distinguished: the initial 
immunosuppressive phase accompanied by the ADR, and the second, the viral reactivation 
phase with exacerbation of the clinical symptoms. lmmunomodulating effects of specific drugs 
such as anticonvulsants, minocycline, allopurinol and sulfonamides, presumably also promote 
HHV-6 reactivation.76•77 Moreover, sequential reactivation of several herpes viruses is sometimes 
observed, a phenomenon that can also be seen in immunocompromised patients with graft­
versus-host disease.42•72•73•78 
Contrary to TEN, which shows transitory impairment in the function of regulatory T cells 
(Tregs), DRESS displays a dramatic expansion of functional Tregs during the acute phase. 
Hypogammaglobulinemia and a profound decrease in the number of B cells can be found at 
the onset of DRESS, probably related to the expansion of functional Tregs, that possibly induce 
B cell-death. The vast population of Tregs may also prevent activation and expansion of antiviral 
T cells, thereby reducing lesion severity and possibly allowing latent herpes viruses to reactivate 
in an uncontrolled way.79 Antiviral cytotoxic T cells probably play the most important role in 
controlling viral reactivation; virus-specific CDB+ T cells for instance can prevent herpes simplex 
virus reactivation.80 After resolution of DRESS a gradual loss of the function ofTregs may increase 
the risk of subsequently developing autoimmune diseases.79 
1.4.9 Risk factors 
By definition, DRESS is drug-induced. For the first time, this type of reaction was described 
for phenobarbital and phenytoine, and later also for the other older AED such as CBZ, and 
primidone.2-3 Cross-sensitivity between these older AED is very frequent (70-80%). 1 9•22 Later, 
DRESS was also associated with sulphonamides such as sulfasalazine and dapsone, and 
allopurinol, minocyclin, mexiletine, lamotrigine and few other drugs.8•20•22•29A3•48•81-85 Compared 
to other SCAR, the number of drugs implicated seems far more limited, with AED, especially 
CBZ, allopurinol and sulphonamides in the leading position, while latency time after drug 
introduction is usually longer.29 
Since long it has been suspected that DRESS may have a genetic background, suggesting a 
direct involvement of HLA in the pathogenesis of drug hypersensitivity when the HLA molecule 
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presents the binding site for an antigenic drug inducing T cell activation. Recently it was found 
that the HLA-8*5801 allele presents an important genetic risk factor for allopurinol-induced 
DRESS and SJSffEN, especially in the Han Chinese, whereas only a moderate association was 
observed in the European and Japanese population with this allele, so apparently ethnicity also 
matters.86-89 Moreover, the HLA-8*5801 allele is far more prevalent in the Han Chinese. However, 
since up to now only for few drugs a strong genetic association is found, more research is 
needed to clarify yet unknown risk factors and to explore further the pathophysiology of these 
reactions, so that better diagnostic tests and treatment methods can be developed. The high 
sensitivity and specificity of some markers provide a plausible basis for developing screening 
tests to identify individuals at risk for this type of drug hypersensitivity. Taking into account 
the rarity of the disease, further refinement of the pharmacogenetic base depends on future 
international collaborative efforts. 
1.4.10 Management and Therapy 
Early recognition, followed by prompt withdrawal of the culprit drug is the most decisive step to 
avoid disease progression, unnecessary investigations and treatment, thus potentially resulting 
in less morbidity and mortality and restoring health. 
The benefit of an accelerated elimination of the causative drug and other specific 
therapeutic interventions remains to be established since only few studies have focused hereon 
and controlled studies regarding management of DRESS are lacking. Management is aimed at 
(muco)cutaneous as well as systemic care, including close observation and supportive care with 
strict attention to hydration and electrolyte balance, prevention of infection, and, if still needed, 
alternative treatment of the original disease, e.g. epilepsy. Cutaneous symptoms respond well 
to antihistamines and high-potency topical steroids.31  Severe erythroderma or exfoliative 
dermatitis significantly increases the cutaneous blood flow, raising risk for cardiac failure, 
particularly in the elderly or those with prior cardiac impairment. Oral antipyretics and topical 
corticosteroids are helpful to decrease this risk, while for exfoliative dermatitis local antiseptics 
can be added.44 
Systemic corticosteroids can reduce symptoms of delayed hypersensitivity reactions; 
they are known to inhibit for instance the effect of IL-5 on eosinophil accumulation in vivo.90 
Accumulation of eosinophils is believed to attribute to internal organ involvement in DRESS. 
As in other al lergic diseases, preactivation or priming of eosinophils by (proinflammatory) 
cytokines is important in DRESS. Several priming-dependent eosinophil responses, such as 
migration and adhesion, are reduced by treatment with corticosteroids.91 Although the role of 
corticosteroids is still not evidenced in DRESS, systemic corticosteroids are often administered 
in cases with internal organ involvement. 1 1 •22•92 Most clinicians start prednisone at a dose of 
0,5-2 mg/kg per day when signs or symptoms are severe.32 Dramatic improvement in clinical 
symptoms and laboratory abnormalities is usually observed soon after corticosteroid therapy, 
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but its impact on the long term disease course is not known, and internal manifestations seem 
not always to be reversed.3 1 •34•92 Noteworthy, relapses can be observed when corticosteroids 
are tapered and withdrawal of steroid treatment may result in a rapid return of the symptoms 
followed by resolution at readministration.22•92•93 HHV6 (re)activation, potentially promoted by 
systemic steroids could be responsible for these relapses. While waiting for better evidence, 
it is probably wise to recommend systemic steroids only for patients with life-threatening 
visceral manifestations such as interstitial pneumonitis or nephritis. Administration of other 
immunosuppressive agents (e.g. cyclophosphamide, cyclosporine) has also been suggested, 
mainly for patients that are not improving after discontinuation of the offending agent and 
high dose corticosteroid administration.94 To address the state of transient immunosuppression, 
IVIG could have a rationale.95•96 Other treatment options mentioned are interferon and 
N-acetylcystei ne.97 
To prevent recurrences, it is essential to avoid the suspected drug, including cross-reacting 
drugs. Cross-reactions are especially frequent between the older AED, making it difficult to find 
a safe alternative. Because of a potential genetic predisposition, first-degree relatives should be 
informed on a potentially elevated risk for DRESS when using the same or cross reacting drugs.98 
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1 a. DRESS with maculopapular eruption 
on trunk and arms. 
1 b. Detail 1 a. with firm erythematous 
pa pules on the bel ly. 
1 c. DRESS with urticaria I exanthema on 
trunk and arms. 
1 d. Detail of urticaria! exanthema on arm. 
Drug reaction with eosinophilia and systemic symptoms 
■ 
1 e. DRESS with exfoliative presentation on the trunk. 
1 f. Lichenoid presentation on the trunk with detail. 
1 g. DRESS with purpuric presentation. 
1 h. DRESS with an eczematous presentation. 
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2a. Peri-orbital oedema, scaling, and residual 
facial erythema. 
2b. Peri-orbital oedema, scaling, and residual 
facial erythema. 
2c. Facial oedema, scaling, and residual facial 
erythema and pustules. 
3a. Hyperkeratosis with parakeratosis, diffuse 
superficial perivascular and interstitial 
infi ltrates with variable amounts of eosinophils 
(H&E, original magnification 1 Ox1 O). 
3b. Detail 3a of dermal 
infi ltrate showing several 
eosinophils (H&E, original 
magnification 40x 1 0). 
3c. Extensive superficial 
dermal oedema 
and dermal, mainly 
perivascular, mixed 
infiltrates (H&E, original 
magnification Sxl O). 
3d. Detail of dense band­
l ike dermal infiltrate 
containing lymphoid 
cells including large 
cerebriform mononuclear 
cells (some in mitosis), 
many histiocytes, and 
eosinophils H&E, original 
magnification 40xl O). 




1 .5 Aims and outl ine of this thesis 
This thesis addresses challenges in  case definition, diagnosis and treatment of  a number of 
SCAR: SJS/TEN, AGEP, and DRESS. 
Chapter 2 describes the results of treatment with dexamethasone pulse therapy in a series 
of patients with SJS/TEN. Although treatment of SJS/TEN with corticosteroids became highly 
controversial in literature since the mid 80's of the past century, corticosteroids are worldwide 
still regularly administered. 
Chapter 3 focuses on detection of differential diagnostic clues in bullous manifestations in SJS/ 
TEN and (S)LE, and evaluation of the prevalence of (S)LE in a large population based cohort of 
SJS/TEN patients. 
Chapters 4 and 5 are complementary to each other. Chapter 4 describes the spectrum of 
histopathological features in a large, multinational, validated series of patients with AGEP, while 
chapter 5 is aimed at differentiation of AGEP and GPP, based on histopathological features, in a 
single centre series. 
Chapters 6a and 6b are also complementary to each other. Both chapters describe a case of 
AGEP caused by morphine, a drug rarely implicated in cADR and not earlier reported as causative 
agent for AGEP. Moreover, the use of in-vitro and/or in-vivo testing in AGEP is addressed in both 
cases. Of note, the patient in chapter 6b showed features, resembling TEN. 
Chapters 7 and 8 describe two cases of less serious cADR which due to the presence of pustules 
next to bright erythema had AGEP in their differential diagnosis. These cases, in chapter7 with a 
type B reaction and in chapter 8 with a type A reaction, demonstrate that also other conditions 
than SCAR may mimic AGEP. 
Chapters 9 and 1 0  are complementary, and address the issue of the case definition of DRESS. 
This hypersensitivity reaction is a topic in dermatologic literature for over 50 years, under a 
multitude of names and case definitions. In chapter 9 a diagnostic validation score is presented, 
while in chapter 1 0  the features, validated according to this score in a first large multinational 
series, are presented. The proposal for consensus on unification of case definition and criteria 
has met a positive response in literature since its publication. 
In chapter 1 1  the interesting observation is presented that "homing" of drug specific T cells 
in the skin probably also plays a role in cADR. The observation also underlines that clinically 
negative patch tests are no absolute proof of absence of a hypersensitivity reaction. 
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Chapter 2 
Summary 
Mortality in Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) is high. Apart 
from intensive supportive therapy, no generally accepted specific treatment regimen exists. The 
role of corticosteroids in SJS/TEN is controversial. It is possible that high-dose pulse therapy 
with corticosteroids might be an improvement compared to long-term lower dose therapy, 
by combining higher efficacy with a diminished risk both of infection and of delayed wound 
healing. The aim of this study was to evaluate the efficacy of dexamethasone pulse therapy 
with respect to mortality and healing time of patients with SJS/TEN. A small, uncontrolled series 
of consecutive inpatients with SJS/TEN was treated with dexamethasone pulse therapy. The 
efficacy of this treatment was assessed retrospectively using SCORTEN. Twelve patients were 
included over a period of 1 0  years. One patient died, while SCORTEN predicted a fatal outcome 
of 4 patients. Stabilization was reached after 2.3 days on average, total re-epithelialization 
after 1 3.9 days. The results of this study bear no statistical relevance due to the small number 
of patients. In conclusion, short-term dexamethasone pulse therapy, given at an early stage of 
the disease, may contribute to a reduced mortality rate in SJS/TEN without increasing healing 
time. A larger controlled trial is warranted to investigate further the use of dexamethasone pulse 
therapy in SJS/TEN. 
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I ntroduction 
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but serious 
mucocutaneous reactions with extensive epithelial sloughing and systemic symptoms, 
most often caused by drugs.1 More than 100 drugs have been associated with SJS/TEN, most 
often implicated are anti-epileptics, sulphonamides, B-lactam antibiotics, non-steroidal anti­
inflammatory drugs and allopurinol. SJS and TEN are part of a spectrum, which is artificially 
divided into 3 groups: SJS when the total detached and detachable body surface area (TBSA) is 
less then 10%, TEN when it is over 30%, and SJS/TEN-overlap when it is between 10% and 30%.2 
The incidence of SJS is 1.2-6 per million per year and that of TEN 0.4-1.2 per million per year.1 
Mortality rates reported in the literature vary due to differences in the definition of SJS and TEN, 
in populations and in treatment, but they are generally high. In adults mortality due to TEN is 
most often cited as 30-50%.1 •3-5 Sepsis and multi-organ failure are the main causes of death. 
Recovery is usually slow and may take 3-6 weeks.1 As a rule skin lesions heal without scarring, 
whereas mucosa! scarring and strictures are frequent late complications. Late eye complications, 
potentially leading to blindness, occur in up to 50% of cases.6 
Apart from intensive supportive therapy, a generally accepted regimen for specific 
treatment of SJS/TEN is lacking. Treatment options include systemic corticosteroids, intravenous 
immunoglobulin therapy (IVIG), other immunosuppressive therapy, or no systemic treatment. 
Historically high-dose corticosteroids were advocated, but since the mid-1980s the use of 
corticosteroids in SJS/TEN has been controversial and is even considered detrimental by some 
authors.1 ,7-9 
Intravenous (i.v.) pulse therapy with corticosteroids is used in severe, often autoimmune, 
diseases, as it is assumed to share high efficacy with fewer side-effects than long-term lower 
dose corticosteroids. It has been used in dermatology since 1 982 for several dermatological 
diseases that are often refractory to standard therapy, such as pyoderma gangrenosum and 
pemphigus.1 0  Although we demonstrated recently that there was no benefit of giving long-term 
adjuvant oral corticosteroid pulse therapy in addition to conventional treatment in patients 
with pemphigus vulgaris, the hypothesis that i.v. corticosteroid pulse therapy could be useful 
in TEN is still valid, since the pathomechanism of both diseases is different, and corticosteroid 
pulse therapy is applied as short-term monotreatment in TEN.1 1  There are only a few case reports 
describing pulse therapy in TEN.1 2•1 3  Initially, 1000 mg methylprednisolone was usually used, but 
recently dexamethasone has often been chosen for pulse therapy because it combines a strong 
immunosuppressive glucocorticoid with a negligible mineralocorticoid effect. We studied the 





From 1993 to 2003, we treated 12 consecutive patients who were referred to our department 
with SJS/TEN, using a standardized care protocol that did not require ethics review from our 
institution. All data were analysed retrospectively. 
After anamnesis and physical examination, diagnosis was verified by histopathology of direct 
fresh-frozen sections of the skin, enabling quick diagnosis and differentiation from other 
diseases, especially staphylococcal scalded skin syndrome. Diagnosis was subsequently 
confirmed by routine histopathology, while immunofluorescence analysis of the skin and serum 
was performed in order to exclude immuno-bullous diseases. The date of onset of disease was 
determined from the patient's medical history. Assessment of drug culpability (i.e. the empirical 
risk of a drug and the time-relation between drug use and the adverse reaction) was also based 
on the patient's history. All suspected and non-essential drugs were stopped. Demographic and 
specific disease data are presented in Table 1 .  
Table 1 .  Clinical characteristics of patients with toxic epidermal necrolyis (TEN) o r  Stevens­
Johnson syndrome (SJS) 
Pat. Age (years)/ TBSA on TBSA No. of mucosal Diagnosis SCORTEN on 
no. Sex admission max. sites involved admission 
7 1 /M 26 32 5 TEN 4 
2 33/M 45 62 4 TEN 2 
3 44/F 30 72 5 TEN 2 
4 1 5/M 3 9 3 SJS 0 
5 62/F 60 70 3 TEN 3• 
6 70/F 1 8  1 9  3 SJS/TEN 3 
7 78/M 23 41 2 TEN 5• 
8 53/F 53 61  4 TEN 3 
9 58/F 1 1  20 2 SJS/TEN 3b 
1 0  77/M 6 1 9  2 SJS/TEN 3 
1 1  84/F 20 29 2 SJS/TEN 3 
1 2  22/M 25 48 2 TEN 2c 
Mean 55.6 26.7 40.2 3.1 2.8 
• Brain tumour/metastasis. 
h Systemic lupus erythematosus (SLE). 
c Bone marrow transplant for haematological malignancy. 
TBSA, total detached and detachable body surface area in %. 
Specific systemic therapy was started as soon as the diagnosis was established. In the first 4 
patients we combined i.v. dexamethasone 100 mg, given within 30-60 min on 3 consecutive 
days, with one dose of cyclophosphamide 500 mg on the first day, analogous to the pulse for 
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pemphigus vulgaris used by Pasricha.14 After the fourth patient, cyclophosphamide was omitted 
and the regimen changed to i.v. dexamethasone 1.5 mg/kg body-weight as pulse therapy for 3 
consecutive days. 
The patients were seen by a multidisciplinary team and received intensive supportive 
care according to a standard protocol. This included early fluid and electrolyte replacement, 
aggressive nutritional supplementation, and monitoring of vital functions. An ophthalmologist 
was routinely consulted about daily eye care. Meticulous wound care included lubricants, topical 
antibiotics and non-adhesive silicone wound dressings. Nursing was barrier protected and 
the patients were treated on an air-fluidized bed in a specialized humidity- and temperature­
controlled unit with, for aseptic reasons, a laminar down-flow stream. Epidermal involvement 
and TBSA were charted daily to determine the date of arrest of progression and of complete re­
epithelialization (Table 2). Additional investigations, including haemograms, biochemical tests, 
urine analysis, coagulation tests, fluid balance, body weight and bacteriological analysis, were 
performed on a regular basis. The use of lines and catheters was avoided as much as possible, 
Table 2. Suspected drugs and course of the disease (in days) before and after dexamethasone 
pulse therapy (DPT) 
Patient no. Suspected drug Lag Blister DPTto DPTto Blister Remarks 
time• to DPT stabili- healing to 
zation healing 
l b  
Sulphamethoxazole + 
2c 2 72 73 Burn scars, HSY 
trimethoprim 
2b Acetylsalicylic acid < 1 4  3 2 1 5  1 8  
3b Carbamazepine 1 2  2 1 7  1 8  
4b Carbamazepine 1 4  2 2 8 1 0  
5 Phenytoin 36d 6 2 24 30 Late referral, HSY 
6 Allopurinol 5 4 1 1 4  1 8  
7 Phenytoin 37d 1 3 9 1 0  
8 Carbamazepine 1 7  2 2 1 7  1 9  
9 Omeprazole 29d 4 3 1 4  1 8  
1 0  Amoxicillin + clavulanic acid 4 3 5 1 4  1 7  
1 1  Terbinafine 1 9  2 1 2  1 4  
1 2  
Sulphamethoxazole + 
trimethoprim 
1 0  4 3 9 1 3  
Mean 1 -1 2  2.8 2.3 1 8.8 2 1 .5 Overall 
Mean 2-1 2  2.9 2.4 1 3.9 1 6.8 Excluding case 1 
• Lag time: time between first drug administration and first blister. 
b Also received cyclophosphamide 500 mg on day 1 .  
c Eight years earlier: toxic epidermal necrolysis after sulphamethoxazole + trimethoprim. 
d Chronic corticosteroid use: daily dose equivalent to 1 5-30 mg prednisolone. 




and the venous line was maintained as short as possible. H2-blocking agents were administered 
in case of a history of gastric upset. To prevent intestinal Candida overgrowth we supplied oral 
nystatin, and for thrombosis prophylaxis nadroparin was given subcutaneously. Pain killers and 
sedatives were provided as needed. Antibiotic prophylaxis was not given, but antibiotics were 
supplied immediately when clinically warranted. After discharge, a follow-up of 8±2 weeks was 
performed, and in cases where late sequelae were observed, also 2 years later. 
SCORTEN, a validated TEN-specific severity-of-illness-score, ranking severity and predicting 
mortality, was calculated retrospectively to assess the efficacy of DPT. SCORTEN is based on 
seven independent risk factors (age, heart rate, malignancy, TBSA, and serum urea, bicarbonate 
and glucose levels). The predicted mortality progressively depends on the number of factors 
present.15 
Results 
Twelve consecutive patients (6 males, 6 females) were treated. Their mean age was 55.6 years 
(age range 15-84 years). TBSA and characteristic cutaneous findings led to the classification of 
1 SJS, 4 SJS/TEN-overlap and 7 TEN. In all patients, 2 or more mucosae were affected. The mean 
SCORTEN on admission was 2.8 (range 0-5) and predicted a mortality of 4 cases (25%). The mean 
delay between occurrence of first blister and first DPT was 2 .8 days (range 1-6 days). Disease 
stabilization was achieved after a mean of 2 .3 days (range 1-5 days) after DPT. The mean time of 
healing (not stabilization) was strongly influenced by patient 1, who had extensive pre-existing 
burn scars. When we exclude these data, healing time from first DPT was 13.9 days (range 8-24 
days), while from first blister it was 16.8 days (range 10-30 days). 
Patient 7 died; according to the consulting neurologist the cause of death was brain oedema 
due to metastasis, while his skin had practically healed. All other patients survived without major 
sequelae. Sepsis was found in patients 1 and 2, and suspected in patient 5. In addition, patients 
1 and 5 had serologically proven herpes simplex virus (HSV) type 1 infection while leukopaenia 
was present, probably contributing to protracted healing. In patient 1 neutropaenia (0.04x103/ 
µI) accompanied severe leukopaenia (0.4x103/µI). In patients 2 and 3 the respiratory tract was 
involved, leading to respiratory insufficiency; patient 3 needed mechanical ventilation .  Though 
all patients experienced eye involvement in the acute phase, late sequelae were relatively mild 
and severe impaired vision was not encountered. Patients 2 and 8 developed mild trichiasis, while 
patients 2 and 12 were left with dry eyes. Five patients (nos 2, 3, 4, 8 and 12) experienced hyper­
and/or hypo-pigmentation of the skin, most often transient. Hypohidrosis and dystrophic nails 
were observed in patient 8. Apart from slight transient glycaemia in some patients that might 
have been caused by dexamethasone, we did not observe any side-effects of dexamethasone. 
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Discussion 
The pathophysiology of SJS/TEN is not yet fully elucidated, although significant progress 
has been made. Massive accelerated apoptosis has been proposed as the main mechanism 
underlying keratinocytic death in SJS/TEN. Several pathways can lead to apoptosis. COB­
positive T cells and macrophages play an important role in the extensive epithelial necrosis and 
subepithelial detachment.16 Various (pro)inflammatory cytokines including tumour necrosis 
factor (TNF)-a may contribute to epidermal cell death, as well as to fever and malaise. It has 
been suggested that, in SJS/TEN, apoptosis is mediated principally through activation of the 
Fas receptor by increased Fas ligand expression, but others have suggested that it is mediated 
mainly by TNF-a, perforin and granzyme B. lnterferon-y up-regulation of keratinocytes also 
plays a role. 17•1 9 
In SJS/TEN the barrier function of the skin is lost due to full-thickness epithelial necrosis. 
Hence, disturbance of fluid, protein, and electrolyte balance leading to hypovolaemic shock and 
local and systemic infection with the threatening of sepsis, often leading to multi-organ failure, 
are the most important causes of death. The main point in dealing with SJS/TEN patients is to 
restore the barrier function of the skin and mucosae as quickly as possible and in the meantime 
prevent the effects of this barrier loss. 
Knowledge of the treatment of SJS/TEN rests greatly on anecdotal observations, empirical 
experience and retrospective studies. Apart from direct withdrawal of the culprit drug and 
supportive care, there are no generally accepted guidelines for the specific treatment of SJS/ 
TEN, and few controlled clinical trials have been performed due to the rarity and severity of 
the disease.5•1 9  Several specific treatment options have been proposed on theoretical grounds. 
Some with promising results and others, e.g. thalidomide, with increased mortality, possibly due 
to paradoxically enhanced TNF-a production.4•1 9 The supposed rationale for IVIG is its capacity 
to inhibit activation of the death receptor by Fas-blocking antibodies, but its clinical results 
were contradictory.3•5•1 7•20•21 The use of corticosteroids in SJS/TEN is controversial.7-10•22•23 The 
precise action of corticosteroids in inflammatory diseases is still not well understood. They have 
pleomorphic immune-modulating effects, e.g. through inhibition of numerous cytokines.1 0 
Nowadays the use of corticosteroids in SJS/TEN is generally not advocated because of the 
possibility of delayed healing and the risk of infection.7•9•23 However, this opinion is based on only 
a few case series. Moreover, some cases in which it was stated that a better outcome was related 
to avoidance of corticosteroids had in fact taken corticosteroids for a mean of 3.5 days prior 
to referral. The general negative opinion of corticosteroids is probably because they are often 
given too late, in too low a dose, and for too long during the process. During the healing phase 
corticosteroids may indeed impair wound healing and promote sepsis. However, short courses 
of high-dose corticosteroids in early SJS/TEN have a good rationale, as immune mechanisms are 
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directly responsible for the cascade of events leading to apoptosis. Hence, we challenged the 
general opinion of corticosteroids being detrimental in the treatment of SJSffEN. 
Dexamethasone is a potent glucocorticoid (about 7 times as potent as the same dose of 
prednisolone) with a continuous action level, due to its relative long biological half-life (36-54 
h). It has pleomorphic effects on the immune system and may inhibit epidermal apoptosis by 
several mechanisms: inhibition of T-cell activated apoptosis by suppression of various cytokines 
such as TNF-a; inhibition of interferon-y induced apoptosis; and inhibition of Fas-mediated 
keratinocyte apoptosis.10•24 
We gave DPT 1.5 mg/kg i.v. in 30-60 min on 3 consecutive days, thus avoiding long-term use 
of corticosteroids. Cyclophosphamide, added in the pemphigus regimen to prevent relapses, 
was omitted after patient 4 (see table 2), as relapses are not to be expected after withdrawal of 
the culprit drug. We saw no significant change in outcome and healing time. 
Patients 5 and 7 had metastatic brain tumours, and patient 9 had systemic lupus 
erythematosus, for which they chronically received corticosteroids. These patients developed the 
SJSffEN reaction after a longer lag time (time between first drug administration and first blister). 
This phenomenon has been described previously;22 however, in patients 5 and 7 it might also be 
attributed to the culprit drug phenytoin, known for its potentially long lag time. Leukopaenia, 
regularly encountered in TEN, occurred in patients 5 and 1, in the latter neutropaenia was also 
present. Both patients experienced sepsis and HSV infection, probably attributing to delayed 
wound healing. 
The efficacy of DPT was evaluated according to arrest of further epidermal or mucosa! 
detachment, healing time in days, outcome and sequelae. The patients stabilized after an 
average of 2.3 days, while total re-epithelialization was reached after 13.9 days. Despite SCORTEN 
predicting a mortality of 4 patients, only one died. Serious late sequelae of the mucosae, 
especially of the eyes were not found. 
Comparison with published results is difficult. Most records of therapeutic trials in TEN 
are case series without controls. We calculated SCORTEN as validated predictive score for the 
outcome in SJSffEN. 
In a large, multi-centre, epidemiological study the average period for stabilization was 4 days 
for SJS and 5.8 days for TEN. Healing was almost complete 20-30 days after hospitalization.25 
In another study, therapy with IVIG was started 4.1 days after the start of the disease and 
healing was complete 18 days after admission. SCORTEN predicted 8.2 deaths, while 11 actually 
occurred.3 The authors concluded IVIG could not be recommended as a standard treatment 
for SJSffEN. On the other hand, several IVIG studies mention surprisingly short periods of 
stabilization and/or healing.20·21 In interpreting these results, one should also consider the time­
lapse before treatment is started, as without treatment the period of progression may last 7-1 0  
days.19•25 Starting treatment late in the process implies that it is difficult to measure the effect of 
treatment on stabilization. Since we started quite early, we believe from our data that DPT did 
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result in a relatively quick stabilization and healing and suggest that DPT may even have halted 
the process of apoptosis. 
Although the results of this study bear no statistical relevance due to the small number of 
patients, we conclude that short-term DPT, given at an early stage of the disease, may contribute 
to a reduced mortality rate in SJS/TEN without increasing healing time. A larger controlled trial 
is warranted in order to investigate further the use of DPT in SJS/TEN. 
References 








Roujeau JC, Stern RS. Severe cutaneous 9. Chave TA, Mortimer NJ, Sladden MJ, et al. 
adverse reactions to drugs. N Engl J Med 1 994; 
331 :  1 272-85. 
Bastuji-Garin S, Rzany B, Stern RS, et al. 
A clinical classification of cases of toxic 
epidermal necrolysis, Stevens-Johnson 
syndrome and erythema multiforme. Arch 
Dermato/ 1 993; 1 29: 92-6. 
Bachot N, Revuz J, Roujeau JC. Intravenous 
immunoglobul in treatment for Stevens­
Johnson syndrome and toxic epidermal 
necrolysis: a prospective noncomparative 
study showing no benefit on mortality or 
progression. Arch Dermatol 2003; 1 39: 33-6. 
Arevalo JM, Lorente JA, Gonzales-Herrada 
C, Jimenez-Reyes J. Treatment of toxic 
Toxic epidermal necrolysis: current evidence, 
practical management and future directions. 
Br J Dermatol 2005; 1 53: 241 -53. 
1 0. Nesbitt LT. Minimizing complications 
from systemic glucocorticosteroid use. 
Dermato/ogic Clinics 1 995; 1 3: 925-39. 
1 1 .  Mentink LF, Mackenzie MW, Toth GG, et al. 
Randomized control trial of adjuvant ora l  
dexamethasone pulse therapy in pemphigus 
vulgaris. Arch Dermato/ 2006; 1 42: 570-6. 
1 2. Sherertz EF, Jegasothy BY, Lazarus GS. 
Phenytoin hypersensitivity reaction 
presenting with toxic epidermal necrolysis 
and severe hepatitis. J Am Acad Dermatol 
1 985; 1 2: 1 78-81 . 
epidermal necrolysis with cyclosporin A. J 1 3. Barman KO, Verma KK, Agrawal S, et al. 
Trauma, Injury, Infection and Critical Care 2000; Stevens-Johnson syndrome with idiopathic 
48: 473-8. thrombocytopenic purpura treated with 
Brown KM, Silver GM, Halerz M, et al. Toxic 
epidermal necrolysis: does immunoglobulin 
make a difference? J Burn Care Rehabil 2004; 
25: 81 -8. 
Oplatek A. Brown K, Sen S, et al. Long-term 
follow-up of patients treated for toxic 
epidermal necrolysis. J Burn Care Res 2006; 27: 
26-33. 
Halebian PH, Corder VJ, Madden MR, et a/. 
Improved burn center survival of patients 
with toxic epidermal necrolysis managed 
without corticosteroids. Ann Surg 1 986; 204: 
5 1 2-3. 
Fine JD. Management of acquired bul lous 
skin diseases {correspondence). N Engl J Med 
1 996; 334: 864-5. 
dexamethasone pulse therapy. J Dermatol 
2003; 30: 54-8. 
1 4. Pasricha JS, Das 55. Curative effect of 
dexamethasone-cyclophosphamide pulse 
therapy for the treatment of pemphigus 
vulgaris. /nt J Dermatol 1 992; 3 1 :  875-7. 
1 5. Bastuji-Garin 5, Fouchard N, Bertocchi M, et 
al. SCORTEN: a severity-of-il lness score for 
toxic epidermal necrolysis. J Invest Dermatol 
2000; 1 1 5: 1 49-53. 
1 6. Friedman PS, Strickland CK, Pirmohamed 
M, Park BK. Investigation of mechanisms 
in toxic epidermal necrolysis induced by 




1 7. Viard I, Wehrli P, Bul lani R, et al. Inhibition using SCORTEN: The University of Miami 
of toxic epidermal necrolysis by blockade experience. Arch Dermatol 2003; 1 39: 39-43. 
of CD95 with human intravenous 22. Guibal F, Bastuji-Garin S, Chosidow 0, 
immunoglobulin. Science 1 998; 282: 490-3. et al. Characteristics of toxic epidermal 
1 8. Nassif A, Bensussan A, Dorothee G, et al. Drug necrolysis in patients undergoing long-term 
specific cytotoxic T-cel ls in the skin lesions of glucocorticoid therapy. Arch Dermatol 1 995; 
a patient with toxic epidermal necrolysis. J 1 31 :  669-72. 
Invest Dermatol 2002; 1 1 8: 728-33. 23. Rasmussen JE. Update on the Stevens-
1 9. Wolkenstein P, Latarjet J, Roujeau JC, et al. Johnson syndrome. Cleve Clin J Med 1 988; 55: 
Randomised comparison of thalidomide 41 2-4. 
versus placebo in toxic epidermal necrolysis. 24. Trautmann A, Akdis M, Schmid-Grendelmeier 
Lancet 1 998; 352: 1 586-9. P, et al. Targeting keratinocyte apoptosis 
20. Prins C, Kerdel FA, Padi l la RS. Treatment of in the treatment of atopic dermatitis and 
toxic epidermal necrolysis with high-dose al lergic contact dermatitis. J Allergy Clin 
intravenous immunoglobulins: multicenter lmmunol 200 1 ;  1 08: 839-46. 
retrospective analysis of 48 cases. Arch 25. Roujeau JC. Treatment of SJS and TEN. In: 
Dermatol 2003; 1 39: 26-32. Kauppinen K, Alanko K, Hannuksela M, 
21 . Trent JT, Kirsner RS, Romanelli P, Kerdel FA. Maibach H, editors. Skin reactions to drugs, 
Analysis of intravenous immunoglobulin for 1 st edn. Boca Raton: CRC Press, 1 998: p. 




Stevens-Johnson syndrome and toxic 
epidermal necrolysis in patients with 
lupus erythematosus: 
A descriptive study of 1 7  cases from a 
national registry and a review of the 
literature. 
Ziemer M 1 *, Kardaun  SH2*, Liss Y3, 
Mocken haupt M3 • 
* corresponding authors SHK or MZ, 
both contributed equally to this study 
1 University Hospital Leipzig, Germany; 
2University Medical Center Groningen, University of Groningen, The Netherlands; 
3Ookumentationzentrum schwerer Hautreaktionen (dZh), University Medical 
Center Freiburg, Germany 
British Journal of Dermatology 20 1 2; 1 66: 575-600. 
Chapter 3 
Summary 
Background: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe 
cutaneous adverse reactions with high morbidity and mortality. Some expressions of lupus 
erythematosus (LE) may cause enormous difficulties in differentiating them from SJS and TEN 
by showing large areas of sheet-like epidermal necrosis. 
Objective: To evaluate clinically and histopathologically probable or definite cases of SJSffEN 
with a history of systemic or other LE [(S)LE]. 
Methods: This was a retrospective analysis of validated cases of SJSffEN with a history of (S)LE, 
based on a large population-based national registry. 
Results: Among 1366 patients with SJSffEN, 17 with a sufficiently documented history of (5) 
LE and representative histological material could be identified, suggesting a considerable 
over-representation of LE in patients with SJSffEN. Eight of these showed clinically and/or 
histopathologically some LE-characteristic features interfering with the diagnosis of SJSffEN. 
Differentiation could be elaborated on clinical and histopathological grounds: four  patients were 
classified as SJSffEN with a preceding (S)LE exacerbation and/or LE-typical histopathological 
features, and four as 'TEN-like' (S)LE. 
Conclusion: Most patients with SJS/TEN and a history of (S)LE demonstrate clinical and 
histopathological properties allowing clear differentiation. However, occasionally acute 
cutaneous manifestations of (S)LE and SJSffEN can be phenotypically similar, caused by 
extensive epidermal necrosis. Although no feature by itself is conclusive, a combination of 
recent (S)LE exacerbation, evident photodistribution, annular lesions and absent or only mild 
focal erosive mucosa! involvement may favour LE over SJS/TEN clinically. Histopathologically, 
in particular, junctional vacuolar alteration, and the presence of solitary necrotic keratinocytes 
at lower epidermal levels, combined with moderate to dense periadnexal and perivascular 
lymphocytic infiltrates with a variable presence of melanophages, and mucin point to a LE­
related origin. 
1 04 
Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with lupus erythematosus 
Introduction 
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe cutaneous 
adverse reactions (SCAR), mainly caused by drugs but also related to infections and unidentified 
causes. They are characterized by an acute onset of erythema with detachment of the 
epidermis and epithelia of mucous membranes resulting in extensive areas of denuded skin.1 -2 
Classification of SJS/TEN is based on three clinical criteria: the pattern of individual skin lesions, 
their distribution and the maximum extent of epidermal detachment.1 Atypical target lesions 
and/or erythematous or purpuric macules are present. Detachment of < 10% of the body 
surface area (BSA) is defined as SJS, 1 0-30% as SJS/TEN-overlap and > 30% as TEN.1 •2 SJS and TEN 
are considered to be severity variants of the same disease entity with SJS being the milder and 
TEN the most severe form.3 In contrast, erythema multiforme with mucosa! involvement, also 
called erythema multiforme majus (EEMM), which for a long time has been considered to be SJS, 
presents with typical target lesions mainly on the limbs. Both entities can be separated in more 
than 90% of the cases.4•5 The mean age for SJS/TEN ranges between 48·2 and 53·4 years (range 
1-98), and both sexes are affected in almost equal distribution but with a female preponderance 
in SJS/TEN-overlap.2•5 SJS/TEN is rare, with one to two cases per million inhabitants per year, and 
causes high mortality, exceeding 40% for TEN, and, frequently, long-lasting disability.2•6 
Histopathologically, the common pattern of SJS/TEN and EEMM is that of erythema 
multiforme. Early lesions show mostly sparse superficial perivascular and interstitial lymphocytic 
infiltrates, some lymphocytes at the dermoepidermal junction (DEJ), and necrotic keratinocytes 
(etymologically more correctly keratocytes) scattered throughout the lower epidermis and, 
sometimes, the upper part of the infundibular epidermis and eccrine ducts. Additionally, in 
fully developed lesions, subepidermal vesiculation appears secondary to extensive necrotic 
keratinocytes, resulting in confluent epidermal necrosis. The cornified layer retains its basket­
weave pattern.7•8 
By contrast, lupus erythematosus (LE) is a common autoimmune disease.9•1 0 Diagnosis relies 
on clinical, histopathological and serological criteria. Cutaneous and systemic manifestations of 
LE are different clinical expressions of the same underlying autoimmune process.9 Cutaneous 
manifestations in LE are very heterogeneous, varying from disco id atrophic erythematosquamous 
plaques to generalized maculopapular erythematous rashes.1 1  Symptom-based diagnostic 
classification divides LE into cutaneous-limited LE, intermediate LE and systemic LE (SLE). 
Morphological classification of specific cutaneous manifestations distinguishes acute cutaneous 
LE (ACLE), subacute cutaneous LE (SCLE) and chronic cutaneous LE (CCLE), with subtypes.1 2 
The incidence of SLE among populations of European descent strongly varies from 1 ·8 to 7-6 
cases per 100 000 persons per year, while the prevalence varies from 17 to 48 per 100 000.1 3•14 
In further studies, incidence rates for male and female subjects were calculated to be 3.7 and 
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45·4 cases per 100 000 per year, respectively.1 5The highest incidence is mentioned for women of 
child-bearing age. Cutaneous variants of LE are two to three times more frequent than SLE.1 0  
Cutaneous manifestations of SLE or other LE [(S)LE] demonstrate a broad histopathological 
spectrum.11 •1 6  Early findings include sparse superficial perivascular lymphocytic infiltrates, 
neutrophils and sometimes nuclear dust immediately beneath the DEJ. Few individual 
apoptotic keratinocytes, focal vacuolar alteration of basal cells and extracellular mucin 
deposition in the reticu lar dermis may be found. Fully developed lesions show moderately 
dense perivascular and periappendageal lymphocytic infiltrates in the papillary and reticular 
dermis, and abundant mucin deposits in the latter. There is focal or continuous epidermal 
thinning, smudged appearance of the DEJ with vacuolar degeneration of basal cells, individual 
necrotic keratinocytes and a thickened basement membrane zone (BMZ). Moreover, compact 
orthokeratosis, follicular horny plugs and melanophages in the upper dermis may be found. In 
late lesions, inflammatory cell infiltrates subside and there is follicular and epidermal atrophy 
with loss of rete ridges, vacuolar alteration of basal cells, marked thickening of the BMZ and 
mild interface dermatitis.7 However, SCLE is characterized by rather cell poor infiltrates, without 
follicular plugging and severe epidermal atrophy. Furthermore, hyperkeratosis, BMZ thickening 
and pigmentary incontinence are less pronounced. 
Some clinical expressions of LE may cause extreme difficulties in differentiation from SJS/ 
TEN. Large areas of sheet-like epidermal cleavage may develop, resulting in TEN-like changes 
in both cutaneous-limited LE and SLE. Overlap of clinical and histopathological findings in SJS/ 
TEN and vesiculobullous LE manifestations have led to the assumption of 'TEN-like LE' or 'LE­
associated TEN'.17-24 
This is the first clinical and histopathological evaluation of probable or definite cases of SJS/ 
TEN with a history of (S)LE conducted in a nation-wide, population-based registry. 
Patients and methods 
German registry of severe skin reactions 
For this analysis, cases of SJS/TEN, ascertained and validated by the German registry were 
used. Cases are actively detected in a network of approximately 1700 hospitals including all 
departments of dermatology and paediatrics, burn units, and departments of internal medicine 
with intensive care facilities in Germany. Each patient meeting inclusion criteria for potential 
SJS/TEN is seen by a physician investigator of the registry centre, and interviewed using a 
standardized disease-specific questionnaire. The interview contains questions regarding 
demographics, current illness, morphological and biological data, recent and past medical 
history including (S)LE and other autoimmune diseases, prior infections, use of medication 
including indication, and earlier adverse drug reactions. A dermatological expert committee 
reviews all cases, following a structured scoring system, using clinical data, photographs, 
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distribution drawings and histopathological reports/photographs, but blinded for drug 
exposure and other risk factors. Based on the consensus definition published by Bastuji-Garin 
et al. in 1993, cases are classified as 'definite: 'probable' or 'possible' SJS/TEN or are excluded.1 In 
a minority of about 7-8%, a definite differentiation between SJS and EEMM is not possible.2.4.5 
As patients with SJS/TEN require hospitalization, only very few patients should be missed. Thus, 
the registry is considered to be exhaustive for detection of SJS/TEN in Germany.25 Since 2003 all 
cases of the German registry are included in the RegiSCAR-project (an international registry of 
SCAR and collection of biological samples) which is coordinated by the German registry (this 
concerns cases 13 , 14, 15, 16 and 17 which correspond to the RegiSCAR-interview numbers 
9150175, 9160189, 9160252, 9170392 and 9160264, respectively).25 
Selection of cases with lupus erythematosus among registry cases of 
Stevens-Johnson syndrome/toxic epidermal necrolysis and retrieval 
of additional data 
All consecutive cases from 1990 to 2006 validated as probable or definite SJS/TEN with an 
affirmative answer to SLE in their history were selected. In addition, the database was searched 
for any mention of (S)LE in the free text. To substantiate the diagnosis of (S)LE, the treating 
physician was asked for additional documents, including discharge letters, hospital charts, 
laboratory results including histopathology and immunofluorescence, and other information 
from the general practitioner and from specialists. Patients with cutaneous LE or fulfilling 
the criteria of the American College of Rheumatology (ACR) for SLE were selected for further 
histopathological evaluation. 
Clinical investigation 
General, clinical and histopathological data on SJS/TEN were collected prospectively for case 
validation, whereas details for substantiation of (S)LE were gathered retrospectively for this study 
including the request for skin biopsy material. Clinical characteristics at the event included age, 
sex, duration and type of LE, substantiation of LE diagnosis, immunosuppressive therapy before 
the event, pre-existing (muco)cutaneous lesions, (muco)cutaneous involvement at the time of 
the event, and outcome. Skin and mucous membrane involvement as well as photodistribution 
were evaluated on clinical photographs and distribution drawings. In a second and independent 
step, the index-day, i.e. onset of the reaction, which is usually the appearance of first cutaneous 
or mucosa! symptoms, sometimes fever and malaise 1 day before, is determined for each 
validated case. Drug causality was evaluated based on an algorithm including relevant exposure 
time before the index-day, potential earlier reactions to the drug, potential alternative causes 




For all selected cases, relevant slides or paraffin blocks were requested from the treating 
departments; cases without an informative biopsy were excluded. Haematoxylin and eosin 
sections, including recuts, were independently examined by two of the authors (M.Z. and 
S.H.K.), using a predetermined panel of histopathological criteria considered diagnostic for LE 
and SJS/TEN (Table 1 ). In case of discordant results, consensus was reached after discussion. 
Histopathological changes were interpreted as suggestive for LE if at least four LE-characteristic 
features were observed. Histopathological features were compared against history and clinical 
information at the time of the event, including clinical photographs and drawings, and course 
of the disease. 
Table 1. H istopathological features, typical for lupus erythematosus (LE) and Stevens­
Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) 
Epidermal changes LE-typical: ortho-/hyperkeratosis, intrafollicular hyperkeratosis, atrophic 
epidermis, solitary necrotic keratinocytes in the lower epidermal layers 
SJSffEN-typical: multiple necrotic keratinocytes within the entire 
epidermis 
Changes at the dermoepidermal LE-typical: presence of vacuolar degeneration, thickened basement 
junction 
Dermal changes, including 
characteristics of the 
inflammatory infiltrate 
membrane zone 
SJSffEN-typical: necrotic keratinocytes dominate the junctional changes, 
vacuolar changes being absent or present only sparsely 
LE-typical: moderate or dense, superficial and deep lymphocytic 
infiltrate, presence of melanophages, plasma cells or mucin 
SJSffEN-typical: sparse, superficial lymphocytic infiltrate 
Involvement of adnexa LE-typical: periadnexal lymphocytic infiltrates, basal vacuolar 
(hair follicles and sweat glands) degeneration at infundibula and solitary necrotic keratinocytes 
Statistical analysis 
SJSffEN-typical: solitary or multiple necrotic keratinocytes possible, 
however without considerable inflammatory infiltrate 
Statistical analysis was done on a descriptive and analytical basis. Data were analysed using MS 
Excel Data Analysis. 
108 
Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with lupus erythematosus 
Literature research of Stevens-Johnson syndrome/toxic epidermal 
necrolysis (TEN) in patients with lupus erythematosus (LE) 
and TEN-like LE 
To allocate reports of a possible combination of (S)LE and SJS/fEN, a Medline search was 
conducted, finalized in November 2009, using combinations of the preferred terms of lupus, 
lupus erythematosus, SLE, or LE on one hand and Stevens-Johnson syndrome, SJS, toxic 
epidermal necrolysis, TEN or Lyell on the other hand. Two reviewers (M.Z., S.H.K.) independently 
screened all the articles on title/abstract. The reference lists of these articles were screened for 
additional studies. Final selection was based on assessment of the full text of the article with a 
sufficient description of both (S)LE and SJS/fEN. Data extraction was independently performed 




Among a total of 2590 cases, 1366 had been validated as definite or probable SJS/TEN, 27 of 
which had a history of (S)LE. Because of insufficiently documented LE diagnosis, six cases were 
excluded. Out of the remaining 21 cases, representative histopathological slides or sufficient 
paraffin material were provided for 17 patients: one EEMM/SJS, seven SJS, six SJS/fEN-overlap 
and three TEN. 
Clinical characteristics 
The clinical characteristics of these 17 patients are summarized in Table 2. All cases are 
represented by patients of European descent. The average age was 49·2 years (range 22-
80 years); two patients were male (12%) and 15 female (88%). Mortality rate was 35% (six of 17). 
SLE was concomitantly present in 13 patients, two had cutaneous-limited LE, one SCLE and, in 
one, diagnosis of either cutaneous-limited LE or SLE was not clarified. Median duration of (5) 
LE before occurrence of SJS/fEN was approximately 3 years (varying between several weeks 
and 20 years). In one patient, duration was not mentioned and, in a further patient, SLE was 
diagnosed concomitantly with SJS. Positive anti-Ro or anti-La antibodies were mentioned in six 
of 17 cases. Thirteen patients were on significant systemic immunosuppressive therapy prior 
to their diagnosis of SJS/fEN (76%); the majority of these (10/13; 77%) used a combination of 
systemic glucocorticosteroids and another immunosuppressive drug such as azathioprine, 
cyclophosphamide, leflunomide and chloroquine. The median time from the index-day to the 




an exacerbation of LE prior to the event, five showed lesions compatible with LE, four of these 
evidently with photodistribution (Fig. 1 a-c; case 6). Drugs potentially causal for SJS/TEN could 
be identified in 15 of 17 patients (88%), one drug in five cases, two in eight and three in two 
cases. 
Figure 1 .  Case 6. A female patient with 'Stevens-Johnson syndrome/toxic epidermal necrolysis-like' systemic 
lupus erythematosus. (a) Extensive erythema with large areas of erosion, erosive cheilitis and accentuation 
on sun-exposed skin. (b) Complete epidermolysis with only residual intact epithelium of acrosyringia; 
moderate, superficial and mid-dermal, perivascular and periadnexal lymphocytic infiltrates [haematoxylin 
and eosin (H&E); original magnification x 40]. (c) Vacuolar alteration at the dermoepidermal junction 
of a sebaceous gland with solitary necrotic keratinocytes associated with lymphocytes (H&E; original 
magnification x 200). 
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Table 2. Clinical characteristics of re-evaluated cases 
No. Age Diagnosis/ Duration LE criteria cllnlcally LE characteristic lmmunosup- Skin lesions Time Skin LE typical Involve- Involve- outcome Potential cause (1) :::, 
(years)/ event and type and previous changes laboratory values presslve before event perlodb Involve- photo- mentof mentof ofSJS/TEN VI � 
sex of LE therapy before ment dlstrlbu- palms, mucous 0 
event• tlon soles membranes ::T :::, 
VI 
45/F 01 /94 01 /92 SCLE 08/93 skin lesions after sun ANA 1 : 320, ANA Yes (p, c) No 7 Atypical No Soles Oral Discharge Multiple medlca- 0 
:::J 
definite SJS 1 995 SLE exposure, 1 1/93 LE exacer- (Hep2) quantitative targets flat, tion use;' VI 
bation, suspected autoan- speckled 1 : 1 280, spots wide- possible doxy- '< :::, 
tibody haemolysis and anti-Sm positive, C4 spread cycline, ciprof- a. 
thrombopenia, suspected decreased, DIF: no loxacin a 
vasculitis; 1995 autopsy, lupus band 3 
(1) 
vasculitis due to LE with Q) 
pancreas, renal and central :::J a. 
nervous system involvement ..+ 
0 
2 76/F 01 /93 1 992 SLE LE-associated autoimmune 1 992 ANA 1 :  1 60, Yes (p) No 2 Erythema No Oral, eyes Discharge 5 different >< ri' 
probable TEN on hepatitis SMA 1 :  1 60 with large long-term drugs, (1) 
large erythema epidermal none could be -0 
0..: sheets identified as the (1) 
culprit 3 
23/F 04/96 1 987 SLE Photosensitivity, 1 986/87 1 996 ANA 1 : 2560, Yes (p,c) No 3 Spots No Palms, soles Lips, eyes Discharge Multiple medica- � 
probable SJS recurrent fever, 1987 skin anti-dsDNA widespread tion use; pos- :::J 
(1) 
lesions and polyarthritis, 1 36·7 kU L 1, sible imipenem, r'\ 
skin biopsy vasculitis, later leucopenia tramadole a '< increasing skin lesions with VI 
scarring and contractures, vi' 
1 996 cerebral vasculitis with 5· 
hemiparesis, pleurisy, peri- -0 Q) 




4d 52/F 07/01 02/2001 Photosensitivity, annular 2001 ANA 1 :  1 280, Yes (d) -5 months prior 1 0  Spots No Oral Death Possible � 
definite SCLE/SLE scaling skin lesions since SS-NRo-52, SS-A/ event increasing widespread, valaciclovir, ;::..· 
SJS/TEN 02/2001 mainly on sun- Ro-60 and SS-B/ red macules, patchy herpes labialls ::, c exposed areas, long-lasting La positive, C4 first blistering -0 
liver function disturbances decreased, anaemia, -6 weeks prior C 
VI 
leucopenia to event (1) 
Sd 36/F 1 0/99 1 994 SLE N.m.; at time of the event N.m. No No 4 Atypical tar- No Palms, soles Lips, oral, Discharge Probable co- � 
definite SJS only mentioned 'no com- gets raised, trimoxazole, ::, eyes (1) 
plaints concerning previ- atypical possible 3 
ously diagnosed LE' targets flat amoxicillin 0J ..+ 
widespread 0 ... VI ... C VI 
L E  c h a r a c t e r i s t i c  S k i n  l es i o n s  S k i n  L E  t y p i c a l  I n v o l v e -
I n v o l ve - O u t c o m e  
P o t e n t i a l  c a u s e  
n  
...  
N o . A g e  D i a g n o s i s /  D u r a t i o n  L E  c r i t e r i a  c l i n i c a l l y  
l m m u n o s u p - T i m e  
( y e a r s ) /  e v e n t  a n d  t y p e  a n d  p r e v i o u s  c h a n g e s  l a b o r a t o r y  v a l u e s  
p r e s s i v e  
b e f o r e  e v e n t  p e r i o d "  I n v o l v e -
p h o t o - m e n t o f  m e n t o f  
o f  S J S /T E N  
s e x  
o f  L E  
t h e r a p y  b e fo r e  
m e n t  d l s t r l b u - p a l m s ,  
m u c o u s  
e v e n t '  t l o n  




3 1 / F  0 6 / 0 0  
1 9 9 6 S L E  P o l y s e r o s i t i s ,  h a e m a t o l o g i -
2 0 0 0  A N A  1  :  1 2 8 0 ,  Y e s  ( p ,  a )  O v e r  - 6  w e e k s  1 1  S p o t s  F a c e ,  
L o c a l i z e d  L i p s . o r a l ,  
D i s c h a r g e  P o s s i b l e  r o f e -
d e fi n i t e  c a l ,  c a r d i a c  i n v o l v e m e n t ;  1 2  
a n t i - R o  1 4 1 2 · 7  
p r i o r  t o  e v e n t  w i d e s p r e a d ,  d e c o l l e t e ,  b u l l a  s o l e  
a n a l  
c o x i b ,  d i c l o f e n a c  
S J S / T E N  c y c l o p h o s p h a m i d e  c o u r s e s  
p o s i t i v e ,  a n t i - L a  1  S 4 · 6  d e v e l o p m e n t  o f  e r o s i o n s  i n  u p p e r  
1 9 9 7 / 9 8  
b o r d e r l i n e ;  a n t i h i s - e r y t h e m a  f a c e ,  p h o t o d i s t r i - b a c k ,  e x -
t o n e  4 2 - S  p o s i t i v e ;  
d e c o l l e t e  a n d  b u t i o n  t e n s o r  s i t e  
a n t i - d s D N A  p o s i t i v e ;  u p p e r  a r m s  a f t e r  o f  a r m s  
a n a e m i a ,  l e u c o p e n i a ,  s u n  e x p o s u r e  
C 3  d e c r e a s e d ;  D I F :  
fi b r i n  b a n d - l i k e ,  C 3  
g r a n u l a r  a t  b l i s t e r  
fl o o r  
7  3 1 / F  0 6 / 9 7  1 9 8 8  S L E  1 9 8 8  d e e p  v e n o u s  l e g  
1 9 9 6  d i r e c t  C o o m b s  Y e s  ( p ,  I ,  c h )  N o  ( l e s i o n s  d i d  1 8  S p o t s  N o  
L i p s  
D i s c h a r g e  P r o b a b l e  c o -
d e fi n i t e  
t h r o m b o s i s  a n d  p o s i t i v e  t e s t :  a n t i - e r y t h r o c y t e  s t a r t  o n  t h e  f a c e )  w i d e s p r e a d  
t r i m o x a z o l e ,  
S J S / T E N  
l u p u s  a n t i c o a g u l a n t ,  1 9 9 5  a u t o a n t i b o d i e s ,  c o l d  
p o s s i b l e  h y d r o x y -
a r t h r a l g i a s ,  p h o t o s e n s i t i v i t y ,  r e a c t i v e  e r y t h r o c y t e  
c h l o r o q u i n e  
f a t i g u e ,  h a i r  l o s s ,  c h r o n i c  a l l o a n t i b o d i e s ;  1 9 9 7 :  
l y m p h a d e n i t i s  w i t h  h i g h - C 3  b o r d e r l i n e  
g r a d e  l y m p h o f o l l i c u l a r  
h y p e r p l a s i a  l i k e  i n  R A  o r  
c o l l a g e n o s i s ;  1 9 9 7  c e r e b r a l  
L E  v a s c u l i t i s  ( M R I  a n d  C T ) ,  
s u s p i c i o n  o f  c a r d i a c  L E  
i n v o l v e m e n t  
2 2 / M  0 8 / 9 7  0 4 / 1 9 9 7  S L E  S k i n  l e s i o n s ,  p h o t o s e n s i t i - A N A  1  : 8 0 0 ,  Y e s ( p , c )  N o ; a f t e r  1  6  S p o t s  N o  
P a l m s ,  s o l e s  L i p s ,  o r a l ,  
D i s c h a r g e  P r o b a b l e  a l l o -
d e fi n i t e S J S  
v i t y ,  m e s a n g i o p r o l i f e r a t i v e  
a n t i - S m  a n d  a n t i - R N P  
w e e k  s u n  e x p o - w i d e s p r e a d  
g e n i t a l  
p u r i n o l  
g l o m e r u l o n e p h r i t i s ,  p o s i t i v e ,  a n t i - d s D N A  s u r e ,  e r y t h e m a  
a r t h r i t i s ,  r e c u r r e n t  f e v e r  
p o s i t i v e ,  l e u c o p e n i a ,  f a c e  a n d  t r u n k  
t h r o m b o p e n i a ,  C H S 0  
d e c r e a s e d  
g
e  
5 0 / F  0 8 / 9 8  1 9 9 8  O r g a n i c  p s y c h o s i s  0 7  / 1 9 9 8  A N A  e l e v a - Y e s  ( p ,  c h )  F i r s t  E E M - l i k e  6  T y p i c a l  a n d  
N o  E r o s i v e  
D i s c h a r g e  P o s s i b l e  h y d r o x y -
d e fi n i t e  s u s p e c t e d  
a t t r i b u t e d  t o  L E  o r  s t e r o i d  
t e d ,  a n t i - R o  1  :  1 2 9 6  s k i n  l e s i o n s  a t y p i c a l  
m u c o s a (  
c h l o r o q u i n e  
E E M M / S J S  S C L E  i n d u c e d  ( 0 9 / 9 8  a n t i - R o  a b o u t  6  w e e k s  t a r g e t s  
i n v o l v e m e n t  
n e g a t i v e ) ,  a n t i p - p r i o r  t o  t h e  r a i s e d ,  s p o t s  
( o r a l  s l i g h t l y ,  
h o s p h o l i p i d  d i s c r e t e ,  e v e n t  ( S C L E  w i d e s p r e a d  
g e n i t a l  a n d  
e l e v a t e d  c r e a t i n i n e ,  s u s p e c t e d )  
a n a l )  
D I F  n e g a t i v e  
V'I 
No. Age Diagnosis/ Duration LE criteria clinically LE characteristic lmmunosup- Skin lesions Time Skin LE typical Involve- Involve- Outcome Potential cause rl 
(I) 
(years)/ event and type and previous changes laboratory values presslve before event perlodb Involve- photo- mentof mentof of SJS/TEN 
sex of LE therapy before ment dlstrlbu- palms, mucous ::, 
event" tlon soles membranes 
V, 
0 
10 45/F 01/99 1 980 SLE Anti-phospholipid syn- Anti-phospholipid, Yes (p, a) No 7 Atypical No Palms, soles Lips, oral Death Possible ::r 
:::, 
definite TEN drome, involvement of elevated transaml- targets flat, amoxlcilfln, V, 
skin, heart, lung, kidney; spots wide- diclofenac 0 nases ::, 
last exacerbation 1995 with spread V, 
extensive skin and liver ::, 
involvement 0. a 
1 ld 78/F 02/99 CLE N.m. DIF negative No No 1 2  Atypical Yes Death Possible sertra- 3 
probable SJS targets line, amitriptyline (I) 
0) 
flat, spots ::, 
widespread; 0. rl 





12 59/F 1 2/02 For a few 2002 for a few months fever 1 1/2002 high Yes (p, a, c) No 1 0  Spots No Palms Lips Death Multiple medica-
(I) 
3 definite TEN weeks SLE and exanthema, pulmonary positive anti-dsDNA, widespread tion use; pos-
0) 
infiltrate, antibiotics not anti-SS-A, slightly sible metamizole -:::, 
effective, after prednisolone i ncreased transami- (more likely), (I) 
immediately afebrile and nases, leucopenia, piperacillin/tazo-
n a 
improved general condition anaemia, positive RF, bactam '< 
C4 decreased V, vi' 
1 3d 67/F 08/04 2001 2001 acute dermatitis Positive ANA, Yes (pl 1 month prior to 1 0  Type of Yes Discharge Multiple medica- 5· 
probable SJS suspected sun-exposed skin; 2003 positive nDNA exacerbation of targets tion use; pos- "O 
0) 
CLE, 2003 admission with acute LE LE with cutane- unknown, sible cefazolin, rl 
iti' question- exacerbation; 2005 (after ous lesions face, in parts metamizole, :::, 
able SLE; SCAR) SLE, recent acute shoulders, back annular, amoxicillin/ rl 
2005 proven exacerbation with severe crusted clavulanic acid :E 
SLE skin involvement (exfoliative � ::r 
dermatitis) c 
14 80/F 09/04 2004 pos- During SCAR erythema ANA 1 : 640, anti- No No 3 Type of No Palms, soles Lips, oral, Discharge Probable allo- "O C 
definite SJS sible SLE periungual, cheeks; mucosal dsDNA 271 (< 30), targets eyes, nasal purinol V, 
(I) 
erosions and pericardia! Crithidia-ab 1 : 1 0  unknown, 
� fluid (< 1 :  10), SMA 1 :  1 60 mostly ::r 







C w V, 
N o . A g e  D i a g n o s i s /  D u r a t i o n  
L E  c r i t e r i a  c l i n i c a l l y  
L E  c h a r a c t e r i s t i c  l m m u n o s u p -
S k i n  l es i o n s  Ti m e  
S k i n  L E  t y p i c a l  I n v o l v e -
I n v o l v e -
O u t c o m e  P o t e n t i a l  c a u s e  
( y e a r s ) /  e v e n t  
a n d  t y p e  
a n d  p r e v i o u s  c h a n g e s  l a b o r a t o r y  v a l u e s  p r e s s i v e  b e f o r e  e v e n t  p e r i o d �  i n v o l v e - p h o t o - m e n t o f  
m e n t o f  
o f S J S /T E N  
s e x  
o f L E  t h e r a p y  b e fo r e  m e n t  d l s t r l b u - p a l m s ,  m u c o u s  
e v e n t '  
t l o n  s o l e s  m e m b r a n e s  
1 5 •  3 0 / M  0 2 / 0 5  
1 9 9 4 C L E ,  1  m o n t h  b e f o r e  S C A R  a c u t e  A N A  1  :  8 0 0 ,  a n t i - S S - Y e s  ( p ,  a ,  c )  1  m o n t h  
7  
A t y p i c a l  N o  P a l m ,  s o l e s  L i p s ,  o r a l ,  
D i s c h a r g e  M u l t i p l e  m e d i c a -
d e fi n i t e  
2 0 0 1  S L E  e x a c e r b a t i o n  L E ;  p h o t o s e n - A ,  a n t i - S S - 8  p o s i t i v e ;  p r i o r  t o  a c u t e  
t a r g e t s  f l a t ,  e y e s  
t i o n  u s e ;  p o s s i b l e  
S J S /T E N  
s i t i v i t y ,  b u t t e r f l y  e r y t h e m a ,  p r o t e i n u r i a ,  p a t h o l o - e x a c e r b a t i o n  s p o t s  w i d e -
p h e n o x y m e -
d i s c o i d  s k i n  l e s i o n s ,  d i f f u s e  g i c a l  c r e a t i n i n e  c l e a - o f  L E  w i t h  s p r e a d  
t h y l p e n i c i l l i n ,  
g e n e r a l i z e d  p a i n ,  e m o t i o n a l  r a n e e ,  l e u c o p e n i a ,  c u t a n e o u s  e t o r i c o x i b ,  
! a b i l i t y  w i t h  a g g r e s s i o n  
t h r o m b o c y t o p e n i a ,  l e s i o n s  f a c e ,  m e t a m i z o l e  
a t t r i b u t e d  t o  L E ,  c r i t i c a l -
a n a e m i a  t r u n k ,  f e e t  
i l l n e s s - p o l y n e u r o p a t h y  
1 6  7 8 / F  
0 3 / 0 6  
2 0 0 5 C L E  2 0 0 5  s u s p e c t e d  a c u t e  A N A : w e a k l y  N o  
N o  4  S p o t s  N o  S o l e s  L i p s ,  o r a l ,  
D e a t h  M u l t i p l e  m e d i c a -
d e fi n i t e  
o r S L E  L E - n e p h r i t i s  i n  p o s i t i v e ,  E N A  1 · 0  
w i d e s p r e a d  e y e s ,  n a s a l  
t i o n  u s e ;  p o s s i b l e  
S J S /T E N  l o n g s t a n d i n g  n o t  ( <  1  • O ) ,  p r o t e i n u r i a ,  
a l l o p u r i n o l  
s y s t e m i c  L E ,  s k i n :  h e a l i n g  c r e a t i n i n e  c l e a r -
s m a l l  b l i s t e r s  b a c k  a n d  a n c e  2 7 · 8  m l  m i n  
1
,  
a r m s ,  e r y t h e m a  r i g h t  f a c e  
a n a e m i a ,  R F  2 5  ( <  1 5 ) ,  
l g M  1 9 · 4 5  ( <  1 5 ) ,  
W a a l e r - R o s e  t e s t  
1  : 1 2 8 0 ( < 1  : 4 0 )  
1 7
d  
3 4 / F  
0 3 / 0 5  1 9 8 5  S L E  0 1 / 2 0 0 5  m a l a r  r a s h  w i t h  0 1 / 2 0 0 5 A N A  Y e s  ( p ,  a ,  c )  E x a c e r b a t i o n  o f  4  
A t y p i c a l  N o  P a l m s ,  s o l e s  L i p s ,  o r a l ,  
D e a t h  M u l t i p l e  m e d i c a -
d e fi n i t e  
p a r t i a l l y  e r o s i v e  l e s i o n s  o n  1  :  5 1 2 0 ,  d s D N A  
L E  w i t h  c h a r a c -
t a r g e t s  fl a t ,  e y e s  t i o n  u s e ; <  n o n e  
S J S / T E N  t h e  f a c e ,  fi n g e r t i p s  a n d  >  2 0 0 ,  a n t i - R o  2 2 · 7 ,  
t e r i s t i c  c u t a n e -
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Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with lupus erythematosus 
Histopathological characteristics 
Detailed histopathological findings are listed in Table 3. Characteristic features of SJS/TEN 
including a normal basket-woven cornified layer, scattered necrotic keratinocytes often 
resulting in subepidermal vesiculation and confluent necrosis of the surface epidermis, and a 
mostly sparse superficial perivascular and interstitial lymphocytic infiltrate were found in 1 0  out 
of 17 patients. Sometimes secondary changes were present such as focal parakeratosis, serum 
crusts or neutrophilic granulocytes in the horny layer or ulcerated surface. 
As expected, in all biopsies, necrotic keratinocytes up to complete necrosis were present 
throughout the entire epidermis. Nevertheless, six biopsies were interpreted as compatible with 
LE, based on four or more histopathological LE-characteristic criteria such as vacuolar alteration 
at the DEJ, presence of solitary necrotic keratinocytes at lower epidermal levels with analogous 
changes of acrosyringia and follicular infundibula combined with periadnexal lymphocytic 
infiltrates, thickened BMZ and moderate to dense superficial and deep dermal lymphocytic 
infiltrates with variable presence of plasma cells, melanophages and mucin (Fig. 2a-d; case 5). 
Two of these biopsies met seven, three met five and one met four of the listed LE criteria. In five 
of six cases vacuolar degeneration at the DEJ was present, a feature found only in two cases not 
suggestive for LE. A thickened basement membrane was found in only one case, a phenomenon 
explainable by the acuteness of the evaluated cases, as a thickened basement membrane is 
found only in long-standing, mostly discoid LE plaques. Moreover, we noticed the absence of 
plasma cells in all except one case. 
Figure 2. Case 5. A female patient with Stevens-Johnson syndrome showing concomitant histological 
features of lupus erythematosus. (A) Moderate, superficial and deep, perivascular and periadnexal 
infi ltrates, extensive epidermolysis; the blister roof is completely necrotic [haematoxylin and eosin (H&E), 
original magnification x 40]. (B) Epidermis adjacent to the areas of epidermolysis shows vacuolar alteration 
at the dermoepidermal junction, solitary necrotic keratinocytes at lower epidermal levels with analogous 
changes at foll icular epithelium combined with periadnexal lymphocytic infi ltrates, and moderate to dense 
superficial and deep perivascular lymphocytic infiltrates with presence of melanophages (H&E; original 
magnification x 1 00). (C) Erythematous erosive papules on the face with erosive cheilitis. (D) Disseminated 
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Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with lupus erythematosus 
Cases of Stevens-Johnson syndrome/toxic epidermal necrolysis in 
patients with lupus erythematosus in the literature 
A total of 14 publications with SJS or TEN in the context of (S)LE have been published between 
1961 and 2009.26-39 Of these, 11 publications, including 12 patients and 14 episodes contained 
sufficient data for evaluation (Table 4).26•2s-36•39 All concerned female subjects, median age 29 years 
(range 9-76). The authors interpreted nine episodes as SJS and five as TEN. In one, SJS and TEN 
subsequently appeared, while, in a child, recurrent SJS was reported. Clinical presentations were 
illustrated by representative photographs for eight episodes. Histopathology of the skin was 
performed in 10 and photodocumented in four episodes, of which three could not be interpreted 
because of very limited high-power details. SLE was diagnosed simultaneously with SJS or TEN in 
four episodes, (S)LE prior to the event in nine (range 11 months to 16 years, two not mentioned), 
and 5 months after the event in one. However, pre-existing LE-suspicious mucocutaneous 
lesions and/or systemic symptoms suggest that (S)LE in three of the simultaneous and in the 
later diagnosed case was already present at the event. 
Six of nine patients with pre-existing SLE used corticosteroids, one additionally 
cyclophosphamide and another mizoribine. In all episodes, a potentially culprit drug for SJS/ 
TEN was assigned, generally introduced or reintroduced within hours (three of 14), several 
days (two of 14), 'recently' (one of 14), 1-6 weeks (three of 14) and in 1-6 months (three of 14) 
prior to the event. One child used the medication 3-5 years before the first episode, followed by 
3 years of mild recurrences and a second episode. In a second child the reaction occurred after 
11 months. 
Analysing the published data of these 14 episodes we concluded the following points. (i) 
Seven events could fit a diagnosis of SJS (or EEMM)28•30•31•34 or TEN.29•30•33 Although some aspects 
were presented fragmentarily, clinical pictures and precise descriptions did allow for diagnosis. 
(ii) The diagnosis of SJS or TEN could not be evaluated in five events, due to inconclusive clinical 
and histopathological description and/or pictures.26•32•39 However, the recurrent cases are far 
more suggestive for EMM than for SJS.26 (iii) In two reports the presentation was based on 
clinical and histopathological findings more likely to be related to (drug-induced) LE.35•3 6  
1 1 7 
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Activity of LE TEN/SJS-features Histology ,-+ I (l) 
(l) 
Age lmmuno- Mucous mem- :::J 1/1 
Author/reported LE-type/ (years) suppres- LE-specific Lesions/time of deve- brane Involve- � 
SJS/TEN duration /sex Laboratory/dlnlcally slve drugs skin lesions lopment Localization mentw Description Figure Culprit drug(s) Outcome 0 � 
:::J 
Mendoza 1 97318 SLE/simulta- 40/F Simultaneously with Cortico- Erythema- Fever, erythematous Face, genitalia Erosive cheilitis, Not performed No 2 months 64 mg Deltlsone 
1/1 
0 
SJS neously the event lupus steroid (for tosquamous, oedema of eyelids, erosions of oral before acetyl- and dose reduc- :::J 
1/1 
nephritis, anti-DNA arthralgias) crusted blepharitis, conjunctivi- mucosa, erosive salicylic acid, tion, 6 weeks later '< 
:::J 
negative, LE cells lesions ears, tis/acute c:olpitis streptomycin, worsening of lupus a. 
depigmented tetracycline symptoms and 0 
macules face increase to 1 28 mg 3 
Deltisone, patient (l) 
QJ 
died from cardiac :::J 
fibrillation a. ,-+ 
Sayag 19801' SLE/after 65/F 1 month before car- None None Fever, generalized purpu- Generalized Ocular and oral Complete Detail Aprindine Dexamethasone X 
TEN event diopathy, increased ric erythematopapular, mucous mem- epidermal only hydrochloride 8-1 2 mg daily, then ;:;· 
(l) 
ESR, cytopenias; after extensive epidermal branes involved necrosis, no and cloraze- betamethasone/ -0 
the event LE diagno- detachment/rapid inflammatory pate 4 days prednisolone 0..: 
(l) 
sis based on pro- infiltrate, DIF before the 15 mg kg·• 3 longed fever, myalgia, (bullous lesion) event daily; discharge � pleurisy, pericardltis, llnear homo- after 1 month (skin :::J 
LE cells, ANA 1 : 1 000, geneous lgG, healed). Died se- (l) n 
anti-dsDNA lgM, C3 at BMZ, veral months later 0 
later linear from tuberculosis '< 
homogeneous 1/1 in' 
lgG at BMZ in 3· 
healthy skin -0 
QJ 
Burge 198530 ,-+ 
iii' 
First episode SLE/before 73/F History of cerebral Predniso- None Erythematous rash/not Face, trunk, Mouth ulcers, Extensive vacu- High- Phenytoin, Phenytoin stopped, :::J ,-+ 
SJS event and pulmonary LE, lone 15 mg reported limbs nasal crusting, olar degenera- power 6 weeks before prednisolone 
1/1 
� no further details genital erosions tion,indi- detail rash 60 mg daily; slowly ;::;: 
reported vidual necrotic of epi- improvement, � 
keratinocytes, der- discharge after c 
-0 mononuclear mis 6 weeks C 
cell infiltrate, only 1/1 
(l) 
coalescent 
� necrosis of � 
keratinocytes (l) 
in roof of a 3 
QJ 
subepldermal 0 .... bulla, horny 1/1 
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B l i s t e r i n g ,  p e e l i n g ,  ( e r y t h e m a )  n e c r o s i s ,  
c h e s t  i n f e c t i o n  f u l l y ,  d i s c h a r g e  a f t e r  
s c a l d e d  a p p e a r a n c e  
s u b e p i d e r m a l  
2  m o n t h s  
s p l i t  
S a v i / 1 1 9 8 8
3
1  
A c t i v e  
4 6 / F  P r e s e n t l y  5  w e e k s  N o n e  
N o n e  F e v e r ,  l a r g e  u l c e r o n e - E x t e n s o r  a s p e c t  P a i n f u l  e r o s i o n s  S e v e r e  N o  
l o p a m i d o l  8  h  D e x a m e t h a s o n e  
5 1 5  S L E / 1 6  y e a r s  m a l a i s e  a n d  w e i g h t  e r o t i c  p l a q u e s ,  s o m e  o f  t h e  l i m b s ,  
o f  m o u t h  a n d  
l y m p h o h i s t i o - b e f o r e  t h e  
h i g h  d o s e ,  l a t e r  
l o s s ,  f o r  1 6  y e a r s  w i t h  b u l l o u s  
b u t t o c k s ,  a n d  n a r e s ,  n a s a l  c y t i c  i n fi l t r a t e  e v e n t  
c y c l o p h o s p h a m i d e  
r e c u r r e n t  f e v e r ,  s k i n  c h a n g e s / 8  h  a f t e r  t r u n k  
c r u s t i n g  t h r o u g h o u t  
7 0  m g  d a i l y  a d d e d  
r a s h e s ,  p o l y a r t h r a l g i a ,  u r o g r a p h y ,  t a r g e t  t h e  d e r m i s ,  
f o r  1  w e e k .  P a t i e n t  
A N A  >  1  :  3 2 0 ,  D N A  l e s i o n s  m a r k e d  d i e d  6  w e e k s  a f t e r  
b i n d i n g  5 2 % ,  d e c r e -
o e d e m a ,  f o c a l  
a d m i s s i o n  f r o m  
a s e d  c o m p l e m e n t ,  e p i d e r m a l  
m u l t i o r g a n  f a i l u r e  
a n a e m i a ,  l e u c o p e -
n e c r o s i s  w i t h  
n i a ,  l y m p h o p e n i a ,  s u b e p i d e r m a l  
a c t i v e  S L E  w i t h  b u l l a  f o r m a -
r e c e n t  d e t e r i o r a t e d  t i o n ,  D I F  
r e n a l  f u n c t i o n  w i t h  ( l e s i o n a l  a n d  
p r o l i f e r a t i v e  g l o m e r u - n o n l e s i o n a l )  
l o n e p h r i t i s  l i n e a r  l g M  a n d  
C 3  a t  B M Z  
M o s h f e g h i 1 9 9
3
3 1  
S L E / 1 5  y e a r s  3 1  / F  
N o r m a l  r e n a l  f u n c -
V a r y i n g  
N . m .  D i f f u s e  e r y t h e m a t o u s ,  M o r b i l l i f o r m  
D e s q u a m a t i o n  S k i n  n e c r o s i s  N o  
A f t e r  1 s t  d o s e ,  P a r e n t e r a l  f o l l o w e d  
T E N  
t i o n ,  o t h e r w i s e  n o t  
d o s e s  o r a l  
p a i n f u l ,  m o r b i l l i f o r m  
r a s h  o n  t r u n k ,  l i p s  w i t h  m i n i - w i t h  s l o u g h i n g  c i p r o f l o x a c i n  
b y  o r a l  m e t h y l -
s p e c i fi e d  
p r e d n i s o n e  r a s h ,  e r o d e d  b u l l a ,  e r o - u p p e r  a n d  l o w e r  m a l  c r u s t i n g ,  n o  a n d  s u b e p i - 7 5 0 m g  
p r e d n i s o l o n e  a n d  
p a s t  s i o n s ;  f e w  d a y s  l a t e r  ' d e s - e x t r e m i t i e s ,  f a c e  o r a l  u l c e r a t i o n s ,  d e r m a l  b u l l a e ,  t w i c e  d a i l y ,  
p r e d n i s o n e  d u r i n g  
1 3  y e a r s  q u a m a t i o n '  a n d  p o s i t i v e  a n d  p a l m s ,  o n e  n o  e y e - i n v o l v e - c o n s i s t e n t  p r o l o n g e d  
h o s p i t a l  s t a y ;  
N i k o l s k y ;  h o s p i t a l  d a y  4  b u l l a  a r m ,  o n e  m e n t  w i t h  T E N  u s e  f o r  6  d a y s  r e c o v e r e d  a f t e r  
f u r t h e r  e x t e n t  ' d e s q u a - e r o s i o n  l a b i a ,  ( r a s h  1  y e a r  p r o l o n g e d  h o s p i -
m a t i o n ' / f e w  d a y s  l a t e r ' d e s q u a m a - e a r l i e r  a f t e r  
t a l i z a t i o n  
t i o n '  p o s t e r i o r  c i p r o f l o x a c i n ,  
t h i g h s ,  b a c k  a n d  r e s o l v i n g  a t  
a r m s  d r u g  d i s c o n -
t i n u a t i o n )  
Activity of LE TEN/SJS-features 
Age lmmuno-
Author/reported LE-type/ (years) suppres- LE-specific Lesions/time of deve-
SJS/TEN duration /sex Laboratory/clinkally sive drugs skin lesions loprnent Localization 
Moallem 200233 SLE/simulta- 1 4/F During the event None 5 months Fever, flaccid blisters/few Generalized 
TEN neously ANA 1 : 5 1 20, later malar days exfoliation > 40% 
5 months later ANA rash after sun BSA, Nikolsky positive, 
1 : 1 0,240, thrombo- exposure mechanical ventilation 
penla, hypocomple-
mentaemia, anaemia, 
later anti-dsDNA and 
lupus nephritis 
5amimi 200234 SLE/recent 9/F Directly before the Methylpred- Erythema Fever, diffuse blistering Face and trunk 
515 event elevated ESR, nisolone on cheeks, and desquamation, 
ANA 1 : 640, anti- 4 mg kg-• eyelids, mechanical ventilation/ 
DNA, anti-cardiolipin, daily for superficial progressive few days 
decreased com- 6 days, oral 
plement, lupus- followed by erosions 
nephritis, elevated prednisone 
liver function tests, 60 mg daily, 
cardiomegaly cyclophos-
phamlde 
Jongen- Lavrencic SLE/6 years 27/F N.m., treated with No N.m. Fever, diffuse rash, Diffuse, upper/ 
200339 hydroxychloroquine diarrhoea, epidermal lower extre-









Blisters on Full-thickness 
palate, later epidermal 
keratopathy necrosis 
Ocular, oral and Numerous 





Desquamation Skin necrosis 





Figure Culprit drug(s) Outcome 
No Amoxiclllln/ Discharged, methyl-
clavulanic acid prednlsolone, IVIG, 
1 week prior to antibiotics 
the event 
No Azithromycln 4-day course 
2 weeks prior IVIG 750 mg kg·• 
to event daily, methylpred-
nisolone 2 mg kg-1 
daily; discharged 
3 weeks later 
No Second dose Day 7 cortico-
of ciprofloxa- steroids 65 mg 
cin; 2 weeks dai ly, died day 28 
before event due to severe acute 
5-day course respiratory distress 
without reac- syndrome and 
tion cardiac arrest 
f 
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A c t i v i t y  o f  L E  T E N / S J S - f e a t u r e s  





A g e  l m m u n o-
M u c o u s m e m •  
A u t h o r / r e p o r t e d  L E - t y p e /  
( y e a r s )  s u p p r e s •  
L E - s p e c i fi c  
L e s i o n s / t i m e  o f  d e v e •  
b r a n e  I n v o l v e -
w  
S J S /T E N  d u r a t i o n  
/ s e x  L a b o r a t o r y / c l i n i c a l l y  s l v e  d r u g s  
s k i n  l e s i o n s  
l o p m e n t  L o c a l i z a t i o n  
m e n t w  D e s c r i p t i o n  
F i g u r e  C u l p r i t  d r u g ( s )  O u t c o m e  
M a t s u s h i t a  
S L E  f o r  
3 2 / F  H i s t o r y  o f  S L E  f o r  P r e d n i -
O r a l  u l c e r ,  
F e v e r ,  f a c i a l  e r y t h e m a ,  F a c e ,  f o r e a r m  
E r o s i o n s  o f  t h e  S o m e  
O K  M i z o r i b i n e  M e t h y l p r e d n i s o -
2 0 0 6
3 5  
1 1  m o n t h s  
1 1  m o n t h s  w i t h  l u p u s  s o l o n e  f a c i a l  s m a l l  b u l l o u s  e r u p -
o r a l  c a v i t y  a n d  a p o p t o t i c  s i n c e  
l o n e  5 0 0  m g  f o r  
S J S  
n e p h r i t i s ,  a n t i p h o s - 1  m g  k g -
1  
o e d e m a  
t i o n s  ( <  5  m m )  f a c e  a n d  
e y e  m u c o s a  
k e r a t i n o c y t e s  6  m o n t h s ,  
1  d a y  
p h o l i p i d  s y n d r o m e ,  d a i l y ;  
l a t e r  f a c i a l  
f o r e a r m s / p r o g r e s s i o n  
( a c c o r d i n g  t o  
r e i n t r o d u c e d  f o l l o w e d  b y  p r e d -
a r t h r i t i s ,  o r a l  u l c e r s ,  m i z o r i b i n e  
e r y t h e m a  o v e r  1  w e e k  
m i c r o p h o t o - a f t e r  b r e a k  
n i s o l o n e  1  m g  k g -
1  
f a c i a l  o e d e m a ,  p l e u - 1 5 0  m g  
g r a p h  i n  l o w e r  2  m o n t h s  
d a i l y ,  I V I G ;  
r i s y ,  h a e m a t o l o g i c a l  d a i l y  
e p i d e r m i s ) ,  e a r l i e r  
s y m p t o m s  
a n d  i m m u n o l o g i c a l  
i n f l a m m a t o r y  
d i s a p p e a r e d  
d i s o r d e r s  
i n fi l t r a t e  w i t h  w i t h i n  1  m o n t h  
l y m p h o c y t e s  
a n d  n e u t r o -
p h i l s  ( a c c o r d -
i n g  t o  m i c r o -
p h o t o g r a p h  
m o d e r a t e l y  
d e n s e ,  s u p e r fi -
c i a l  a n d  d e e p )  
Te rr a b  2 0 0 6
3 6  
S L E  f o r  
2 5 / F  S t a b l e  S L E  p r e - C o r t i c o s t e -
B u t t e r fl y  
M a c u l o p a p u l a r  p u r p u r i c  
I n i t i a l l y  o n  
D i s c r e t e  c h e i l i t i s ,  S u b e p i d e r m a l  D e t a i l  T e r b i n a fi n e  
T e r b i n a fi n e  
S J S  4 y e a r s  
e x i s t i n g ,  p o l y a r t h r i t i s ,  r o i d  2 0  m g  r a s h ,  p h o - e x a n t h e m a ,  e p i d e r -
t h e  f a c e  w i t h  
b i l a t e r a l  c o n - d e t a c h m e n t  o n l y  
7  d a y s  p r i o r  s t o p p e d ,  c o r t i c o -
l y m p h o p e n i a , A N A  
d a i l y  t o s e n s i t i v - m o l y s i s  1 0 %  o f  b o d y  s p r e a d i n g  
j u n c t i v i t i s  w i t h  f u l l - t h i c k - t h e  e v e n t  s t e r o i d s  1  m g  k g - •  
1  :  1 2 8 0 ,  a n t i - n a t i v e  
i t y ,  c h r o n i c  
s u r f a c e / 7  d a y s  a f t e r  d r u g  o v e r  t r u n k  a n d  n e s s  e p i d e r m a l  d a i l y  a n d  b o l u s  
D N A ,  d e c r e a s e d  c o m -
d i s c o i d  i n t a k e  
e x t r e m i t i e s  
n e c r o s i s  c y c l o p h o s p h a m i d e ,  
p l e m e n t ;  s i m u l t a n e - e r y t h e m a -
( a c c o r d i n g  t o  f a v o u r a b l e  
o u s l y  w i t h  t h e  e v e n t  t o s q u a m o u s  
m i c r o p h o t o - o u t c o m e  a f t e r  
l u p u s  n e p h r i t i s ,  h i g h  
a t r o p h i c  
g r a p h  m o d -
1 5  d a y s .  1 8  m o n t h s  
a n t i h i s t o n e ,  a n a e m i a  p l a q u e s  o n  
e r a t e l y  d e n s e  l a t e r :  d e c r e a s e d  
e a r s ,  t h i g h s ;  
i n fl a m m a t o r y  A N A ,  a n t i - D N A  a n d  
b u c c a l  
i n fi l t r a t e s ) ,  D I F  a n t i h i s t o n e  n e g a -
u l c e r a t i o n s ,  
n e g a t i v e  t i v e ,  n o r m a l i z a t i o n  
n e c r o t i c  
r e n a l  f u n c t i o n ,  n o  
p u l p i t i s  
n e w  s k i n  l e s i o n s  
N . m . ,  n o t  m e n t i o n e d ;  D I F ,  d i r e c t  i m m u n o fl u o r e s c e n c e ;  e o s ,  e o s i n o p h i l s ;  B M Z ,  b a s a l  m e m b r a n e  z o n e ;  E S R ,  e r y t h r o c y t e  s e d i m e n t a t i o n  r a t e ;  A N A ,  a n t i n u c l e a r  a n t i b o d i e s ;  
d s - D N A ,  d o u b l e - s t r a n d e d  D N A ;  B S A ,  b o d y  s u r fa c e  a r e a ;  I V I G ,  i n t r a v e n o u s  i m m u n o g l o b u l i n s .  
Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with lupus erythematosus 
Cases of toxic epidermal necrolysis-like lupus erythematosus in the 
literature 
Eight publications with 12 patients (comprising 1 3  episodes) were related to 'TEN-like LE' 
(Table S).1 1·24 Most patients experienced unusual subacute progression of LE over weeks or 
months, showing clinically 'TEN-like' features, but lacking an apparent trigger. TEN-like skin 
lesions did evolve from pre-existing annular or papulosquamous LE lesions, often accompanied 
by circulating Ro/SS-A autoantibody or minimal SLE activity. In some patients, however, TEN-like 
skin lesions rapidly evolved from a photodistributed confluent or patchy erythema otherwise 
characteristic for ACLE. Typically, such patients showed clear SLE activity with positive serological 
markers (antinuclear antibodies, anti-Ro/SS-A or rheumatoid factor).19 Although clinically rather 
similar to SJS/TEN, the progression of 'TEN-like LE' developed rather slowly. Mucous membranes 
were most often not, or only focally, involved. 
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T a b l e  5 .  L i s t  o f  r e p o r t e d  c a s e s  o f  t o x i c  e p i d e r m a l  n e c r o l y s i s  ( T E N ) - l i k e  l u p u s  e r y t h e m a t o s u s  ( L E )  i n  t h e  l i t e r a t u r e  
Cl.I  
A c t i v i t y  o f  L E  ' T E N / S J S ' - l l k e  f e a t u r e s  
H i s t o l o g y  
M u c o u s  
w  
A u t h o r /  A g e  
l m m u n o s u p - m e m b r a n e  
t y p e  o f  
( y e a r s )  L a b o r a t o r y / e l l - p r e s s l v e  L e s i o n s / t i m e  o f  d e v e - I n v o l v e -
C u l p r i t  
LE  L E  t y p e  / s e x  n l c a l l y  m e d i c a t i o n  L E- s p e c i fi c  s k i n  l es i o n s  l o p m e n t  L o c a l i z a t i o n  
m e n t  D es c r i p t i o n  
F i g u r e  d r u g ( s )  O u t c o m e  
B i e / s a  S L E  f o r  4 2 / F  
H i s t o r y  o f  h y p o - P r e d n i s o l o n e  V i o l a c e o u s  p o l y c y c l i c  P r o g r e s s i v e  a g g r a v a t i o n  A b d o m e n ,  
A f f e c t e d  N e c r o t i c  e p i d e r m i s ,  S m a l l  
D o u b t f u l l y  M e t h y l p r e d n i -
1 9 8
7
1 7  
2  y e a r s  c o m p l e m e n t a e m i c  6 0  m g  d a i l y ,  e r y t h e m a t o p a p u - o f  p r e v i o u s  l e s i o n s  o n  t h i g h s ,  l e g s  l i p s ,  b u t  i s o l a t e d  n e c r o t i c  
h i g h - f u r o s e m i d e  s o l o n e  1  g  f o r  
S L E  
u r t i c a r i a !  v a s c u l i t i s ,  c y c l o p h o s p h a - l o s q u a m o u s ,  p a r t l y  t o  l a r g e  b l i s t e r s  l e a v i n g  a n d  f e e t  m u c o u s  k e r a t i n o c y t e s  i n  t h e  a d - p o w e r  
c o m m e n c e d  3  d a y s ,  r e m i s s i o n  
n e u r o l o g i c a l  a n d  m i d e  1 0 0 m g  a n n u l a r  l e s i o n s  w i t h  d e n u d e d  a r e a s ,  N i k o l s k y  P h o t o - d i s t r i - m e m b r a n e s  j a c e n t  e p i d e r m i s  w i t h  d e t a i l  B  m o n t h s  
o b t a i n e d  
r e n a l  L E ;  h i g h  d a i l y  v e s i c u l o b u l l o u s  e d g e s  p o s i t i v e  b u t i o n  n o t  i n - e x o c y t o s i s  o f  l y m p h o -
o f  t h e  b e f o r e  t h e  
f e v e r ,  m a l a i s e ;  
o n  p h o t o e x p o s e d  s k i n  
v o l v e d  c y t e s  a n d  n e u t r o p h i l s ;  b l i s t e r  
e v e n t  
a n t i - R o ,  p r o t e i n u -
a r e a s  s u p e r fi c i a l  p e r i v a s c u l a r  o n l y  
r i a ,  d e c r e a s e d  
l y m p h o c y t i c  i n fi l t r a t e ;  
c o m p l e m e n t ,  
D I F :  l g G ,  l g M ,  C 3  a t  B M Z  
p r e v i o u s l y  A N A  
1  :  1 6 0 0 ,  a n t i - D N A  
B r a v e r m a n  1 9 9 8
1 8  
F o u r  p a t i e n t s  w i t h  S L E /S C L E  
P a t i e n t  1  C L E  f o r  2 7 / F  P e r i c a r d i t i s ,  l u p u s  P r e d n i s o l o n e ,  B u l l a e  a r i s i n g  f r o m  B u l l a e  a r i s i n g  f r o m  D e n u d e d  s k i n  N . m .  N o  d e t a i l e d  d e s c r i p - N o  
N o  
R e p e a t e d l y  
9 y e a r s ,  n e p h r i t i s  
a z a t h i o p r i n e  u r t i c a r i a !  p l a q u e s  u r t i c a r i a !  p l a q u e s / r e c u r - u p t o 4 0 %  B S A  t i o n ,  ' c h a n g e s  o f  
r e m i s s i o n s  a f t e r  
S L E  f o r  
r e n t  e p i s o d e s  
e r y t h e m a  m u l t i f o r m e ;  
p r e d n i s o n e ,  
3  y e a r s  
D I F  n o t  p e r f o r m e d  
d e a t h  f r o m  
s e p s i s  a n d  o r g a n  
f a i l u r e  
P a t i e n t  2  S L E  f e w  
4 0 / F  A n a e m i a ,  l e u c o - N . m .  
D i f f u s e  n o n s c a r r i n g  F e v e r ,  s l o w l y  s p r e a d i n g  F a c e ,  t r u n k ,  N . m .  N o  d e t a i l e d  d e s c r i p - N o  N . m .  P r o m p t  
m o n t h s  
p e n i a ,  b o r d e r l i n e  
a l o p e c i a ,  p e r i u n g u a l  m a c u l o p a p u l a r  r a s h ,  
e x t r e m i t i e s  t i o n ,  ' c h a n g e s  o f  
r e s o l u t i o n  w i t h  
e a r l i e r  t h r o m b o p e n i a ,  
e r y t h e m a  
l a t e r  b u l l a e  w h i c h  b r o k e /  e r y t h e m a  m u l t i f o r m e /  p r e d n i s o l o n e ,  
d e c r e a s e d  c o m -
r e c u r r e n t  o v e r  3  m o n t h s  
T E N ;  D I F  p o s i t i v e  l u p u s  
r e c u r r e n c e  w h e n  
p l e m e n t ,  A N A  
b a n d  t e s t  
p r e d n i s o l o n e  
1  :  1 2 8  h o m o g e n e -
w a s  t a p e r e d  
o u s ,  a r t h r a l g i a s ,  
f e v e r  
P a t i e n t  3  S C L E  f o r  5 1 / M  
A N A  1  :  5 1 2 5 ,  a n t i - N . m .  G e n e r a l i z e d  p a p u - V e s i c l e s ,  b u l l a e  a n d  
W i d e s p r e a d  N . m .  N o  d e t a i l e d  d e s c r i p - N o  N . m .  
I m m e d i a t e  h e a l -
5  y e a r s  R o ,  l e u c o p e n i a ,  
l o s q u a m o u s  l e s i o n s  e r o s i o n s  w i t h i n  a n d  a t  t i o n ,  ' c h a n g e s  o f T E N ;  i n g  w i t h  s t e r o i d  
t h r o m b o p e n i a  
m a r g i n s  o f  p a p u l o s q u a -
D I F  n o t  p e r fo r m e d  
t h e r a p y  
m o u s  l e s i o n s ,  p e e l i n g  o f f  
i n  l a r g e  s h e e t s  
V"I 
Activity of LE 'TEN/SJS'•llke features Histology 
r-+-
Mucous 
Author/ Age lmmunosup- membrane ::, V'I 
type of (years) Laboratory/ell- presslve Lesions/time of deve- involve- Culprit ..'... 
0 
LE LE type /sex nlcally medication LE-specific skin lesions lopment Localization ment Description Figure drug(s) Outcome ::,-
::, 
Patient 4 SLE for Lupus nephritis, N.m. Maculopapular eruption N.m. N.m. No detailed descrip- No No Successfully trea-
V'I 
35/F N.m. 0 
2 years cerebritis evolving into TEN/over tion, 'corresponding ted with predni- ::, 
V'I 
6-Bweeks to TEN' solone; however '< ::, 
recurrence after a. 
2 years a 




Patient SLE for 42/F Arthritis, serositis, Prednisone Acral violaceous Afebrile, systemically Widespread Multiple Scattered necrotic No No Prednisone ::, 
1 ,  9 years malar rash, restric- 5 mg daily macules and patches well, gradual developing erosions keratinocytes in basal 1 -5 mg kg·' a. r-+-
First tive lung disease, on the distal painful annular, target- on buccal layer and epidermis dally tapered 
episode no flare in the extremities suggestive oid, red to violaceous mucosa and with focal vacuolar over 2 months n· 
SLE 12 months before of chilblains plaques, some ulcer- tongue changes, sparse upper with gradual (0 
-0 
presentation, at ated with haemorrhagic dermal lymphocytic resolution of 0.: 
presentation ANA crusts/gradual over infiltrate, DIF negative symptoms (I) 
1 : 2560 homage- 7 weeks 3 
neous, anti-Ro and � 
anti-La, anti-DNA ::, 
(0 
1 :  1 280, RF n 
Afebrile, systemi- Extensive Erosions Complete epithelial ne- No IVIG 1 g kg·' 
a 
Patient No -<" 
1 ,  cally well, erythema and distribution oral mucosa crosis, sparse lympho- daily for 3 days, V'I iii" 
Second painful erosions, partly on face, trunk, cytlc infiltrate in upper prompt and 5· 
episode encrusted, involving extremities dermis, large numbers complete resolu- -0 
(3 more than 70% BSA; of bacterial colonies in tion in 2 weeks, 
months Nikolsky sign positive/ the necrotic epithelium, without recur- rii" 
later) gradual over 8 weeks indicative of secondary rence 
SLE impetiginization, DIF 
V'I 
:\E negative ;:;: 
::,-
Patient 2 No prior 76/F ANA 1 : 320 No N.m. Afebrile, systemically Face, trunk, Oral and Complete necrosis of No No new medi- Prednisone 1 00 c 
SCLE history speckled (1 : 1 60 well, painful erythema, and extre- genital epidermis, separation cation within mg daily 5 days -0 
of LE homogeneous), bul lae, and erosions mities ulceration of necrotic epithelium, 3 months no improvement, C V'I 
-Ro, anti-La, RF; > 80% BSA, Nikolsky sign and extremely sparse before onset followed by !VIG (I) 
during previous positive/progressive lymphocytic infiltrate of the erup- 1 g kg·' daily � 
4 years 3 episodes over 3 weeks in papillary dermis, DIF tion for 3 days, skin ::,-
of mild general- negative lesions resolved 3 
ized annular over 3 weeks, ... bullous eruptions without recur- V'I t-.J with oral ulcers rence C V1 V'I 
...  
C\  
A c t i v i t y  o f  L E  
A u t h o r /  A g e  l m m u n o s u p -
t y p e  o f  ( y e a r s )  L a b o r a t o r y / e l l - p r e s s f v e  
L E  L E  t y p e  / s e x  
P e r e r a  
2 0 0 4
20  
B u /J a u s  
S C L E  
N o  p r i o r  5 9 / F  
h i s t o r y  
o f  L E  
M u t a s i m  N o  p r i o r  3 1 / F  
2 0 0 3
1 1  
h i s t o r y  
S C L E  o f  L E  
n l c a l l y  m e d i c a t i o n  
H i s t o r y  o f  
N o  
a u t o i m m u n e  
d i s e a s e s  ( G r a v e s  
d i s e a s e ,  p e r n i c i o u s  
a n a e m i a ,  a l o p e c i a  
a r e a t a ) ,  a n t i - R o ,  
H L A  D R 3  
R e c e n t l y  c h i l l s ,  
N o  
l e u c o p e n i a ,  A N A  
1  :  1 6 0  s p e c k l e d ,  
a n t i - R o ,  a n t i - L a ,  
p h o t o  r e l a t e d  
l e s i o n s  
' T E N / SJ S ' - l l k e  f e a t u r e s  
L e s i o n s / t i m e  o f  d e v e -
L E - s p e c i fi c  s k i n  l es i o n s  l o p m e n t  
R e c e n t l y  b l i s t e r i n g  s k i n  
A f e b r i l e ,  r e c u r r e n t  
e r u p t i o n  i n  a  p h o t o - e r y t h e m a t o u s  t o  
a g g r a v a t e d  d i s t r i b u t i o n  p a p u l o s q u a m o u s  
d u r i n g  s u n n y  h o l i d a y  l e s i o n s  c o a l e s c i n g  a n d  
d e n u d i n g  i n  s h e e t s ,  
i n  o t h e r  a r e a s  i n t a c t  
a n d  d i s r u p t e d  b u l l a e ,  
l e s i o n s  c o n fi n e d  t o  s k i n  
n o t  c o v e r e d  b y  b a t h i n g  
c o s t u m e  
P r o g r e s s i v e  d e e p l y  E r y t h r o d e r m a  w i t h  
e r y t h e m a t o u s  c o n fl u e n t  b u l l a e  
p a t c h e s  w i t h  b r o w n i s h  
d e s q u a m a t i o n  o v e r  
1  y e a r  
M u c o u s  
m e m b r a n e  
I n v o l v e -
L o c a l i z a t i o n  
m e n t  
E x t e n s i v e  N o  
l e s i o n s  o n  
t r u n k  a n d  
e x t r e m i t i e s ,  
p h o t o -
d i s t r i b u t i o n ,  
p a l m s ,  s o l e s  
u n a ff e c t e d  
L a r g e  b u l l a e  o n  N o  
f e e t ,  p h o t o -
r e l a t e d  fl a r e  
6 w e e k s a f t e r  
c l e a r a n c e  
H i s t o l o g y  
C u l p r i t  
D e s c r i p t i o n  F i g u r e  
d r u g ( s )  
O u t c o m e  
I n i t i a l  b i o p s y :  p r e - S u p e r fi - V i t a m i n  
B
1 2  
d o m i n a n c e  o f v a c u o l a r  c i a l  d e t a i l  3 - m o n t h l y ,  
I n i t i a l l y  g i v e n  
s y s t e m i c  s t e r o i d s  
d i s c o n t i n u e d ,  
t o p i c a l  
c l o b e t a s o l ;  
c l e a r e d  f o r  
d e g e n e r a t i o n  a t  
B
M Z ,  
t h y r o i d  
s p a r s e  a p o p t o t i c  
k e r a t i n o c y t e s ;  a t  a d  m i s ­
s i o n :  s u b e p i d e r m a l  
b l i s t e r ,  n e c r o s i s  o f  
t h e  e p i d e r m i s ,  b a s a l  
l a y e r  v a c u o l i z a t i o n ,  
a p o p t o t i c  k e r a t i n o c y t e s  
t h r o u g h o u t  a l l  l e v e l s  
o f  t h e  e p i d e r m i s ,  D I F  
n e g a t i v e  
3  b i o p s i e s :  fo c a l  t o  d i f - O K  
f u s e  p a r a k e r a t o s i s ,  m i l d  
t o  s e v e r e  d y s k e r a t o s i s  
o f  k e r a t i n o c y t e s ,  f o c a l  
f u l l - t h i c k n e s s  e p i d e r -
m a l  n e c r o s i s ,  m i l d  t o  
m i n i m a l  s u p e r fi c i a l  
l y m p h o c y t i c  i n fi l t r a t e ,  
D I F  p o s i t i v e  
h o r m o n e  
r e p l a c e m e n t  
i n  G r a v e s  
d i s e a s e  
2  m o n t h s ,  
s p o n t a n e o u s  
r e c u r r e n c e  
w i t h  b l i s t e r i n g  
o n  e r y t h e m a ,  
d i s t r i b u t i o n  
t y p i c a l  fo r  S C L E  
D o u b t f u l l y ,  
P r e d n i s o n e  
c h l o r d i a z -
1  m g  k g -
1  
d a i l y  
e p o x i d e  H C L /  f o r  2  w e e k s  t h a n  
d u r a t i o n  n . m .  t a p e r e d ,  c o m -
p l e t e  c l e a r a n c e  
i n  4 - 5  w e e k s ,  
g e n e r a l i z e d  
p h o t o  r e l a t e d  
fl a r e  6 w e e k s  
a f t e r  d i s c o n t i n u ­
a t i o n  s u c c e s s ­
f u l l y  t r e a t e d  w i t h  
h y d r o x y c h l o r o ­
q u i n e ,  a l t o g e t h e r  
e r u p t i o n  c o n t i ­
n u e d  f o r  s e v e r a l  
m o n t h s  a f t e r  
d i s c o n t i n u a t i o n  





Activity of LE 
Author/ Age 
type of (years} Laboratory/di-
LE LE type /sex nlcally 
Ting No prior 53/F ANA 1 : 640-
200411 history 1 : 1 080 nucleolar, 










Parade/a ACLE 72/F Leuco- and lym-
2007n likely for phopenia, anae-
ACLE l·S years mia, decreased 
C3 and C4, ANA 
1 : 320 nucleolar, 
positive ENA and 
anti ribosomal 
antibody, elevated 
liver function tests 
'TEN/SJS'-llke features 
lmmunosup-
presslve Lesions/time of deve-
medication LE-specific skin lesions lopment Localization 
No No Afebrile, acute onset, Face, neck, 
dusky, partly patchy ery- trunk and 
thema with numerous extremities, 
intact, but also denuded photodistribu-
bullae, associated with tion (tanning 
positive Nikolsky sign bed), palms 
and soles 
uninvolved 
Prednisone During the previous No fever or systemic Face neck, 
15 mg daily 1 ·5 years 2 episodes of symptoms, painful trunk and 
erythematous papular generalized slightly extremities, 
eruption on upper squamous erythema, involving 
trunk. Later discoid LE bullae, erosions with > 70% BSA 
lesions haemorrhagic crusts; 
Nikolsky negative; palms 





ment Description Figure 
Small ero- Biopsy blister edge: OK 
sion of the subepidermal blister-
tongue ing with full-thickness 
epidermal necrosis, 
adjacent epidermis 
with marked basal 
layer necrosis with 
satellite cell necrosis, 
mild lymphohistiocytic 
infiltrate at the DEJ 
and superficial and 
deeper perivascular 
infiltrates; DIF granular 
C3, fibrinogen at BMZ, 
perivascular granular 
C3, lgM, lgG 
No, in the Hyperkeratosis (from OK 
course one microphotograph), 
ulcer on the atrophic epidermis, 
hard palate necrotic keratinocytes 








mild dermal mucin; DIF: 




Nap- IVIG 0·75 g kg·' 
roxen since daily for 7 days, 
6 months, methylpredni-
rabeprazole so lone 40 mg 2 










gabapentin lone 20 mg for 
3 days, followed 
by prednisone 
1 mg kg·1 
daily tapered 
over 2 weeks, 
discharged 
with 15 mg and 
complete heal-
ing of eroded 
lesions within 
3 weeks 1 year 
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A c t i v i t y  o f  L E  
' T E N / S J S ' - l l k e  f e a t u r e s  H i s t o l o g y  
M u c o u s  
A u t h o r /  A g e  l m m u n o s u p - m e m b r a n e  
t y p e  o f  ( y e a r s )  L a b o r a t o r y / e l l - p r e s s l v e  L e s i o n s / t i m e  o f  d e v e -
i n v o l v e -
C u l p r i t  
L E  
L E  t y p e  / s e x  
n i c a l l y  m e d i c a t i o n  L E - s p e c i fi c  s k i n  l e s i o n s  l o p m e n t  L o c a l i z a t i o n  m e n t  D e s c r i p t i o n  F i g u r e  d r u g ( s )  
O u t c o m e  
S i m s e k  
S L E  fo r  2 8 / F  
P o l y a r t h r i t i s ,  P r e d n i s o l o n e  S u b a c u t e  p r e s e n t a - A f e b r i l e ,  s y s t e m i c a l l y  E r y t h e m a  f a c e ,  N o  m u c o s a !  F u l l - t h i c k n e s s  e p i d e r - N o  N o  
A t  a d m i s s i o n  
2 0 0 8
2 4  
7 y e a r s  
p l e u r i s y ,  5  m g  d a i l y  t i o n  o v e r  w e e k s  w i t h  w e l l ;  3  w e e k s  h i s t o r y  o f  a r m s ,  u p p e r  i n v o l v e - m a l  n e c r o s i s ,  s e p a r a -
i . v .  m e t h y l -
S L E  p h o t o s e n s i t i v i t y ,  w i d e s p r e a d  e r y t h e m a ,  w i d e s p r e a d  e r y t h e m a ,  c h e s t ,  g r a d u - m e n t  
t i o n  e p i t h e l i u m  a n d  
p r e d n i s o l o n e  
A N A ,  a n t i - d s D N A ;  m u l t i p l e  b u l l a e  g r a d u a l l y  b e c o m i n g  a l l y  g e n e r a l - s p a r s e  l y m p h o c y t i c  
1 0 0 0  m g  d a i l y  
l e u c o p e n i a ,  b u l l o u s  a n d  g e n e r a l i z e d  i z e d  i n fi l t r a t e  u p p e r  d e r m i s ;  
3  d a y s  f o l l o w e d  
a n t i - D N A  1  :  1 0 8 0 ,  a n d  d e t a c h m e n t  7 0 %  D I F  g r a n u l a r  l g G ,  f a i n t  
b y  i n c r e a s i n g  
a n t i - d s D N A  
B
S A ,  u n a f f e c t e d  p a l m s ,  
l g A  a n d  C 3  a t  B M Z  
p r e d n i s o l o n e  t o  
1 4 0  I U  m L · '  s o l e s  8 0  m g  d a i l y  a n d  
s i m u l t a n e o u s l y  
I V I G  2 5  g  d a i l y  
5  d a y s  w i t h o u t  
i m p r o v e m e n t  
a n d  p r o g r e s s i o n  
t o  >  9 0 %  
B
S A  a t  
d a y  1 5  a n d  s t a r t  
p l a s m a p h e r e s i s  
t w i c e  a  w e e k s  
s e s s i o n s  w i t h  
p r e d n i s o l o n e ;  
a t  3  w e e k s  
m a r k e d  d e c r e a s e  
d e t a c h m e n t ;  
a f t e r  5  w e e k s  
i n  h o s p i t a l  
a l m o s t  c l e a r e d ;  
s y m p t o m  f r e e  
a t  1 8  m o n t h s  
o n  h e r  e a r l i e r  L E  
m e d i c a t i o n  
A N A ,  a n t i n u c l e a r  a n t i b o d i e s ;  A C L E ,  a c u t e  c u t a n e o u s  L E ;  B M Z ,  b a s a l  m e m b r a n e  z o n e ;  B S A ,  b o d y  s u r f a c e  a r e a ;  D E J ,  d e r m o e p i d e r m a l  j u n c t i o n ;  D I F ,  d i r e c t  
i m m u n o f l u o r e s c e n c e ;  d s D N A ,  d o u b l e - s t r a n d e d  D N A ;  E N A ,  e x t r a c t a b l e  n u c l e a r  a n t i g e n ;  I V I G ,  i n t r a v e n o u s  i m m u n o g l o b u l i n ;  N . m . ,  n o t  m e n t i o n e d ;  R F ,  r h e u m a t o i d  
fa c t o r ;  S L E ,  s y s t e m i c  L E .  
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Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with lupus erythematosus 
Discussion 
Patients with LE and extensive, partly bullous or erosive exanthema can be misinterpreted as 
SJS or TEN. Differentiation between SJSffEN in patients with LE and TEN-like LE is sometimes 
complicated and relies on thorough analysis of complete clinical and histopathological data. 
Unfortunately, most blistering skin lesions seen in the context of LE have been lumped into 
the broad designation of 'bullous LE� However, a clear differentiation must be made between 
'bullous SLE'in the strict sense, developing as a result of subepidermal blistering with neutrophilic 
infiltrate, clinically characterized by blisters being tense and raised, and bullous lesions in LE as 
a result of dramatic extension of the interface dermatitis.9 Usually, LE-specific vesiculobullous 
skin lesions in LE develop as a result of the latter. Marked necrosis of keratinocytes of the 
(supra)basal layer and vaculoar degeneration lead to subepidermal blistering and almost full­
thickness epidermal necrosis. Blisters can appear on active borders of annular lesions in SCLE or 
on chronic discoid LE lesions and can also develop in ACLE in patients with SLE.22 Mandelcorn 
and Shear reported two patients with LE-associated TEN with features different from classic 
TEN and speculated about a novel manifestation.1 9 However, it remains unclear whether or 
not such cases are indeed related to TEN or represent 'TEN-like LE Also, drug-induced SJS with 
'concomitant aggravation of LE' has been reported.36 Moreover, several case reports and small 
case series suggested that (S)LE is a risk factor for developing SJSffEN.40-42 In the international 
case-control study on SCAR as well as in the later EuroSCAR study, the frequency of so-called 
collagen vascular disease including SLE, rheumatoid arthritis, scleroderma, etc. was much higher 
in patients with SJSffEN than in those with EEMM and control subjects. However, to date, (S)LE 
could not be identified as a risk factor by itself. 
One special clinical expression of vesiculobullous LE was described by Rowell et a/. in 1 963.43 
They first described an erythema multiforme-like cutaneous eruption in LE in the setting of 
positive (speckled) antinuclear antibodies, anti-La/SS-B antibodies and rheumatoid factor 
without identifiable precipitating cause.43 Progression to TEN has not been noted.19 However, 
more recently published cases also reported TEN-like features.44.45 Braverman suggested Rowell's 
syndrome as a limited form of 'TEN-like' ACLE or SCLE, both entities sharing the same pathogenic 
process.18 
Furthermore, drug-induced LE more frequently is bullous.46.47 Time latency between 
initiation of a drug and onset of LE ranges from 4 to 20 weeks.46 Systemic manifestations are 
usually lacking. Data in the literature concerning the presence of antihistone antibodies are 
controversial and several authors do not consider them to be serological markers of drug­
induced SCLE, although they are present in up to 95% of drug-induced SLE cases.46•48 Most 
patients experience improvement or resolution of skin lesions within 8 weeks and decrease of 
titres of anti-Ro/SS-A, if present, within 8 months after discontinuation of drug treatment.46 
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SCLE and ACLE, in particular, may share clinical features of SJS/TEN. Generalized ACLE may 
present with morbilliform or maculopapular exanthema, spreading symmetrically, often also 
involving the palms and soles and the back of the hands and extensor surfaces of the fingers. 
Bullous lesions with epidermal detachment and painful mucosa! erosions and ulcerations 
affecting the mouth (mostly focally on the hard palate, but also buccal mucosa, gingiva and 
uvula}, nose, pharynx and vagina as well as the orificium urethrae may develop. The lips may 
present as erosive, crusty cheilitis.49 Generally, about 20% of patients with LE have a history of 
oral ulcers at the onset of disease.50•51 However, oral ulcers are rare and mostly focal.22•51 
This study in a nation-wide registry allows detailed analysis of clinical and histopathological 
features of validated cases of SJS/TEN with a history of (S}LE. Contributing to the reliability of the 
diagnosis of SJS/TEN are the prospective and structured inclusion, data collection and validation, 
independent of outcome, exposure to medication or other risk factors. On the other hand, the 
nature of our study introduces the risk of underscoring the incidence of SJS/TEN in patients with 
a history of (S}LE. Retrospective retrieval of additional data on (S}LE and histological material 
implicates less complete information, resulting in insufficient substantiation of (S}LE, and/or 
unobtainable/irrelevant histological material, leading to exclusion of potential cases. Moreover, 
potential cases may have been missed when SJS/TEN was not suspected but lesions were 
directly ascribed to (S}LE by the treating physician. 
In all cases, clinical and histopathological diagnostic criteria for SJS/TEN were in 
principle fulfilled. Although all patients also had a history of (S}LE, diagnosis of SJS/TEN was 
straightforward in nine of the 17 cases. These cases did not feature typical LE morphology, 
distinct photodistribution, LE flare shortly before the event or four or more histopathological 
features of LE. Furthermore, all had evident mucosa! erosions, which in seven patients were not 
restricted to the lips and/or mouth. 
In the other eight patients, sex, age (average age 47 years, range 30-78), mortality rate (37%}, 
immunosuppressive therapy before the event (75%}, median time between the index-day and 
the date of maximum blisters and erosions (8·5 days, range 4-12), and drug causality did not 
significantly differ from the total group of validated registry cases. However, several features did 
interfere with a straightforward diagnosis of SJS/TEN. Histopathological LE features (case 5), a 
preceding LE exacerbation (cases 9 and 15) or a combination of both (case 17) were interfering in 
four cases, while in the remaining four (cases 4, 6, 11 and 13) both clinical and histopathological 
LE features were found. Three of these (cases 4, 6 and 13) had exanthematic, often widespread 
LE-suspicious skin lesions weeks to months prior to the event. Mucous membrane involvement 
was absent in two (cases 11 and 13), compared with presence in all other patients. Evident 
photodistribution was recognized in cases 6, 9, 11 and 13. Positive anti-Ro or anti-La antibodies 
were mentioned in five of the eight cases, but only in one of the remaining nine patients. 
Based on knowledge of the complete data, including medication and other risk factors, 
additionally supplied information on history of (S}LE and histopathological refinements, 
diagnosis in four cases was re-evaluated as SJS with concomitant histological features of LE 
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(case 5), SJS/fEN-overlap and EEMM/SJS, respectively, with an exacerbation of LE 1 month 
before the event (cases 15 and 9), and SJS/fEN-overlap with a relapse of cutaneous features 
of SLE 2 months before the event and concomitant histological features of LE (case 17). In four 
patients, a bullous manifestation of LE with a SJS/fEN-like appearance was more likely: 'SJS/TEN­
like' SCLE/SLE (case 4), 'SJS/fEN-like' SLE (case 6) and 'SJS-like' (S)CLE and SLE (cases 11 and 13, 
respectively) (Fig. 3a-c; case 11 ). 
In a retrospective analysis of SLE in 500 children, the prevalence of SJS was 1 ·2%.40 However, 
criteria used for diagnosing SJS do not correspond to the criteria accepted nowadays and it 
is likely that the prevalence was considerably overestimated due to EEMM considered as SJS, 
especially in children.40.42 
The frequency of (S)LE in the registry on SJS/fEN was 17 out of 1362 (substantiated) and 27 
of 1362 (potentially), taking into account the excluded cases due to insufficient information on 
(S)LE, inappropriate histological material, and re-evaluation of SJS/fEN cases (1 ·2-2%). 
The spectrum of drugs inducing SJS/fEN and LE is different.46•52•53 Drugs highly suspected of 
causing SJS/fEN (allopurinol, three cases, and co-trimoxazole, two cases) were proportionally 
more often present in cases re-evaluated as SJS/fEN than in 'TEN-like' (S)LE.40-42 Whether or 
not SLE is an independent risk factor for SJS/fEN is a matter of debate. The proportional over­
representation in our study might also be due to co-dependent risk factors such as use of 
immunosuppressive drugs, or other shared risk factors such as genetic make-up resulting in a 
possible shared mechanism of acute diffuse epidermal apoptosis with associated production 
of inflammatory cytokines. From the results of the EuroSCAR study, it could not be concluded 
whether or not corticosteroids are a direct cause of SJS/fEN, a risk factor because of modifying 
the immune response, or a confounder.52 Striking in that study was the fact that the multivariate 
relative risk for corticosteroids was restricted to the first 8 weeks of use, while the patients in 
this study were generally on long-term use. Although numbers are too small for statistically 
significant conclusions, the interval between the index-day and the date of maximum extent 
Figure 3. Case 1 1 . A female patient with Stevens-Johnson syndrome-like cutaneous lupus erythematosus. 
(A) Erythematous erosive papules and plaques on the trunk. (B) Atrophic epidermis with compact 
hyperkeratosis. Scant vacuolar alteration at the dermoepidermal junction (DEJ)  together with solitary 
necrotic keratinocytes mostly at lower levels [haematoxylin and eosin (H&E); original magnification x 1 00]. 
(C) Complete epidermal necrosis, vacuolar alteration at the DEJ of a sebaceous gland with solitary necrotic 




of detachment was generally slightly shorter in SJS/TEN cases compared with TEN-like LE. As 
illustrated by our study, the generally accepted qualification 'TEN-like' does not only concern 
cases mimicking TEN, but also the less severe variants-SJS and SJS/TEN-overlap. 
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Chapter 4 
Summary 
Background: Acute generalized exanthematous pustulosis (AGEP) is a rare severe pustular 
reaction pattern with a typical clinical picture. 
Objectives: To characterize the histopathological features of AGEP in a large series of cases with 
a validated diagnosis. 
Methods: A multinational retrospective histopathological study was conducted. It included 102 
hospitalized patients (recruited within the EuroSCAR and RegiSCAR studies) with a validated 
diagnosis of probable or definite AGEP. A systematic description of the histopathological 
features in AGEP was done based on a standardized grading system. 
Results: Sub/intracorneal pustules (41 %), intraepidermal pustules (20%) or combinations of 
them (38%) were observed in 102 cases. The pustules were usually large (> 15 keratinocytes) 
(82% and 89%, respectively) and regularly contained eosinophils (36% and 32%, respectively). 
Spongiform features were less prominent in the sub/intracorneal pustules compared with 
the intraepidermal pustules (44% and 95%, respectively). The main epidermal features were 
necrotic keratinocytes (67%), including incidental segmental necrosis (7%), and spongiosis 
(80%) with neutrophil exocytosis (77%). The main dermal features were papillary oedema 
(88%) and mixed superficial (100%), interstitial (93%), and mid/deep-dermal infiltrates (95%) 
containing neutrophils (100%) and eosinophils (81%). Follicular pustules were also seen (23%), 
but vasculitis generally was absent. Classical features of plaque-type psoriasis were infrequent 
and usually mild. No significant differences were observed between a subgroup of 16 cases with 
and 86 cases without psoriasis. 
Conclusions: The present histopathological study concerns a large series of cases with a 
validated diagnosis of AGEP. It provides diagnostic clues in favour of AGEP in patients with a 
pustular eruption. 
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Introduction 
Acute generalized exanthematous pustulosis (AGEP) is a rare, severe, acute-onset pustular 
reaction pattern characterized by a typical clinical picture and course. AGEP is attributed 
mostly to drugs, although other aetiologies such as viral infections due to human parvovirus 
B19, cytomegalovirus and Coxsackie B4, hypersensitivity to mercury and spider bite have been 
implicated.1 •1 2 
Clinically, AGEP is characterized by the sudden appearance of dozens of sterile, nonfollicular 
pinhead-sized pustules arising on oedematous erythema with a predilection of the big folds, or 
widespread distribution. Mild, nonerosive mucous membrane involvement (mostly oral) may 
occur in about 20% of cases. Other skin symptoms, such as marked oedema of the face, purpura, 
'atypical target-like lesions' and blisters have been described but are not typical for AGEP. The 
course of AGEP is characterized in most cases by fever (� 38 °C) and elevated blood neutrophil 
count (� 7·0 x 109 L-1). Mild eosinophilia may be present in about one-third of patients.1 3 
Pustules resolve spontaneously within a few days, followed typically by postpustular, pin-point 
desquamation. The reaction resolves fully in � 15 days. Internal organs are generally not involved 
and the disease has a favourable prognosis, although secondary infection might pose a danger 
to patients in poor general medical condition. The reported mortality is 5%.14 
Eruptions similar to AGEP have been described in the literature as toxic pustuloderma 
or pustular drug eruption, 15-21 or have been interpreted as special variants of other pustular 
diseases, such as exanthematic pustular psoriasis (PP), suspected to be triggered by drugs or 
infections.22•23 
Knowledge of the histopathology of AGEP is based primarily on case reports and a few 
clinical studies.1 ,3A,1 3,24-29 The aim of the present study was to characterize the histopathological 
features in a large series of cases with a validated diagnosis of AGEP. 
Patients and methods 
Source of patients 
The patients with AGEP came from two multinational studies devoted to Severe Cutaneous 
Adverse Reactions (SCAR): The EuroSCAR study, conducted in France, Germany, Italy, the 
Netherlands, Austria, Spain and Israel during the years 1997-20012•30 and the RegiSCAR study, 
conducted in France, Germany, Italy, the Netherlands, Austria and Israel since 2003.31 •32 In 
both studies AGEP cases were actively detected in a network of hospitals in Europe and Israel. 
Potential AGEP cases were patients admitted to hospital due to acute pustular skin reactions (i.e. 
community cases) or who developed such reactions during a hospital stay (i.e. hospital cases). 
They had dozens of pustules that could not be attributed to another definitive diagnosis. All 
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patients gave written informed consent to participate in these studies. The study was approved 
by the Helsinki Committee of each participating centre that recruited patients. 
Case validation 
An international committee of experts validated the diagnosis of AGEP based on a special 
standardized scoring system that was developed in the EuroSCAR study, the AGEP validation 
score.2•33 Based on the score, patients were either excluded from the study or classified as 
definite, probable or possible cases. 
Inclusion of cases 
The present study population comprised patients with a definite or probable diagnosis of AGEP 
and a skin biopsy with slides available for histopathological investigation. 
Histopathological evaluation 
The histopathological study was performed on haematoxylin and eosin-stained sections. All 
four readers viewed the same slide with a multi headed microscope and discussed it together at 
that time. When several sections were available for a particular patient only the most informative 
specimen was chosen, based on the proper representation of the epidermis and dermis and 
the presence of an acute inflammatory process, preferentially including a pustule. When several 
pustules were present in a section, the largest was evaluated. 
Evaluation was based on a standardized list of histopathological parameters used for the 
diagnosis of AGEP. A severity scale of the various histopathological parameters, ranging from 0 
to 3, was developed (Table 1 ), and the degree of severity was determined by consensus. 
Analysis and statistics 
Data were analysed using SPSS version 12 (SPSS, Chicago, IL, U.S.A.). The frequencies of different 
variables in two subgroups (with and without a background of psoriasis) were compared using 
the t-test for continuous variables, or the x2 or Fisher's exact test for differences in proportions, 
as appropriate. 
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> 2 cells 2 
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Granular cell layer/parakeratosis" 
Absent 0 
Up to 1 /3 the length of the biopsy 1 
Up to 2/3 the length of the biopsy 2 
Almost total 3 
Suprapapillary plate thinning1 
1 papilla 
2 papi llae 2 
> 2 papillae 3 
Tortuous and dilated blood vessels/vasculitis9 
1 vessel 
2 vessels 2 
> 2 vessels 3 
Rete ridges elongation/clubbing/fusion 
1 1 
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Number per high power field (x40 magnification) 
•In cases with several pustules, the largest is used. hAccumulation of microaggregates of neutrophils 
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The present study included 102 cases with a definite or probable diagnosis of AGEP: 86 of 134 
cases from the EuroSCAR study and 16 of 70 cases from phase I of the RegiSCAR study (cases 
enrolled in the study until the end of 2004). Seventy cases (69%) originated from France, 22 (22%) 
from Israel (see Ref. 5 for the clinical profile of nine cases), and 10 (10%) from the Netherlands. 
A personal history of psoriasis was recorded in 16 cases (16%) (11 from the EuroSCAR study and 
five from the RegiSCAR study). 
The skin biopsies were taken from a known clinical lesion in only 45 of the 102 cases (44%): 
40 biopsies (39%) were obtained from pustules (sometimes associated with erythema, oedema 
or purpura) and five (5%) from nonpustular clinical lesions, described as erythema or oedema. 
The prevalence rates of the broad range of histopathological parameters seen in the 102 
cases are presented in Table 2. Pustules were found in 94 cases (92%) and the location of the 
pustules was sub/intracorneal in 41 %, intraepidermal in 20%, and combined in 38%. In addition 
to subcorneal pustules, subcorneal pustules contiguous with intracorneal pustules, and 
intracorneal pustules were also seen. The intraepidermal pustules were located in the upper 
part of the epidermis, most often contiguous with subcorneal or sub/intracorneal pustules. The 
sub/intracorneal and intraepidermal pustules were usually large (> 15 keratinocytes) in 82% and 
89%, respectively, and regularly contained eosinophils (36% and 32%, respectively). Spongiform 
features were less prominent in the sub/intracorneal pustules compared with the intraepidermal 
pustules (44% and 95%, respectively). Follicular pustules were seen in 22 cases (23%). They 
were accessory, predominant, or alone. The main epidermal features (Fig. 1-3) were necrotic 
keratinocytes (67%) including segmental necrosis (7%), and spongiosis (80%) with neutrophil 
exocytosis (77%). The main dermal features were papillary oedema (88%), mixed superficial 
(100%), interstitial (93%), and mid/deep-dermal infiltrates (95%) containing neutrophils (100%) 
Figure 1 .  Large nonspongiform Figure 2. Small subcorneal pus- Figure 3. Large spongiform in­
subcorneal pustule, papillary tule, presence of neutrophils traepidermal pustule with necrot­
oedema, and erythrocyte extrava- and eosinophils in the epidermis ic keratinocytes and spongiosis in 
sation (H&E, original magnification and in the superficial dermis (H&E, the lower part of the epidermis. In 
20x1 O). original magnification 40x1 O). the dermis there is discrete leuco-
142 
cytoclasia, but no vasculitis (H&E, 
original magnification 20x1 O) 
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and eosinophils (81%). Erythrocyte extravasation (54%) was also observed, but vasculitis 
occurred only once (1 %). Classical features of plaque-type psoriasis were infrequent and usually 
mild. These included the presence of Munro abscesses (17%), parakeratosis (62%), suprapapillary 
plate thinning (7%), tortuous and dilated blood vessels (16%), and absence of the granular layer 
(3%). The calculated mean mitosis was 0-95 per high-power field at magnification x40. 
Table 2. The prevalence of histopathological parameters in 102 patients with acute 
generalized exanthematous pustulosis 
Histopathological parameter 
Pustules 










Presence of eosinophils 
Combined (sub/intracorneal and intraepidermal) 
Follicular pustules 






Exocytosis of neutrophils 
A few 
Necrotic keratinocytes 
1 -2 keratinocytes 
> 2 keratinocytes 
Segmental necrosis 
Dermis 




Superficial infi ltrates 
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39 (41 )  
3 2  (82) 
4 (1 0) 
1 7 (44) 
1 4 (36) 
1 9 (20) 
1 7  (89) 
2 (1 0) 

























Histopathological parameter Degree of severity Prevalence (%) 
Interstitial infiltrates 95 (93) 
Discrete 38 (40) 
Moderate 2 36 (38) 
Dermal neutrophils 1 02 ( 100) 
A few 1 24 (23) 
Scattered 2 60 (59) 
Dermal eosinophils 83 (81 ) 
A few 61 (73) 
Vasculitis 1 (1 ) 
Erythrocyte extravasation 55 (54) 
1 -2 cells 1 27 (49) 
> 2 cells 2 26 (47) 
Many 3 2 (4) 
Classical plaque-type psoriatic changes 
Munro abscess 1 7  ( 1 7) 
1 0  (59) 
� 2  2, 3 7 (41 )  
Granular cell layer 99 (97) 
None 0 3 (3) 
Parakeratosis 63 (62) 
Mild 35 (55) 
Moderate 2 24 (38) 
Hyperkeratosis 26 (25) 
Mild 25 (96) 
Suprapapil lary plate thinning 7 (7) 
Mild 7 (1 00) 
Tortuous and dilated blood vessels 1 6  ( 16) 
Mild 8 (SO) 
Moderate 2 8 (50) 
Rete ridge elongation 78 (76) 
Mild 38 (49) 
Moderate 2 32 (41 )  
Rete ridge clubbing 52 (51 )  
Mild 39 (75) 
Rete ridge fusion 83 (81 ) 
Mild 35 (42) 
Moderate 2 39 (47) 
Mitosis 
Number per high-power field (x40 magnification) Mean 0-95 
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Three levels of prevalence were observed. All AGEP cases showed superficial infiltrates (mostly 
moderate) and dermal neutrophils (mostly scattered). Additional features observed in 80-99% of 
AGEP cases were large sub/intracorneal or intraepidermal pustules, spongiform intraepidermal 
pustules, spongiosis (mostly mild), papillary oedema, mid/deep-dermal infiltrates (mostly 
discrete), interstitial infiltrates (mostly discrete to moderate), dermal eosinophils (usually just a 
few), absence of vasculitis, presence of granular cell layer, fusion of rete ridges (mild to moderate), 
and absence of classical features of plaque-type psoriasis (Munro abscesses, suprapapillary 
plate thinning, tortuous and dilated blood vessels, and a high mitotic rate). Additional features 
observed in 50-79% of AGEP cases were necrotic keratinocytes, parakeratosis, extravasation 
of erythrocytes, exocytosis of neutrophils (usually just a few), rete ridge elongation (mild to 
moderate), and clubbing (mostly mild). 
There were no statistically significant differences in the prevalence of histopathological 
parameters between a subgroup of 16 AGEP cases (16%) with a personal history of psoriasis and 
the 86 AGEP cases with no personal history of psoriasis (data not shown). 
Discussion 
The present study, which focused on the histopathological evaluation of AGEP, included unique 
features in design and methodology: (i) the study population consisted of patients recruited in 
two multinational studies with a validated diagnosis of probable or definite AGEP; (ii) validation 
of the diagnosis was based on a special standardized scoring system, the AGEP validation 
score;2•33 (iii) it included the largest series of AGEP cases; (iv) the histopathological evaluation of 
AGEP was based on direct investigation of the slides by four investigators using a multi headed 
microscope; and (v) evaluation was based on a standardized grading system developed by the 
authors, related to pustules, epidermis, dermis, and psoriasis-like changes. 
The main histopathological findings, in a previous clinical study of 63 cases of AGEP1 3  with 64 
biopsies from 48 patients reviewed by two investigators, were superficial spongiform pustules 
(66%), papillary oedema (61 %), polymorphous perivascular infiltrate with eosinophils (34%), 
and leucocytoclastic vasculitis with fibrinoid deposits (20%). Focal necrosis of keratinocytes was 
observed in 25% and the epidermis was normal or spongiotic without psoriasiform hyperplasia 
in 61%. 
lncomparison,thepresentstudyof102AGEPcasesdisclosed severaluniquehistopathological 
features: (i) sub/intracorneal pustules and intraepidermal pustules, often contiguous with sub/ 
intracorneal pustules; (ii) pustules that showed a higher prevalence of spongiform features (95% 
of intraepidermal pustules); (iii) a higher prevalence of necrotic keratinocytes (67%), papillary 
oedema (88%) and dermal eosinophils (81 %); (iv) a marked prevalence of interstitial and mid/ 
deep-dermal infiltrates (93% and 95%, respectively) and of dermal neutrophils (100%), not 
emphasized previously; (v) psoriasiform hyperplasia (rete ridge elongation, clubbing and fusion 
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at rates of 76%, 51 % and 81 %, respectively) that was usually mild, although more common 
than previously reported. Munro abscesses, which are generally associated with psoriasis, 
were observed in 17% of cases; (vi) on the other hand, vasculitis, which was strictly defined by 
the presence of vascular fibrinoid alteration and leucocytoclasia, was observed in the present 
study only once, indicating that vasculitis is not a diagnostic feature of AGEP. As erythrocyte 
extravasation occurred in 54% of cases, the previously reported high rate of vasculitis in AGEP 
might be attributed to misinterpretation of leucocytoclasia and/or erythrocyte extravasation 
as vasculitis, or to a diagnostic confusion of AGEP with pustular vasculitis.34 (vii) Histologically, 
follicular pustules were found in 23% of cases. Although the distribution of the pustular 
eruption in AGEP is mostly nonfollicular, 13 the occurrence of follicular pustules in association 
with nonfollicular pustules has been reported.3•5 Thus, the presence of follicular pustules would 
appear not to exclude the diagnosis of AGEP. 
Differences between the histopathological features of AGEP reported in various case reports 
and clinical studies might be attributed to case definition or different stages in the evolution of 
the skin lesions analysed. It was shown in a study of 21 AGEP cases26 that the histopathological 
features vary in relation to the age of the skin lesion. Thus, biopsies of early lesions showed 
marked to moderate papillary dermal oedema and a mixed dermal inflammatory infiltrate, 
often with erythrocyte extravasation, and some leucocytoclasia. Biopsies of well-developed 
lesions showed spongiform pustules within the epidermis and occasional dyskeratotic cells with 
residual perivascular dermal oedema. Although no definitive vasculitis was seen, leucocytoclasia 
was observed within the dermal infiltrate in the majority of biopsy specimens obtained > 48 h 
after the onset of the eruption. 
A wide spectrum of pustular reactions can easily be differentiated from AGEP both clinically 
and histologically (e.g. bacterial folliculitis, acne, dermatophyte infections, impetigo, infantile 
chronic acropustulosis, Sweet syndrome, lgA pemphigus, necrolytic migratory erythema, bowel 
bypass syndrome, Behc;et disease and staphylococcal scalded skin syndrome). However, the 
differential diagnosis between AGEP and generalized PP, especially the acute von Zumbusch 
type, may be difficult clinically and histologically. Various histological features in PP bear 
similarity to AGEP, including superficial spongiform pustules, neutrophils beneath the stratum 
corneum, acanthosis and papillary oedema. On the other hand, characteristic for PP is the 
spongiform macropustule, arising from neutrophils that migrate from the dermal papillary 
capillaries into the epidermis, while dermal infiltrates are superficial and lymphocytic, usually 
lacking eosinophils. In addition, classical epidermal changes of psoriasis vulgaris vary and may 
be rather prominent in PP.35•36 
Several histopathological features that were observed in the present study may point to 
the diagnosis of AGEP. These include superficial spongiform pustules, spongiosis, exocytosis of 
neutrophils, necrotic keratinocytes, papillary oedema, mixed dermal infiltrates, including mid/ 
deep-dermal and interstitial infiltrates, containing neutrophils and eosinophils, and the paucity 
of classical plaque-type psoriatic changes (i.e. Munro abscesses, absence of granular layer, 
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suprapapillary plate thinning, tortuous and dilated blood vessels). The diagnosis of AGEP may 
be based on these key histopathological features combined with clinical signs in favour of AGEP 
including an abrupt onset, a short duration (� 15 days), association with recently introduced 
drugs, spontaneous resolution after withdrawal of the culprit drugs, and a nonrecurrent 
tendency.2•6•1 3  
I t  has been reported that AGEP may occur in patients with psoriasis.2•1 3 Accordingly, AGEP 
has been alleged to be a variant of PP, that could be triggered by a variety of exogenous factors 
such as drugs or infections. 1 3•22-25•37 In the present study a personal history of psoriasis was 
recorded in 16 (16%) of the 102 AGEP cases. No significant differences were observed between 
the subgroup of 16 AGEP cases with a personal history of psoriasis and the other 86 AGEP cases. 
Nevertheless, our study does not support the assumption that any acute pustular eruption 
occurring in patients with a psoriatic background is necessarily PP. 
Several of the prevalent key features in favour of AGEP may imply its aetiopathogenesis: 
1. The prominent presence of eosinophils in the skin of patients with AGEP, both within the 
pustules and in the dermis, is in agreement with the presence of blood eosinophilia observed 
in about a third of patients with AGEP.1 3 The presence of tissue and blood eosinophilia, which 
is a hallmark of many drug-induced allergic reactions, suggests that AGEP is a hypersensitivity 
reaction, probably drug-induced.38•39 Eosinophilia observed in AGEP may be attributed to the 
rare presence of interleukin (I L)-8/CXCL8-producing T-cell clones, which display a Th2-type 
cytokine profile with high IL-4 and IL-5 secretion.40-42 
2. The presence of necrotic keratinocytes in AGEP has been reported in other drug eruptions 
including exanthematic drug eruptions and drug eruptions characterized primarily by interface 
dermatitis such as lichenoid drug eruptions, Stevens-Johnson syndrome (SJS), toxic epidermal 
necrolysis (TEN) and fixed drug eruptions.43 Although SJS and TEN are drug-induced reactions 
manifested by full-thickness epidermal necrosis and only a very sparse inflammatory infiltrate, 
some similarity may exist between AGEP and SJS orTEN .27•44 The necrotic keratinocytes observed 
in AGEP can be induced by cytotoxic drug-specific T cells (CD8+ or CD4+).45 
3. The neutrophilic inflammation observed in AGEP is unusual in allergic drug reactions. The 
prominent presence of dermal neutrophils in AGEP may reflect their recruitment by the potent 
neutrophil-attracting chemokine IL-8/CXCL8, secreted by drug-specific T  cells (CD4+ and CDS+) 
and keratinocytes. Factors produced by the IL-8/CXCL8-producing T cells reduce neutrophil 
apoptosis, thus enhancing neutrophil survival and leading to the sterile pustular eruption found 
in AGEP.39-42 
4. The mid/deep-dermal perivascular infiltrates and extravasation of erythrocytes which were 
observed in AGEP have been reported in other drug-induced eruptions, even in the absence of 
vasculitis, and may point to a drug aetiology.38•46 
In conclusion, the present study, conducted in a large series of patients with AGEP with a 
validated diagnosis, disclosed a spectrum of histopathological features that provides additional 
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support for the concept that AGEP is a separate entity that can occur as an acute episode, even 
in patients with psoriasis. 
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Chapter 5 
Abstract 
Background: Acute generalized exanthematous pustulosis (AGEP) represents a severe, acute, 
pustular skin reaction that is most often induced by drugs. AGEP can be difficult to differentiate 
from generalized pustular psoriasis (GPP) both clinically and histopathologically. We present 
a systematic description of the histopathological spectrum of AGEP and GPP with a focus on 
discriminating features. 
Materials and methods: A retrospective, descriptive, comparative histopathological study 
was completed utilizing step sections of 43 biopsies of 29 cases with a validated diagnosis of 
probable or definite AGEP and 24 biopsies of 19 cases with an established diagnosis of GPP. 
Results: In AGEP, biopsies from erythema and pustules showed minor differences, whereas 
histopathology of the acute stage of GPP showed major differences compared to the chronic 
stage. Comparing AGEP and GPP, the presence of eosinophils, necrotic keratinocytes, a mixed 
interstitial and mid-dermal perivascular infiltrate and absence of tortuous or dilated blood 
vessels were in favor of AGEP. Moreover, chronic GPP was characterized by prominent epidermal 
psoriatic changes. The frequency of a psoriatic background of AGEP patients in our study was 
higher than that of psoriasis in the general population. However, histopathology of a subgroup 
of AGEP patients with a personal history of psoriasis revealed no significant differences from the 
other AGEP patients. 
Conclusions: The spectrum of histopathological features of both AGEP and GPP is presented. 
Despite considerable overlap, subtle consistent histopathological differences and the grade 
of severity of specific features can help in differentiation. We could neither substantiate earlier 
reports that follicular pustules exclude AGEP nor did we see vasculitis as a specific feature in 
AGEP. Our study also supports the concept that AGEP is a separate entity that is distinct from 
GPP. 
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and its differentiation from generalized pustular psoriasis. 
I ntroduction 
In  the past, most widespread sterile pustular eruptions were classified as  generalized pustular 
psoriasis (GPP), a rare variant of psoriasis with several subtypes. The most severe and recalcitrant 
variant, the von Zumbusch type, is characterized by an acute generalized eruption of pustules 
on an erythematous base, sometimes lasting for weeks and often accompanied by fever and 
leukocytosis. Other types, such as annular pustular psoriasis, are subacute or even chronic and 
can either be widespread or localized. Psoriasis vulgaris may proceed, accompany or follow the 
pustular episode.1 -3 
In 1968, in a comprehensive review of 104 cases of GPP, Baker and Ryan1 identified on clinical 
grounds five cases of exanthematous pustular psoriasis with short self-limiting courses which 
were presumably precipitated by infections and/or drugs. In 1980, Beylot et al.4 termed this rare 
reaction type as acute generalized exanthematous pustulosis (AGEP). AGEP is mainly induced 
by drugs, but occasionally it can be precipitated by other causes such as viral infections.5 
Pustular rashes similar to AGEP have been described as toxic pustuloderma, pustular drug rash, 
(subcorneal) pustular drug eruption or drug-induced GPP.6-10 
Clinically, AGEP is characterized by the sudden appearance of dozens of sterile, non-follicular, 
small pustules on edematous erythema with a widespread distribution or a predilection for the 
face and/or skin folds. Mild non-erosive mucosa! involvement, mostly oral, may sometimes 
occur. Other skin signs such as facial edema, purpura, target-like lesions and blisters have been 
described but are not typical for AGEP. Fever, neutrophilia and mild peripheral blood eosinophilia 
(in a third of patients) are present. After elimination of the causative culprit, pustules associated 
with AGEP disappear in a few days, typically followed by postpustular desquamation, and the 
reaction fully resolves within 15 days. Usually, internal organs are not involved and overall 
prognosis is good, although lethal outcome has been reported.1 1 • 1 2  
AGEP can be difficult to differentiate from GPP both clinically and histopathologically. 
Clinically, signs in favor of AGEP are abrupt onset, short duration, polymorphous lesions, 
association with recently started drugs and spontaneous healing after their elimination, non­
recurrence and absence of arthritis or a personal or family history of psoriasis. Knowledge of the 
histopathology of both AGEP and GPP is based on case reports and small clinical studies.4•1 3-22 
Histopathological differentiation of AGEP from GPP has not been well documented and some 
even consider distinction based strictly on dermatopathology to be impossible.23The aim of the 
present study was to characterize the histopathological spectrum of AGEP and GPP and to find 
clues for differentiating these two disorders. 
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Materials and methods 
Materials 
We included 29 consecutive cases, evaluated as definite or probable AGEP, and 19 consecutive 
cases of GPP, that visited the Department of Dermatology of the University Medical Center 
Groningen between 1992 up until mid-2009 and for which biopsies of the active phase were 
available. All patients were seen in the active phase of the disease. Clinical information, charts, 
photographs, slides and information on the type and duration of the lesion from which the 
biopsy was taken were available. Diagnosis and grade of probability of AGEP (23 definite and 6 
probable) were evaluated according to the validation system of Sidoroff et al.1 1  Diagnosis of GPP 
was based on history, course, clinical charts and photographs. 1-3 
Biopsies were divided into subgroups: those for AGEP taken from erythema or a visible 
pustule, and those for GPP taken from acute pustules on erythematous, recently uninvolved 
skin representing acute GPP (aGPP), or from pustules on longer existing lesions, representing 
chronic GPP (cGPP). In each subgroup, only one biopsy of a case was randomly selected. 
From the enrolled cases of AGEP, 43 biopsies (27 from visible pustules and 16 from erythema) 
and from GPP, 24 biopsies (14 from aGPP and 10 from cGPP) were studied. 
Pathologic evaluation 
The study was performed on step sections (regularly including additional step sections) of 
paraffin-embedded tissue, stained with hematoxylin and eosin. All processed slides were 
systematically evaluated according to parameters and grades listed in Table 1. Scoring was 
based on independent investigation by the first two authors, followed by a mutual meeting 
at a two-headed microscope where consensus was reached. The first author was the treating 
physician, not blinded for diagnosis, while the second author had no other information than the 
pending differential diagnosis. 
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and its differentiation from generalized pustular psoriasis. 
Table 1. Scoring system of histopathological parameters used for evaluation of acute 
generalized exanthematous pustulosis and generalized pustular psoriasis 
Parameter/severity score 0 2 3 
Pustule size No < 1 0  1 0-1 5 1 6-30 
Keratinocytes Keratinocytes Kerati nocytes 
Macro-pustule size No 3 1 -60 >60 Keratinocytes 
Keratinocytes 
Spongiform character pustule No Mild Moderate Severe 
Munro(-like) abscesses No 1 2 >2 
Hair follicular pustule No Accessoryt Predominant Solitary* 
Necrotic keratinocytes No 1 or 2 3-1 0 > 1 0  
Neutrophilic exocytosis No Few Scattered Many 
Spongiosis No Mild Moderate Vesicles 
Papillary edema No Mild Moderate Severe 
Infiltrates No Mild Moderate Dense 
Eosinophils (pustule) No 1 or 2 3-5 >5 
Eosinophils (dermal) No 1 or 2 3-1 0 > 1 0  
Neutrophils (dermal, papillary) No Few Scattered Full fields 
Leukocytoclasia No Mild Moderate Severe 
Vasculitis No 1 Vessel 2 Vessels >2 Vessels 
Hyperkeratosis No Mild Moderate Severe 
Parakeratosis No Mild Moderate Severe 
Granular cell layer Totally Mostly Severely Missing 
preserved preserved diminished 
Rete ridge changes No Mild Moderate Severe 
(elongation, fusion and/or 
clubbing) 
Mitosis No <1 .5/HPF 1 .5-2.4/HPF �2.5/HPF 
Suprapapillary plate thinning No 1 Papilla 2 Papillae >2 Papillae 
Tortuous, dilated blood vessels No 1 Capillary loop 2 Capillary loops >2 Capillary loops 
HPF, high power field at magnification 40x (0.25 mm2) .  
·Pustule size: in case of several pustules, the largest is documented. 
tonly in conjunction with other types of pustules (hair follicular pustule, accessory). 
*Without other types of pustules (hair follicular pustule, solitary). 
Statistical analysis 
We used the Fisher exact test for comparison of groups with respect to dichotomous variables. 
For comparison of groups with respect to severity scores, a linear trend test with exact calculated 
p values was used. A two-sided p value of 0.05 or less was considered as statistical ly significant. 




The gender-age distribution in AGEP was 12 male, 17 female, mean age 58.2 years (range 3-86), 
and in GPP 5 male, 14 female, mean age 55.6 years (range 0-80). 
The detailed spectrum of the histopathological features in our study of 43 biopsies (27 from 
pustules and 16 from erythema) of AGEP is presented in Table 2. All biopsies showed at least 
one pustule. We observed intracorneal and subcorneal pustules, sometimes contiguous to 
intraepidermal or intracorneal, and combinations of these pustules in various sizes (Fig. 1 a,e). 
Although often present at several levels, the accent of the pustules was generally subcorneal to 
subcorneal/intraepidermal. All pustules were neutrophil-rich with acantholytic epidermal cells 
and 58% also contained eosinophils (generally sparse). Most spongiform were the subcorneal/ 
intraepidermal pustules (Fig. 1 c). Although pustules were generally non-follicular, follicular 
pustules were observed as well (26%), most often accessory to other pustules, but incidentally 
also solitary. Munro(-like) abscesses (Fig. 1 e) were noticed in 21 % and macro-pustules in 40% of 
the biopsies (Fig. 1 a,b,d). 
Solitary necrotic keratinocytes (88%), most often discrete, neutrophilic exocytosis (91%) and 
spongiosis (100%) were common (Fig. 1 c,e). Papillary edema (91 %) was mostly discrete (Fig. 
1 a,c,d). Superficial and mid-dermal perivascular infiltrates, as well as interstitial infiltrates, were 
always present and of a mixed cellular type, generally also containing neutrophils (100%) and 
eosinophils (95%) (Fig. 1 a-e). Often, mid-dermal infiltrates were also localized rather deep, lower 
than the upper third of the mid-dermis. The majority of cases showed erythrocyte extravasation 
and leukocytoclasia (Fig. 1 e), but vasculitis, expressed by fibrinoid changes of the endothelial 
wall, was seen in only one patient. 
Parakeratosis and rete ridge changes such as elongation, clubbing and fusion were 
regularly present, but often rather discrete. Other psoriasiform features such as hyperkeratosis, 
suprapapillary plate thinning and tortuous, dilated blood vessels were absent or only seen in a 
minority (Fig. 1 d). The mitotic rate was generally under 1.5/high power field of 0.25 mm2• 
Histopathologically biopsies taken from erythema all revealed small pustules, mainly 
subcorneal to subcorneal/intraepidermal, whereas those from visible pustules were generally 
large with a more varied localization (Fig. 1 a-d). Moreover, biopsies from pustules showed more 
pronounced rete ridge changes (Fig. 1 c,d) and heavier infiltrates. 
Comparison of 27 biopsies from pustules in AGEP with 14 biopsies of aGPP and 10 of cGPP 
showed several significant differences (Table 3). In GPP, pustules contained no eosinophils. 
Compared toAGEP, they generally contained more lysed keratinocytesand were more spongiform 
and were situated at a slightly higher epidermal level. Macro-pustules were prominent in GPP; in 
cGPP they were often situated at a more superficial epidermal level (Fig. 2a), while in aGPP they 
were often quite large (Fig. 3a). Psoriasiform epidermal changes were most prominent in cGPP 
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Figure 1 .  Histopathology of acute generalized exanthematous pustulosis. a) Spongiform pustules at 
various epidermal levels. b) Sl ightly spongiform subcorneal macro-pustule with a superficial and (lower) 
mid-dermal, perivascular and interstitial dermal infi ltrate. c) Sl ightly spongiform subcorneal-intraepidermal 
pustule, minor acanthotic rete ridge changes, spongiosis, neutrophi lic exocytosis, papil lary edema and a 
mixed perivascular and interstitial infi ltrate. d) Subcorneal macro-pustule, sl ightly acanthotic rete ridge 
changes, papil lary edema, di lated papil lary vessels, mixed perivascular and interstitial infiltrates. e) Small 
sub-/intracorneal pustule contiguous with a Munro-like abscess (arrow), spongiosis, few epidermal necrotic 
keratinocytes (arrowheads), erythrocyte extravasation, discrete leukocytoclasia and mixed perivascular and 
interstitial infiltrate including eosinophils. Hematoxylin and eosin, original magnification: (a) xso, (b) x40, 




(Fig. 2a,b). Most striking in GPP was the consistent presence of tortuous, dilated blood vessels 
(96%) (Figs. 2a,b and 3b). Compared with AGEP, necrotic keratinocytes and dermal eosinophils 
were significantly less present in GPP. The infiltrate in GPP was mainly superficial, perivascular, 
less pronounced and mainly mononuclear, while in AGEP the infiltrate was also deeper and 
interstitial. Neutrophils in aGPP were markedly located in the papillary dermis in comparison to 
AGEP and cGPP (Fig. 3a-c). 
Table 2. Prevalence of histopathological features in pustules and erythema in AGEP 
Histopathological parameters Prevalence 
AGEP total n = 43 AGEP pustule n = 27 AGEP erythema n = 1 6  
(grade 2,3) (grade 2,3) (grade 2,3) 
Pustules 
Munro(-like) abscesses 9 (5) 7 (4) 2 ( 1 )  
lntra-/subcorneal pustules 39 (24) 24 ( 1 8) 1 5  (6) 
Spongiform 3 7  (76) 78 (12) 73 (4) 
Subcorneal-intraepidermal pustules 26 (24) 1 8 ( 1 8) 8 (6) 
Spongiform 26 (78) 78 (15) 8 (3) 
Eosinophi ls in  pustule 25 ( 1 0) 1 6  (9) 9 ( 1 )  
Macro-pustules 1 7  ( 1 2) 1 7  ( 1 2) 0 (0) 
Hair foll icular pustules 1 1  8 3 
Epidermis 
Necrotic keratinocytes 38 (23) 22 ( 1 6) 1 6  (7) 
Neutrophil ic exocytosis 39 (20) 26 ( 1 6) 1 3  (4) 
Spongiosis 43 ( 1 9) 27 (1 2) 1 6  (7) 
Dermis 
Papillary edema 39 ( 1 7) 25 (1 2) 1 4  (5) 
Superficia l  i nfiltrate 43 (37) 27 (25) 16 ( 1 2) 
Interstitial infi ltrate 43 (21 )  27 ( 1 7) 1 6 (4) 
Upper mid-dermal infiltrate 43 (33) 27 (23) 1 6 ( 1 0) 
Lower mid-dermal infiltrate 30 (8) 1 8 (5) 1 2  (3) 
Eosinophils 41 (32) 26 (21 )  1 5  ( 1 1 )  
Neutrophils infiltrate 43 (32) 27 (22) 1 6  ( 1 0) 
Neutrophils papi l lary 38 ( 1 4) 26 ( 1 3) 12 ( 1 )  
Leukocytoclasia 33 ( 1 1 )  24 (7) 9 (4) 
Psoriasiform (epidermal) changes 
Hyperkeratosis 7 (0) 5 (0) 2 (0) 
Parakeratosis 1 6  (3) 1 2  (3) 4 (0) 
Stratum g ranulosum 9 ( 1 )  8 (1 ) 1 (0) 
Rete ridge changes 20 ( 1 1 )  1 6  ( 1 1 )  4 (0) 
Mitosis 43 (6) 27 (4) 1 6 (2) 
Suprapapi l la ry plate thinn ing 0 (0) 0 (0) 0 (0) 
Tortuous, di lated blood vessels 7 ( 1 )  6 ( 1 ) 1 (0) 
AGEP, acute general ized exanthematous pustulosis. 
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Table 3. Comparison of histopathological features in pustular lesion in AGEP, aGPP and cGPP 
Prevalence Significance (p value) 
AGEP pustule 
n = 27 aGPP n =  14  cGPP n =  10  
Histopathological parameters (grade 2,3) (grade 2,3) (grade 2,3) AGEP aGPP AGEP cGPP 
Pustules 
Munro(-like) abscesses 7 (4) 1 (1 ) 8 (8) NS <0.01 
lntra-/subcorneal pustules 24 (1 8) 14 ( 14) 1 0 (1 0) <0.01 0.02 
Spongiform 18 (12) 14 (13) 10 (5) <0.01 NS 
Subcorneal-intraepidermal 
18 (1 8) 8 (8) 3 (3) NS 0.02 pustules 
Spongiform 18 (15) 8 (8) 3 (3) NS NS 
Eosinophils in pustule 1 6 (9) 0 (0) 0 (0) <0.01 <0.01 
Macro-pustules 1 7  (1 2) 1 4 (1 3) 10 (4) <0.01 0.01 
Hair fol licular pustules 8 3 2 NS NS 
Epidermis 
Necrotic keratinocytes 22 (1 6) 2 (0) 1 (0) <0.01 <0.01 
Neutrophilic exocytosis 26 (1 6) 1 3  (1 1 )  1 0  (6) NS NS 
Spongiosis 27 (1 2) 14 (5) 9 (0) NS <0.01 
Dermis 
Papillary edema 25 (1 2) 13 (4) 7 (1 ) NS NS 
Superficial infiltrate 27 (25) 14 (7) 10 (4) <0.01 <0.01 
I nterstitial infi ltrate 27 (1 7) 9 (3) 3 (1 ) <0.01 <0.01 
Upper mid-dermal infiltrate 27 (23) 5 (0) 7 (2) <0.01 <0.01 
Lower mid-dermal infiltrate 1 8  (5) 3 (0) 0 (0) 0.01 <0.01 
Eosinophils 26 (21 )  1 (0) 2 (0) <0.01 <0.01 
Neutrophils infiltrate 27 (22) 1 4  (6) 8 (4) 0.04 0.02 
Neutrophils papi llary 26 (1 3) 1 4 ( 1 3) 8 (5) <0.01 NS 
Leu kocytoclasia 24 (7) 7 (2) 2 (0) 0.03 <0.01 
Psoriasiform (epidermal) changes 
Hyperkeratosis 5 (0) 4 (2) 1 0  (8) NS <0.01 
Parakeratosis 1 2  (3) 4 (2) 9 (6) NS <0.01 
Stratum granulosum 8 (1 )  1 0  (3) 1 0  (7) 0.03 <0.01 
Rete ridge changes 16 (1 1 )  6 (4) 1 0  (9) NS 0.02 
Mitosis 27 (4) 1 4 (5) 1 0  (7) 0.05 <0.01 
Suprapapil lary plate thinning 0 (0) 1 (0) 5 (2) NS <0.01 
Tortuous, dilated blood vessels 6 ( 1 )  1 3  (1 2) 1 0 (1 0) <0.01 <0.01 
AGEP, acute generalized exanthematous pustulosis; aGPP, acute generalized pustular psoriasis; cGPP, chronic 
generalized pustular psoriasis; NS, non-significant. 
Histopathology of a subgroup of seven AGEP patients with a personal history of psoriasis 
showed no significant differences with cases without pre-existing psoriasis. However, slight 
psoriasiform changes and presence of tortuous/dilated blood vessels were seen more often in 
this subgroup (Fig. 1 d). 




Figure 2. Histopathology of chronic generalized pustu lar psoriasis (cGPP). a) Club-shaped psoriatic rete 
ridges with hyperkeratosis, parakeratosis, Munro abscesses (arrows), epidermal plate thinning and sub-/ 
intracorneal pustule with dilated, tortuous vessels (arrowhead) and superficial perivascular mononuclear 
infi ltrates. b) Hyperkeratosis, parakeratosis and psoriatic rete ridge elongation with pustules at several levels 
(arrows), neutrophilic exocytosis, mainly mononuclear perivascular infiltrate, and di lated papillary vessels. 
Hematoxylin and eosin, original magnification: (A,B) x1 00. 
Discussion 
We believe that the strength of our study i s  the comparison of  both AGEP and GPP by an  identical 
set of histopathological parameters. Both AGEP and GPP represent a dynamic spongiotic 
pustular process. This presumably starts with dermal edema and a perivascular infiltrate, and 
this is followed by pustules in different stages of evolution. Because of this evolution, we studied 
the features of AGEP in erythema and visible pustules. While cGPP develops over time, aGPP 
represents acute pustule formation on previously uninvolved skin. Differential diagnostic 
problems between AGEP and GPP particularly arise in the acute phase of GPP. 
It is noteworthy that we found small pustules in all biopsies from erythematous lesions of 
AGEP. In aGPP, pustules were concentrated somewhat deeper in the epidermis than in cGPP. In 
biopsies from pustular lesions of AGEP, pustules of different sizes were distributed over several 
levels, probably reflecting the ongoing process with pustules at consecutive stages in one biopsy. 
Subcorneal pustules, contiguous to intraepidermal ones, were markedly spongiform in AGEP 
but were generally less prominent than in GPP.4•1 9•20•24 Differences in localization and spongiform 
character of pustules in a biopsy can provide a hint for differentiating AGEP from GPP. Although 
in AGEP, pustules were generally non-follicular, follicular pustules could sometimes be observed 
as well. In our experience, follicular pustules do not exclude the diagnosis of AGEP. 
Munro micro-abscesses, representing collections of neutrophils within parakeratosis, are 
generally associated with psoriasis. However, in AGEP we also observed variously sized late­
stage (dried) intracorneal pustules that assumed the configuration of Munro micro-abscesses. 
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Figure 3. Histopathology of acute generalized pustular psoriasis (aGPP). a) Subcorneal macro-pustule, 
neutrophilic exocytosis, superficial perivascular, mainly mononuclear, infiltrates with papil lary neutrophils. 
b) Subcorneal/intraepidermal spongiform macro-pustule of Kogoj, neutrophilic exocytosis, sl ightly 
psoriasiform rete ridge changes and di lated papil lary vessels. c) Detail macro-pustule: neutrophil ic 
exocytosis, papi l lary neutrophils and superficial perivascular, mainly mononuclear infiltrate. Hematoxylin 




The higher frequency of Munro micro-abscesses and of other intracorneal pustules in cGPP can 
be explained by its more protracted course compared with AGEP or aGPP. Spongiform macro­
pustules were dominantly present in GPP. Although generally associated with GPP and not with 
AGEP, those macro-pustules were also regularly (63%) observed in biopsies of AGEP when taken 
from pustular lesions. 
Whether histopathological features of conventional plaque-type psoriasis can be seen 
in GPP is controversial.18•25•26 Our study suggests that this controversy is mainly a matter of 
timing, because psoriatic changes such as hyperkeratosis, parakeratosis, a diminished stratum 
granulosum, rete ridge changes, elevated mitotic index and suprapapillary plate thinning were 
far more prominent in cGPP. We believe this is because of its more chronic stage in comparison 
with aGPP. In aGPP the epidermis was often only slightly acanthotic, as in AGEP. Absent or 
minor alterations of the stratum corneum, particularly in early lesions of AGEP but also in aGPP, 
indicate an acute process. Rete ridge change (such as elongation), generally mild, was more 
frequent in AGEP than generally reported and in our view is apparently less a key point in favor 
of GPP than previously assumed.1 1 •18•19 Alterations in rete ridge point to a more developed stage 
of lesion, since we found them more prominently in pustular than erythematous AGEP lesions 
(59%), especially when desquamating intracorneal pustules were present. Although substantial 
psoriasiform changes in a pustular lesion are suggestive of GPP, their absence (such as in aGPP) 
does not necessarily exclude GPP. On the other hand, minor psoriasiform changes do not rule 
out AGEP. 
While tortuous, dilated vessels were expected in cGPP, we surprisingly also observed them 
significantly more in aGPP than in AGEP. Moreover, in AGEP they were strongly associated with 
cases having a personal history of psoriasis (data not shown). Presumably vascular alterations 
are very specific for psoriasis and are widely present in patients with the disease. 
Necrotic keratinocytes, also observed in other drug eruptions, were generally few or 
scattered outside the pustule in AGEP (88%), while in GPP we hardly found them.24 On the other 
hand, lysed keratinocytes within the pustules were more pronounced in GPP, resulting in slightly 
more spongiform pustules, especially in aGPP.15•1 8•25 In AGEP, apoptosis of activated keratinocytes 
is mainly caused by CDS+ lymphocytes, but CD4+ drug-specific cytotoxic T cells also play a 
role.27 
Dermal edema is relatively characteristic (but not specific) for AGEP, especially in its early 
stages.16•20 Although less marked than often suggested, moderate to severe papillary edema was 
present in 40% of biopsies from patients with AGEP, in 29% of biopsies from patients with aGPP 
and almost absent in biopsies from patients with cGPP. 
Eosinophils in pustules, in the dermis and also in the peripheral blood, a hallmark of many 
drug-induced allergic reactions, suggests that AGEP is a hypersensitivity reaction.18•28 Although 
the process of eosinophilic exocytosis was observed in just four biopsies (data not shown), sparse 
eosinophils were found in 58% of the pustules.4•16 Dermal eosinophils were more frequent (95%) 
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although less pronounced than sometimes reported.4•1 7• 1 8•22-24 In contrast to AGEP, eosinophils 
were only found sporadically in GPP.26 
Remarkably, an interstitial and perivascular mid-dermal infiltrate is not generally considered 
a feature of AGEP. We found such an infiltrate to be pronounced and mixed, often including 
numerous neutrophils. In GPP, the infiltrate was less dense, was located more superficially and 
was mainly mononuclear, while neutrophils were found predominantly in the papillary dermis. 
We believe these differences in composition and distribution can be diagnostically meaningful. 
We regularly noticed erythrocyte extravasation (not generally reported) and mild 
leukocytoclasia, but alterations suggesting possible vasculitis, including fibrin deposition in the 
vessel wall, was seen only once in AGEP. Absence of clear evidence for vasculitis in the presence 
of erythrocyte extravasation and leukocytoclasia has been mentioned before/0•21 Acute 
vasculitis in AGEP is sometimes reported in a connection of subepidermal with intraepidermal 
pustules, which is something we did not observe.1 7•24 Overreporting of vasculitis might be 
caused by interpretation of leukocytoclasia and/or erythrocyte extravasation as vasculitis or 
by diagnostic confusion with pustular vasculitis. Purpura may occur in AGEP and other drug­
induced eruptions, even in the absence of vasculitis. 
An earlier clinical study of 63 cases of AGEP, including 64 biopsies from 48 patients, mentions 
superficial spongiform pustules (66%), focal necrotic keratinocytes (25%), psoriasiform 
hyperplasia (39%), mixed perivascular infiltrates with eosinophils (34%), papillary edema (61 %) 
and leukocytoclastic vasculitis (20%) including fibrinoid changes (11 %).16 Remarkably, our study 
showed far more pustules, papillary edema (91 %), dermal eosinophilia (95%) and necrotic 
keratinocytes (88%). This might indicate that biopsies in these two studies were taken at 
different stages. We found far less fibrinoid alteration, while psoriatic changes were comparable. 
Differences might also be attributed to case definition, inclusion criteria and use of step sections 
in our study. 
AGEP can also occur in patients with plaque psoriasis. It has been suggested that AGEP 
merely represents a variant of GPP, and thus signifies an acute exacerbation of psoriasis caused 
by a variety of exogenous triggers. However, analysis of a subgroup of seven AGEP cases with 
a known personal history of psoriasis in our study did not show significant differences with the 
other cases. Also, the observation of several significant differences in GPP vs. AGEP supports 
the concept that AGEP is a separate entity that can occur as an acute eruption in patients with 
a history of psoriasis. On the basis of our findings, there are no grounds to assume that an acute 
pustular rash, occurring in patients with known psoriasis, is necessarily GPP or that AGEP is a 
variant of pustular psoriasis. 
As noticed before, the prevalence of patients with a personal history of psoriasis in our study 
of AGEP (26.9%) was higher than could be expected from the general population (1-4%).3•5•1 6•29•30 
This higher prevalence might indicate that patients with GPP and AGEP share a common genetic 
background, which directs them to react with neutrophil-attracting mechanisms. 
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The etiopathogenesis of AGEP is still not fully elucidated although some progress has been 
made. Positive results from patch and lymphocyte transformation tests with the suspected agent, 
indicating a delayed type IV hypersensitivity reaction, support a drug etiology and the concept 
that T cells play a crucial role.21 •31 It was recently appreciated that interleukin-8 (IL-8), secreted 
by T cells and keratinocytes, enhances neutrophilic inflammation and survival, thus leading to 
sterile pustular lesions.31•32 Similar mechanisms seem to be relevant for other T-cell-mediated 
diseases with neutrophilic inflammation, like GPP, which has an underlying tendency for a Th 1-
dominated immune response.32-35 Besides, few CXCL8+ T cells displaying a Th2-type cytokine 
profile with high IL-4 and IL-5 secretions, may contribute to the eosinophilia, regularly observed 
in AGEP.32 In GPP, IL-5 is not secreted, which might explain the absence of eosinophilia.28•36 
Conclusions 
In summary, the present study found a spectrum of histopathological features of both AGEP and 
GPP. Differentiating AGEP from GPP, especially aGPP, presents a clinical and histopathological 
challenge. Whereas no single histopathological feature is decisive on its own, the combination 
of features and their grade of severity can substantially contribute to negotiating this differential 
diagnosis successfully. Features pointing at AGEP instead of GPP include the presence of 
eosinophils in the pustules or dermis, necrotic keratinocytes, a mixed neutrophil-rich interstitial 
and mid-dermal infiltrate and the absence of tortuous, dilated blood vessels. Moreover, cGPP 
showed significant epidermal psoriasiform changes. These key histopathological features, 
combined with clinicopathological correlation, will assist in differentiation between AGEP and 
GPP in most instances. 
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Chapter 6a 
Summary 
Morphine, an opium alkaloid, frequently causes side effects such as hyperhidrosis and facia l 
flushing, but serious cutaneous adverse d rug reactions are seldom observed. Best known are 
urticaria, erythema, and pruritus; sometimes pseudoal lergic anaphylactoid reactions, and 
bl isters are reported. 
Acute generalized exanthematous pustulosis (AGEP) is a serious, mainly d rug-induced 
eruption, general ly accompanied by fever and neutrophil ic leukocytosis, showing widespread 
bright erythema studded with many small, nonfoll icular pustules.1-3 We present a patient with 
AGEP. Time relation, epicutaneous testing, as well as a lymphocyte transformation test (LTT) 
identified morphine as the culprit. 
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Case report 
Acute generalized exanthematous pustulosis caused by morphine, 
confirmed by positive patch test and lymphocyte transformation test. 
A 27-year-old healthy man underwent osteosynthesis because of a fracture of the tibia and 
fibula of his right leg. His medical history was unremarkable, and he had no personal or family 
history of skin disease or cutaneous adverse drug reactions (CADR). He received preoperatively 
subcutaneous nadroparin and one dose of cefazolin. Next day (day 1) fasciotomy was 
performed because of suspicion for compartment syndrome. On both occasions paracetamol, 
diclofenac, and morphine were given postoperatively. Morphine was stopped after day 1. On 
day 10 abdominal and inguinal erythema was noticed, and paracetamol and diclofenac were 
withdrawn. A few hours later the patient's temperature was 39.4°C. On day 11 he underwent 
split-skin transplantation. All 3 operations were performed with the patient under spinal 
anesthesia, for which lidocaine, bupivacaine, ephedrine, midazolam, and mannitol were given. 
On day 11, postoperatively, his temperature was 38.4°( and for pain prophylaxis one dose of 
morphine, 10 mg, was given intravenously. A few hours later his temperature was 40.8°( and 
extending itching and burning erythema was observed. Next day fever rose to 41.2°( and with 
the suspicion of toxic shock syndrome he was transferred to the intensive care unit and given 
intravenous gentamicin, followed by dexamethasone, cefuroxime, and metronidazole, and 
again paracetamol and diclofenac. That day the widespread bright exanthems had numerous 
tiny nonfollicular pustules, most pronounced in inguinal and axillary areas, but also on the trunk, 
face, and proximal limbs (Fig. 1 ). On day 13 the patient's fever dropped to 39.2°C. On day 14 the 
patient felt well, his temperature had abated, and the pustules were clearing. Because clinical 
and laboratory examinations revealed no infection, a CADR was considered and dexamethasone 
and antibiotics were stopped. On day 20 he was dismissed, the skin was healing with extensive 
postpustular desquamation, followed by full recovery within 2 weeks. 
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Figure 1 .  Bright generalized erythema, studded with Figure 2. (A) Photomicrographs show intraepider­
many pinheaded pustules. mal pustules and spongiosis with mixed perivascular 
infiltrate spreading into interstitium. (B) lntraepider­
mal pustu le with spongiosis and edema in papillary 
dermis with some leukocytoclasia. (A and B Hema­
toxylin-eosin stain; original magnifications: A x lO; B 
X40.) 
On day 12 laboratory investigations showed marked leukocytosis (27.6 x 109/L), neutrophilia 
(25.1 x 1 09/L), eosinophilia (0.6 x 1 09/L), and raised levels of aspartate aminotransferase (54 U/L), 
alanine aminotransferase (83 U/L), erythrocyte sedimentation rate (25 mm/h) and C- reactive 
protein (185 mg/ml); otherwise his blood chemistry was normal. Gram staining of a pustule, 
blood and skin cultures, anti-streptolysin O titer, and streptococcal antibodies revealed no 
microbial involvement. Histologic examination showed spongiosis, spongiform intraepidermal 
and subcorneal pustules, and focal dyskeratotic epidermal cells. The upper dermis demonstrated 
papillary edema, a perivascular mixed infiltrate with many neutrophils, some leukocytoclasia, 
erythrocytes, and eosinophils (Fig. 2). 
Six months later patch tests were positive for morphine HCI, 10 mg/ml as is (3+) and morphine 
1 % in an aqueous solution (2+) after 72 hours, while the European Standard Series and all other 
drugs used perioperatively yielded negative findings.4 Powderized commercial preparations 
were tested pure and diluted at 30% in petrolatum and in water; liquids were tested as is.5 Results 
from 1 0  control patients with morphine 1 % in aqua were negative.4 Histologic examination of 
the positive test showed slight spongiosis and exocytosis of mainly CDS+ lymphocytes with 
cytotoxic granules and a moderate perivascular lymphocytic infiltrate containing several CDS+ 
cells. Four months later LTTs in triplicate (for all drugs used perioperatively) demonstrated that 
morphine had a positive stimulation index of 4.2 for 1 µg/ml, whereas for 100 µg/ml it was 2.3 
(positive >2.0).6 All other drugs used perioperatively caused no stimulation. Lymphocytes from 
a control patient showed no stimulation for morphine. There was no relapse during a follow-up 
period of more than 2 years. 
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Discussion 
Acute generalized exanthematous pustulosis caused by morphine, 
confirmed by positive patch test and lymphocyte transformation test. 
According to a recently developed validation score for AGEP, our patient was a definite case 
(maximum score of 12).3 Diagnosis of CADR in patients receiving multiple drug therapy mainly 
relies on history, if necessary in combination with different tests, as none of the single tests 
available has sufficient sensitivity per se. In our patient, time relation, positive patch tests, 
and positive LTTs all confirmed morphine as the culprit. Although cefazolin, paracetamol, and 
diclofenac are known as offending drugs in AGEP,2•3 it is unlikely that these were the culprit. 
One dose of cefazolin was given 10 days before the eruption, and subsequent administration 
of cefuroxime (another cephalosporin) caused no further exacerbation. Paracetamol and 
diclofenac, given 10 days before the eruption, were temporarily stopped and reintroduced 
without complications. 
Patch tests can be performed with the pure substance, diluted at 10% in petrolatum and/ 
or water, but generally any commercialized form can be tested as is (facultative) and diluted at 
30% in petrolatum and/or in water.5 In CADR testing of suspected drugs yields positive findings 
in 32% to 50% of patients. A positive patch test is an indicator of a hypersensitivity reaction, 
whereas a negative test does not exclude it. The clinical relevance of patch testing depends 
on the type of CADR and is usually of value in eczematous eruptions, baboon syndrome, 
macular/papular rash, AGEP, hypersensitivity syndrome, as well as lichenoid and fixed drug 
eruptions. Positive tests most frequently are related to 13-lactam antibiotics, sulfamethoxazole/ 
trimethoprim, corticosteroids, heparin derivatives, carbamazepine, and diltiazem.5 
The LTT measures proliferation ofT cells to a drug in vitro, indicating sensitization. Drugs can 
directly interact with the T-cell receptor, without previous metabolization or earlier binding to 
proteins. The LTT has a sensitivity of 60% to 70%; however, this figure is based mainly on analysis 
of 13-lactam sensitivity. A positive LTT helps to define the culprit drug, but negative tests cannot 
rule out drug hypersensitivity. The LTT has been found positive in generalized macular/papular 
exanthems, bullous exanthems, AGEP, and hypersensitivity syndrome, but is rarely positive in 
toxic epidermal necrolysis, vasculitis, macular exanthems, and fixed drug eruption.6 
In severe CADR, patch testing is relatively safe compared with rechallenge. In one study, 7 
of 14 AGEP cases were positive, suggesting that in AGEP sensitivity is relatively high. However, 
this might also be related to the characteristics of the offending drugs.7 Positive patch tests 
for morphine are mainly known from persons handling opium alkaloids, who generally present 
with contact dermatitis.8•9 Only rarely have these been described after systemic use of opium 
alkaloids.10-12 Given the relatively long interval between the start of morphine and the appearance 
of the eruption, previous sensitization seems unlikely. Besides, our patient experienced no 
earlier CADR and had not used or handled opium alkaloids before his presentation to us. 
Sporadically positive LTTs have been reported in AGEP, but not for morphine.13·17 In most of 
these cases, however, patch tests were negative or not performed.1 3•14•16•1 7  
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The pathogenesis of AGEP remains hypothetical. Patch testing may provoke relapses, 
supporting the idea that the immune system is involved and that a positive test has relevance. 
18•1 9  This reactivation seems to be triggered by a "memory;' possibly related to T cells homing in 
the skin. The positive patch test and LTT are arguments for a delayed type IV hypersensitivity, 
suggesting involvement ofT cells. This is also suggested by the observation that patch tests can 
mimic the morphologic characteristics of the original skin reaction.15 In AGEP the infiltration 
of neutrophils and some eosinophils as well as CD4+ and CD8+ lymphocytes is striking. Drug­
specific T-cell clones from lesional skin as well as from the circulation have been found positive 
for the neutrophil-attracting cytokine interleukin 8. This type of T-cell-mediated neutrophilic 
inflammation has been coined a type IV-d reaction.20 Since keratinocytes also show positive 
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Acute generalized exanthematous pustulosis (AGEP), presenting with toxic epidermal 
necrolysis-like features, a neglected culprit? 
For severe backache, a 70-year-old female started naproxen and omeprazole, replaced by 
morphine 10 mg two days later. History revealed stable psoriasis, treated by local corticosteroids, 
and an earlier serious cutaneous adverse reaction (cADR), resembling toxic epidermal necrolysis 
(TEN), ascribed to azapropazone. Eight days after starting morphine, an increasing erythematous 
rash developed, preceded by fever. 
On admission, one day later, we observed widespread oedematous erythema, accentuated 
on the main flexures, but also on the face, studded with many tiny pustules and superficial 
erosions at sites of extensive coalescence of pustules. Arthritis and mucosal involvement 
were absent. TEN, pustular psoriasis, acute generalized exanthematous pustulosis (AGEP) and 
infection were considered; prednisolone 40 mg and erythromycin 500 mg QID were initiated and 
morphine was switched to tramadol 100 mg TID. Laboratory examinations revealed elevated C 
reactive protein (154 mg/L), leukocytosis (13.6x109/L), and neutrophilia (11.4x109/L), but were 
otherwise normal. Investigations for infections were negative, including anti-streptolysin O titre 
and bacterial cultures (pustule and throat). Histology showed slightly spongiform subcorneal 
pustules, neutrophilic spongiosis, a few necrotic keratinocytes, dermal oedema and mixed 
neutrophil-rich infiltrates, both perivascular and interstitial. TEN-like features such as extensive 
keratinocyte apoptosis and subepidermal blistering were absent (Fig. 1 D).Three days later, 
improvement started with postpustular desquamation, while superficial erosions and some 
pustular lesions were still present (Fig. 1 A, B), followed by rapid healing within 2 weeks. During 
an 18 month follow-up there was no recurrence. 
According to the criteria of Sidoroff et a/.1 definite AGEP was established. AGEP is mainly 
induced by drugs and characterized by the sudden appearance of dozens of sterile, non-follicular, 
small pustules on oedematous erythema with a widespread distribution or predilection for 
the face and/or skin folds. Coalescence of pustules in AGEP may result in superficial erosions, 
suggesting TEN, histopathology however is discriminative. Pustular psoriasis was thought 
unlikely because of the abrupt onset, short duration, association with recently started drugs and 
full, quick recovery after their elimination, and non-recurrence. Of note, AGEP has been reported 
before in patients with a history of psoriasis and more frequently than could be expected in the 
general population.2•3 Moreover, histology favoured AGEP over pustular psoriasis, showing some 
necrotic keratinocytes and mixed neutrophil-rich interstitial and mid-dermal infiltrates, whereas 
significant epidermal psoriasiform changes were lacking.3 
Patch testing was performed three months later, including all the drugs the patient had 
been exposed to, using their commercialized form.4 The European standard series, naproxen 
and omeprazole pure pulverized, 30% in aqua and 30% in petrolatum, and morphine pure 
pulverized gave negative test results; pulverized morphine 30% in aqua, 30% in petrolatum (Fig. 
1 C), and morphine 1 % solution in aqua showed a 3+ reaction with erythema and pustules after 
96hours, while in 1 O controls all morphine tests were negative. Histology of a positive patch 
test revealed subcorneal pustules, neutrophilic spongiosis, scattered apoptotic keratinocytes, 
dermal oedema and mixed dermal infiltrates, a picture compatible with AGEP (Fig. 1 E). 
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Remarkably, the patch test resembled the original eruption both clinically and histologically; 
pustular test results have been described before. Patch testing, more often positive in AGEP 
compared to other cADR, contributes to identification of the culprit and to narrowing down 
differential diagnoses in ambiguous cases.4•5 
In conclusion, we describe the third case of AGEP induced by morphine, the second 
confirmed by positive patch tests.5•6 Morphine, regularly used, often short-term in the peri­
operative situation or for chronic pain relieve, has a rather safe profile concerning cADR, which 
include pruritus, erythema, urticaria and flushing. Although rarely associated with AGEP, 
morphine should not be overlooked as a potential culprit. 
D E 
Figure 1 A) Extensive oedematous erythema accentuated in the main folds with desquamating superficial 
erosions and some pustules; B) oedematous erythema with extensive coalescence of pustules resulting in 
superficial erosions; C) patch test showing oedematous erythema with tiny pustules; Histopathology D) 
(pustule abdomen) and E) (positive morphine patch test at 96hours): subcorneal slight spongiform pustules, 
a few necrotic keratinocytes, neutrophilic spongiosis, papillary oedema and mixed neutrophil-rich superficial 
and middermal perivascular and interstitial infiltrates. Hematoxylin and eosin, original magnification x l O. 
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Symmetrical drug-related intertriginous and flexural exanthema 
(baboon syndrome) induced by omeprazole 
We describe two cases of symmetrical drug-related intertriginous and flexural exanthema 
(SDRIFE) with remarkable cutaneous symptoms, slight systemic involvement, and a relative long 
latency time, caused by omeprazole. 
A 67-year-old woman demonstrated symmetric, confluent erythematopapular lesions on 
inner gluteal areas, groins, and neck, accompanied by itching, burning, and a feverish feeling, 17 
days after starting omeprazole. Two days later, omeprazole was discontinued, and a short course 
of prednisolone was given. The gluteal rash improved, while on the neck it worsened (Fig. l a). 
Mometasone ointment, 9 days after discontinuing omeprazole, resulted in rapid healing. The 
patient had no co-medication, previous use of omeprazole, or history of cutaneous adverse drug 
reactions (cADR). H istopathology showed small intra/subcorneal pustules, slight epidermal 
spongiosis, and vacuolar degeneration with moderate, mainly superficial, perivascular infiltrates, 
with some neutrophils and eosinophils (Fig. 1 b). Patch tests with omeprazole were negative. 
The second case, a 27-year-old woman, started omeprazole for stomach ache during 
methotrexate maintenance therapy, 15 mg weekly. At day 6, intense itching and increasing 
flexural redness developed. At day 9, she presented with symmetric, sharply demarcated, bright 
erythema, studded with several tiny non-follicular pustules on the buttocks, inguinal extending 
to the upper-inner thighs and anogenital, axillary, and (sub)mammary areas (Fig. 2). Furthermore, 
faint erythematous upper eyelids and few pinpoint blanchable erythematous macules on 
the ventral side of wrists and hands were observed. For psoriasis vulgaris, she had received 
methotrexate for four months, while local treatment consisted of desoximetasone emulsion for 
the scalp and emollient. Except for the scalp, the psoriasis was in remission; fever, malaise, and 
arthritis were absent. Laboratory investigations were normal, except for slightly elevated alanine 
transaminase (88 U/1}, eosinophils (5.7%) and neutrophils (80.6%), with leukocytes 5.4 x 109/1. 
Pustular swabs revealed no yeasts or bacteria. Omeprazole was stopped, and clemastin 1 mg 
and triamcinolone acetonide in ketoconazole cream were started. One day later progression 
halted; the eruption was resolved within two weeks. The patient refused patch testing. 
a . -., 
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Figure 1 .  (a) Large, rather sharply 
demarcated, confluent erythemato­
papular lesions in the neck spreading 
to the upper chest and on the i nner 
gluteal areas. (b) Histology of the neck 
(H&E, original mafgnification x 40): 
small intra-/subcorneal pustules and 
moderate, main ly superficial perivas­
cular infi ltrates also containing neu­




SDRIFE, a benign, probably underreported cADR with male predominance, is supposedly 
homogenous for the range of primary cutaneous lesions, clinical distribution (excluding face 
and palmae), and latency period. Particularly amoxicillin and other �-lactam antibiotics are held 
responsible.1 
Diagnostic criteria are systemic drug exposure, sharply demarcated erythema of the gluteal/ 
perianal and/or V-shaped erythema of the inguinal/perigenital area, involvement of more 
than one other intertriginous/flexural fold, symmetric distribution, and absence of systemic 
symptoms and signs.1 Distribution and characteristics of the lesions in both cases were typical for 
SDRIFE.1 •2 However, of note was the extensive participation of the neck in patient 1 ,  and pustules, 
widespread intertriginous and flexural involvement, and facial and palmar participation in 
patient 2. Although the absence of systemic involvement is a criterion for SDRIFE, we noted a 
feverish feeling in one and a mild disturbed liver function, eosinophilia, and neutrophilia in the 
other.2-3 Characteristic is a latency period of hours to days after drug initiation, but longer periods 
(1 7 and 5 days in our cases) may occur, depending on drug- and patient-related factors.1 •2•4•5 
The histopathology of SDRIFE is variable and non-specific, mainly showing superficial, 
mononuclear perivascular infiltrates, sometimes with neutrophils and eosinophilsY Patient 1 
also displayed small intra/subcorneal pustulesY 
Pustules in SDRIFE (patient 2 and, histopathologically, patient 1 )  necessitate differentiation 
from acute generalized exanthematous pustulosis (AGEP)Y Both also share a short latency 
period, flexural affection, potential immunological pathogenesis, including neutrophilic 
involvement, and potential culprits. However, AGEP was unlikely considering the absence of 
disseminated erythema, high fever, neutrophilia >7 x 1 09/I and, histopathologically, papillary 
edema and necrotic keratinocytes.6•7 Distribution of the sharply demarcated lesions, quick 
recovery after omeprazole withdrawal, absence of psoriatic activity, fever and arthritis, and the 
presence of transient eosinophilia make pustular psoriasis unlikely in patient 2. 
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Figure 2. Symmetric, 
rather sharply demarcat­
ed, bright erythematous 
lesions on the axi l lary, 
inguinal, (sub)mammary, 
and inner g luteal areas 
and buttocks, studded 
with several tiny pustules 
Symmetrical drug-related intertriginous and flexural exanthema 
{baboon syndrome) induced by omeprazole 
The etiology of SDRIFE is not yet elucidated. Occlusion, sweating or mechanical injury, or a 
type of recall phenomenon of a past, unrelated dermatitis, occurring in precisely the same areas, 
have been postulated.1 ,4,s Patch tests in SDRIFE can be positive; a type IV delayed-hypersensitivity 
immune response is presumed. In a review of 42 cases, 12 out of 24 showed positive drug patch 
test results.1 
Omeprazole, a potent and widely used proton pump inhibitor, is a prodrug and usually well 
tolerated. Although rare and most often mild, omeprazole has been associated with a variety of 
cADR, especially non-specific rashes, anaphylaxis, urticaria, angioedema, edema, and pruritus. 
However, also lichenoid eruptions, leukocytoclastic vasculitis, toxic epidermal necrolysis, contact 
dermatitis, and alopecia have been mentioned.9•1 0  
In  conclusion, we describe two females with SDRIFE, induced by omeprazole, a drug not 
appointed before. Fulfilling basic characteristic criteria of SDRIFE, both cases additionally 
revealed remarkable uncommon features. SDRIFE may display less homogeneity than suggested 
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Chapter 8 
Summary 
Erlotinib (Tarceva ™) is an epidermal growth factor receptor (EGFR) inhibitor, a member of a new 
group of molecular targeted drugs that combine high efficacy against tumours with less, often 
self-limiting, toxicity, compared with traditional chemotherapeutics. It is used for treatment of 
solid-organ tumours, especially as second- or third-line therapy for non-small-cell lung cancer. 
Dose-related cutaneous side-effects and diarrhoea may be a significant obstacle to treatment 
compliance. We present two cases with long-lasting acneiform eruptions, complicated by 
significant impetiginization, resulting in hospitalization in one case. The other patient suffered 
from sleep-disturbing, itching crusts on the scalp. As the use of EGFR inhibitors is increasing, 
clinicians should be aware of their side-effects. Early and timely dermatological intervention 
may diminish adverse events for patients treated with these agents and improve quality of life. 
Acneiform eruptions are common side-effects of erlotinib (Tarceva™), an epidermal 
growth factor receptor inhibitor that is increasingly being used in the treatment of solid-organ 
tumours. Generally, side-effects are dose-dependent and self-limiting. We report two patients 
with long-lasting acneiform eruptions, complicated by significant impetiginization. Proactive 
dermatological intervention can improve compliance and quality of life for patients on EGFR 
inhibitors. 
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Case reports 
Patient 1. A 74-year-old white man started erlotinib monotherapy 1 50 mg for progression of 
stage 111B non-small-cell lung cancer (NSCLC} after earlier lobectomy and chemotherapy. 
Within days pustules developed, followed by dry skin. Five weeks later, the patient presented 
with sterile, widely dispersed, inflammatory follicular papulopustules, predominantly in the 
seborrhoeic areas, and dry skin with slightly erythematosquamous lesions on the face, arms and 
legs. Erythema with maceration of the groins was treated with triamcinolone in ketoconazole 
cream. One week later, the patient was hospitalized for malaise, subfebrile temperature, 
increasing diarrhoea, otitis externa, ectropion and purulent conjunctivitis. The skin was painful, 
with extensive, partly oozing erythema and yellowish crusts mainly extending from the body 
folds, causing disability in walking (Fig. 1 a,b}. We diagnosed erlotinib-induced acneiform rash 
and xerosis cutis with extensive secondary impetiginization. 
Blood investigations were normal except for slightly raised erythocyte sedimentation 
rate, (-reactive protein and eosinophils (5.2 x 1 09/L}. Pustules revealed Staphylococcus aureus, 
Pseudomonas aeruginosa, and Candida albicans; tests on faeces were negative. Histology 
showed spongiform pustules, dermal perivascular lymphoid infiltrates with some neutrophils 
and eosinophils, and a folliculitis in deeper sections (Fig. 1 c}. Local silver sulfadiazine, zinc oil, 
antibacterial baths, ear and eye drops, neutral emollients, and systemic amoxicillin/clavulanic 
acid resulted in rapid improvement. Increasing diarrhoea required interruption of erlotin ib 
for 12 days, during which all symptoms improved. Erlotinib was restarted at 50 mg/day and 
gradually raised with minocycline 1 00 mg and continuing emollients. Ten days later, the patient 
experienced mild diarrhoea, as well as erythema on the face and groins, which improved after 
silver sulfadiazine cream twice daily. Residual maculopapules on the trunk gradually faded 
away. 
Figure 1 .  (a) Acneiform eruption with partly oozing erythema; (b) ectropion and erythema with yellowish 
crusts on the face; (c) a dermal mixed perivascular lymphoid infi ltrate and folliculitis (haematoxylin and 
eosin, original magnification x 40). 
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Patient 2. A 55-year-old white man started erlotinib 1 50 mg/day for stage T2N2M0 NSCLC 
after earlier lobectomy, chemotherapy, and radiotherapy. Four months later, he presented 
with a 4-week history of progressive, severely itching, sleep-disturbing, yellowish crusts, firmly 
attached to the scalp (Fig. 2a). We also noticed dry skin and generalized acneiform follicular 
lesions, mainly located in seborrhoeic areas. Laboratory investigations showed no abnormalities 
except slight eosinophilia (3.2 x 109/L). Histology of the trunk revealed neutrophilic infiltration 
of the infundibular and deeper follicular wall, with superficial follicular dilatations containing 
denaturated keratin and some yeasts (Fig. 2b); the scalp showed epidermal ulceration with 
neutrophils and extensive, deeply extending mixed infiltrates. Minocycline 100 mg/day for 
7 days, salicylic acid 7.5% in castor oil, bath oil, emollients, and hydroxyzine 10 mg nightly 
resulted in rapid improvement. Stopping minocycline caused the crusts to worsen. Because 
5. aureus was cultured, cefradine was given for 10 days. Minocycline was restarted, which 
maintained improvement (Fig. 2c). 
a C 
Figure 2. (a) Acneiform eruption and yellowish crusts on the scalp; (b) superficial foll icular di lations 
containing denaturated horn and neutrophilic infi ltration of the follicle wall (haematoxylin and eosin, 
original magnification x 40); (c) improvement after 7 days on minocycline. 
Discussion 
Erlotinib, an oral reversible intracellular tyrosine kinase inhibitor that blocks downstream 
signalling pathways for cellular proliferation and differentiation, is used as monotherapy or in 
combination with other chemotherapeutics for several solid tumours. This EGFR inhibitor has an 
established role in the treatment of advanced, refractory NSCLC.1-2 
EGFR is expressed in proliferating undifferentiated basal epidermal keratinocytes, eccrine 
and sebaceous glands, the outer follicular root sheath, the respiratory system and the 
gastrointestinal tract.3 Because dysregulated EGFR expression is associated with aggressive 
tumours, increased resistance to chemotherapy and radiotherapy, and poor clinical prognosis, 
new chemotherapeutics focus on EGFR inhibition.1A,5 
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The maximum tolerated dose of continuous administration is 150 mg/day.5 Generally mild, 
dose-dependent, and self-limiting side-effects are seen, particularly acneiform rashes and 
diarrhoea. Others include painful fissures on the palms and soles, paronychia, dry skin, eczema, 
mucositis, conjunctivitis, nausea, vomiting, malaise, alopecia, slower growing and/or brittle 
hair, and trichomegaly.6-a Rare but severe side-effects are interstitial lung disease and corneal 
ulceration. Marked haematological effects are absent.1.4·6 
Within 8-10 days on average, a mild or moderate acneiform eruption without comedones, 
characterized by numerous monomorphic, sterile, sometimes itching, inflammatory follicular 
papulopustules, mainly in seborrhoeic areas, occurs in most patients; in 5-10%, this reaction 
is severe.1·4-9 Maximum intensity is reached within 3 weeks. Despite continued treatment with 
erlotinib, the reaction often gradually subsides.5•6•9 A similar eruption is also often seen with other 
EGFR inhibitors (cetuximab, gefitinib), and shows similar histology, with neutrophilic dermal 
infiltrates, neutrophilic (peri)folliculitis, and ectatic appearance of the infundibula, indicating a 
class effect.5•7-9 Sometimes a suppurative superficial folliculitis, like that in patient 1, is observed.a 
After several weeks, xerosis cutis may develop, predominantly on the arms, legs, and areas 
previously affected by the acneiform eruption, sometimes resulting in secondary infection.7 For 
erlotinib and the related gefitinib, we did not find any reports of eosinophilia. 
The mechanism of the rash is unknown, but points to an imbalance in differentiation 
and maturation causing secondary inflammation.7 EGFR blockade increases expression of 
proinflammatory chemokines and p27KiP,1 a negative growth regulator enhancing apoptosis 
and promoting keratinocyte differentiation.3·a This may lead to a thin stratum corneum and 
inflammatory infiltration of the follicles, which often become dilated and plugged by excessive 
keratin, occasionally with microorganisms as observed in patient 2.s.7.a 
Treatment of the eruption is not yet standardized. Because some studies suggest that the 
presence and severity of the eruption correlates with response and prognosis, and because 
it is often self-limiting, side-effects should not necessarily be an indication to discontinue 
treatment.1 •2·a Systemic antibiotics, especially tetracyclines (mainly for anti-inflammatory 
effects), should be considered for severe acneiform eruptions.7They can quickly be discontinued 
in some, but in others, continued treatment is required.2•10 Local antibiotics, antimycotics, 
emollients, retinoids and corticosteroids have produced variable responses.1-7-10 To prevent 
bacterial superinfection, care should be taken when using steroids.a 
Both of our patients experienced long-lasting widespread acneiform eruptions and 
xerosis cutis, probably rendering them susceptible to infection, resulting in acute oozing and 
hospitalization in case 1.7 Patient 2, in contrast to most reports, had extensive scalp involvement, 
in which aggregation of dried-out pustules may have formed yellowish crusts.7•9 Because both 
patients experienced a widespread pustular rash, acute generalised exanthematous pustulosis 
could be considered. However, the less acute and follicular presentation and the absence of 
neutrophilia argue against this diagnosis. 
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Oncologists and dermatologists should actively communicate and cooperate to recognize 
side-effects that are secondary to the direct inhibitory effect of EGFR inhibitors on the epidermis 
and pilosebaceous fol licle. Proactive dermatological intervention can improve compliance and 
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Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: 
does a DRESS syndrome really exist? 
S1R, In a recent study Peyriere et al/ stated that the existence of a clinical entity, known under 
various names including HSS (anticonvulsant hypersensitivity syndrome), DRESS (drug reaction 
with eosinophilia and systemic symptoms), DIDMOHS (drug-induced delayed multiorgan 
hypersensitivity syndrome) and DIHS (drug-induced hypersensitivity syndrome) cannot be 
denied but that its definition, clinical and biological pattern, and limits must be more accurately 
reappraised. We can fully endorse that a gold standard is lacking, as is also repeatedly stated 
in the literature. Also the lack of consensus on nosology is obvious, but this is minor if there 
is agreement on what are the main characteristics of the 'syndrome� Although it is generally 
accepted that a syndrome by its nature comprises a variable combination of symptoms, the 
acronym DRESS is questioned as eosinophilia need not necessarily be present in this syndrome. 
The diversity of cutaneous adverse drug reactions is nearly infinite. It makes sense to isolate 
syndromes, rather than to consider the whole as a continuum, if it helps in finding original 
clinical patterns, courses, causes, mechanisms and treatment. From long discussions between 
experts from different countries in recent medical meetings on drug hypersensitivity it appears 
that whatever the denomination, HSS/DRESS is characterized by a variable combination of: (i) 
drug-induced immunological background; (ii) later onset than other drug reactions; (iii) longer 
duration than common 'drug rashes'; (iv) multiorgan involvement; (v) lymphocyte activation 
(node enlargement, lymphocytosis, atypical lymphocytes); (vi) eosinophilia; and (vii) frequent 
virus reactivation. 
HSS/DRESS is specifically complicated because besides its rather variable presentation it 
is a diagnosis by exclusion. Its main features such as rash, fever and organ involvement can 
also be attributed to a wide range of other causes such as infections, and to concomitant and 
pre-existing diseases. Hence each symptom should always be thoroughly investigated for its 
relation to the syndrome. Not all symptoms and signs are always recognized, and asymptomatic 
systemic involvement such as eosinophilia and atypical lymphocytes are often not determined 
or are determined too late, leading to their under-reporting. In addition, partly due to the 
relatively long latency after initiation and the long duration after cessation of the culprit drug, 
the symptoms are often not recognized as drug related. General awareness of HSS/DRESS is very 
important due to the severity and life-threatening potential of this type of drug reaction. 
The RegiSCAR study group (as its predecessors EuroSCAR and SCAR) is performing a 
prospective study of severe cutaneous adverse reactions (SCAR) in Austria, France, Germany, 
Israel, Italy and the Netherlands, in order to investigate their risk factors and mechanisms 
based on a large multinational registry. Former projects of the group dealt with the spectrum 
of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN)2 and acute generalized 
exanthematous pustulosis (AGEP).3 Crucial to these studies has been a clear case definition. 
The combination of a scoring system and judgement of cases by a review committee (blinded 
for possible risk factors) has proven effective for validation in SJS/TEN and AGEP. The group's 
intention to extend investigations to HSS/DRESS raised the need for an equally reliable approach 
for those cases. 
201 
Chapter 9 
RegiSCAR has collected cases of HSS/DRESS since 2002. Patients are actively detected 
through a hospital network covering about 170 million inhabitants, using selected inclusion 
criteria (Table 1 ). Information on reported cases of HSS/DRESS is obtained by trained local 
interviewers using standardized questionnaires, comprising elaborate questions on drug use, 
morphology and extent of the rash, involvement of lymph nodes and other organs, laboratory 
and clinical parameters to judge organ involvement as attributable to HSS/DRESS, and course of 
the disease. Where possible, clinical pictures and results of histological examination in the active 
phase of the eruption are collected. Interviews take place at the acute stage of the disease with a 
follow up at 8 ± 2 weeks and 1 year, if the patient's informed consent for participation in a cohort 
is obtained. In addition, blood samples are taken for immunological and genetic research. 
Table 1. Inclusion criteria for potential case of HSS/DRESS in RegiSCAR 
Hospitalization 
Reaction suspected to be drug related 
Acute skin rasha 
Fever above 38 °ca 
Enlarged lymph nodes at at least two sitesa 
Involvement of at least one internal organa 
Blood count abnormalities 
Lymphocytes above or below the laboratory l imitsa 
Eosinophils above the laboratory l imits (in percentage or absolute count)a 
Platelets below the laboratory limitsa 
aThree or more required. 
Due to the complexity and variability of HSS/DRESS, interpretation of clinical findings and 
laboratory data by an unorganized reviewing process would not have produced consistent 
results. Based on information from the literature and clinical experience of the review committee 
we reached consensus on a scoring system for our study which would allow for reproducibly 
classifying cases as definite, probable, possible or no case. Thorough case assessment was done 
on the basis of clinical pictures and analysis of the collected data by experienced clinicians, as 
this cannot be replaced by a scoring system alone, but will always need professional judgement. 
An overview of the scoring system is given in Table 2. To prevent bias, the review committee was 
blinded to the suspected drugs. 
Although we are aware that virus reactivation may play a role in the syndrome, we do 
not count the related organ in case of a positive virus serology. However, it is still a matter of 
debate whether reactivation of several herpesviruses in the course of the disease is part of 
the syndrome or should be interpreted as a complication, resulting in a more protracted and 
relapsing disease.4•5 
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In pharmacovigilance, data are often only received retrospectively, whereas we most often 
see the patient in the acute stage of the disease and systematically collect far more detailed 
data, permitting us better to judge the presented symptoms. Moreover, the advantages of the 
scale of our multinational study over a national one, as proposed by Peyriere et al., 1 in a rare 
syndrome such as HSS/DRESS, are obvious. 
Table 2. Scoring system for classifying HSS/DRESS cases as definite, probable, possible or 
no case 
Score -1 0 2 Min. Max. 
Fever � 38·5 °C No/U Yes -1 0 
Enlarged lymph nodes No/U Yes 0 
Eosinophil ia No/U 0 2 
Eosinophils 0·7-1 -499 X 1 09 L-1 � 1 -5 X 1 09 L- 1 
Eosinophils, if leucocytes 
1 0-1 9·9% � 20% < 4·0 X 1 09 L-1 
Atypical lymphocytes No/U Yes 0 
Skin involvement -2 2 
Skin rash extent (% body surface 
No/U > 50% area) 
Skin rash suggesting DRESS No u Yes 
Biopsy suggesting DRESS No Yes/U 
Organ involvement• 0 2 
Liver No/U Yes 
Kidney No/U Yes 
Lung No/U Yes 
Muscle/heart No/U Yes 
Pancreas No/U Yes 
Other organ No/U Yes 
Resolution � 1 5  days No/U Yes -1  0 
Evaluation of other potential causes 
Antinuclear antibody 
Blood culture 
Serology for HAV/HBV/HCV 
Chlamydia/mycoplasma 
If none positive and � 3 of above 
Yes 0 negative 
Total score -4 9 
U, unknown/unclassifiable; HAV, hepatitis A virus; HBV, hepatitis B virus; HCV, hepatitis C virus. 
•After exclusion of other explanations: 1, one organ; 2, two or more organs. 




We anticipate our case definition and system of validation will lead to a reliable identification 
of cases of HSS/DRESS for further studies of pharmacoepidemiological and genetic risk factors, 
as well as the immunological background. We expect to be able to answer several long-standing 
questions after further case enrolment in 1 2- 1 8 months. 
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Background: Cases of severe drug hypersensitivity, demonstrating a variable spectrum of 
cutaneous and systemic involvement, are reported under various names, especially DRESS (drug 
reaction with eosinophilia and systemic symptoms). Case definition and overlap with other 
severe cutaneous adverse reactions (SCAR) are debated. 
Aim of the study: Analysis of the spectrum of signs and symptoms of DRESS and distribution of 
causative drugs in a large multicenter series. 
Patients and methods: RegiSCAR, a multinational registry of SCAR, prospectively enrolled 201 
potential cases from 2003 to mid 2009. Using a standardized scoring system, 117 cases were 
validated as probable or definite DRESS. 
Results: The male/female ratio was 0.77; females were significantly younger than males. Next to 
ubiquitous exanthema, main features were eosinophilia (95%), visceral involvement (91 %), high 
fever (90%), atypical lymphocytes (67%), mild mucosa I involvement (56%) and lymphadenopathy 
(54%). The reaction was protracted in all but 3 cases; 2 patients died during the acute phase. Drug 
causality was plausible in 88% of cases. Antiepileptic drugs were involved in 36%, allopurinol in 
1 8%, antimicrobial sulfonamides and dapsone in 12% and other antibiotics in 11 %. Mean time 
interval after drug intake was 25.9 ± 19.1 days for all drugs with (very) probable causality, with 
differences between drugs. 
Conclusion: This series supports that DRESS is an original phenotype among SCAR in terms of 
clinical and biological characteristics, causative drugs, and time relation. The diversity of inciting 
drugs was rather limited, and mortality was lower than suggested by prior publications. 
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I ntroduction 
Drug reaction with eosinophilia and systemic symptoms (DRESS), a rare but potentially 
life threatening adverse drug reaction (ADR) is characterized by a variable combination of 
symptomatic and asymptomatic features, both in time and course. 1 Commonly reported features 
are multi-organ involvement, lymphocyte activation (lymph node enlargement, lymphocytosis 
including "atypical" activated lymphocytes), eosinophilia, reactivation of herpes viruses, later 
onset and longer duration than other cutaneous adverse drug reactions (cADR), and a drug­
induced aetiology. 
The syndrome, first ascribed to aromatic antiepileptic drugs (AED), has been reported 
under various names, including anticonvulsant hypersensitivity syndrome, drug induced 
hypersensitivity syndrome (DIHS), DRESS or names referring to the causative drug, the most 
prominent affected organ or the disease mimicked.2-5 Since the word hypersensitivity is rather 
uninformative and ambiguous, the more informative and clinically relevant acronym DRESS is 
gaining use. 
Besides AED, many other drugs have been reported to be associated, such as sulphonamides, 
allopurinol, minocycline, mexiletine and dozens of other drugs.1 ·6-8 The estimated risk at first or 
second prescription of AED is 1-4.5 in 10,000.9 The onset is rather delayed, often 2 to 8 weeks 
after introduction of the inciting drug, although rechallenge can result in a reaction within hours 
to days.1 .4, ,0-1 3 Recovery after withdrawal of the culprit is often complete, but symptoms may 
persist for weeks to months.1 2  Mortality rates of about 10% are regularly reported.1 •1 2-16 
DRESS is quite a challenging diagnosis, reached after exclusion of other diseases. Diagnosis 
can be delayed or go unrecognized as drug related because of the variable presentation, course, 
and severity, relatively late onset, gradual evolution and long duration, even after cessation of 
the culprit, or because of clinical similarity to infections, collagen vascular or lymphoproliferative 
diseases. 
Knowledge on DRESS mostly relies on case reports and retrospective series, often originating 
from dermatologists because skin involvement is one of the first and most frequent symptoms 
noticed.1 •2.4, ,s-,a At onset, the eruption is often morbilliform and indistinguishable from ordinary 
drug eruptions or viral rashes. Facial oedema is regularly observed and the eruption may 
become widespread and polymorphous.1 •2.4 Because the severity of the skin eruption does 
not necessarily reflect that of the overall reaction, involvement of liver, kidney, lung, and other 
visceral organs requires independent assessment. Notwithstanding general agreement on the 
main characteristics of the syndrome, its definition, clinical and biological features needs more 
accurate appraisal. 
Complete pathogenesis is not yet understood and appears to be complex, combining 




reactivation of latent herpes virus infections.5•1 9-21 A genetic predisposition was observed in Han 
Chinese, with a 100% association between allopurinol induced DRESS and HLA-B*S801.22 
Because clear case definition including cut-off points of abnormal biological and laboratory 
values was lacking, and in order to obtain a homogenous cohort of patients for further study, 
the RegiSCAR study group developed a diagnostic validation score, combining clinical and 
biological criteria for validating potential cases of DRESS as definite, probable, possible, or no 
case (appendix).23 We present the first large prospective series of 117 cases, collected by the 
RegiSCAR group, validated probable or definite DRESS according to this score. 
Patients and methods 
Setting 
RegiSCAR, a multinational registry of severe cutaneous adverse reactions (SCAR), conducts a 
prospective, ongoing pharmaco-epidemiological study on Stevens Johnson syndrome (SJS)/ 
toxic epidermal necrolysis (TEN), acute generalized exanthematous pustulosis (AGEP), and 
DRESS, including collection of biological samples, since 2003. Through a network of hospitals 
in Austria, England, France, Germany, Israel, Italy, Taiwan, and The Netherlands about 120-1 SO 
million inhabitants are covered. The study has been approved by the ethical committee of each 
participating national centre. 
Recruitment of cases 
Hospitalized patients, notified to the national investigators and meeting three or more of the 
inclusion criteria (acute rash, fever above 38° C, enlarged lymph nodes on at least two sites, 
involvement of at least one internal organ, or blood count abnormalities), are consecutively 
enrolled as potential cases of DRESS.23 After informed consent and using a structured, reaction­
specific questionnaire, trained interviewers collect detailed data on morphology and extent of 
the rash, clinical and biological data on organ involvement, course of the disease, concomitant/ 
earlier diseases and infections, and exposure to medication. 
Validation of cases 
Based on clinical photographs, histopathology, and completed questionnaires with clinical and 
biological information, but without information on drug exposure and other risk factors, an 
international expert committee validates potential cases as definite, probable, possible or no 
case, following a standardized procedure and scoring system (appendix).23 Signs and symptoms 
are only attributed to DRESS after exclusion of alternative causes. 
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Assessment of drug causality 
Evaluation of drug causality was an expert decision by consensus between 3 authors (SHK, 
MM, JCR). A first selection, blinded for name and indication of drugs, was based on the time 
relation between onset of the reaction and initiation and withdrawal of each drug. The probable 
index-day, representing the most likely onset of the reaction, is defined as the earliest date of 
a clinical sign or symptom consistent with a continuum in the disease. Latency was defined as 
the number of days between initiation of medication with a probable or very probable causality 
and the probable index-day. Drugs taken long term (>3 months), or stopped > 14 days before 
or initiated <3 days before the probable index-day, were considered unlikely. Prior use without 
cADR decreased suspicion, while an earlier reaction made the drug a first rank suspect. Hereafter, 
remaining suspects were unblinded and evaluated according to a list of notoriety for eliciting 
DRESS, based on literature review. Causality in cases with a single remaining drug was considered 
"very probable" in presence of highly notorious medication, and "probable" when medication 
was not notorious or had low notoriety. For cases with several remaining drugs, those with high 
notoriety were considered "probable" and those with low notoriety possible. Causality in cases 
with concomitantly used drugs without notoriety was classified as undetermined. 
Data management and statistical analysis 
All collected data are entered by investigators into a centralized data base (Oracle, version 
8.1.7 (Si), Redwood Shores, CA, USA) at the University Medical Center Freiburg, Germany, using 
the internet based remote-data-entry system MACRO (version 3.0, lnferMed, London, UK). 
For subsequent data processing (including regular data checks, data preparations and data 
analyses), the software package SAS (version 9.2, Cary, NC, USA) is used. For statistical analysis, 
the software package SAS, SPSS (version 16, SPSS, Chicago, IL), and MS Excel Data Analysis were 
used. Categorical/dichotomous variables are presented in absolute numbers and percentages, 
while mean and standard deviation or, if more appropriate, median and interquartile range are 
presented for continuous variables. For testing differences between groups, we used the non­
parametric Wilcoxon test for continuous variables and Chi-square test for categorical variables 
assuming a two sided 5% significance level. 
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Resu lts 
Inclusion 
Between February 2003 and May 2009, a total of 201 potential cases of DRESS was included. 
Of these, 27 were validated no case, 56 possible, 59 probable, and 59 definite cases of DRESS. 
With exception of one probable case, also fulfilling criteria for definite acute generalized 
exanthematous pustulosis (AGEP), all probable and definite cases (n=1 1 7) were analyzed in this 
study (Fig. 1 ). 
Demographics 
As shown in Table 1, 97 were community cases, admitted because of the reaction, whereas in 
20 cases the reaction started in hospital. An earlier cADR had been experienced by 22 patients, 
including one case with a prior episode of DRESS to the same drug. Females were predominant 
and significantly younger than males (p=0.03), especially in cases related to antiepileptics 
(median 37 vs. 47 years) and antibiotics (median 38 vs. 58 years), while no difference was 
observed for allopurinol (median 63 vs. 61 years). There was no patent difference by gender in 
indication for treatment. The most frequent co-morbidity was epilepsy (1 9.7%). We considered 
1 6  patients (1 3.7%) to be immunocompromised: 1 by co-morbidity (HIV infection) and 1 5  by 
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Drug Reaction with Eosinophi lia and Systemic Symptoms (DRESS): 
an original m ultisystem adverse drug reaction. Results from the prospective RegiSCAR study. 
Characteristics 
As shown in Table 2, fever �38.s'C was documented in 90% (and fever 38.0'C-38.s' C in 7%); 2 1 %  
experienced more than one episode of fever. Lym phadenopathy was observed i n  54%. 
Almost a l l  cases (99%) showed one or more haematological abnormal ity. Eosinophi lia, 
defined as an  absolute eosinophil count �700/µL, was present in  95% and � 1 ,500/µL in  8 1 %. 
Atypical lymphocytes were observed in 68 cases (67%). Although no part of the val idation 
score, we also noticed other haematological abnormal ities. Leukocytosis (median 1 8,950/ 
µL, interquartile range (IQR) 1 5,500-29,000/µL) was found in 95% and lymphocytosis in 48%. 
Neutrophi l ia (78%) was predominantly present in the early phase of the reaction, whi le 
monocytosis (67%) occurred later. Lymphopenia (5%, data not shown), thrombocytopenia (7%), 
and thrombocytosis ( 1 9%) were infrequent. 
Table 1. Demographics, co-morbidities, concomitant medication 
DRESS SJS/TEN* 
n =  1 1 7 n = 379 
Demographics 
Sex, male/female ratio 0.77 (5 1 /66) 0.62 ( 1 45/234) 
Age all (median, interquartile range) 48 (30-62) so (28-68) 
Age male (median, interquartile range) 57 (34-66) 47 (30-62) 
Age female (median, interquartile range) 44 (29-59) 51  (28-72) 
Community cases 97 (82.9%) 379 ( 1 00%) 
Earlier cADR 22 ( 1 8.8%) 52 (1 3.7%) 
Co-morbidities 
Convulsive disorders 23 (1 9.7%) 47 (1 2.4%) 
Col lagen vascular disease 1 0  (8.5%) 27 (7.1 %) 
Diabetes mellitus 1 4  (1 2.0%) 36 (9.5%) 
Pre-existing kidney disorder 7 (6.0%) 30 (7.9%) 
Pre-existing liver disorder 6 (5. 1 %) 26 (6.9%) 
Recent cancer** 6 (5.1 %) 40 (1 0.6%) 
radiation therapy (0.9%) 1 6  (4.2%) 
HIV 1 (0.9%) 25 (6.6%) 
Acute infections (4 wks before onset reaction) 25 (21 .4%) 1 65 (43.5%) 
Concomitant medication 
lmmunosuppressive / -modulating agents*** 
- corticosteroids � 8 weeks / > 8 weeks 7/3 (8.5%) 1 4.8% 
- other � 8 weeks / >8 weeks 3/2 (4.3%) 
* EuroSCAR-study 32 
** Recent cancer: diagnosed during last 2 years before index date or, if diagnosed earlier, still treated 
*** Not including colchicine, combined with al lopurinol �8 weeks in 4 cases 
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Table 2. Characteristics of probable and definite cases of DRESS 
Total 1 1 7 
number 
Fever � 38.5°C 1 03/1 1 4  
Lymphadenopathy 61/ 1 1 2  
Haematological abnormalities 1 1 3/1 1 4  
- Eosinophilia 1 08/1 1 4  
- grade 2 (� 1500/µLJ 92 
- grade 1 (700- 1499/µLJ 16 
- Atypical lymphocytes 68/ 1 02 
- Leukocytosis > 1 0.000/µL 99/1 04 
- Neutrophilia > 7000/µL 8 1 / 1 04 
- Lyrnphocytosis > 3000/µL 50/1 04 
- Monocytosis > 1 000/µL 47/70 
- Thrombocytosis > 400.000/µL 20/1 04 
- Thrombocytopenia < 1 00.000/µL 7/1 04 
Skin** 1 1 7/1 1 7  
- rash extent > 50% 79/1 04 
- rash suggestive 68/ 1 04 
- facial oedema 89/1 1 7  
- monomorphic maculopapular 1 8/1 1 7  
- polymorphous maculopapular 99/1 1 7  
- urticaria/ 12 
- exfoliative 1 1  
- lichenoid 4 
- pustules 35 
- purpura 3 1  
- infiltrated plaques 27 
- blisters 1 9  
- target-like lesions 14 
- eczema-like lesions 8 
- duration exanthema � 1 5  days 5 1 / 1 1 7  
Mucosal involvement 66/1 1 7  
- mouth/throat/lips 6 1  
- eyes 15 
- genitalia 8 
- other 8 
Internal organ involvement 107/1 1 7  
- 1 organ involved 42 
- 2 organs involved 41 
- > 2 organs involved 24 
- liver 86/1 14 
- kidney 40/108 
- lung 33/104 
- muscle/heart 13/99 
- spleen 12/79 
- pancreas 3/77 
- other*** 13/1 1 7  
Duration DRESS � 1 5  days 1 07/1 09 
* Denominator number of cases, investigated for the feature 
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98 
*** Including gastro-intestinal tract (6) central nervous system (5), thyroid gland (2) 
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Figure 2. Skin reaction. A. Extensive erythematous maculopapular rash with indurated papules. B. Close-up 
of indurated papules on belly. C. Exfoliative dermatitis. D. Peri-orbital oedema, scal ing, and residual facial 
erythema and pustules. 
All patients experienced an acute skin eruption (Fig. 2). Extent and morphology however 
were only rated when photographs were available and informative (n=1 04). In 76% skin 
involvement exceeded 50% of the body surface area (BSA}, while in 65% morphology fulfilled 
two or more criteria suggesting DRESS (see appendix). The rash concerned a monomorphic 
maculopapular, sometimes confluent and/or oedematous erythema in 15%, while in all other 
cases it was polymorphous, including additional varying combinations of other lesions such 
as pustules or tense blisters with, except for two cases, negligible detachment. Pruritus (81%) 
was more frequent than burning/pain (35%). Facial oedema was observed in 76%. Mild mucosa I 
involvement was recorded in 56%; in 1 5% more than one mucosa was affected. Most frequent 
were oral lesions (52%), including lips (42%) oral cavity (40%), and throat (8%). 
Two or more internal organs were involved in 56%, and one in 36%. Most frequently it 
concerned liver (75%), kidney (37%), and lung (32%). Kidney involvement was significantly more 
frequent in allopurinol than in carbamazepine related cases (60% vs. 17%, p<O.O 1 ), whereas liver 
involvement did not differ significantly. 
HHV6 (re)activation was demonstrated on serum samples in 20 of 56 routinely investigated 
cases in the active phase of the disease (36%) by PCR and/or positive lgM or a fourfold rise in lgG 
titre. EBV/CMV (re)activation was observed in 3 cases. 
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Day of onset of early signs and symptoms in relation to onset of erythema 
Onset of erythema is defined as Day 0. 
Horizontal bars= extreme values, boxes= interquartile range, vertical bars= median 
Figure 3.  Latency prodromal symptoms (days) 





I Lymph nodes 
Some signs or symptoms such as pruritus, skin pain, fever, dysphagia and lymphadenopathy 
may appear before skin lesions (Fig. 3). In nearly half the cases the skin eruption persisted 2:15 
days, while in all but two the full course of DRESS lasted �15 days. Mean in-hospital stay for 
community cases was 18.7 ± 11 .5 days (median 1 7, IQR 11 -23 days). During the acute phase, 
2/1 17  patients died. 
Culprit drugs 
The results of the expert decision on drug causality are presented in Table 3. Overall 642 
medicines (median 4, IQR 2-7 per patient), containing 31 6 different therapeutically active 
components, were used in the month before the probable index-day. The number of suspects 
was substantially reduced after elimination as a result of time relation. In 66 cases, only one (43) 
or two (23) drugs remained, most often including a single drug of high notoriety. All cases in 
which highly notorious drugs were eliminated because of long term use (allopurinol 6 1 ,  102, 
and 1 32 months, oxcarbazepine 1 1  months, and fluindione 408 months) were exposed to an 
alternative highly notorious drug within the chosen time window. 
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AED were considered responsible in 36%. Epilepsy was the most common indication for 
use of phenytoin or lamotrigine, while carbamazepine was prescribed for other indications, 
e.g. mood disorders or pain, in 65%. Only once an AED (phenytoin) was combined with 
dexamethasone for seizure prophylaxis in brain tumour. Allopurinol ( 1 8%), was prescribed for 
Table 3. Culprit drugs and time relation of drugs taken within one month before the reaction 
Exposure cases median interquartile range 
At least one drug 1 1 5 (98%) 
Total number of drugs used 642 4 2-7 
Causality cases drugs 
Very probable 38 {32%) 38 
Probable 55 {47%) 58* 
Possible 1 0  { 9%) 
undetermined 5 { 4%) 
unl ikely 9 (  8%) 
Associated (very) probable drugs cases median latency interquartile range 
AED 43 {36%) 
- carbamazepine 23 29 20-36 
-phenytoin 8 29.5 26.5-37 
- /amotrigine 8 26.5 20-34 
- oxcarbazepine 2 n.a. n.a. 
-phenobarbital 2 n.a. n.a. 
Allopurinol 21 { 1 8%) 20 1 6.5-3 1 
Sulphas 14 ( 1 2%) 
- sulfasalazine 8 20 7 7.5-25 
- dapsone 3 n.a. n.a 
- sulfamethoxazo/e-trimethoprim 2 n.a. n.a 
- sulfadiazine n.a. n.a. 
Antibiotics 1 3  { 1 1 %) 
- vancomycin 7 77  73.5-20 
- minocyclin 4 20 76.5-26 
- amoxicillin n.a. n.a. 
- ampicillin/su/bactam n.a. n.a. 
Other drugs** 5 ( 4%) 26 1 6-29.5 
n.a.: not applicable 
* Equally suspected high notorious drugs in the same case: a l lopurinol/fluindione, oxcarbazepine/ 
phenobarbital, and carbamazepine/phenytoin. 
** Flavoxate, fluindione, nevirapine, phenylephedrine-acetaminophen, strontium ranelate. 
217 
Chapter 10 
gout in 6 and hyperuricemia in 15 cases, with a starting daily dose of 300 mg in 15, 200 mg in 
two, and 100 mg in four cases. Antimicrobial sulfonamides/dapsone (sulphas) were suspect in 
12%, especially sulfasalazine and dapsone, other antibiotics in 11 %, predominantly vancomycin 
and minocycline, and other drugs in 4%. In 9%, drugs of low notoriety were concomitantly 
used with drugs without notoriety, while another 4% was classified as undetermined, due to 
polypharmacy and absence of a notorious drug. No likely drug could be detected in 8%. 
For all cases with a "very probable" or "probable" causality, median latency was 22 days (IQR 
16-30 days) and mean latency 25.9 ± 19.1 days. Between the two most often appointed drugs, 
carbamazepine and allopurinol, latency differed significantly (p<0.0 1) with a mean of 32.0 ± 16.7 
days and 24.5 ± 13.6 days respectively. 
Overlap with other types of SCAR 
Of 118 probable/definite DRESS cases, 8 shared some features with SJS/fEN or AGEP and were 
re-reviewed for the alternative SCAR. Three cases (3%) were considered true overlap: one 
probable DRESS fulfilled the criteria of definite AGEP and was discarded from analysis in this 
study, one probable DRESS also validated as probable AGEP, and one definite DRESS as probable 
SJS/fEN, both were included as DRESS. 
Discussion 
Strengths and weaknesses of the study 
This large prospective multinational study allows detailed analysis of clinical and biological 
features of DRESS and the relative contribution of "high risk" drugs. Since notification and 
enrolment of cases was independent of outcome, exposure to specific medication or other 
risk factors, we consider our results as likely less biased than those of most prior series. 15•16•24-29 
Moreover, prospective collection of data through direct interviews of patients and treating 
physicians using a structured reaction-specific questionnaire, and validation by an expert 
committee using a standardized scoring system, clinical photographs, clinical and biological 
parameters contributes to the strength of the study. Our validation criteria and cut-off points 
are stricter than earlier case series including those which used RegiSCAR inclusion criteria as 
diagnostic criteria, resulting in less heterogeneity of cases (see Appendix).16•23•29 Moreover, 
evaluation of case reports (of DRESS) is often not possible due to lacking transparency of data.1 8  
Combining a scoring system with an expert review, blinded for drug exposure and other risk 
factors, has proven to be effective for validationin SJS/fEN and AGEP.30•31 
On the other hand, the natureofourstudy implies limitations to address adequately questions 
such as efficacy of treatment, late complications and sequelae. Cutaneous manifestations were 
part of our inclusion criteria, implicating that potential cases without overt skin lesions were 
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likely missed. However, a recent review of the literature indicated that almost all reported cases 
experienced a skin reaction.18 
Not all physicians are familiar with DRESS, introducing risk of biased notification and absence 
of relevant laboratory investigations during the first days of the reaction, potentially resulting in 
underscoring of asymptomatic features. Moreover, recognition of the syndrome and complete 
collection of its symptomatic and asymptomatic features is often complicated. First symptoms 
may be seemingly harmless and each feature may be of variable onset and severity, leading 
to confusion and delay in diagnosis. Furthermore, features like eosinophilia and internal organ 
involvement tend to abate or disappear after treatment with systemic corticosteroids. 
Several findings have been mentioned in previous reports and could be expected since they 
were part of our diagnostic score. However, the prospective and structured nature of our study 
enables a more detailed description of mucocutaneous involvement, and better assessment of 
the prodromal period, prevalence of key features such as eosinophilia and organ involvement, 
and distribution of inciting drugs. 
Demographics 
Contrary to most reports, our study showed slight female predominance (male/female ratio 
0.77).5•7•1 0•1 3•1 5•1 8•24•25 This predominance has also been reported for SJS/TEN (0.62), and AGEP  (0.80) 
in a comparable population.32•33 Striking and unreported hitherto, women were significantly 
younger than men, a difference not observed in SJS/TEN or AGEP (EuroSCAR, unpublished data). 
We do not have a satisfactory explanation for this finding. 
As shown in Table 1, the frequency of prior rheumatic/collagen vascular disease was 
strikingly high (8.5%) as previously reported for SJS/TEN, while that of cancer (5.1 % vs. 10.6%) 
was lower and close to the control group for SJS/TEN.32 Our collection also included less HIV 
infected patients than observed in SJS/TEN or earlier reported in DRESS.24•25•29•32This may reflect 
a different or changing medication profile or that abacavir hypersensitivity does not sufficiently 
meet our criteria for DRESS (appendix).23 
Contrary to SJS/TEN and earlier case series in DRESS, immunocompromised patients were 
not clearly overrepresented, and their profile did not significantly differ from that of other cases 
in our study (data not shown).25•29•32 Related to the relative high prevalence of corticosteroid 
maintenance therapy in the context of brain tumour and co-medication with AED in SJS/TEN, 
exposure to corticosteroids was lower (8.5% vs. 14.8%). 
Characteristics 
High fever usually starts at the beginning of the reaction, and regularly precedes the eruption, 
generating concern for underlying infections.1 -4 A long lasting, polymorphous rash, and 
facial oedema are characteristic for DRESS. Facial oedema (76%) is more manifest than often 
stated.4•1 5•16•25 Especially in combination with high fever and an eruption, it constitutes a warning 
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signal because in common cADR the face is usually spared. Mucosa I involvement (56%), mainly 
of lips and oral cavity, was more frequent than generally assumed, however, contrary to SJS/TEN 
rather mild and less haemorrhagic. 
Haematological abnormalities were far more frequent and diverse than usually described, 
reflecting that retrospectively collected cases are prone to missing informative biological data 
and underlining the importance of a full haemogram in DRESS. In our study, leukocytosis was 
common (95%) and often considerable. Transient eosinophilia (95%) was far more present 
than usually reported.7•1 5•1 6•24•25•34 Hypereosinophilia > 1 500 cells/µL, if persistent, can be toxic to 
endothelial cells and contributes to organ damage such as interstitial nephritis, pneumonitis, 
myositis, eosinophilic carditis, pancreatitis, thyroiditis or encephalitis.4•35•36 Remarkably, also 
neutrophilia (78%), and monocytosis (67%), usually not reported in DRESS, were frequent. 
Neutrophils, especially when activated, may also be implicated in tissue damage. Atypical 
lymphocytes, often regarded as characteristic for DRESS, were found in 67%, while lym phocytosis 
was observed in 48%. The pattern of leukocytosis, combined with neutrophilia in the early 
stage and monocytosis in a later stage is frequent in other strong inflammatory reactions; the 
combination with eosinophilia however is rather characteristic for DRESS. Thrombocytopenia/ 
thrombocytosis, both occasionally reported, were quite infrequent. 
Lymphadenopathy (54%) was observed more frequent than sometimes reported.16•24•25•29 
Visceral involvement often determines severity in DRESS. Liver involvement was frequent (75%), 
most often expressed by transiently disturbed liver function tests, although also hepatomegaly, 
sometimes with coagulopathy, was observed. In addition, we regularly noted participation of 
kidney (37%), ranging from mild proteinuria to severe renal function disturbances needing 
transient haemodialysis (data not shown), lung (32%), and more incidentally of muscle/heart, 
spleen, pancreas, gastrointestinal tract, central nervous system, and thyroid gland. 
Reactivation of herpes viruses, especially HHV-6, often described in DRESS and even 
considered a criterion by Japanese experts, is held responsible for a more severe and/or 
protracted course.5•7•1 9•2 1 •34•37•38 HHV6 reactivation was observed in 20 of 56 of our cases (36%), 
routinely investigated by the treating physicians. This is less than in earlier, especially Asian series, 
where it reaches 60%.7•21 This discrepancy might be explained by less elaborate investigations in 
our cases. 
Course and outcome 
For assessment of course, latency time and drug culpability, correct establishment of onset 
of the reaction is essential. The prodromal stage, defined as the period between onset of 
the reaction and start of the exanthema, lasted up to 2 weeks (median 1 day, IQR 0-4, range 
0-14 days). Early signs and symptoms such as fever, lymphadenopathy, flu-like symptoms, 
sore throat/dysphagia, burning pain and pruritus can easily be overlooked or misdiagnosed. 
Incidentally, we also noticed asymptomatic organ or haematological involvement before the 
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onset of erythema. However, laboratory investigations or medical imaging wil l  general ly only be 
performed at a later stage, after admission or suspicion of DRESS. Notwithstanding our efforts 
on systematical ly col lecting early signs and symptoms as these are crucial for determining the 
index date, we cannot exclude that these were sometimes missed, and that the onset of the 
disease was occasional ly a few days earlier. This might partial ly contribute to the longer latency 
time in DRESS compared to other SCAR. 
Mortality was considerably lower in the acute phase than usually reported, likely reflecting 
bias in published retrospective studies. 
Culprit drugs 
The process of determining drug causality was quite straightforward, and (very) probable 
causality was more frequent than in SJS/TEN (80% vs. 69%).39 Selection of potential culprits, 
based on temporal relation but blinded for drug names, clearly pointed towards notorious 
suspects in the majority of cases. Noteworthy is the rather limited spectrum of causative 
drugs in DRESS, with carbamazepine as leading drug fol lowed by allopurinol. Although lack of 
controls and validated rules for causality assessment could easily have led to spurious temporal 
associations of widely used drugs, these did not appear. 
Although latency times exceeding 3 months have been reported, risk was mostly confined 
to medication started within 2 months. Cases in which highly notorious drugs were eliminated 
because of long-term use were all exposed to another highly notorious drug at a later date. Risk, 
confined to relative recently introduced exposure has also been reported for SJS/TEN and is of 
considerable relevance for long-term use of e.g. allopurinol or AED.40 In addition, most cases 
using drugs without significant risk had been exposed to a highly notorious drug in parallel. 
As could be expected, epilepsy (19.7%) was a frequent indication for AED in DRESS, although 
carbamazepine was used in 65% for other indications than epilepsy, reflecting increasing use 
for new indications. Allopurinol seems to have passed sulphas as frequent inducer of DRESS.1 1  
I t  concerned first use except for one case in which prior exposure also resulted in DRESS. 
Noteworthy was the significantly higher prevalence of renal involvement in cases related 
to allopurinol compared with carbamazepine, whereas earlier reported differences in liver 
involvement were not found.1 5•24.41 Allopurinol is increasingly prescribed, also without clear 
indication and in high doses; 17/21 patients started al lopurinol with a daily dose of �200 mg. 
Daily doses equal to or exceeding 200 mg were also associated with a higher risk for SJS/TEN.42 
The prodromal stage and the quite prolonged latency time in DRESS introduces risk of 
protopathic bias, especially for antibiotics and NSAIDs, necessitating scrutinous investigation 
of the prodromal stage. Of interest is the variation in drug-specific latency time. The difference 
between carbamazepine (median 29 days) and al lopurinol (median 20 days) was significant 
(p<O.O 1 ).This difference in dynamics of the reaction suggests a drug-specific pathomechanism, 
which has to be further elucidated. Also remarkable are different latency times between some 
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earlier series and our findings.7•15•1 6•24 Responsible could be a less strict case definition, leading to 
a more heterogeneous study population, retrospective assessment or incomplete collection of 
data, different drug profiles, and underestimation of the prodromal period. 
Overlap 
SJS/TEN and AGEP can share some features of internal involvement with DRESS, although to a 
milder and more limited extent.43 Mucocutaneous features however, are quite discriminative in 
all three types of SCAR. Blisters, occasionally present in DRESS, are generally tense and related 
to dermal oedema.4 Mucosal involvement differs from SJS/TEN in being rather mild. Compared 
to AGEP, flexural accentuation is lacking, while pustules, if present, are follicular and mainly 
limited to the face and upper thorax. Striking is also the subacute character and protracted 
course in DRESS, while particularly AGEP is characterized by an acute onset and quick resolution. 
Histopathology of DRESS is quite distinct from that of TEN and AGEP and lacks full thickness 
necrosis or sterile nonfollicular subcorneal pustules.44.45 Applying the RegiSCAR validation 
score systems for SJS/TEN and AGEP to cases, validated probable or definite DRESS, resulted 
in negligible overlap.23•30•3 1  This supports that DRESS is an original phenotype and confirms a 
reliable performance of our scoring systems. 
There is a remarkable overlap of several major culprit drugs in DRESS and SJS/TEN, such 
as allopurinol, carbamazepine, phenytoin, lamotrigine, and sulfasalazine. In a comparable 
population, overall latency in SJS/TEN and AGEP were shorter than in DRESS.32•33 Compared to 
SJS/TEN or AGEP, latency is prolonged and the prodromal period is more variable and extended 
in DRESS. Comparing latency in DRESS and SJS/TEN for the two most prevalent drugs in our 
study, we noticed a significant difference for carbamazepine (median 29 days versus 15 days, 
(Fig. 2) while for allopurinol (median 20 days versus 1 9  days) differences were less obvious 
(EuroSCAR unpublished data). 
On the other hand, AED and allopurinol, important culprits both in SJS/TEN and DRESS, 
constitute no clear risk in AGEP. Quinolones and aminopenicillins, important triggers for both 
SJS/TEN and AGEP, are not clearly associated with DRESS, while vancomycin and minocycline, 
less prominent in other SCAR, are regularly implicated in DRESS. Co-trimoxazole and oxicam 
NSAIDs, showing a strong association with SJS/TEN, seem less a risk factor in DRESS.7•15•25•32•46 
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Conclusion 
Our validation scoring system for DRESS, based on clinical and biological parameters and 
exclusion of other entities, resulted in only minor overlap with other SCAR. Clinical and biological 
characteristics, causative drugs, and time relation support that DRESS is an original phenotype 
among the spectrum of ADRs. 
DRESS is a serious and multiorgan ADR, exhibiting variable combinations of features. Because 
cutaneous symptoms are generally present and often the first and most visible manifestation, 
the syndrome is classified as a SCAR. However, potentially severe involvement of visceral organs 
makes this syndrome of interest for all physicians. 
Awareness of DRESS is a prerequisite for diagnosis, since it is a syndrome in which signs 
and symptoms often evolve sequential ly. This introduces risk of delayed diagnosis and separate 
treatment of each symptom. In particular high and spiking fever and haematologic abnormalities 
may raise suspicion of an infection. Early recognition, followed by prompt withdrawal of the 
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DRESS validation score 
SCORE -1 0 2 min max 
Fever � 38.5 ° C No/U Yes -1 0 
Enlarged lymph nodes No/U Yes 0 1 
Eosinophilia No/U 0 2 
Eosinophils 700-1 499/µI �1 500/µI 
Eosinophils, if leukocytes <4000 1 0-1 9.9% �20% 
Atypical lymphocytes No/U Yes 0 1 
Skin involvement -2 2 
Skin rash extent (% BSA) No/U >50% 
Skin rash suggesting DRESS No u Yes 
Biopsy suggesting DRESS No Yes/U 
Organ involvement * 0 2 
Liver No/U Yes 
Kidney No/U Yes 
Lung No/U Yes 
Muscle/heart No/U Yes 
Pancreas No/U Yes 
Other organ(s) No/U Yes 
Resolution � 1 5  days No/U Yes -1 0 
Evaluation other potential causes: 0 
ANA 
Blood culture 
Serology for HVA/ HVB/ HVC 
Chlamydia-/ Mycoplasma pneumoniae 
Other serology/PCR 
If none positive and � 3 of above Yes 
negative 
TOTAL SCORE -4 9 
U = unknown/unclassifiable 
* After exclusion of other explanations: 1 = 1 organ, 2 = � 2 organs 
Final score <2: No case 
Final score 2-3: Possible case 
Final score 4-5: Probable case 
Final score >5: Definite case 
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Fever (- 1, 0) 
If core temperature is < 38.5°(: deduction of 1 point 
Lymphadenopathy (0, + 1) 
Tender enlarged lymph nodes at least at two different anatomic locations: > 1 cm. 1 point 
Peripheral blood: 
Eosinophilia: (0, + 1,+2) 
-Absolute eosinophilia of 700-1500 109E/l:1 point, if � 1500 109E/I: 2 points 
- If leukocyte count is < 4000 109E/I : % eosinophils �10%-20%: 1 point, eosinophils � 20%: 2 
points 
Atypical lymphocytes: (0, + 1) 
I f  present: 1 point 
Skin reaction (morphology, extent) (-2, - 1, 0,+ 1, +2) 
a. Morphology (-1, 0, +1): If morphology is suggestive for DRESS: 1 point; if suggestive for a 
different type of reaction: deduction of 1 point, otherwise O points. 
Morphology is considered suggestive for DRESS at presence of � 2 of following criteria: 
- scaling/desquamation e.g. exfoliative dermatitis 
- oedema, especially facial oedema (excluding lower leg oedema) 
- purpura (excluding lower leg) 
- induration 
b. Extent rash (0, + 1) If morphology is compatible with DRESS and extent rash > 50% body 
surface area (BSA): 1 point 
c. Histology (-1, 0): When histology is compatible with DRESS: 0 points, when suggestive for 
another diagnosis: deduction 1 point; 
Involvement internal organs: (0, 1, 2) For acute involvement of each organ, 1 point is given, with 
a maximum of 2 points. Organ involvement is based on history, clinical investigation, medical 
imaging, biopsy or other tissue/fluid investigation. Organ involvement is also calculated at 
presence of the following abnormal laboratory values: 
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Liver (0, 1 )  
- ALAT > 2  times upper normal limit (*UNL) on at least 2 successive dates or 
- conjugated bilirubin >2* UNL on at least 2 successive dates or 
- ASAT, total bilirubin, alkaline phosphatase (AP) all >2* UNL at least 
Kidney (0, 1 )  
Serum creatinine more than 1.5 times above the base value for the patient on at least 2 
successive dates, and/or proteinuria above 1 g/day, haematuria, decreased creatinine clearance, 
decreased GFR 
lungs (0, 1 )  
Cough and/or dyspnoea in conjunction with 
- evidence of interstitial involvement on imaging and/or 
- abnormal broncho-alveolar lavage fluid, or biopsy and/or 
- abnormal blood gasses 
Muscle, heart (0, 1 )  
Muscle pain and/or weakness, myocarditis (often nonspecific symptoms: hypotension, fatigue, 
chest pain, dyspnoea, malaise, palpitations, tachycardia, cardiac dysfunction, cardiomegaly, 
sudden cardiac death), with 
- Raised serum creatine phosphokinase (CPK) > 2*UNL 
- Raised isoenzymes: CPK-3/CPK-MM (indicative for skeletal muscle), raised CPK-2/MB fraction 
(indicative for heart muscle involvement). 
- Serum troponin T > 0.01 µg per liter 
- Abnormal imaging: chest X-ray/ECHO/CT/MRI/EMG including ECG: ST-T electrocardiogram 
abnormalities or conduction defects (ST-segment depression, T-wave inversions or non­
diagnostic ECG changes (paced or bundle branch block)). 
Endomyocardial biopsy . 
Pancreas (0, 1 )  
Amylase and/or lipase � 2*UNL 
Other organs: spleen, thyroid gland, central nervous system, gastrointestinal tract 
- Clinical symptoms and additional investigations: enlargement/imaging, including EEG 
- Abnormal lab values: TSH, FT4, FT3. 
- Biopsy 
Duration (-1 ,  0) 
If the total duration of the reaction is � 15 days or unknown: deduction 1 point 
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Exclusion of other causes, e.g. infections, virus (re)activation (0, 1) 
- Hepatitis A/8/C 
- Mycoplasma- /Chlamydia pneumoniae 
- Blood cultures � 3 days of index date 
- Other (infections): serology, PCR, microbiological cultures 
- ANA 
In case of a positive result for any of these, organ involvement is re-evaluated for a possible 
alternative cause. If ;;;:: 3 mentioned groups are investigated and no positive result is found, an 
extra point is given to express thorough investigation for alternative causes. 
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Chapter 1 1  
Summary 
We report a flare-up reaction on earlier patch test sites of trimethoprim-sulfamethoxazole (co­
trimoxazole) during oral desensitization with this drug. Similar local flare-up reactions have 
been described in contact dermatitis, but to the best of our knowledge, they have not yet been 
reported for systemically administered drugs. 
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Case report 
A 36-year-old HIV-positive male developed an itchy maculopapular rash with fever (>39°(), 
11 days after starting trimethoprim-sulfamethoxazole 960 mg daily for pneumocystis carinii 
pneumonia prophylaxis (CD4 lymphocyte count 74 x 109/1). At the time of the rash, and in the 
weeks before, he had not used any other medication. Trimethoprim-sulfamethoxazole was 
replaced by pentamidine inhalations, and the rash and fever disappeared within a week. 
Two months later, highly active antiretroviral therapy (HAART) was started with good 
response and without complications. One year later, the patient was referred for evaluation of 
the reaction. 
The patient had never used trimethoprim-sulfamethoxazole prior to the above. Two 
months before the rash started, he applied topical silver sulfadiazine without adverse effects. 
Patch testing with trimethoprim-sulfamethoxazole 10% (pure substance) and 30% (commercial 
preparation) in pet. resulted in a doubtful positive reaction; silver sulfadiazine cream 10 mg/ml 
and the European baseline series were negative. 
One week later, retesting trimethoprim-sulfamethoxazole in duplicate on two different 
sites gave negative results. Subsequent in-patient oral desensitization with trimethoprim­
sulfamethoxazole was attempted (Table 1 ). On D3, a few hours after the last desensitization 
step at a dose of 480 mg, he developed fever (38.3°(), a non-itchy flare-up of all six previous 
trimethoprim-sulfamethoxazole patch test sites, and a slightly increased CRP (18 mg/I, normal 
<5 mg/I) and eosinophilia (6.7%, normal <3%). On continuation of the therapeutic dose of 
trimethoprim-sulfamethoxazole (480 mg/day with a CD4 lymphocyte count between 100-
200 x 109/1), the fever and the flare-up reactions disappeared within 1 week. 
Table 1. Desensitization schedule 
Day 1, suspension trimethoprim-sulfamethoxazole 48 mg/ml, diluted 1: 10 
9.00 hours 1 ml 
1 1 .00 hours 2 ml 
1 3.00 hours 5 ml  
1 7.00 hours 1 0  ml  
Day 2, suspension trimethoprim-sulfamethoxazole 48 mg/ml, undiluted 
9.00 hours 2 ml 
1 5.00 hours 4 ml 
21 .00 hours 5 ml 
Day 3, tablet trimethoprim-sulfamethoxazole 480 mg 




Opportunistic infections, such as pneumocystis carinii pneumonia, constitute a major problem in 
patients with HIV/ AIDS for which sulfonamides like trimethoprim-sulfamethoxazole are the first 
choice for treatment and prophylaxis. Unfortunately, HIV/AIDS patients also have an increased 
risk of cutaneous adverse drug reactions to trimethoprim-sulfamethoxazoleY These are often 
due to a type 4 delayed-type hypersensitivity reaction, presenting with a maculopapular rash 
and fever, 7-14 days after initiation of the drug, although severe cutaneous adverse drug 
reactions like Stevens-Johnson syndrome/toxic epidermal necrolysis or a drug-induced multi­
organ syndrome (DRESS) may develop.3.4 
In HIV and AIDS, a shift from Th1 to Th2 cytokine profile can be observed; during HAART, 
this shift may be partly reversed. Adverse drug reactions related to Th2 cytokines thus could be 
expected (e.g. urticaria and anaphylaxis). Somewhat unexpectedly, many HIV-infected patients 
also show delayed-type hypersensitivity reactions (e.g. maculopapular rash and DRESS). The 
relative preponderanceofCD8cells over CD4cells in HIV and AIDS could be relevant because CDS 
cells have been implied as effector cells in some drug reactions.5 In the abacavir hypersensitivity 
syndrome, a direct role for human leucocyte antigen-8*5701-restricted CDS+ T cells was shown.6 
Although delayed-type hypersensitivity reactions are mainly Th1 driven, Th2 and regulatory 
cytokines are also involved in these reactions.7 We assume that the generally increased risk of 
adverse drug reactions in these patients could be related to changes in regulatory T cells and 
cytokines. Initial studies indeed showed functional deficiencies in spite of increased numbers of 
regulatory T cells with progressive disease; recent studies, however, have not confirmed these 
observations.8 Thus, the immunological basis of the increased rate of adverse drug reactions 
in HIV and AIDS is not yet fully understood. Moreover, (subclinical) viral infections and drug 
interactions may further complicate the analysis of such events. 
Possible solutions when a reaction has occurred include continuation of treatment with 
antihistamines and steroids, a switch to an alternative drug or to stop and restart through 
desensitization or full dose. Although not yet fully proven, desensitization appears to result in 
fewer treatment discontinuations and adverse reactions compared with a stop and restart at full 
doseY Generally, patch tests are regarded safe for determining the culprit in cutaneous adverse 
drug reactions, and they are positive in 32-50%.9 
In contact dermatitis, flare-up reactions of earlier patch test sites have been described for 
nickel and gold after systemic provocation.10•1 1  To the best of our knowledge, these reactions 
have not been reported in cutaneous adverse drug reactions. 
In allergic contact dermatitis, resident CD4+CCR1 0+ T cells can still be detected in clinically 
normal skin on patch test sites 3 weeks after testing.12 Persistent local CD4+CCR1 0+ T cells may 
possibly be triggered by later allergen ingestion, resulting in a flare-up. Moreover, in flare-ups 
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of nickel patch tests, activation of local memory function seems to be inversely related to the 
period until reactivation.10 
In our case, all six sites earlier tested with trimethoprim-sulfamethoxazole showed a clear 
flare-up reaction at provocation, possibly reflecting the presence of local memory in the skin. 
Restriction of the clinical reaction to earlier tested skin could be explained by the long interval 
between the original reaction and desensitization, compared with the short interval between 
patch testing and desensitization. 
Conclusion 
We report a flare-up of previous patch test sites after oral desensitization with trimethoprim­
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Summary of the chapters 
Safety, efficacy and quality of drugs are issues of all ages. Adverse drug reactions (ADR), 
inevitable consequence of drug therapy, are amongst the most important causes of iatrogenic 
illness in terms of morbidity and mortality, and are as old as medicine itself. Particularly in the 
last decades, a more variable array of new drugs, e.g. targeted drugs and biologicals, have been 
introduced, resulting in prolonged life expectancy and better quality of life. On the other hand, 
a significantly increased frequency, quantity, and diversity of drug-intake contribute to more 
frequent and heterogeneous ADR. The incidence of ADR is high and not expected to decrease 
in future, due to an increasing l ife expectancy, partially facilitated by medicines and addition 
of targeted and immune modulating drugs to the vast array of drugs. Polypharmacy, a change 
in metabolism and a decreasing function of organs in the elderly are risk factors for ADR, and 
prevention and management of ADR constitute an important issue for healthy aging and quality 
of life in the elderly. Moreover, the potency of new drugs for causing ADR often only becomes 
clear after their introduction to the market: on the one hand because of the relative rarity of 
ADR compared to the rather limited number of persons participating in premarketing trials, on 
the other hand because premarketing testing is preferably performed in healthy young males, 
while frail patient groups such as babies, pregnant and fertile women, the elderly, and people 
with pre-existing diseases are excluded from testing. 
Dermatologists regularly see patients who are supposed to have a (muco)cutaneous ADR 
(cADR). Virtually all drugs can provoke cADR, although each drug by itself is generally only rarely 
responsible. The incidence of cADR rather reflects the vast use of medicines than their individual 
reactivity. In addition, cADR can present a wide range of distinct pictures with a multitude 
of clinical and biological features, which regularly show resemblance or some overlap with 
other diseases, including idiopathic dermatoses. Also, the variety of cADR is probably based 
on various pathomechanisms, most of which are sti ll largely unknown. Moreover, it is often 
difficult to assign a single drug as the culprit, particularly in cases of polypharmacy. The huge 
clinical variability and heterogeneity, and resemblance with many other conditions can easily 
result in misdiagnosis. Both under- and over-diagnosis are important issues, especially in cases 
with hypersensitivity reactions. Misclassification as drug allergy has consequences for future 
treatment choices and may result in the use of more expensive and/or less effective treatment 
modalities, while under- diagnosis may result in a potentially more severe reaction at future re­
administration of the drug. 
Awareness of cADR is a prerequisite for proper diagnosis, and identification of the reaction 
type and the causative drug can be quite challenging. Similar to idiopathic dermatoses, case 
definition of the various types of cADR is mainly based on the morphology and distribution of 
the (muco)cutaneous lesions. A clear case definition can help to recognize clinical patterns and 
establish diagnosis, treatment, and prognosis in cADR. Fortunately, most cADR are mild and 
transient and apart from supportive treatment, early recognition followed by prompt withdrawal 
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of the culprit drug is most often sufficient to avoid progressive development and restore health. 
In some types of severe cutaneous adverse reactions (SCAR), however, also specific therapeutic 
intervention seems to be warranted to inhibit the cascade of immunological and non­
immunological processes, elicited by the adverse reaction. This thesis explores various aspects 
of case definition, differential diagnosis, and treatment modalities of cADR and SCAR, with a 
focus on Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), acute generalized 
exanthematous pustulosis (AGEP), and drug reaction with eosinophilia and systemic symptoms 
(DRESS). 
Chapter 1 gives a general introduction to cADR and more specifically on a limited number 
of SCAR: SJS/TEN, AGEP, and DRESS, highlighting classification, case definition, and current 
understanding of pathogenesis and treatment. 
The diversity of cADR is nearly infinite. However, it makes sense to distinguish entities rather 
than to consider all as a continuum, if it helps in finding original clinical patterns, with different 
courses, mechanisms, causes, prognosis and/or treatment modalities. SCAR and some of the 
other cADR are not necessarily restricted to the skin. 
Often a skin reaction reflects a more general involvement of the body. Perhaps the most 
appealing example is DRESS, a multi-organ syndrome, in which besides a skin reaction, also 
lymphadenopathy, haematological abnormalities and visceral organ involvement can occur. 
Other SCAR such as SJS/TEN and AGEP can also display visceral involvement, although most 
often to a more limited degree, and differences in (muco)cutaneous features, combined with 
separate assessment of the extent and/or type of involvement of other organs, will generally 
assist in establishing diagnosis. 
In chapter 2 the controversy regarding the treatment of SJS/TEN with corticosteroids is 
addressed. Aim of this retrospective study in a small, uncontrolled series of twelve consecutively 
hospitalised patients with a validated diagnosis of SJS/TEN was to evaluate the efficacy of 
dexamethasone pulse therapy. 
Besides multi organ failure, infections are the major cause of mortality in SJS/TEN. Historically, 
corticosteroids were advocated for treatment, but since the mid-1980s the use of corticosteroids 
in SJS/TEN became controversial and was considered detrimental by some authors as a 
reaction to some reports with a negative outcome. Subsequently, therapeutic intervention 
with other agents such as thalidomide, intravenous immunoglobulin (IVIG) or ciclosporin has 
been proposed, but good evidence that, in addition to optimal supportive therapy, specific 
drug treatment is beneficial in SJS/TEN is still lacking. A double blind randomized controlled 
study with thalidomide had to be stopped due to increased mortality, at hindsight in the active 
treatment arm. Results of uncontrolled case series, treated with IVIG are contradictory and and 
provide insufficient evidence for promoting IVIG as standard treatment in SJS/TEN. Recently, 
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although not statistically significant, favourable outcomes have been reported in an open trial 
with ciclosporin. 
Although the precise action of corticosteroids is still not well understood, corticosteroids 
are thought to have pleomorphic immunomodulating effects, probably probably through the 
inhibition of various cytokines. We believe that these drugs have ambiguous effects on SJS/ 
TEN. If started too late and used for too long in too low a dose, their immunosuppressive effects 
may promote infections, and possibly delay wound healing. On the other hand, short courses 
of high-dose corticosteroids in early SJS/TEN have a good rationale, since they might inhibit 
immune mechanisms, also responsible for the cascade of events leading to apoptosis. High 
dose corticoids, given immediately after onset of SJS/TEN, may moderate the disease process by 
weakening the cytokine storm and reducing the excessive apoptosis that leads to full-thickness 
necrosis and extensive epidermal loss. 
In our study, high dose therapy with dexamethasone (1 .5 mg/ kg body weight/ day) was 
given as an intravenous pulse on three consecutive days, starting immediately after establishing 
the diagnosis of SJS/TEN. The study supported that short-term dexamethasone pulse therapy, 
given at an early stage of the disease, may contribute to a reduced mortality rate in SJS/TEN 
without increasing healing time. 
Recent reports tend to be less negative towards corticosteroids, and seem to suggest that a 
larger multinational study on the effect of short courses of high dose corticosteroids in SJS/TEN 
is warranted. 
Chapter 3 presents a retrospective analysis of patients with SJS/TEN and a history of lupus 
erythematosus (LE). The data were extracted from a large population based national registry of 
patients with a validated diagnosis of SJS/TEN. In addition, a review of the literature is given on 
this topic. The main purpose of this study was to evaluate differential diagnostic features for SJS/ 
TEN and bullous manifestations in LE, clinically as well as histopathologically. A secondary aim 
was to evaluate the prevalence of LE in this group of patients with SJS/TEN. 
Among 1 366 patients with SJS/TEN in the study period (1 990 to 2006), 1 7  with a sufficiently 
documented history of LE and available representative histologic material could be identified. 
In nine of these, no clinical or histopathological features of LE could be found shortly before or 
during the episode with SJS/TEN. The other eight patients, however, showed clinically and/or 
histopathologically some LE-characteristic features interfering with the diagnosis of SJS/TEN. A 
distinction could be made on clinical and histopathologic grounds: four patients were classified 
as SJS/TEN with a preceding LE exacerbation, and/or LE-typical histopathological features, and 
four as "TEN-like" LE. 
SJS/TEN can occur in patients with LE and bullous manifestations in LE need not necessarily 
be interpreted as manifestation of LE. Most patients with SJS/TEN and a history of LE show 
clinical and histopathologic properties allowing clear differentiation. Occasionally however, 
acute cutaneous manifestations of LE and SJS/TEN can be phenotypically similar, caused by 
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extensive epidermal apoptosis. In these cases, especially history and clinical course may assist 
in their differentiation. Although no feature by itself is conclusive, a combination of recent LE 
exacerbation, evident photo-distribution, annular lesions and absent palmoplantar lesions and/ 
or absent or only mild focal erosive mucosal involvement may favour LE over SJS/TEN clinically, 
while histopathologically particularly junctional vacuolar alterations combined with moderate 
to dense peri-adnexal and (deep) perivascular lymphocytic infiltrates point at a LE-related origin. 
The relative high proportion of patients with a history of LE amongst the patients with 
SJS/TEN suggests a correlation between both, either LE being a risk factor for SJS/TEN or both 
sharing a mutual risk factor. 
Chapter 4 presents the first systematic description of the histopathological spectrum of AGEP, 
based on a large series of cases, derived from two prospective multinational studies. All included 
cases were validated as probable or definite AGEP, according to a generally accepted validation 
score. Previous knowledge on the histopathology of AGEP mainly relied upon case reports and 
a few small clinical series. AGEP presents a rare, generally drug-induced reaction pattern, for 
which a range of differential diagnoses may apply. Key histopathological features in AGEP are 
superficial spongiform pustules, exocytosis of neutrophils, necrotic keratinocytes, papillary 
oedema, mixed dermal infiltrates, including (lower) middermal and interstitial infiltrates, 
containing neutrophils and eosinophils, and the paucity of classical plaque-type psoriatic 
epidermal changes. The diagnosis of AGEP can be based on these key histopathological features 
combined with clinical signs in favour of AGEP. These include an abrupt onset, short duration (� 
15 days), association with recently introduced drugs, spontaneous resolution after withdrawal of 
the culprit drugs, and a non-recurrent tendency. The study also supports the concept that AGEP 
is a separate entity, which can also occur in patients with psoriasis. Interestingly, it was noticed 
that AGEP was more common in patients with a history of psoriasis than could be expected from 
the general population. 
Chapter 5 presents a comparative study on the spectrum of histopathological features in 
patients with either probable or definite AGEP or with generalized pustular psoriasis (GPP). 
Differentiating AGEP from GPP, especially the acute "von Zumbusch" type, presents a clinical 
and histopathological challenge. Step sections of paraffin-embedded tissue, stained with 
hematoxylin-eosin, of both AGEP and GPP were systematically evaluated according to identical 
parameters and grades of severity. Whereas no single histopathological feature is diagnostic 
on its own, the combination of features and their grade of severity can substantially contribute 
to differentiate diagnosis. Features pointing at AGEP instead of the acute phase of GPP are the 
presence of eosinophils in the pustules or dermis, necrotic keratinocytes, mixed neutrophil-rich 
interstitial and (lower) middermal infiltrates, and absence of tortuous, dilated blood vessels. 
Moreover, chronic GPP demonstrated significant epidermal psoriasiform changes. In both 
acute and chronic GPP, dilated and tortuous superficial vessels were often found. These key 
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histopathological features, combined with the clinicopathological correlation, can assist in the 
distinction between AGEP and GPP in most cases. This study also supported that AGEP is not 
a variant of pustular psoriasis, but represents a separate entity. It also substantiated that AGEP 
is more often observed in patients with a history of psoriasis than could be expected from the 
general population. 
In chapters 6a and 6b two cases of AGEP, induced by morphine are described. Morphine has 
a relatively safe profile regarding cADR, and has not previously been incriminated in eliciting 
AGEP. 
Morphine is regularly administered post-operatively in short courses, but also for longer 
periods for the relief of severe chronic pain. Especially in the post-operative period, symptoms 
of fever, erythema and pustules can easily be erroneously ascribed to other factors such as 
infection, as in the first case; besides, the sometimes very small pinpoint pustules may easily 
be overlooked. Because AGEP is self-limiting and heals quickly after cessation of the culprit, 
the reaction can go unrecognised as drug related after a short course of drug therapy. After 
resolution of the reaction, morphine hydrochlorid was confirmed as the culprit by positive results 
of patch tests and a lymphocyte transformation test. Subsequently we observed a second case 
where morphine sulphate, amongst other drugs, was given in the setting of severe back pain. 
Complicating in this case, presenting with a TEN-like appearance, was a history of psoriasis, and 
a possible earlier SCAR, necessitating differentiation from GPP and TEN. Histology, however, was 
fairly discriminative in showing spongiform subcorneal pustules and mixed perivascular and 
interstitial dermal infiltrates, compatible with AGEP, as was the quick healing without recurrences 
after morphine was withdrawn. Morphine could be identified as the culprit through positive 
patch test results. Both cases demonstrate the importance of awareness of a cADR, especially 
when seemingly unexplainable symptoms occur, even when a drug has not previously been 
incriminated in the literature. Positive in vitro and/or in vivo tests, as reported, can be helpful in 
establishing a drug related aetiology and point at the specific offending medication. Of note is 
that the pustular patch test reaction nicely mirrored the original reaction of AGEP in the second 
case. Positive test results also support that AGEP is a delayed type hypersensitivity reaction, in 
which in addition to neutrophils also T-cells are involved. 
In chapter 7, two patients are presented with symmetrical drug-related intertriginous and 
flexural exanthema (SDRIFE), previously also known as the "baboon syndrome'� The reaction was 
in both cases induced by omeprazole, a potent, widely used and well tolerated proton pump 
inhibitor, which has not earlier been explicitly associated with SDRIFE. Diagnostic criteria for 
SDRIFE are systemic drug exposure, sharply demarcated erythema of the gluteal/perianal area 
and/or V-shaped erythema of the inguinal/perigenital area, involvement of at least one other 
intertriginous/flexural fold in a symmetrical distribution, and absence of systemic symptoms 
and signs. Although distribution and characteristics of the lesions in both patients were typical 
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for SDRIFE, our cases also showed some rather unusual features such as pustules, concomitant 
participation of other skin creases, minor systemic symptoms and signs, including mild relative 
neutrophilia and eosinophilia, and a longer latency time after start of the inciting drug than 
generally reported. Apart from localisation in the flexures, the presence of pustules, a wider 
distribution of lesions than commonly reported for SDRIFE, and mild systemic symptoms 
necessitated differentiation from AGEP. 
In chapter 8, two patients are described who, after treatment with erlotinib (Tarceva®) for non­
small-cell lung cancer, developed long-lasting widespread acneiform eruptions and xerosis 
cutis, probably rendering them susceptible to infection, resulting in extensive and disabling 
impetiginisation. Because both patients experienced a widespread itching pustular rash with 
accentuation of the lesions in the flexures, accompanied by fever in one patient, AGEP was 
considered. 
Erlotinib is an epidermal growth factor receptor (EGFR) inhibitor, a member of a new group 
of molecularly targeted drugs that combines high efficacy against tumours with less and often 
self-limiting toxicity, as compared with traditional chemotherapeutics. Targeted agents are 
increasingly used for the treatment of cancer, especially in case of resistance to conventional 
anti neoplastic drugs. Drawback is the frequent occurrence of adverse mucocutaneous reactions, 
resulting in substantial discomfort and morbidity. Besides, apart from well known cADR, these 
drugs may introduce several unfamiliar reactions, quite different from conventional medication. 
Acneiform eruptions, caused by erlotinib, are based on the pharmacological properties of 
the drug, are class specific and dose related, and can be qualified as a type A reaction. Since 
acneiform eruptions more often occur in connection with a good therapeutic response, a 
proactive policy and good knowledge are important in the management of patients. Early 
and timely dermatological intervention may diminish the severity of this side effect, enable 
continuation of therapy and improve quality of life. Although the mechanism underlying this 
rash is not fully understood, probably an imbalance in the differentiation and maturation is 
involved, causing secondary inflammation. This may lead to a thinned stratum corneum and 
inflammatory infiltration of the follicles, which often become dilated and plugged by excessive 
keratin, occasionally promoting extensive secondary infection. 
Chapter 9 addresses the issue of case definition and features of DRESS. These have been 
proposed, based on a review of the literature, pilotstudies, and consensus meetings of a 
multidisciplinary group of experts, mainly originating from Europe. 
Already in 1950, both Welton and Chaiken et al. independently reported a case with a 
pronounced cutaneous and visceral reaction to phenobarbital respectively phenytoin (Dilantin®), 
both structurally related drugs. Subsequently a syndrome defined by "a triad of fever, skin rash 
and internal involvement" has been reported for the same and several other medicines under 
a wide variety of names, either related to the drug (anticonvulsant hypersensitivity syndrome), 
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to the organ most involved or the disease mimicked (mononucleosis-like syndrome) or the 
supposedly involved pathomechanisms (drug induced hypersensitivity syndrome or HSS). 
However, the term hypersensitivity for the reaction is rather unspecific and prone to confusion. 
It has led to the qualification as HSS of some cases of SJS/TEN and AGEP and even of some 
cases of more common cADR with one or more systemic signs or symptoms. It also introduced 
qualification of SJSfTEN as a variant of HSS and reports on overlapping entities. Since the word 
hypersensitivity is rather uninformative and ambiguous, the more informative and clinically 
relevant acronym DRESS is gaining use. In order to obtain a multinational homogenous cohort 
of patients for further study of DRESS, while a clear case definition was lacking, a diagnostic score 
was developed for validation of potential cases of DRESS as definite, probable, possible, or no 
case. A clear trend has been noticed that this new case definition is gaining general acceptance 
and is regularly referred to in literature nowadays. 
Chapter 10 presents the description and analysis of a first prospective multicenter study of 
1 1 7 cases validated as definite or probable cases of DRESS according to the newly developed 
validation score. In addition it also gives an overview of the clinical criteria and cut-off points 
of abnormal biological and laboratory findings for considering signs and symptoms as being 
DRESS-related. 
Since notification and enrolment of cases were independent of outcome and exposure 
to specific medication or other risk factors, the results of this study are considered as likely 
less biased than those of prior retrospective series. Moreover, collection of data by trained 
interviewers through direct interviews of patients and treating physicians using a reactionspecific 
questionnaire, followed by a structured validation by an expert team according to the newly 
developed validation system using clinical photographs, structured data on course, clinical 
and biological parameters, and histopathology, but blinded for risk factors, contributes to the 
strength of the study. At validation, findings that could potentially be attributed to an alternative 
cause were excluded from attribution to the score. Besides confirmation of the rather variable 
character of DRESS with various combinations and severity of signs and symptoms, a delayed 
onset, and protracted course, original findings were female predominance, significant younger 
age of females, high prevalence of rather mild mucosal symptoms, frequent eosinophilia and 
atypical lymphocytes, and lower mortality than generally stated. In addition, a description was 
given of the prodromal symptoms that arise before mucocutaneous symptoms are noticed. The 
spectrum of inciting drugs was rather limited, with aromatic antiepileptics and allopurinol as the 
main culprits. Reassuring was that the newly developed validation score system resulted in only 
minor overlap with SJS/TEN and AGEP. The findings confirm that DRESS is an original phenotype 
among SCAR in terms of clinical and biological characteristics, causative drugs, time relation, 
and course. 
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Chapter 1 1  presents an interesting observation during a desensitisation procedure with 
trimethoprim-sulfamethoxazole (co-trimoxazole), because of an earlier severe cutaneous 
adverse drug reaction in a HIV-positive patient. About one year after the original reaction, 
two successive series of patch tests with cotrimoxazole were evaluated as weakly positive, 
respectively negative. Shortly thereafter desensitisation was performed. A few hours after the 
last desensitisation step (day 3) the patient developed erythema, confined to the sites of the 
previous patch tests, combined with transient fever, malaise, elevated C reactive protein and 
peripheral eosinophilia. The phenomenon of flaring of earlier patch tests has been described 
previously for nickel and gold after systemic provocation in contact dermatitis, but not for cADR. 
Because in contact dermatitis T cells at earlier positive patch tests can persist for some time, 
we hypothesised that homing of drug specific T-cells in the skin also plays a role in cADR, and 
was responsible for the localized flaring of earlier performed patch tests at desensitisation. Our 
observation also underlines that clinically negative patch tests a year after clinical recovery are 
no proof of the absence of a hypersensitivity mechanism. 
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Veiligheid, effectiviteit en kwaliteit van geneesmiddelen zijn aloude vraagstukken. Bijwerkingen 
van geneesmiddelen {BG), onlosmakelijk verbonden met medicamenteuze therapie, behoren 
tot de meest belangrijke oorzaken van iatrogene ziekten wat betreft morbiditeit en mortaliteit 
en zijn zo oud als de geneeskunde zelf. Daarnaast is vooral in de laatste decennia een 
verscheidenheid aan geheel nieuwe middelen ge"introduceerd, zoals de "targeted drugs" en 
"biologicals': die behalve nieuwe therapeutische mogelijkheden en een vebeterde kwaliteit 
van leven, naast de gebruikelijke BG ook een heel scala aan nieuwe en voorheen weinig 
voorkomende BG hebben ge·introduceerd. 
De incidentie van BG is hoog, en zal naar verwachting in de toekomst niet afnemen onder 
invloed van de toenemende levensverwachting, mede gefaciliteerd door een groeiend gebruik 
van geneesmiddelen en toevoeging aan het arsenaal van steeds meer biofarmaceutica en 
andere nieuwe soorten geneesmiddelen. Polyfarmacie, veranderingen in het metabolisme en 
het verminderd functioneren van organen bij ouderen vormen risicofactoren voor BG, en het 
voorkomen of management van BG vormen daarmee dan ook een belangrijk vraagstuk bij het 
gezond oud worden {"healthy aging") en de kwaliteit van leven bij ouderen. Dit klemt temeer 
omdat de potentie tot het veroorzaken van BG door nieuwe middelen vaak pas na de introductie 
van het middel op de markt aan het licht komt; enerzijds door de relatieve zeldzaamheid van 
veel van de BG ten opzichte van de premarketing geteste aantallen proefpersonen {enkele 
duizenden proefpersonen ten opzichte van relatieve risico's die lager kunnen zijn dan 
1 : 1 .000.000), anderzijds omdat premarketing in eerste instantie bij voorkeur "gezonde jonge 
mannen" worden getest en kwetsbare patientgroepen zoals baby's, zwangeren, vrouwen in de 
vruchtbare leeftijd, ouderen, en mensen met een reeds bestaande aandoening bij premarketing 
onderzoek vaak als proefpersoon worden uitgesloten. 
Dermatologen warden regelmatig geconfronteerd met patienten waarbij gedacht wordt 
dat zij mogelijk {muco)cutane oftewel huid-en/of slijmvliesafwijkingen hebben als reactie op 
geneesmiddelgebruik {cBG). Alhoewel nagenoeg elk middel cBG kan veroorzaken, is de kans 
hierop voor een individueel middel doorgaans laag. Behoudens uitzonderingen, weerspiegelt 
de hoge incidentie van cBG eerder de omvang van het geneesmiddelgebruik dan de reactiviteit 
van ieder middel op zich. Daarnaast kunnen cBG een zeer uiteenlopende verscheidenheid aan 
klinische en biologisch kenmerken vertonen die bovendien nog eens sterk kunnen lijken op 
andere ziektebeelden, inclusief idiopathische aandoeningen. De grote verscheidenheid aan cBG 
berust waarschijnlijk op verschillende pathomechanismen, die bovendien vaak niet of slechts 
ten dele zijn opgehelderd. Bovendien is het vaak niet eenvoudig het veroorzakende middel 
aan te wijzen, vooral wanneer sprake is van polyfarmacie. De grote klinische variabiliteit en 
heterogeniteit van cBG, in combinatie met de soms sterke gelijkenis met andere aandoeningen, 
kan gemakkelijk leiden tot een onjuiste diagnose. Zowel over- als onderdiagnose kan belangrijke 
gevolgen hebben, vooral wanneer sprake is van overgevoeligheidsreacties of allergie. Een 
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onterechte bestempeling als allergie heeft consequenties voor toekomstige therapeutische 
opties en kan resulteren in het onnodig uitwijken naar een duurdere en/of minder effectieve 
behandeling, terwijl het niet onderkennen van een allergische achtergrond kan resulteren in 
een soortgelijke of zelfs ernstiger reactie bij hergebruik van het veroorzakende middel. 
De differentiaaldiagnostische overweging dat eventueel ook sprake zou kunnen zijn van 
een cBG is een premisse voor het onderkennen van een geneesmiddelgerelateerde aandoening, 
het reactietype en daarnaast het potentieel veroorzakende middel. Net als bij idiopatische 
aandoeningen, berust het onderscheid tussen de verschillende cBG vooral op de morfologie 
en distributie van de (muco)cutane afwijkingen. Een heldere definitie van de verschillende 
ziektebeelden die bij cBG kunnen optreden, kan helpen bij de herkenning van klinische 
patronen en daardoor bij het stellen van de diagnose, de daarop gebaseerde behandeling, de 
prognose en het veroorzakende middel. 
Gelukkig zijn de meeste cBG mild en voorbijgaand. Behalve eventueel ondersteunende 
therapie is vroegtijdige herkenning, gevolgd door het prompt staken van het veroorzakende 
middel doorgaans voldoende om progressie van het beeld te voorkomen en volledige genezing 
te bewerkstelligen. Bij sommige ernstige vormen van cBG (severe cutaneous adverse ractions, 
ook wel afgekort als SCAR), kan echter aanvullend therapeutische interventie aangewezen 
zijn om de cascade van immunologische en nietimmunologische reacties, uitgelokt door de 
bijwerking, te blokkeren dan we[ te matigen. 
In dit proefschrift komen verschillende aspecten van classificatie en definitie van cBG, in 
het bijzonder van SCAR, de daarbij optredende differentiaal diagnostische overwegingen en 
therapeutische opties aan de orde. De focus ligt hierbij op Stevens-Johnson syndroom I toxisch 
epidermale necrolyse (SJS?TEN), acute gegeneraliseerde exanthemateuze pustulose (AGEP) en 
drug reaction with eosinophilia and systemic symptoms (DRESS). 
Hoofdstuk 1 geeft een algemene inleiding over cBG en behandelt meer specifiek een aantal 
SCAR: SJS/TEN, AGEP, en DRESS. Hierbij wordt in het bijzonder ingegaan op de definitie, 
classificatie en afgrenzing van deze beelden, en daarnaast op recente kennis over de behandeling 
en pathogenese ervan. 
De diversiteit van cBG is nagenoeg onbegrensd. Toch is het zinnig een duidelijk onderscheid 
te maken tussen de diverse beelden en niet het geheel als een continuum te zien, indien dit een 
bijdrage kan leveren aan het vinden van originele klinische patronen met een eigen beloop, 
causaliteit, pathomechanisme, prognose en/of behandeling en de verantwoordelijke medicatie. 
SCAR en enkele andere cBG zijn niet altijd uitsluitend beperkt tot de huid. Regelmatig 
"weerspiegelt" de huid als het ware bijwerking(en) die zich in andere organen afspelen. Het 
meest treffende voorbeeld hiervan is DRESS, waarbij naast een huidreactie tevens veelvuldig 
lymfadenopathie en hematologische afwijkingen kunnen voorkomen en vaak een of meerdere 
inwendige organen kunnen participeren. Bij andere SCAR zoals SJS/TEN en AGEP kan weliswaar 
ook systemische betrokkenheid optreden, maar de afwijkende mucocutane presentatie, in 
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combinatie met de mate van betrokkenheid van andere organen maakt het doorgaans mogelijk 
de diagnose te differentieren. 
In hoofdstuk 2 wordt ingegaan op de controverse die bestaat rond de behandeling van SJS/ 
TEN met corticostero'iden. Dael van de retrospectieve studie, die werd uitgevoerd in een kleine 
serie van 12 achtereenvolgens ge'includeerde patienten met een gevalideerde diagnose van 
SJS/TEN, was het evalueren van de effectiviteit van een kortdurende puls therapie met hoge 
dosis dexamethason .  
Naast orgaanfalen zijn infecties, waaronder sepsis, de belangrijkste oorzaak van de hoge 
mortaliteit bij SJS/TEN. Oorspronkelijk werden meestal corticostero'iden gepropageerd als 
behandeling voor SJS/TEN. Sinds het midden van de jaren 80 van de vorige eeuw echter, werd 
toepassing van corticostero'iden controversieel geacht en door sommige auteurs in reactie 
op enkele publicaties met negatieve uitkomsten zelfs als funest bestempeld. Daarna werd 
behandeling met andere middelen ,  zoals thalidomide, IVIG, of ciclosporine voorgesteld, maar 
een sluitend bewijs dat naast ondersteunende therapie ook specifieke behandeling een gunstig 
effect laat zien bij SJS/TEN, ontbreekt nog steeds. De enige uitgevoerde dubbelblinde, placebo 
gecontroleerde therapeutische studie bij SJS/TEN is die met thalidomide. Deze moest echter 
voortijdig worden afgebroken wegens oversterfte, waarna bij analyse bleek dat deze juist optrad 
in de actieve behandelingsarm. Resultaten van enkele ongecontroleerde studies van series 
patienten die met intraveneus immuunglobuline (IVIG) werden behandeld zijn niet eenduidig 
en geven onvoldoende aanleiding IVIG als standaardtherapie aan te bevelen. Recent werden, 
hoewel niet significant, gunstige resultaten beschreven bij een open trial waarbij behandeling 
met ciclosporine plaatsvond. 
Corticostero'iden hebben pleiomorfe immunomodulerende effecten, ondermeer door 
remming van diverse cytokines die vrijkomen bij SJS/TEN. Naar onze mening kunnen 
corticostero'iden een paradoxaal effect hebben op SJS/TEN. Te laat gestart en in een te lage 
dosis voortgezet tijdens het beloop van de aandoening kunnen zij via immunosuppressieve 
effecten infecties in de hand werken en mogelijk ook de wondheling vertragen. Daarentegen 
lijkt een aannemelijke basis aanwezig voor toepassing van een kortdurend hoge dosis in de 
acute beginfase van SJS/TEN. Daarbij kunnen zij potentieel immuunmechanismen blokkeren ,  
die mede verantwoordelijk geacht worden voor de cascade die uiteindelijk leidt tot apoptose 
van keratinocyten, gevolgd door uitgebreide necrose en verlies van epidermis in SJS/TEN. In 
the uitgevoerde studie werd direct na het stellen van de diagnose SJS/TEN een hoge dosis 
dexamethason (1.5 mg/ kg lichaamsgewicht/ dag) gegeven als intraveneuze puls therapie op 
drie achtereenvolgende dagen. De uitkomsten van de studie ondersteunen de aanname dat 
kortdurende puls therapie met dexamethason, vroegtijdig gegeven in het acute proces, kan 
bijdragen aan verminderde mortaliteit bij SJS/TEN, zonder daarbij de duur van wondgenezing 
te verlengen. 
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Recente publicaties neigen er overigens toe minder negatief te zijn ten aanzien van 
corticostero·iden bij SJS/TEN, en een aantal auteurs onderschrijven het pleidooi voor een grotere 
multinationale studie naar het effect van een kortdurende, hoge dosis corticostero"iden bij SJS/ 
TEN. 
Hoofdstuk 3 laat de resultaten zien van een retrospectieve analyse van patienten met SJS/TEN 
waarbij in de voorgeschiedenis op enigerlei wijze sprake was van lupus erythematosus (LE). De 
gegevens zijn ontleend aan een omvangrijke, op de gehele populatie gebaseerde nationale 
database van patienten met een gevalideerde diagnose van SJS/TEN. Daarnaast werd tevens 
een review gegeven van de internationale literatuur over dit onderwerp. Hoofddoel van 
dit onderzoek was het vinden van differentiaal diagnostische verschillen tussen SJS/TEN en 
bulleuze vormen van LE, zowel op klinische als histopathologische gronden. Nevendoel was 
onderzoek naar de prevalentie van LE bij deze groep patienten met SJS/TEN. 
Van 1366 patienten met SJS/TEN uit de onderzochte periode (1990 tot en met 2006) werden 
er 17 aangetroffen met een afdoende gedocumenteerde voorgeschiedenis van LE, waarvan 
tevens representatief histologisch materiaal van de huid ten tijde van de SJS/TEN beschikbaar 
was voor analyse. Bij negen van de 17 patienten waren geen LE kenmerken gedocumenteerd 
kart voor of tijdens de periode met SJS/TEN; de andere acht daarentegen toonden klinisch 
en/of histopathologisch een aantal LE- kenmerken die tot een differentiaal diagnostische 
vraagstelling leidden. Nadere differentiatie kon warden gemaakt op basis van klinische en 
histopathologische gronden: vier van hen werden nader geclassificeerd als SJS/TEN met een 
voorafgaande LE uitbraak en/of LE-typische histopathologische kenmerken, terwijl de andere 
vier nader werden geduid als "TEN-like" LE. 
SJS/TEN kan bij patienten met LE optreden en bulleuze afwijkingen bij patienten met LE 
hoeven niet per definitie te warden ge"interpreteerd als een manifestatie van LE. Daarbij zijn 
de meeste patienten met SJS/TEN en een voorgeschiedenis van LE op grand van klinische en 
histopathologische kenmerken goed van elkaar te onderscheiden. In sommige gevallen kunnen 
de acute huidverschijnselen van LE en SJS/TEN echter fenotypisch sterke overeenkomsten 
vertonen, veroorzaakt door uitgebreide epidermale apoptose bij beide ziektebeelden. In deze 
geval len kunnen in het bijzonder anamnese en klinisch beloop aanwijzingen geven voor het 
onderscheid tussen beide beelden. Ofschoon geen enkel kenmerk op zich doorslaggevend 
is, wijzen een combinatie van recente LE exacerbatie, uitgesproken fotodistributie, annulaire 
laesies en afwezigheid van palmoplantaire afwijkingen of afwezige of slechts mi Ide, plaatselijke 
erosieve afwijkingen van de slijmvliezen klinisch eerder in de richting van LE dan op SJS/TEN. 
Histopathologisch wijzen in het bijzonder vacuolaire veranderingen, vooral op het grensvlak van 
epidermis en dermis, en matig tot dichte peri-adnexale en (diepe) perivasculaire lymfocytaire 
infiltraten eerder in de richting van LE. 
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Het relatief hoge aandeel patienten met een voorgeschiedenis van LE in patienten met SJS/ 
TEN suggereert een verband tussen beide ziektebeelden, mogelijk doordat LE een risicofactor is 
voor SJS/TEN, dan wel dat beide een gezamenlijke risicofactor delen.  
In hoofdstuk 4 is een studie opgenomen met de eerste systematische beschrijving van het 
histopathologische spectrum van AGEP, gebaseerd op een grote serie casus die werden ontleend 
aan 2 prospectieve multinationale studies. Alie ge·includeerde casus waren aan de hand van 
een algemeen aanvaard validatie score systeem gevalideerd als een waarschijnlijk of zeker 
geval van AGEP. Eerdere kennis betreffende de histopathologie van AGEP was hoofdzakelijk 
gebaseerd op case reports en enkele kleine klinische series. AGEP vertegenwoordigt een 
tamelijk zeldzaam, doorgaans geneesmiddel ge'induceerd reactie patroon, dat differentiaal 
diagnostisch onderscheiden moet worden van een aantal andere pustuleuze dermatosen. 
Doorslaggevende histopathologische kenmerken blijken superficiele spongiforme pustels, 
exocytose van neutrofiele granulocyten, necrotische keratinocyten, oedeem van de papillaire 
dermis, gemengdcellige dermale infiltraten die zich niet alleen superficieel maar ook dieper 
dermaal en interstitieel bevinden met neutrofiele en regelmatig ook eosinofiele granulocyten, 
en een doorgaans milde psoriasiforme epidermis. De diagnose kan worden gebaseerd op 
genoemde histopathologische kenmerken, in samenhang met klinische symptomen die op 
AGEP wijzen. Hieronder zijn te rekenen een acuut begin, koorts, neutrofilie, een kort beloop 
(� 15 dagen), verband met recent ge·introduceerde medicatie, spontaan herstel na staken van 
het mogelijk veroorzakende middel en het achterwege blijven van een recidief na genezing. 
De studie ondersteunt tevens het concept dat AGEP een a pa rte entiteit is die ook kan optreden 
bij patienten met een voorgeschiedenis van psoriasis. Opmerkelijk was dat AGEP relatief vaker 
werd gezien bij patienten met psoriasis in de voorgeschiedenis dan verwacht zou kunnen 
worden op basis van het voorkomen van psoriasis in de algemene bevolking. 
In hoofdstuk 5 wordt het spectrum van histopathologische kenmerken van een groep met 
als waarschijnlijk of zeker gevalideerde gevallen van AGEP vergeleken met gevallen van 
gegeneraliseerde pustuleuze psoriasis (GPP). 
Differentiatie tussen AGEP en GPP, en in het bijzonder het acute stadium van het type 
van "von Zumbusch': vormt een klinische en histopathologische uitdaging. Van zowel AGEP 
als GPP werden stapsgewijze doorsneden van de huid, gekleurd met hematoxyline-eosine, 
systematisch geevalueerd volgens identieke parameters en hun gradering. Ofschoon geen 
enkel histopathologisch kenmerk op zichzelf diagnostisch blijkt, kan de combinatie van 
kenmerken en hun gradering bijdragen aan het differentieren van de diagnose. Kenmerken 
die wijzen op AGEP in plaats van op acute GPP zijn de aanwezigheid van eosinofielen in de 
pustels of dermis, necrotische keratinocyten, gemengde neutrofielrijke, interstitiele en diep 
middermale infiltraten, en het ontbreken van verwijde, kronkelige bloedvaten. Bij chronische 
GPP werden daarenboven significante epidermale psoriasiforme veranderingen aangetroffen, 
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terwijl zowel in acute als chronische GPP vaak verwijde, kronkelige en oppervlakkige vaten 
werden aangetroffen in de papillaire dermis. Deze histopathologische sleutelkenmerken, 
gecombineerd met een clinicopathologische correlatie, zal in de meeste gevallen kunnen 
bijdragen aan de differentiatie tussen AGEP en GPP. 
Deze studie ondersteunt tevens dat AGEP niet een variant is van pustuleuze psoriasis, maar 
een afzonderlijke entiteit vertegenwoordigt. Ook werd in deze studie de eerdere suggestie dat 
AGEP proportioneel vaker voorkomt in patienten met psoriasis ten opzichte van de algehele 
bevolking, bevestigd. 
In de hoofdstukken 6a en 6b worden twee gevallen van AGEP beschreven, die konden worden 
toegeschreven aan morfinehydrochloride respectievelijk morfinesulfaat. Morfine heeft wat 
betreft cBG een relatief veilig profiel, en werd niet eerder beschreven als middel dat AGEP kan 
veroorzaken. 
Morfine wordt regelmatig kortdurend postoperatief verstrekt, terwijl het middel daarnaast 
ook wel langduriger wordt gegeven, bijvoorbeeld ter verlichting van ernstige chronische pijn. 
Vooral in de postoperatieve periode, zoals bij onze eerste casus, kunnen symptomen als koorts, 
erytheem en pustels makkelijk worden toegeschreven aan andere oorzaken zoals infectie. 
Bovendien kunnen de soms slechts speldenknop grote pustels licht over het hoofd worden 
gezien. Omdat AGEP spontaan en meestal vrij snel geneest na staken van het veroorzakende 
middel kan de reactie, vooral bij een korte toedieningduur, gemakkelijk gemist worden als 
zijnde geneesmiddelgerelateerd. Na afloop van de reactie werd morfine als oorzakelijk middel 
bevestigd door positieve plakproeven en een positieve lymfocytentransformatietest. 
In hoofdstuk 6b wordt een tweede geval beschreven, waarbij onder andere morfinesulfaat 
werd gegeven wegens ernstige rugpijn. Complicerend in deze casus, die klinisch gelijkenis 
toonde met TEN, was een voorgeschiedenis van psoriasis en een mogelijk eerder doorgemaakte 
SCAR. Dit noodzaakte tot differentiatie van AGEP met GPP en TEN. De histopathologie met 
spongiforme subcorneale pustels en gemengde perivasculaire en interstitiele dermale 
infiltraten, in combinatie met een spoedige genezing zonder recidief na staken gaf aanleiding 
tot de diagnose AGEP. De rol van morfine als oorzaak van de reactie werd later bevestigd door 
de uitkomsten van aanvullend epicutaan allergologisch onderzoek. Beide casus demonstreren 
dat cBG altijd in de diagnostische overweging moet worden meegenomen. Dit geldt temeer bij 
onverklaarbare symptomen, zelfs als het betreffende middel niet eerder als veroorzaker werd 
beschreven. 
Positieve in vitro en/of in vivo testen kunnen helpen bij het vaststellen van een 
geneesmiddel gerelateerde etiologie en het veroorzakende middel aanwijzen. Opmerkelijk 
was dat de positieve, pustuleuze plakproef bij de tweede casus de oorspronkelijke huidreactie 




een vertraagde overgevoeligheidsreactie is, waarbij naast neutrofiele granulocyten ookT-cellen 
zijn betrokken. 
In hoofdstuk 7 worden twee patienten gepresenteerd met "symmetrical drug-related 
intertriginous and flexural exanthema" (SDRIFE), eerder ook wel bekend als het "baboon 
syndrome'� De reactie werd in beide gevallen veroorzaakt door omeprazol, een potente, 
veelvuldig gebruikte en doorgaans goed getolereerde proton pomp rem mer, welke niet eerder 
expliciet werd gemeld als veroorzaker van SDRIFE. 
Diagnostische criteria voor SDRIFE zijn, behalve systemisch geneesmiddelengebruik, een 
scherp begrensd erytheem van het gluteale/perianale gebied en/of een V-vormig erytheem 
van het inguinale/perigenitale gebied, betrokkenheid van tenminste een andere intertrigineuze 
plooi waarbij sprake is van een symmetrische verdeling en het afwezig zijn van systemische 
betrokkenheid. Ofschoon de distributie en overige kenmerken van de huidafwijkingen bij 
beide casus typisch waren voor SDRIFE, werden daarenboven enkele nogal ongebruikelijke 
kenmerken waargenomen zoals pustels, betrokkenheid van andere huidplooien, geringe 
systemische betrokkenheid, waaronder neutrofilie en eosinofilie in het bloedbeeld, en een 
langer dan doorgaans gemelde latentietijd voor het ontstaan van de afwijkingen na introductie 
van het veroorzakende middel. Behalve de lokalisatie van de afwijkingen in de flexuren noopten 
vooral de aanwezigheid van pustels, de uitgebreidere distributie dan voor SDRIFE gebruikelijk is, 
en de milde systemische verschijnselen tot differentiatie met AGEP. 
In hoofdstuk 8, worden twee patienten beschreven die na behandeling met erlotinib (Tarceva®) 
wegens kleincellig longcarcinoom langdurig uitgebreide acne'iforme huidafwijkingen en 
een droge huid ontwikkelden. Dit droeg ertoe bij dat zij meer vatbaar waren voor infectie, 
resulterend in uitgebreide en invaliderende secundaire impetiginisatie. Omdat bij beiden een 
uitgebreide pustuleuze rash ontstond, bij een van hen geprononceerd aanwezig in de plooien 
en gepaard met koorts, werd tevens AGEP overwogen. 
Erlotinib is een EGFR rem mer, behorend tot de nieuwe klasse van "molecular targeted drugs'� 
Targeted drugs worden in toenemende mate ingezet, in het bijzonder bij therapieresistentie 
voor conventionele chemotherapeutica, en hiermee vergeleken, combineert erlotinib een hoge 
effectiviteit tegen solide tumoren met een geringere systemische toxiciteit. Keerzijde is het vaak 
optreden van nevenwerkingen, die aanzienlijk ongemak en morbiditeit kunnen veroorzaken. 
Targeted drugs kunnen bovendien, naast de alom bekende bijwerkingen, ook ongebruikelijke 
reacties teweeg brengen die tamelijk afwijken van die welke bij conventionele geneesmiddelen 
kunnen worden gezien. De vaak voorkomende acne'iforme erupties door erlotinib berusten op 
de farmacologische eigenschappen van het middel, zijn klasse gebonden en dosis gerelateerd, 
en worden daarmee tot de veelvoorkomende zogenaamde Type A reacties gerekend. Aangezien 
de ernst van de acne'iforme erupties blijkt te correleren met de effectiviteit van de bedoelde 
werking van erlotinib tegen de tumor, is bekendheid met het voorkomen van dit type reacties 
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en een proactieve benadering van de behandeling ervan gewenst. Tijdige dermatologische 
interventie kan de effecten van deze nevenwerking matigen, voortzetting van de therapie 
mogelijk ma ken en dientengevolge aanzienlijk bijdragen aan de kwaliteit van leven.  
Het pathomechanisme van deze pustuleuze, zogenaamd acne"iforme reactie is voorshands 
nog onvoldoende bekend, maar het wijst in de richting van een disbalans tussen de rijping en 
proliferatie van keratinocyten. Het kan leiden tot een verdund stratum corneum en ontsteking 
met aantasting van de haarfollikels. Deze raken hierdoor verwijd en gevuld met overmatig 
keratine, soms bovendien gevolgd door secundaire infectie. 
In hoofdstuk 9a warden de definitie en kenmerken van DRESS behandeld, opgesteld op basis 
van literatuuronderzoek, pilotstudies en consensusbijeenkomsten van een multidisciplinaire 
groep experts, voornamelijk afkomstig uit Europa. Er lijkt een duidelijk tendens waameembaar 
dat deze definitie en kenmerken ook door andere groepen onderzoekers warden overgenomen. 
Reeds in 1950 rapporteerden zowel Welton als Chaiken et al. onafhankelijk van elkaar 
een geval van een ernstige reactie met huidverschijnselen en betrokkenheid van inwendige 
organen, veroorzaakt door de chemisch verwante middelen phenobarbital respectievelijk 
phenytoine (Dilantin®). Vervolgens is voor deze en enkele andere medicijnen herhaaldelijk 
een syndroom gemeld in de literatuur, gekenmerkt door de trias koorts, huidreactie en 
betrokkenheid van interne organen. Dit syndroom werd een grote verscheidenheid aan namen 
en acroniemen aangeduid, hetzij gerelateerd aan het gebruikte middel ("anticonvulsant 
hypersensitivity syndrome"), hetzij aan het meest aangedane orgaan of het ziektebeeld dat 
werd geYmiteerd ("mononucleosis-like syndrome"), dan wel aan de veronderstelde pathogenese 
("drug hypersensitivity syndrome': of HSS). De in het verleden frequent gehanteerde benaming 
"hypersensitivity syndrome" is evenwel tamelijk aspecifiek, en voor meerderlei uitleg vatbaar, 
kan aanleiding geven tot verwarring en is minder geschikt om onderscheidende kenmerken 
weer te geven. Dit heeft er ondermeer toe geleid dat soms gevallen van SJS/TEN, AGEP, en zelfs 
mi Ide cBG waarbij enige systemische betrokkenheid optrad, werden aangemerkt als HSS. Tevens 
heeft dit geresulteerd in het ten onrechte bestempelen van SJS/TEN als een variant van HSS en 
melding van elkaar overlappende entiteiten. Dit gaf aanleiding tot introductie van het meer 
informatieve en betekenisvolle acronym DRESS (drug reaction with eosinophilia and systemic 
symptoms), dat in toenemende mate wordt gebruikt om het syndroom aan te duiden. 
Teneinde een homogeen cohort van patienten met het syndroom te kunnen verzamelen 
voor verder onderzoek, en omdat bovendien een eenduidige definitie en beschrijving van de 
kenmerken van DRESS ontbraken, werd een diagnostisch score systeem ontwikkeld voor de 
validatie van potentiele gevallen, waarbij tevens de mate van waarschijnlijkheid kon worden 
weergegeven (zeker, waarschijnlijk, mogelijk, of geen geval). 
In hoofdstuk 10 is een studie opgenomen met de analyse van de eerste prospectieve multicenter 
studie van 117 gevallen, gevalideerd als zekere of waarschijnlijke DRESS, volgens het nieuwe 
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bovengenoemde diagnostisch validatie score systeem. Aangezien aanmelding en inclusie van 
de patienten onafhankelijk waren van de uitkomst en blootstelling aan bepaalde medicatie of 
andere risicofactoren, kunnen de resultaten van deze studie als mogelijk minder bevooroordeeld 
worden beschouwd, vergeleken met die van eerdere, retrospectieve series. Bovendien draagt 
verzameling door getrainde interviewers van gegevens via directe interviews met patienten en 
zorgverleners onder gebruikmaking van voor de aandoening specifieke vragenlijsten, gevolgd 
door een systematische en gestructureerde validatie door een "expert comittee" bij aan de 
sterkte van de studie. De validatie vond plaats op basis van foto's en gestructureerde gegevens 
betreffende beloop, klinische en biologische parameters, en histopathologisch onderzoek, doch 
geblindeerd voor de gebruikte medicatie en andere risicofactoren. Afwijkende bevindingen 
worden, indien zij kunnen worden toegeschreven aan een alternatieve oorzaak, uitgesloten bij 
de validatie als DRESS. 
Behoudens bevestiging van het tamelijk variabele karakter van DRESS, met een veelvoud 
aan combinaties van symptomen en afwijkende laboratorium en andere onderzoeksgegevens, 
ook qua mate van ernst, een geleidelijk begin na start medicatie en een !anger aanhoudend 
ziektebeloop vergeleken met andere cBG, waren nieuwe bevindingen een vrouwelijke 
predominantie, de significant jongere leeftijd van vrouwen, en het vaker voorkomen van mi Ide 
slijmvliesafwijkingen, eosinofilie en atypische lymfocyten in het perifere bloed en een lagere 
mortaliteit dan doorgaans gemeld. Daarnaast vond beschrijving plaats van de prodromale 
verschijnselen, die optreden voordat mucocutane of andere afwijkingen gezien worden. 
Ondanks blindering voor geneesmiddelgebruik bij inclusie en validatie bleek het spectrum van 
verantwoordelijke middelen relatief beperkt, met aromatische antiepileptica en allopurinol als 
de belangrijkste veroorzakers. Geruststellend was dat toepassing van het nieuwe diagnostische 
validatie score systeem slechts nauwelijks leidde tot overlap met SJS/TEN en AGEP. De 
bevindingen bevestigen dat DRESS een origineel fenotype vertegenwoordigt binnen de groep 
van SCAR wat betreft klinische en biologische kenmerken, veroorzakende middelen, latentietijd 
en beloop. 
In hoofdstuk 11 wordt een interessante observatie gemeld die werd waargenomen tijdens een 
desensitisatie procedure met trimethoprim-sulfamethoxazole (co-trimoxazol), verricht vanwege 
een eerdere ernstige cBG op dit middel bij een HIV-positieve patient. Ongeveer een jaar na de 
oorspronkelijke reactie werden plakproeven met cotrimoxazol verricht. De uitkomsten werden 
als zwak positief beoordeeld en, bij herhaling van de test, als negatief. Vrijwel aansluitend 
werd de desensitisatie procedure gestart. Enkele uren na de laatste desensitisatie stap (dag 
drie) ontwikkelde patient erytheem, beperkt tot de lokalisaties van de eerdere zwak positieve 
en negatieve plakproeven, in combinatie met voorbijgaande koorts, malaise, een verhoogd 
C-reactief prote"ine en perifere eosinofilie. Het fenomeen van het opvlammen van eerdere 
plakproeven is voorheen beschreven voor nikkel en goud na systemische provocatie bij 
contacteczeem, maar niet eerder voor cBG. Naar analogie van contacteczeem waarbij T cellen 
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gedurende enige tijd aanwezig blijven op plaatsen van een eerder verrichte plakproef, werd 
door ons gepostuleerd dat "homing" van geneesmiddelspecifieke T cellen in de huid ook een rol 
speelt bij cBG, en dat dit fenomeen verantwoordelijk was voor het plaatselijk opvlammen van de 
reactie op de lokalisaties waar op een eerder tijdstip plakproeven met het geneesmiddel waren 
verricht. Onze bevinding onderstreept ook dat klinisch negatief bevonden plakproeven geen 
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Allereerst wil ik alle patienten hartelijk danken voor hun bereidheid mee te werken aan het 
onderzoek dat heeft geleid tot dit proefschrift. Verder gaat mijn dank uit naar vele anderen, 
waaronder huisartsen, andere verwijzers en apothekers, die het geduld opbrachten de vele 
vragen van mij te beantwoorden die nodig waren om ziektebeeld, beloop en medicatie van 
ernstige bijwerkingen van geneesmiddelen zo nauwkeurig mogelijk in kaart te brengen. 
Professor dr. M.F. Jonkman, beste Marcel. Nadat ik me al een groot aantal jaren had 
beziggehouden met bijwerkingen van geneesmiddelen op de huid uitte ik mijn ambitie dit 
om te zetten in een promotie. Jij hebt me de ruimte gelaten en het vertrouwen geschonken 
zelfstandig aan mijn onderzoek verder te werken, ook al sloot dat onderzoek niet direct aan bij 
de bestaande speerpunten van de afdeling. Het was een bekroning dat toxicodermie in 2007 
door de Nederlandse Federatie Universitair Medische Centra werd aangewezen als topreferent 
voor de afdeling Dermatologie van het UMCG. 
Leden van de leescommissie, Prof. dr. W.Bergman, Prof. dr. A.C. van Grootheest en Prof. dr. A.J.H. 
Suurmeijer. Beste Wilma, Kees en Albert, hartelijk dank voor jullie deelname in de leescommissie 
en de beoordeling van het manuscript van mijn proefschrift. 
Collega stafleden en assistenten van de afdeling Dermatologie. Dank voor het begrip en 
de collegialiteit die ik ondervond toen ik ondanks de vele werkzaamheden en nieuwe 
ontwikkelingen op de afdeling ook probeerde mijn proefschrift af te ronden. Bijzondere dank 
gaat hierbij uit naar Dr. P. van Voorst Vader. Beste Pieter, je hebt jarenlang als mijn kamergenoot 
lief en leed met me gedeeld. Jij was het geweten van de afdeling, die steeds als er een patient 
opdook met een mogelijke geneesmiddelbijwerking riep: "haal Kardaun erbit 
REGAS en andere ondersteuners van de afdeling Dermatologie, dank voor de prettige 
samenwerking door de jaren heen. Dames van de "functieafdeling Dermatologie': het opzetten 
van de plakproeven met geneesmiddelen was nieuw voor ons en we hebben samen heel 
wat moeten experimenteren, zowel met de te plakken middelen en hun concentraties, als 
met de interpretatie van de reacties en gewenste afleestijden. P.H. Toonder, beste Piet. Altijd 
hulpvaardig en opgeruimd als ik een vraag had. Of het nu om een instelling van mijn microscoop 
of fototoestel ging, of om het wegwerken van wat vlekjes in een foto, de vraag of je "er een 
keer" naar zou kunnen kijken, resulteerde er meestal in dat het dezelfde dag al geregeld was. 
Hartelijke dank hiervoor! 
Verder gaat grote dank gaat uit naar alle collegae dermatologen en andere specialisten die 
bij verdenking van een ernstige cutane bijwerking van geneesmiddelen deze aan mij hebben 
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gemeld en in  voorkomende gevallen deze patienten hebben doorverwezen voor diagnose, 
overname van de behandeling of verdere voorlichting over de gevolgen op langere termijn. 
Hierdoor werd het mogelijk het aantal casus in mijn onderzoek uit te breiden. 
Professor dr. J.J. Rasker, beste Hans. Met veel plezier denk ik terug aan de samenwerking en het 
vertrouwen dat je in me stelde toen ik, eerst als co-assistent en later als beginnend AIOS lnterne 
geneeskunde, in Enschede in Ziekenzorg in opleiding kwam. Jij hebt destijds mijn speciale 
aandacht voor geneesmiddelbijwerkingen aangewakkerd, niet in de laatste plaats door de grote 
betrokkenheid dieje toonde metje patienten die regelmatig bijwerkingen ondervonden van de 
voor hen zo essentiele antirheumatica en pijnstillers. Samen hebben we een aantal klinische 
trials gedaan, waarbij onze publicatie over zinksulfaat vaak is aangehaald. 
Dr. R.H.B. Meijboom, beste Ronnie. Als AIOS dermatologie in Leiden leerde ik je kennen als 
consulent klinische farmacologie op de afdeling lnterne Geneeskunde en directeur van het 
Landelijk Bureau Bijwerkingen. We deelden vooral dezelfde accuratesse, kritische blik en 
aandacht voor detail die nodig zijn bij de evaluatie van de causaliteit van een geneesmiddel 
bijwerking. Door jou ben ik ook in aanraking gekomen met de pharmacovigilantie. Toen het 
Landelijk Bureau Bijwerkingen opging in het Lareb, en ook later, toen je zelf ging werken bij het 
Uppsala Monitoring Center dat het International Drug Monitoring Programme van de World 
Health Organisation (WHO-UMC) voortzet, bleven we contact houden. 
Professor E. Scheffer, beste Eric. Helaas niet meer onder ons sinds vorig jaar, jij hebt me de liefde 
voor de histopathologie bijgebracht. Je was een geboren leermeester en nam altijd rustig 
de tijd om een coupe met mij te bekijken. Enerzijds heel rustig en aimabel, maar anderzijds 
ook zeer opgetogen als je een bijzondere waarneming deed. Ook nadat ik in Groningen de 
verantwoordelijkheid had gekregen voor de dermatopathologie, was je altijd bereid een 
second opinion te geven als ik een m oeilijke casus tegenkwam. Met veel plezier denk ik terug 
aan je kritische opmerkingen bij het artikel over pseudolymphomen dat werd gepubliceerd 
in de British Journal. De brug van dat artikel naar dit proefschrift waarin ondermeer DRESS is 
onderzocht, is evident. 
Professor dr. W. Bergman, beste Wi I ma. Beha Ive dat je mede assistent Dermatologie in Leiden was, 
heb ik ook warme herinneringen aan je enthousiasme bij mijn voorbereiding van de nascholing 
dermatitis medicamentosa aan Nederlandse en Belgische Dermatologen in Antwerpen. 
Prof. dr. J.B. van der Meer, ons helaas ook te vroeg ontvallen. Je voortijdig overlijden haalde 
een streep door een voorgenomen promotietraject over SJSffEN. lk was destijds hoofd van de 
klinische afdeling en samen ontwikkelden we het initiatief SJSffEN patienten aan te trekken 
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voor behandeling op onze kliniek. Dit heeft uiteindelijk geresulteerd in het "Groninger TEN 
protocol" dat inmiddels ook in een aantal andere ziekenhuizen wordt gehanteerd. 
Professor dr. J.G.R. de Monchy, beste Jan. Samen met jouw afdeling Allergologie hebben we 
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